{
    "(_India_)_MD_final_classification_list_merged.pdf": "Drugs Controller General (India) \nDirectorate General of Health Services \nFDA Bhawan, Kotla Road, New Delhi. \n \nFile No. 29/Misc/3/2017-DC (292)                                       Date: 15.05.2019 \nNotice \nClassification of newly notified Medical Devices \nS. No. \nNotified \nCategory \nIntended Use \nRisk Class \n1.  \nCT scan \nEquipment \nUse of x-ray source and digitally scanned \ncomputer technology to create cross-sectional \nimages of the body.  \nClass C \n \n2.  \nMRI \nEquipment \nIt is a medical imaging procedure using radio \nwaves, magnetic fields, and magnetic field \ngradients to generate images of organs in the \nbody. \nClass C \n3.  \nDefibrillators \nIt is a device that automatically analyzes the \nrhythm of heart of cardiac arrest patients and \ndelivers an electrical shock to the heart for \nrestoring the normal rhythm of heart.  \nClass C \n4.  \nDialysis \nMachine \nIt is used for acute or chronic kidney failure that \nfilters blood to remove excess water and waste \nproducts. \nClass C \n5.  \nPET \nEquipment \nIntended to detect the gamma radiation and \npositron emitting radionuclides in the body and \nproduce cross-sectional images which reflect the \ndistribution in the body or individual organs. \nClass C \n6.  X-Ray Machine \nUse of X-rays to diagnose or treat patients by \nimaging the internal structure of the body to \nassess the abnormalities in the body. \nClass C \n7.  \nBone marrow \ncell separator \nIt is a general lab equipment to be used to isolate \ntarget cells and cells concentrate from bone and \nblood.  \n Class B \n\n8.  \nNebulizer \nIt is device used to administer medications in the \nform of mist to inhale for respiratory disorders. \nClass C \n9.  \nBlood Pressure \nMonitoring \nDevices \nIt is device used to measure the diastolic and \nsystolic blood pressures.  \nClass B \n10.  \nDigital \nThermometer \nIt is device used to record the body temperature. \nClass B \n11.  \n*Glucometer \nIt is a device used to measure the concentration \nof glucose in blood. \nClass C \n12.  \nOrgan \nPreservative \nSolution \nSolution for hypothermic flushing, storage and \ntransport of organs and to maintain the organ \nvitality during transplant into human recipients. \nClass C \n \n* Glucometer will be regulated under IVD category \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \nNotice \n \nFile No. 29/Misc/3/2018-DC(18) \nDate: 16.08.2018 \n \nIn continuation to the earlier Notice vide File No: 29/Misc./3/2017-DC(292) dated \n01.11.2017 and amended classification list dated 06.06.2018  regarding Classification of \nmedical devices and in vitro diagnostic medical devices under the provisions of the Medical \nDevices Rules, 2017, the following Medical Devices have been added in the annexure I : \n \nS. No. \nNotified Category \nDevice name \nGeneral Intended Use \n Risk \nClass \n1.  \nSurgical Dressings \nSuture Anchor \n(Spartan PEEK Suture \nImplant) \nSoft Tissue Repair \nC \n2.  \nDisposable \nHypodermic Needles \nSpecial bevelled \nneedles for implantable \nvascular access system \nPower - injectable safety non-coring \nneedle is a device intended for insertion \ninto the septum of a subcutaneously \nimplanted port for the infusion of fluids \nand drugs, as well as blood sampling \nthrough the port. It is manually \nactivated during needle removal, and is \ndesigned to aid in the prevention of \naccidental needle-sticks. When used \nwith ports that are indicated for power \ninjection of contrast media into the \ncentral venous system, the needle is also \nindicated for power injection of contrast \nmedia. \nC \n3.  \nInternal Prosthetic \nReplacements \nAuditory Brainstem \nImplant System \nAn auditory brain stem implant is a \nsmall device that is surgically implanted \nin the brain of a deaf person whose \nauditory nerves is lacking or damaged. \nThe auditory nerves conduct the sound \nsignals from the ear to the brain. The \nimplant enables otherwise the deaf \npeople to have a sensation of hearing. \nD \n4.  \nSurgical Dressings \nSternal fixation \nReconstructive implant \nSternal Fixation System is intended for \nuse in primary or secondary \nclosure/repair of the sternum following \nsternotomy or fracture of the sternum to \nstabilize the sternum and promote \nfusion. \nC \n5.  \nInternal Prosthetic \nReplacements \nDural Graft Implant \nDural Graft Implant is intended for use \nin procedures where the repair or \nC \n\nsubstitution of the patient’s dura mater \nis needed. \n6.  \nCatheters \nImplantable infusion \npumps with Catheters \nIntended to treat chronic pain and \nspasticity patients. The pump is inserted \nbelow the ribs and it designed to \ncontinually transport medication to the \nsite of action. Doses are accurate, user \nfriendly and the device does not restrict \nmovement. \nD \n7.  \nCatheters \nLaser Sheath \nIntended for use as adjuncts to \nconventional lead extraction tools in \npatients suitable for transvenous \nremoval of chronically implanted \npacing or defibrillator leads constructed \nwith silicone or polyurethane outer \ninsulation \nC \n8.  \nInternal Prosthe",
    "(_India_)246242.pdf": "3485 GI/2023 \n(1) \n \n \nरजिस्ट्री सं. डी.एल.- 33004/99 \nREGD. No. D. L.-33004/99 \n  \n \n \nxxxGIDHxxx \nxxxGIDExxx \nअसाधारण  \nEXTRAORDINARY \nभाग II—खण् ड 3—उप-खण् ड (i)  \nPART II—Section 3—Sub-section (i) \nप्राजधकार से प्रकाजित \nPUBLISHED BY AUTHORITY \nस्ट्वास्ट््य और पररवार कल्याण मंत्रालय \n(स्ट्वास्ट््य और पररवार कल्याण जवभाग) \nअजधसूचना \nनई दिल्ली, 2 िून, 2023 \nसा.का.जन. 409(अ).—िबदक जचदकत्सा उपकरण जनयमावली, 2017 में और संिोधन करने के जलए कुछ जनयमों \nका मसौिा, िो औषजध और प्रसाधन सामग्री अजधजनयम, 1940 (1940 का 23) की धारा 12 और 33 के तहत आवश्यक \nहै, दिनांक 1 माचच, 2023 को भारत के रािपत्र, असाधारण, भाग II, खंड 3, उप- खंड (i) में, स्ट्वास्ट््य और पररवार \nकल्याण मंत्रालय (स्ट्वास्ट््य और पररवार कल्याण जवभाग) में भारत सरकार की अजधसूचना सा.का.जन. संख्या 157(अ) के \nमाध्यम से प्रकाजित दकया गया था, जिसमें इससे प्रभाजवत होने वाले व्यजियों से उि अजधसूचना वाले सरकारी रािपत्र \nकी प्रजतयां िनता के जलए उपलब्ध कराए िाने के सात दिनों की अवजध की समाजि से पहले आपजियां और सुझाव आमंजत्रत \nदकए गए थें;  \nऔर िबदक, 1 माचच, 2023 को उि सरकारी रािपत्र की प्रजतयां िनता के जलए उपलब्ध कराई गई थीं; \nऔर िबदक, उि मसौिा जनयमों पर िनता से प्राि आपजियों और सुझावों पर केंद्रीय सरकार द्वारा जवचार दकया \nगया है; \nसं.   335] \nनई दिल्ली, िुक्रवार, िून 2, 2023/ज् येष् ठ 12, 1945 \n \nNo. 335] \nNEW DELHI,  FRIDAY, JUNE 2, 2023/JYAISHTHA 12, 1945 \n \nसी.जी.-डी.एल.-अ.-02062023-246242\nCG-DL-E-02062023-246242\nसी.जी.-डी.एल.-अ.-02062023-246242\nCG-DL-E-02062023-246242\n\n2  \nTHE GAZETTE OF INDIA : EXTRAORDINARY \n   [PART II—SEC. 3(i)] \nइसजलए, अब औषजध और प्रसाधन सामग्री अजधजनयम, 1940 (1940 का 23) की धारा 12 और 33 द्वारा प्रिि \nिजियों का प्रयोग करते हुए, केन्द्द्रीय सरकार, औषध तकनीकी सलाहकार बोडच के साथ परामिच करने के बाि, जचदकत्सा \nउपकरण जनयमावली, 2017 में संिोधन करने के जलए जनम्नजलजखत जनयम बनाती है, अथाचत् :- \n1. (1) इन जनयमों का नाम जचदकत्सा उपकरण (संिोधन) जनयमावली, 2023 है। \n   (2) ये जनयमावली सरकारी रािपत्र में इनके प्रकािन की तारीख से प्रवृि होंगे। \n2. जचदकत्सा उपकरण जनयमावली, 2017 (यहां इसके बाि उि जनयमावली के रूप में संिर्भचत) में, जनयम 3 में, उप-जनयम \n(य.प) के बाि, जनम्नजलजखत उप-जनयम िोड़े िाएंगे, अथाचत्,  \n(य.प.क) \"राज्य जचदकत्सा उपकरण परीक्षण प्रयोगिाला\" का अथच है जनयम 19 के उपजनयम (3) के तहत राज्य \nसरकार द्वारा स्ट्थाजपत या नाजमत जचदकत्सा उपकरण प्रयोगिाला । \n3. उि जनयमावली में, जनयम 18 में, उप-जनयम (1) में, \"केंद्रीय सरकार\" िब्िों के बाि, \"या, िैसा भी मामला हो, राज्य \nसरकार\" िब्ि अंतःस्ट्थाजपत दकए िाएंगे। \n4. उि जनयमावली में, जनयम 19 में,  \n(क)  हाजिए के िीषचक के स्ट्थान पर जनम्नजलजखत हाजिए का िीषचक रखा िाएगा अथाचत:- \n \"जचदकत्सा उपकरण परीक्षण प्रयोगिाला\"। \n (ख) उप जनयम (2) के बाि, जनम्नजलजखत अंतःस्ट्थाजपत दकया िाएगा, अथाचत:-  \n\"(3) (1) राज्य सरकार, अजधसूचना द्वारा, जनम्नजलजखत के प्रयोिनाथच राज्य जचदकत्सा उपकरण परीक्षण प्रयोगिाला की \nस्ट्थापना कर सकती है, - \n  \n(क) जचदकत्सा उपकरणों का परीक्षण और मूल्यांकन; या \n  \n(ख) कोई अन्द्य कायच करना िो उसे जविेष रूप से सौंपा िाए। \n(4) उप-जनयम (3) को प्रजतकूल रूप से प्रभाजवत दकए जबना, राज्य सरकार उप-जनयम (3) में जवजनर्िचष्ट प्रयोिनों के जलए \nजचदकत्सा उपकरणों के परीक्षण और मूल्यांकन की सुजवधा रखने वाली दकसी प्रयोगिाला को भी राज्य जचदकत्सा उपकरण \nपरीक्षण प्रयोगिाला के रूप में नाजमत कर सकती है: \nबिते दक कोई भी जचदकत्सा उपकरण परीक्षण प्रयोगिाला, तब तक नाजमत नहीं की िाएगी िब तक दक इसे \nपरीक्षण और अंिांकन प्रयोगिालाओं के जलए राष्ट्रीय प्रत्यायन जनकाय द्वारा जवजधवत मान्द्यता प्राि न हो। \n [फा. सं. एक्स.11014/7/2022-डीआर] \n  आराधना पटनायक, संयुक् त सजचव   \nनोट: जचदकत्सा उपकरण जनयमावली 2017, 31 िनवरी, 2017 की अजधसूचना संख्यांक सा.का.जन. 78(अ) द्वारा सरकारी \nरािपत्र में प्रकाजित दकए गए थे और अंजतम बार 14 अक्टूबर, 2022 की अजधसूचना संख्यांक सा.का.जन. 777(अ) \nद्वारा संिोजधत दकए गए थे। \n \nMINISTRY OF HEALTH AND FAMILY WELFARE \n(Department of Health and Family Welfare) \nNOTIFICATION \nNew Delhi, the 2nd June, 2023 \nG.S.R. 409(E).—Whereas a draft of certain rules further to amend the Medical Devices Rules, 2017 was \npublished, as required under sections 12 and 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940) vide notification \n\n[भागII—खण् ड 3(i)]\nभारत का रािपत्र : असाधारण \n3 \nof the Government of India in the Ministry of Health and Family Welfare (Department of Health and Family Welfare) \nnumber G.S.R. 157 (E), dated the 1st March, 2023, in the Gazette of India, Extraordinary, Part II, section 3,  \nsub-section (i), inviting objections and suggestions from persons likely to be affected thereby, before the expiry of a \nperiod of seven days from the date on which the copies of the Official Gazette containing the said notification were \nmade available to the public; \nAnd whereas, copies of the said Official Gazette were made available to the public on the 1st March, 2023; \nAnd whereas, objections and suggestions received from the public on the said draft rules have been \nconsidered by the Central Government; \nNow, therefore, in exercise of the powers conferred by sections 12 and 33 of the Drugs and Cosmetics  \nAct, 1940 (23 of 1940), the Central Government, after consultation with Drugs Technical Advisory Board, hereby \nmakes the follow",
    "(_India)so-1928-e-_25042023_notification-for-testing-covid-kit-nib-noida.pdf": "2742 GI/2023 \n(1) \n \nरजिस्ट्री सं. डी.एल.- 33004/99 \nREGD. No. D. L.-33004/99 \n \n \n \nxxxGIDHxxx \nxxxGIDExxx \nअसाधारण  \nEXTRAORDINARY \nभाग II—खण् ड 3—उप-खण् ड (ii)  \nPART II—Section 3—Sub-section (ii) \nप्राजधकार से प्रकाजित \nPUBLISHED BY AUTHORITY \nस्ट्वास्ट््य और पररवार कल्याण मंत्रालय \n (\nस्ट्वास्ट््य और पररवार कल्याण जवभाग\n )\n \nअजधसूचना \nनई दिल्ली, 25 अप्रैल, 2023 \nका.आ. 1928)अ(.—जचदकत्सा उपकरण जनयम, 2017 के जनयम 19 के उप-जनयम )2) के प्रावधानों के अनुसरण \nमें, केंद्र सरकार, भारत के रािपत्र, असाधारण, भाग II, खंड 3, उप खंड )ii) में प्रकाजित भारत सरकार, स्ट्वास्ट््य और \nपररवार कल्याण मंत्रालय )स्ट्वास्ट््य और पररवार कल्याण जवभाग(  की दिनांक 1 िून, 2018 की अजधसूचना संख्या सा. \nआ. 2237(अ( में संिोधन करने के जलए जनम्नजलजखत संिोधन करती है, यथा:  \nउक्त अजधसूचना में, ताजलका में, क्रम संख्या )1) और उससे संबंजधत प्रजवजियों के स्ट्थान पर, जनम्नजलजखत को \nप्रजतस्ट्थाजपत दकया िाएगा, अथाात्:— \n \n \n \nसं.   1840] \nनई दिल्ली, बुधवार, अप्रैल 26, 2023/वैिाख 6, 1945 \n \nNo. 1840] \nNEW DELHI,  WEDNESDAY, APRIL 26, 2023/VAISAKHA 6, 1945 \n \nसी.जी.-डी.एल.-अ.-27042023-245470\nCG-DL-E-27042023-245470\n\n2  \nTHE GAZETTE OF INDIA : EXTRAORDINARY \n   [PART II—SEC. 3(ii)] \n(1) \n(2) \n(3) \n\"1 \nराष्ट्रीय िैजवक संस्ट्थान \n ,\nनोएडा \nह्यूमन इम्युनोडेदिजिएंसी वायरस के जलए इन-जवरो डायग्नोजस्ट्िक्स \nमेजडकल जडवाइस, हेपेिाइरिस बी सरिेस एंिीिन, हेपेिाइरिस सी \nवायरस, जसिजलस, ब्लड ग्रुपपंग, कोजवड-19 के जनिान के जलए आरिी-\nपीसीआर दकि, कोजवड-19 के जनिान के जलए राइबोन्यूजक्लक एजसड \n)आरएनए( एक्सरैक्िन दकि, कोजवड-19 के जनिान के जलए वायरल \nरांसपोिा मीजडयम )वीिीएम(, कोजवड-19 के जनिान के जलए आरिी-\nएलएएमपी दकि, ग्लूकोि िेस्ट्ि जस्ट्रप और पूरी तरह से स्ट्वचाजलत \nजवश्लेषक आधाररत ग्लूकोि अजभकमाक और ग्लूकोमीिर। \n[िा. सं. : एक्स.11035/22/2018-डीआर] \nआराधना पिनायक,  संयुक्त सजचव \n \nनोि:  मुख्य अजधसूचना भारत के रािपत्र, असाधारण, भाग II, खंड 3, उपखंड )ii) में अजधसूचना संख्या  \nसा.आ. 2237(अ(, दिनांक 1 िून, 2018 द्वारा प्रकाजित की गई थी। \n \n \n \nMINISTRY OF HEALTH AND FAMILY WELFARE \n(Department of Health and Family Welfare) \nNOTIFICATION \nNew Delhi, the 25th April, 2023 \nS.O. 1928(E).— In pursuance of the provisions of sub sub-rule (2) of rule 19 of the Medical Devices Rules, \n2017, the Central Government hereby makes the following amendment to amend the notification of the Government \nof India in the Ministry of Health and Family Welfare (Department of Health and Family Welfare) number S.O. \n2237(E) dated 1st June, 2018, published in the Gazette of India, Extraordinary, Part II, Section 3, sub-section (ii), \nnamely: — \nIn the said notification, in the Table, for serial number (1) and the entries relating thereto, the following shall \nbe substituted, namely: — \n(1) \n(2) \n(3) \n“ 1 \nThe National Institute of \nBiologicals, Noida \nIn-Vitro Diagnostics Medical Device for Human Immunodeficiency \nVirus, Hepatitis B Surface Antigen, Hepatitis C Virus, Syphilis, \nBlood Grouping, RT-PCR Kits for Diagnosis of Covid-19, \nRibonucleic acid (RNA) Extraction Kits for Diagnosis of Covid-19, \nViral Transport Medium (VTM) for Diagnosis of Covid-19, RT-\nLAMP Kit for diagnosis of Covid-19, Glucose Test Strip and Fully \nAutomated Analyser Based Glucose Reagent and Glucometer.”. \n[F. No. : X.11035/22/2018-DR] \n \n \nARADHANA PATNAIK, Jt. Secy. \n \nNote:  The principal notification was published in the Gazette of India, Extraordinary, Part II, section 3, sub-section (ii) \nvide notification number S.O.2237 (E), dated the 1st June, 2018. \n \n \nUploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 \nand Published by the Controller of Publications, Delhi-110054. MANOJ KUMAR \nVERMA\nDigitally signed by MANOJ KUMAR \nVERMA \nDate: 2023.04.27 13:22:42 +05'30'",
    "(Allemagne)_Loi_d'adaptation_de_l'UE_relative_aux_dispositifs_medicaux_(MPEUAnpG).pdf": "Gesetz\nzur Anpassung des Medizinprodukterechts\nan die Verordnung (EU) 2017/745 und die Verordnung (EU) 2017/746\n(Medizinprodukte-EU-Anpassungsgesetz – MPEUAnpG)*\nVom 28. April 2020\nDer Bundestag hat mit Zustimmung des Bundesrates\ndas folgende Gesetz beschlossen:\nA r t i k e l 1\nG e s e t z\nz u r D u r c h f ü h r u n g\nu n i o n s r e c h t l i c h e r V o r s c h r i f t e n\nb e t r e f f e n d M e d i z i n p r o d u k t e\n( M e d i z i n p r o d u k t e r e c h t -\nD u r c h f ü h r u n g s g e s e t z – M P D G )\nI n h a l t s ü b e r s i c h t\nK a p i t e l 1\nZ w e c k ,\nA n w e n d u n g s b e r e i c h\nu n d B e g r i f f s b e s t i m m u n g e n\n§\n1\nZweck des Gesetzes\n§\n2\nAnwendungsbereich des Gesetzes\n§\n3\nErgänzende Begriffsbestimmungen\nK a p i t e l 2\nA n z e i g e p f l i c h t e n ,\nI n v e r k e h r b r i n g e n u n d I n b e t r i e b n a h m e\nv o n P r o d u k t e n s o w i e d e r e n B e r e i t s t e l l u n g\na u f d e m M a r k t , s o n s t i g e B e s t i m m u n g e n\n§\n4\nErgänzende Anzeigepflichten\n§\n5\nAufbewahrung von Unterlagen im Fall der Beendigung der\nGeschäftstätigkeit; Verordnungsermächtigung\n§\n6\nKlassifizierung von Produkten, Feststellung des recht-\nlichen Status, Einstufung von Produkten der Klasse I,\nGenehmigungspflicht einer klinischen Prüfung\n§\n7\nSonderzulassung, Verordnungsermächtigung\n§\n8\nSprachenregelung für die EU-Konformitätserklärung und\nfür Produktinformationen\n§\n9\nSondervorschriften für angepasste Produkte\n§ 10\nFreiverkaufszertifikate\n§ 11\nBetreiben und Anwenden von Produkten\n§ 12\nVerbote zum Schutz von Patienten, Anwendern und Dritten\n§ 13\nVerbote zum Schutz vor Fälschungen und Täuschungen\n§ 14\nAbgabe von Prüfprodukten\n§ 15\nBereitstellen von Sonderanfertigungen auf dem Markt\n§ 16\nAusstellen von Produkten\nK a p i t e l 3\nB e n a n n t e S t e l l e n ,\nP r ü f l a b o r a t o r i e n , K o n f o r m i t ä t s -\nb e w e r t u n g s s t e l l e n f ü r D r i t t s t a a t e n\n§ 17\nSprachenregelung für Konformitätsbewertungsstellen\n§ 18\nAnerkennung von Prüflaboratorien; Widerruf und Rück-\nnahme der Anerkennung\n§ 19\nÜberwachung anerkannter Prüflaboratorien\n§ 20\nBenennung von Konformitätsbewertungsstellen für Dritt-\nstaaten; Widerruf und Rücknahme der Benennung\n§ 21\nÜberwachung benannter Konformitätsbewertungsstellen\nfür Drittstaaten\n§ 22\nBefugnisse der für Benannte Stellen zuständigen Behörde\n§ 23\nAuskunftsverweigerungsrecht\nK a p i t e l 4\nK l i n i s c h e P r ü f u n g e n\nu n d s o n s t i g e k l i n i s c h e P r ü f u n g e n\nAbschnitt 1\nErgänzende Voraussetzungen\n§ 24\nAllgemeine ergänzende Voraussetzungen\n§ 25\nSponsor oder rechtlicher Vertreter des Sponsors\n§ 26\nVersicherungsschutz\n§ 27\nVerbot der Durchführung bei untergebrachten Personen\n§ 28\nEinwilligung in die Teilnahme\n§ 29\nEinwilligung in die Verarbeitung personenbezogener Daten\n§ 30\nPrüfer, Hauptprüfer und Leiter einer klinischen Prüfung\noder sonstigen klinischen Prüfung\nAbschnitt 2\nVoraussetzungen\nfür den Beginn, wesentliche\nÄnderungen und Korrekturmaßnahmen\nU n t e r a b s c h n i t t 1\nK l i n i s c h e P r ü f u n g e n\nn a c h A r t i k e l 6 2 A b s a t z 1\nd e r V e r o r d n u n g ( E U ) 2 0 1 7 / 7 4 5\nTitel 1\nVoraussetzungen für den Beginn\n§ 31\nBeginn einer klinischen Prüfung\nTitel 2\nVerfahren bei der Ethik-Kommission\n§ 32\nAnforderungen an die Ethik-Kommissionen\n§ 33\nAntrag bei der Ethik-Kommission\n§ 34\nPrüfung der Ordnungsmäßigkeit des Antrags durch die\nEthik-Kommission\n§ 35\nEthische Bewertung der beantragten klinischen Prüfung\n§ 36\nFrist zur Stellungnahme der Ethik-Kommission\n§ 37\nStellungnahme der Ethik-Kommission\n* Dieses Gesetz dient der Anpassung des nationalen Medizinprodukte-\nrechts an die Verordnung (EU) 2017/745 des Europäischen Parla-\nments und des Rates vom 5. April 2017 über Medizinprodukte, zur\nÄnderung\nder\nRichtlinie\n2001/83/EG,\nder\nVerordnung\n(EG)\nNr.\n178/2002 und der Verordnung (EG) Nr. 1223/2009 und zur Aufhebung\nder Richtlinien 90/385/EWG und 93/42/EWG des Rates (ABl. L 117\nvom 5.5.2017, S. 1; L 117 vom 3.5.2019, S. 9; L 334 vom 27.12.2019,\nS. 165) und die Verordnung (EU) 2017/746 des Europäischen Parla-\nments und des Rates vom 5. April 2017 über In-vitro-Diagnostika und\nzur\nAufhebung\nder\nRichtlinie\n98/79/EG\nund\ndes\nBeschlusses\n2010/227/EU der Kommission (ABl. L 117 vom 5.5.2017, S. 176;\nL 117 vom 3.5.2019, S. 11; L 334 vom 27.12.2019, S. 167).\n960\nBundesgesetzblatt Jahrgang 2020 Teil I Nr. 23, ausgegeben zu Bonn am 22. Mai 2020\nDas Bundesgesetzblatt im Internet: www.bundesgesetzblatt.de | Ein Service des Bundesanzeiger Verlag www.bundesanzeiger-verlag.de\n\nTitel 3\nVerfahren bei der Bundesoberbehörde\n§ 38\nAntrag\n§ 39\nUmfang der Prüfung des Antrags\nTitel 4\nVerfahren bei wesentlichen Änderungen\nnach Artikel 75 der Verordnung (EU) 2017/745\n§ 40\nZugang der Ethik-Kommission zu Mitteilungen\n§ 41\nStellungnahme der Ethik-Kommission\n§ 42\nEntscheidung der Bundesoberbehörde\nTitel 5\nKorrekturmaßnahmen\n§ 43\nKorrekturmaßnahmen der Ethik-Kommission\n§ 44\nKorrekturmaßnahmen der Bundesoberb",
    "(Allemagne)_Loi_sur_les_dispositifs_medicaux_(Loi_sur_les_dispositifs_medicaux_-_MPG).pdf": "The Act on Medical Devices \n \n \n \n \nnon-official translation \n(Medical Devices Act)  \n____________________________________________________________________________ \n \nStatus: 30.03.2011  \n \nPage 1 of 57 \n \nThe Act on Medical Devices \n \n(Medical Devices Act) \n \nThe Act on Medical Devices of 2nd August 1994 (Federal Law Gazette I, p. 1963), in the version of 7th \nAugust 2002 (Federal Law Gazette I, p. 3146), last amended by Article 12 of the Act of 24th July 2010 \n(Federal Law Gazette I, p. 983) \n \nTABLE OF CONTENTS \n \nPart One \nThe purpose and scope of the Act, definition of terms \n§   1 \nThe purpose of the Act \n§   2 \nThe scope of the Act \n§   3 \nDefinition of terms \nPart Two \nRequirements for medical devices and their operation \n§   4 \nProhibitions to ensure the protection of patients, users and other persons \n§   5 \nPerson responsible for the first placing on the market \n§   6 \nPrerequisites for placing on the market and putting into service \n§   7 \nEssential requirements \n§   8 \nHarmonised standards, common technical specifications \n§   9 \nThe CE marking \n§ 10 \nPrerequisites for the first placing on the market and the putting into service of systems \n \nand procedure packs as well as for the sterilisation of medical devices \n§ 11 \nSpecial regulations regarding placing on the market and putting into service \n§ 12 \nCustom-made devices, medical devices manufactured in-house, medical devices in\n \ntended for clinical investigation, performance evaluation or exhibition \n§ 13 \nClassification of medical devices, differentiation from other devices \n§ 14 \nInstallation, operation, use and maintenance of medical devices \nPart Three \nNotified bodies and certificates \n§ 15 \nDesignation and supervision of bodies, approval and subcontracting to testing laborato- \n \nries \n§ 15a Designation and supervision of conformity assessment bodies for third countries \n§ 16 \nExpiry, withdrawal, revocation and suspension of the designation \n§ 17 \nDuration of the validity of certificates issued by notified bodies \n§ 18 \nRestriction, suspension and withdrawal of certificates, notification obligations \n\nThe Act on Medical Devices  \n \n \n \n \nnon-official translation \n(Medical Devices Act)  \n____________________________________________________________________________ \n \nStatus: 30.03.2011  \n \nPage 2 of 57 \nPart Four \nClinical evaluation, performance evaluation, clinical investigation, \nperformance evaluation studies \n§ 19 \nClinical evaluation, performance evaluation \n§ 20 \nGeneral prerequisites for clinical investigations \n§ 21 \nSpecial prerequisites for clinical investigations \n§ 22 \nProcedure regarding the ethics committee \n§ 22a Authorisation procedure at the competent higher federal authority \n§ 22b Withdrawal, revocation and suspension of the authorisation or of the favourable opinion \n§ 22c Changes subsequent to the authorisation of a clinical investigation \n§ 23 \nExecution of clinical investigations \n§ 23a Announcements regarding completion or early termination of clinical investigations \n§ 23b Exceptions to the provisions governing clinical investigations \n§ 24 \nPerformance evaluation studies \nPart Five \nSupervision and protection from risks \n§ 25 \nGeneral obligation to notify \n§ 26 \nThe conduct of supervision \n§ 27 \nProcedures in the event of the unlawful and wrongful affixing of the CE marking \n§ 28 \nProcedures for the protection against risks \n§ 29 \nMedical Devices Vigilance System \n§ 30 \nSafety officer for medical devices \n§ 31 \nMedical devices consultant \nPart Six \nCompetent authorities, ordinances, miscellaneous provisions \n§ 32 \nTasks and competences of the higher federal authorities in the field of medical devices \n§ 33 \nDatabase-supported information system, European database \n§ 34 \nExport \n§ 35 \nCosts \n§ 36 \nCo-operation between the authorities and notified bodies in the European Economic  \n \nArea and the European Commission \n§ 37 \nDelegated powers to issue ordinances \n§ 37a General administrative ordinances \nPart Seven \nSpecial regulations applying to the Federal Armed Forces \n§ 38 \nApplication and enforcement of the Act \n§ 39 \nExceptions \n\nThe Act on Medical Devices  \n \n \n \n \nnon-official translation \n(Medical Devices Act)  \n____________________________________________________________________________ \n \nStatus: 30.03.2011  \n \nPage 3 of 57 \nPart Eight \nCriminal provisions and regulatory fining provisions \n§ 40 \nCriminal provisions \n§ 41 \nCriminal provisions \n§ 42 \nRegulatory fining provisions \n§ 43 \nConfiscation \nPart Nine \nTransitional provisions \n§ 44 \nTransitional provisions \n \n\nThe Act on Medical Devices  \n \n \n \n \nnon-official translation \n(Medical Devices Act)  \n____________________________________________________________________________ \n \nStatus: 30.03.2011  \n \nPage 4 of 57 \nPart One \nThe purpose and scope of the Act, definition of terms \n \nSection 1 \nThe purpose of the Act \n \n \nThe purpose of the present Act is to regulate the trade in medical devices and, by doing \nso, to guarantee the safety, suitability and perf",
    "(Allemagne)_Ordonnance_sur_l'installation,_l'exploitation_et_l'utilisation_des_dispositifs_medicaux_(Ordonnance_sur_les_exploitants_de_dispositifs_medicaux_-_MPBetreibV).pdf": "Ein Service des Bundesministeriums der Justiz sowie des Bundesamts für\nJustiz ‒ www.gesetze-im-internet.de\n- Seite 1 von 12 -\nVerordnung über das Errichten, Betreiben und Anwenden von\nMedizinprodukten (Medizinprodukte-Betreiberverordnung -\nMPBetreibV)\nMPBetreibV\nAusfertigungsdatum: 29.06.1998\nVollzitat:\n\"Medizinprodukte-Betreiberverordnung in der Fassung der Bekanntmachung vom 21. August 2002 (BGBl. I S.\n3396), die zuletzt durch Artikel 7 der Verordnung vom 21. April 2021 (BGBl. I S. 833) geändert worden ist\"\nStand:\nNeugefasst durch Bek. v. 21.8.2002 I 3396;\n \nzuletzt geändert durch Art. 7 V v. 21.4.2021 I 833\nDie Verpflichtungen aus der Richtlinie 98/34/EG des Europäischen Parlaments und des Rates vom 22. Juni 1998\nüber ein Informationsverfahren auf dem Gebiet der Normen und technischen Vorschriften und der Vorschriften\nfür die Dienste der Informationsgesellschaft (ABl. EG Nr. L 204 S. 37), geändert durch die Richtlinie 98/48/EG des\nEuropäischen Parlaments und des Rates vom 20. Juli 1998 (ABl. EG Nr. L 217 S. 18), sind beachtet worden.\nFußnote\n(+++ Textnachweis  ab: 7.7.1998 +++) \n \n(+++ Amtliche Hinweise des Normgebers auf EG-Recht: \n     Beachtung \n        EWGRL 189/83 (CELEX Nr: 383L0189) \n     Beachtung \n        EGRL 34/98 (CELEX Nr: 398L0034) vgl. Bek. v. 21.8.2002 I 3396 +++) \n \n \n(+++ § 9: Zur Geltung vgl. § 17 Abs. 1 Satz 2 CoronaTestV 2021-01 +++)\n \n \n§ 1 Anwendungsbereich\n(1) Diese Rechtsverordnung gilt für das Betreiben und Anwenden von Produkten nach § 3 Nummer 1 des\nMedizinprodukterecht-Durchführungsgesetzes einschließlich der damit zusammenhängenden Tätigkeiten. Diese\nRechtsverordnung gilt nicht für die im Anhang XVI der Verordnung (EU) 2017/745 des Europäischen Parlaments\nund des Rates vom 5. April 2017 über Medizinprodukte, zur Änderung der Richtlinie 2001/83/EG, der Verordnung\n(EG) Nr. 178/2002 und der Verordnung (EG) Nr. 1223/2009 und zur Aufhebung der Richtlinien 90/385/EWG\nund 93/42/EWG des Rates (ABl. L 117 vom 5.5.2017, S. 1; L 117 vom 3.5.2019, S. 9; L 334 vom 27.12.2019, S.\n165), die durch die Verordnung (EU) 2020/561 (ABl. L 130 vom 24.4.2020, S. 18) geändert worden ist, in der\njeweils geltenden Fassung aufgeführten Produkte. Für In-vitro-Diagnostika ist bis einschließlich 25. Mai 2022 die\nMedizinprodukte-Betreiberverordnung in der bis einschließlich 25. Mai 2021 geltenden Fassung anzuwenden.\n(2) Diese Verordnung gilt nicht für Medizinprodukte\n1.   zur klinischen Prüfung,\n \n2.   zur Leistungsbewertungsprüfung oder\n \n3.   die in ausschließlich eigener Verantwortung für persönliche Zwecke erworben und angewendet werden.\n \n(3) Die Vorschriften des Arbeitsschutzgesetzes sowie die Rechtsvorschriften, die aufgrund des\nArbeitsschutzgesetzes erlassen wurden, die Vorschriften des Gesetzes zum Schutz vor nichtionisierender\nStrahlung bei der Anwendung am Menschen und der auf dessen Grundlage erlassenen Rechtsverordnungen,\nsowie Unfallverhütungsvorschriften bleiben unberührt.\n\nEin Service des Bundesministeriums der Justiz sowie des Bundesamts für\nJustiz ‒ www.gesetze-im-internet.de\n- Seite 2 von 12 -\n§ 2 Begriffsbestimmungen\n(1) Tätigkeiten im Zusammenhang mit dem Betreiben und Anwenden von Medizinprodukten sind insbesondere\n1.   das Errichten,\n \n2.   das Bereithalten,\n \n3.   die Instandhaltung,\n \n4.   die Aufbereitung sowie\n \n5.   sicherheits- und messtechnische Kontrollen.\n \n(2) Betreiber eines Medizinproduktes ist jede natürliche oder juristische Person, die für den Betrieb der\nGesundheitseinrichtung verantwortlich ist, in der das Medizinprodukt durch dessen Beschäftigte betrieben oder\nangewendet wird. Abweichend von Satz 1 ist Betreiber eines Medizinproduktes, das im Besitz eines Angehörigen\nder Heilberufe oder des Heilgewerbes ist und von diesem zur Verwendung in eine Gesundheitseinrichtung\nmitgebracht wird, der betreffende Angehörige des Heilberufs oder des Heilgewerbes. Als Betreiber gilt auch, wer\naußerhalb von Gesundheitseinrichtungen in seinem Betrieb oder seiner Einrichtung oder im öffentlichen Raum\nMedizinprodukte zur Anwendung bereithält.\n(3) Anwender ist, wer ein Medizinprodukt im Anwendungsbereich dieser Verordnung am Patienten einsetzt.\n(4) Gesundheitseinrichtung im Sinne dieser Verordnung ist jede Einrichtung, Stelle oder Institution, einschließlich\nRehabilitations- und Pflegeeinrichtungen, in der Medizinprodukte durch medizinisches Personal, Personen der\nPflegeberufe oder sonstige dazu befugte Personen berufsmäßig betrieben oder angewendet werden.\n§ 3 Pflichten eines Betreibers\n(1) Der Betreiber hat die ihm nach dieser Verordnung obliegenden Pflichten wahrzunehmen, um ein sicheres und\nordnungsgemäßes Anwenden der in seiner Gesundheitseinrichtung am Patienten eingesetzten Medizinprodukte\nzu gewährleisten.\n(2) Die Pflichten eines Betreibers hat auch wahrzunehmen, wer Patienten mit Medizinprodukten zur Anwendung\ndurch sich selbst oder durch Dritte in der häuslichen Umgebung oder im sonstigen privaten Umfeld aufgrund\neiner gesetzlichen oder vertraglichen Verpflichtung versorgt. W",
    "(Allemagne)_Reglement_d'adaptation_de_l'UE_sur_les_dispositifs_medicaux_(MPEUAnpV).pdf": "Verordnung \nzur Anpassung des Medizinprodukterechts \nan die Verordnung (EU) 2017/745 und die Verordnung (EU) 2017/746 \n(Medizinprodukte-EU-Anpassungsverordnung – MPEUAnpV)1 \nVom 21. April 2021   \nEs verordnet auf Grund  \n– des § 88 Absatz 1 Satz 1 Nummer 7 des Medizin-\nprodukterecht-Durchführungsgesetzes vom 28. April \n2020 (BGBl. I S. 960) das Bundesministerium für \nGesundheit im Einvernehmen mit dem Bundesminis-\nterium für Wirtschaft und Energie, mit dem Bundes-\nministerium für Umwelt, Naturschutz und nukleare \nSicherheit und mit dem Bundesministerium des \nInnern, für Bau und Heimat,   \n– des § 137h Absatz 2 Satz 3 des Fünften Buches \nSozialgesetzbuch, der durch Artikel 1 Nummer 66 \ndes Gesetzes vom 16. Juli 2015 (BGBl. I S. 1211) \neingefügt worden ist, das Bundesministerium für \nGesundheit im Benehmen mit dem Bundesministe-\nrium für Bildung und Forschung,   \n– des § 21 Absatz 1 Satz 1 des Apothekengesetzes, \nder durch Artikel 34 der Verordnung vom 31. Oktober \n2006 (BGBl. I S. 2407; 2007 I S. 2149) geändert \nworden ist, das Bundesministerium für Gesundheit,   \n– des § 87 Absatz 2 in Verbindung mit Absatz 1 des \nMedizinprodukterecht-Durchführungsgesetzes vom \n28. April 2020 (BGBl. I S. 960) das Bundesminis-\nterium für Gesundheit im Einvernehmen mit dem \nBundesministerium für Wirtschaft und Energie,  \n– des § 88 Absatz 1 Satz 1 Nummer 6 des Medizin-\nprodukterecht-Durchführungsgesetzes vom 28. April \n2020 (BGBl. I S. 960) das Bundesministerium für \nGesundheit im Einvernehmen mit dem Bundesminis-\nterium für Wirtschaft und Energie, mit dem Bundes-\nministerium für Umwelt, Naturschutz und nukleare \nSicherheit, mit dem Bundesministerium für Arbeit \nund Soziales und mit dem Bundesministerium des \nInnern, für Bau und Heimat,   \n– des § 88 Absatz 1 Satz 1 Nummer 2 und 3 des \nMedizinprodukterecht-Durchführungsgesetzes vom \n28. April 2020 (BGBl. I S. 960) das Bundesminis-\nterium für Gesundheit im Einvernehmen mit dem \nBundesministerium für Wirtschaft und Energie, mit \ndem Bundesministerium für Umwelt, Naturschutz \nund nukleare Sicherheit, mit dem Bundesministe-\nrium für Arbeit und Soziales und mit dem Bundes-\nministerium des Innern, für Bau und Heimat: \nArtikel 1 \nVerordnung \nüber die Meldung von  \nmutmaßlichen schwerwiegenden  \nVorkommnissen bei Medizinprodukten sowie zum  \nInformationsaustausch der zuständigen Behörden \n(Medizinprodukte-Anwendermelde- und  \nInformationsverordnung – MPAMIV) \nA b s c h n i t t  1  \nA n w e n d u n g s b e r e i c h ;   \nM e l d e v e r f a h r e n  \n§ 1 \nAnwendungsbereich \nDiese \nRechtsverordnung \nist \nanzuwenden \nauf \nProdukte im Anwendungsbereich der Verordnung \n(EU) 2017/745 des Europäischen Parlaments und \ndes Rates vom 5. April 2017 über Medizinprodukte, \nzur Änderung der Richtlinie 2001/83/EG, der Verord-\nnung (EG) Nr. 178/2002 und der Verordnung (EG) \nNr. 1223/2009 und zur Aufhebung der Richtlinien \n90/385/EWG und 93/42/EWG des Rates (ABl. L 117 \nvom 5.5.2017, S. 1; L 117 vom 3.5.2019, S. 9; L 334 \nvom 27.12.2019, S. 165), die durch die Verordnung \n(EU) 2020/561 (ABl. L 130 vom 24.4.2020, S. 18) ge-\nändert worden ist, in der jeweils geltenden Fassung. \nFür In-vitro-Diagnostika ist bis einschließlich 25. Mai \n2022 die Medizinprodukte-Sicherheitsplanverordnung \nvom 24. Juni 2002 (BGBl. I S. 2131) in der bis ein-\nschließlich 25. Mai 2021 geltenden Fassung anzu-\nwenden. \n§ 2 \nErgänzende Begriffsbestimmungen \nErgänzend zu Artikel 2 der Verordnung (EU) 2017/745 \nbezeichnet im Sinne dieser Rechtsverordnung der Aus-\ndruck „mutmaßliches schwerwiegendes Vorkommnis“ \nein Vorkommnis, bei dem nicht ausgeschlossen ist, \ndass es auf einer unerwünschten Nebenwirkung eines \nProduktes, auf einer Fehlfunktion, einer Verschlechte-\nrung der Eigenschaften oder der Leistung eines Pro-\nduktes, einschließlich Anwendungsfehlern aufgrund \nergonomischer Merkmale oder einer Unzulänglichkeit \nder vom Hersteller bereitgestellten Informationen be-\nruht und das direkt oder indirekt eine der nachstehen-\nden Folgen hatte oder hätte haben können:  \n1. den Tod eines Patienten, Anwenders oder einer \nanderen Person, \n1 Diese Verordnung dient der Anpassung des nationalen Medizinpro-\ndukterechts an die Verordnung (EU) 2017/745 des Europäischen \nParlaments und des Rates vom 5. April 2017 über Medizinprodukte, \nzur Änderung der Richtlinie 2001/83/EG, der Verordnung (EG) \nNr. 178/2002 und der Verordnung (EG) Nr. 1223/2009 und zur Auf-\nhebung der Richtlinien 90/385/EWG und 93/42/EWG des Rates \n(ABl. L 117 vom 5.5.2017, S. 1; L 117 vom 3.5.2019, S. 9; L 334 \nvom 27.12.2019, S. 165), die durch die Verordnung (EU) 2020/561 \n(ABl. L 130 vom 24.4.2020, S. 18) geändert worden ist, und an die \nVerordnung (EU) 2017/746 des Europäischen Parlaments und des \nRates vom 5. April 2017 über In-vitro-Diagnostika und zur Aufhebung \nder Richtlinie 98/79/EG und des Beschlusses 2010/227/EU der Kom-\nmission (ABl. L 117 vom 5.5.2017, S. 176; L 117 vom 3.5.2019, S. 11; \nL 334 vom 27.12.2019, S. 167). \n833 \nBundesgesetzblatt Jahrgang 2021 Teil ",
    "(canada)_draft-guidance-on-managing-applications-for-medical-device-licences-eng.pdf": "Unclassified / Non classifié \nDraft guidance on \n1 \nmanaging \n2 \napplications for \n3 \nmedical device \n4 \nlicences \n \n5 \n\n \n \n \n2 \nHealth Canada is the federal department responsible for helping the people of Canada maintain and improve \n6 \ntheir health. Health Canada is committed to improving the lives of all of Canada's people and to making this country's \n7 \npopulation among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health \n8 \ncare system. \n9 \n \n10 \n \n11 \n \n12 \n \n13 \n \n14 \n \n15 \nÉgalement disponible en français sous le titre : \n16 \nÉbauche de ligne directrice sur la gestion des demandes d’homologation d’instruments médicaux \n17 \n \n18 \nTo obtain additional information, please contact: \n19 \n \n20 \nHealth Canada \n21 \nAddress Locator 0900C2 \n22 \nOttawa, ON  K1A 0K9 \n23 \nTel.: 613-957-2991 \n24 \nToll free: 1-866-225-0709 \n25 \nFax: 613-941-5366 \n26 \nTTY: 1-800-465-7735 \n27 \nE-mail: publications-publications@hc-sc.gc.ca \n28 \n \n29 \n© His Majesty the King in Right of Canada, as represented by the Minister of Health, 2025 \n30 \n \n31 \nPublication date: February 2025 \n32 \n \n33 \nInformation contained in this publication or product may be reproduced, in whole or in part, and by any means, for \n34 \npersonal or public non-commercial purposes without charge or further permission, unless otherwise specified. \n35 \nCommercial reproduction and distribution are prohibited except with written permission from Health Canada. To obtain \n36 \npermission to reproduce any content owned by the Government of Canada available for commercial purposes, please \n37 \ncontact pubsadmin@hc-sc.gc.ca.  \n38 \n \n39 \n \n40 \n \n41 \n \n42 \n \n43 \n \n44 \n \n45 \n \n46 \n \n47 \n \n48 \n \n49 \n \n50 \n \n51 \n \n52 \n \n53 \n \n54 \n \n55 \n \n56 \n \n57 \n \n58 \n \n59 \n \n60 \n \n61 \n \n62 \n \n63 \n \n64 \n\n \n \n \n3 \nForeword \n65 \nGuidance documents provide assistance to industry on how to comply with governing \n66 \nstatutes and regulations. They also provide guidance to Health Canada staff on how \n67 \nmandates and objectives should be met fairly, consistently and effectively. \n68 \nGuidance documents are administrative, not legal, instruments. This means that flexibility \n69 \ncan be applied. However, to be acceptable, alternate approaches to the principles and \n70 \npractices described in this document must be supported by adequate justification. They \n71 \nshould be discussed in advance with the relevant program area to avoid the possible \n72 \nfinding that applicable statutory or regulatory requirements have not been met. \n73 \nAs always, Health Canada reserves the right to request information or material, or define \n74 \nconditions not specifically described in this document, to help us adequately assess the \n75 \nsafety, effectiveness or quality of a medical device. We are committed to ensuring that \n76 \nsuch requests are justifiable and that decisions are clearly documented. \n77 \nThis document should be read along with the relevant sections of the regulations and other \n78 \napplicable guidance documents. \n79 \n \n80 \n \n81 \n \n82 \n \n83 \n \n84 \n \n85 \n \n86 \n \n87 \n \n88 \n \n89 \n \n90 \n\n \n \n \n4 \nDocument change log \n91 \nDate \nLocation (section, \nparagraph) \nNature of and reason for change \nFebruary 20, 2025 \nReconsideration   \nprocess \nUpdated to reflect the revamped \nreconsideration process and include a \nreconsideration process map and request for \nreconsideration form. \nDeficient \napplications – \nadditional \ninformation letter \nIncluded information on the different types of \nadditional information letters. \nWithdrawal letter \n(under Screening \nprocess) \nIncluded information on withdrawing an \napplication during the screening process. \nDeficient \napplications – \nscreening deficiency \nletter \nAdjusted response times to screening \ndeficiency letters to ensure consistency across \napplications. \nClarification request \n(under Regulatory \nscreening) \nIncluded information on clarification requests \nduring regulatory screening. \nFull document \nEdited to make clearer and enhance flow and \nreadability. \nApril 1, 2020 \nFull document \nMade significant changes as new fees and a \nrevised fee policy came into force on April 1, \n2020. \n\n \n \n \n5 \n \n92 \n \n93 \n \n94 \n \n95 \n \n96 \n \n97 \nDate \nLocation (section, \nparagraph) \nNature of and reason for change \nNovember 4, 2019 \nFull document \nRevised the format of the guidance document. \nJanuary 11, 2019 \nFull document \nRewrote content to make clearer and conform \nto good guidance practices. \nFull document \nRemoved information on investigational testing \nauthorizations as this information is now \npublished in a separate guidance titled \nApplications for Medical Device Investigational \nTesting Authorizations Guidance Document – \nSummary. \nFull document \nAdded information on new and amendment \nprivate label licence applications. \nFull document \nUpdated text in fee status sections throughout \ndocument for clarity and consistency. \nPause the clock \nIncluded information resulting from “pause the \nclock” consultation. \n\n \n \n \n6 \nTable ",
    "(Chine)_Reglement_sur_la_surveillance_et_l'administration_des_dispositifs_medicaux.pdf": "Numéro \nd'index \nFGWJ-2021-10001 \nClassification \ndes sujets \nDocuments réglementaires / \nréglementations légales et \nadministratives \ntitre \nRèglement sur la surveillance et l'administration des dispositifs médicaux \nDate de \nsortie \n19/03/2021 \nRèglement sur la surveillance et l'administration \ndes dispositifs médicaux \nOrdonnance \nn° 739 \n  Le « Règlement sur la surveillance et l'administration des dispositifs \nmédicaux » a été révisé et adopté lors de la 119e réunion exécutive du Conseil \nd'État le 21 décembre 2020 et est par la présente promulgué et entrera en \nvigueur le 1er juin 2021. \n                                    \nPremier ministre Li Keqiang \n                                    9 \nfévrier 2021 \n \nRèglement sur la surveillance et l'administration des dispositifs \nmédicaux \n  (Promulgué par l'ordonnance n° 276 du Conseil des Affaires d'État de la \nRépublique populaire de Chine le 4 janvier 2000, révisé et adopté lors de la \n39e réunion exécutive du Conseil des Affaires d'État le 12 février 2014, révisé \nconformément à la « Décision du Conseil des Affaires d'État sur la modification \ndu Règlement sur la surveillance et l'administration des dispositifs médicaux » \nle 4 mai 2017, et révisé et adopté lors de la 119e réunion exécutive du Conseil \ndes Affaires d'État le 21 décembre 2020) \n\nChapitre I Dispositions générales \n  Article 1 Le présent règlement est formulé afin d'assurer la sécurité et \nl'efficacité des dispositifs médicaux, de protéger la santé et la sécurité des \npersonnes et de promouvoir le développement de l'industrie des dispositifs \nmédicaux. \n  Article 2 Le présent règlement s'applique à la recherche, à la production, à \nl'exploitation, à l'utilisation, à la surveillance et à l'administration des \ndispositifs médicaux sur le territoire de la République populaire de Chine. \n  Article 3 Le département de surveillance et d'administration des \nmédicaments du Conseil des Affaires d'État est responsable de la surveillance \net de l'administration des dispositifs médicaux au niveau national. \n  Les départements compétents du Conseil d’État sont responsables de la \nsupervision et de la gestion des dispositifs médicaux dans le cadre de leurs \nresponsabilités respectives. \n  Article 4 Les gouvernements populaires locaux au niveau du district ou au-\ndessus doivent renforcer le leadership en matière de surveillance et de gestion \ndes dispositifs médicaux dans leurs régions administratives, organiser et \ncoordonner le travail de surveillance et de gestion des dispositifs médicaux et \nle travail d'intervention d'urgence dans leurs régions administratives, renforcer \nla construction des capacités de surveillance et de gestion des dispositifs \nmédicaux et fournir des garanties pour le travail de sécurité des dispositifs \nmédicaux. \n  Le département responsable de la surveillance et de l'administration des \nmédicaments des collectivités locales populaires au niveau du comté ou au-\ndessus est responsable de la surveillance et de l'administration des dispositifs \nmédicaux dans sa zone administrative. Les services compétents des \ngouvernements populaires locaux au niveau du comté ou au-dessus sont \nresponsables de la supervision et de la gestion des dispositifs médicaux dans \nle cadre de leurs responsabilités respectives. \n\n  Article 5 La supervision et la gestion des dispositifs médicaux doivent \nsuivre les principes de gestion des risques, de contrôle de l'ensemble du \nprocessus, de supervision scientifique et de gouvernance sociale. \n  Article 6 L’État met en œuvre une gestion classée des dispositifs \nmédicaux en fonction de leurs niveaux de risque. \n  La première catégorie est celle des dispositifs médicaux à faible risque, \ndont la sécurité et l’efficacité peuvent être garanties par une gestion de \nroutine. \n  La deuxième catégorie est celle des dispositifs médicaux présentant des \nrisques modérés qui nécessitent un contrôle et une gestion stricts pour \ngarantir leur sécurité et leur efficacité. \n  La troisième catégorie est celle des dispositifs médicaux qui présentent \ndes risques plus élevés et nécessitent des mesures spéciales de contrôle et de \ngestion strictes pour garantir leur sécurité et leur efficacité. \n  Lors de l’évaluation du niveau de risque d’un dispositif médical, des \nfacteurs tels que l’usage prévu, les caractéristiques structurelles et la \nméthode d’utilisation du dispositif médical doivent être pris en compte. \n  Le département de surveillance et d'administration des médicaments du \nConseil des Affaires d'État est chargé de formuler les règles de classification et \nles catalogues de classification des dispositifs médicaux, et doit analyser et \névaluer rapidement les changements dans les risques des dispositifs médicaux \net ajuster les règles de classification et les catalogues de classification en \nfonction de la production, du fonctionnement et de l'utilisation des dispositifs \nmédicaux. Lors de la formulation et de l’ajustement des règles de \nclassification et des catalogue",
    "(FDA)_97050-2024-20081.pdf": "This section of the FEDERAL REGISTER\ncontains regulatory documents having general\napplicability and legal effect, most of which\nare keyed to and codified in the Code of\nFederal Regulations, which is published under\n50 titles pursuant to 44 U.S.C. 1510.\nThe Code of Federal Regulations is sold by\nthe Superintendent of Documents.\nRules and Regulations\nFederal Register\n72715 \nVol. 89, No. 173 \nFriday, September 6, 2024 \nDEPARTMENT OF HEALTH AND \nHUMAN SERVICES \nFood and Drug Administration \n21 CFR Part 876 \n[Docket No. FDA–2024–N–3972] \nMedical Devices; Gastroenterology- \nUrology Devices; Classification of the \nHemodialyzer With Expanded Solute \nRemoval Profile \nAGENCY: Food and Drug Administration, \nHHS. \nACTION: Final amendment; final order. \nSUMMARY: The Food and Drug \nAdministration (FDA or we) is \nclassifying the hemodialyzer with \nexpanded solute removal profile into \nclass II (special controls). The special \ncontrols that apply to the device type \nare identified in this order and will be \npart of the codified language for the \nhemodialyzer with expanded solute \nremoval profile’s classification. We are \ntaking this action because we have \ndetermined that classifying the device \ninto class II (special controls) will \nprovide a reasonable assurance of safety \nand effectiveness of the device. We \nbelieve this action will also enhance \npatients’ access to beneficial innovative \ndevices. \nDATES: This order is effective September \n6, 2024. The classification was \napplicable on August 28, 2020. \nFOR FURTHER INFORMATION CONTACT: Jade \nNoble, Center for Devices and \nRadiological Health, Food and Drug \nAdministration, 10903 New Hampshire \nAve., Bldg. 66, Rm. 2684, Silver Spring, \nMD 20993–0002, 240–402–5077, \nJade.Noble@fda.hhs.gov. \nSUPPLEMENTARY INFORMATION: \nI. Background \nUpon request, FDA has classified the \nhemodialyzer with expanded solute \nremoval profile as class II (special \ncontrols), which we have determined \nwill provide a reasonable assurance of \nsafety and effectiveness. \nThe automatic assignment of class III \noccurs by operation of law and without \nany action by FDA, regardless of the \nlevel of risk posed by the new device. \nAny device that was not in commercial \ndistribution before May 28, 1976, is \nautomatically classified as, and remains \nwithin, class III and requires premarket \napproval unless and until FDA takes an \naction to classify or reclassify the device \n(see 21 U.S.C. 360c(f)(1)). We refer to \nthese devices as ‘‘postamendments \ndevices’’ because they were not in \ncommercial distribution prior to the \ndate of enactment of the Medical Device \nAmendments of 1976, which amended \nthe Federal Food, Drug, and Cosmetic \nAct (FD&C Act). \nFDA may take a variety of actions in \nappropriate circumstances to classify or \nreclassify a device into class I or II. We \nmay issue an order finding a new device \nto be substantially equivalent under \nsection 513(i) of the FD&C Act (see 21 \nU.S.C. 360c(i)) to a predicate device that \ndoes not require premarket approval. \nWe determine whether a new device is \nsubstantially equivalent to a predicate \ndevice by means of the procedures for \npremarket notification under section \n510(k) of the FD&C Act (21 U.S.C. \n360(k)) and part 807 (21 CFR part 807). \nFDA may also classify a device \nthrough ‘‘De Novo’’ classification, a \ncommon name for the process \nauthorized under section 513(f)(2) of the \nFD&C Act (see also part 860, subpart D \n(21 CFR part 860, subpart D)). Section \n207 of the Food and Drug \nAdministration Modernization Act of \n1997 (Pub. L. 105–115) established the \nfirst procedure for De Novo \nclassification. Section 607 of the Food \nand Drug Administration Safety and \nInnovation Act (Pub. L. 112–144) \nmodified the De Novo application \nprocess by adding a second procedure. \nA device sponsor may utilize either \nprocedure for De Novo classification. \nUnder the first procedure, the person \nsubmits a 510(k) for a device that has \nnot previously been classified. After \nreceiving an order from FDA classifying \nthe device into class III under section \n513(f)(1) of the FD&C Act, the person \nthen requests a classification under \nsection 513(f)(2). \nUnder the second procedure, rather \nthan first submitting a 510(k) and then \na request for classification, if the person \ndetermines that there is no legally \nmarketed device upon which to base a \ndetermination of substantial \nequivalence, that person requests a \nclassification under section 513(f)(2) of \nthe FD&C Act. \nUnder either procedure for De Novo \nclassification, FDA is required to \nclassify the device by written order \nwithin 120 days. The classification will \nbe according to the criteria under \nsection 513(a)(1) of the FD&C Act. \nAlthough the device was automatically \nplaced within class III, the De Novo \nclassification is considered to be the \ninitial classification of the device. \nWhen FDA classifies a device into \nclass I or II via the De Novo process, the \ndevice can serve as a predicate for \nfuture devices ",
    "(FDA)_crrection_.pdf": "4164-01-P\nDEPARTMENT OF HEALTH AND HUMAN SERVICES\nFood and Drug Administration\n21 CFR Part 820 \n[Docket No. FDA-2021-N-0507]\nRIN 0910-AH99\nMedical Devices; Quality System Regulation Amendments; Correction\nAGENCY:  Food and Drug Administration, HHS.\nACTION:  Final rule; correction.\nSUMMARY:  The Food and Drug Administration (FDA or Agency) is correcting a final rule \nthat appeared in the Federal Register on February 2, 2024.  In that final rule, FDA amended the \ndevice current good manufacturing practice (CGMP) requirements of the Quality System (QS) \nregulation to harmonize and modernize the device CGMP.  FDA is correcting an editorial error \nthat inadvertently omitted a definition in the codified of the final rule.  This action is editorial in \nnature and is intended to ensure the accuracy and clarity of the Agency’s regulations. \nDATES:  Effective February 2, 2026.\nFOR FURTHER INFORMATION CONTACT:  Laurie Sternberg, Center for Devices and \nRadiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. \n5517, Silver Spring, MD 20993-0002, 240-402-0425.\nSUPPLEMENTARY INFORMATION:  In the Federal Register of February 2, 2024 (89 FR \n7496), FDA published a final rule that amended the device CGMPs requirements in 21 CFR part \n820.  The preamble indicated that the definition for “batch” or “lot” was set forth at § 820.3 (21 \nCFR 820.3) but the definition for “batch” or “lot” was inadvertently omitted from the codified \nportion of § 820.3 in the final rule.  FDA is, therefore, correcting the codified for § 820.3 to \ninclude the definition of “batch” or “lot” as was intended and to be consistent with the preamble \nof the final rule. \nThis document is scheduled to be published in the\nFederal Register on 10/15/2024 and available online at\nhttps://federalregister.gov/d/2024-23701, and on https://govinfo.gov\n\nIn FR Doc. 2024-01709 appearing on page 7524 in the Federal Register of Friday, \nFebruary 2, 2024 (89 FR 7496), the following correction is made: \n§ 820.3 [Corrected]\n1.  On page 7524, in amendment number 4, in the first column, in paragraph (a) of \n§ 820.3, the definition for “Batch or lot” is added in alphabetical order to read as follows:\n“Batch or lot means one or more components or finished devices that consist of a single \ntype, model, class, size, composition, or software version that are manufactured under essentially \nthe same conditions and that are intended to have uniform characteristics and quality within \nspecified limits.”\nDated:  October 7, 2024.\nKimberlee Trzeciak, \nDeputy Commissioner for Policy, Legislation, and International Affairs.\n[FR Doc. 2024-23701 Filed: 10/11/2024 8:45 am; Publication Date:  10/15/2024]",
    "(FDA)1080.pdf": "48711 \nFederal Register / Vol. 83, No. 188 / Thursday, September 27, 2018 / Rules and Regulations \n(2) Accomplishment of the actions required \nby paragraph (g) of this AD terminates the \nrequirements of paragraph (h) of AD 2013– \n24–07. \n(k) Alternative Methods of Compliance \n(AMOCs) \n(1) The Manager, Los Angeles ACO Branch, \nFAA, has the authority to approve AMOCs \nfor this AD, if requested using the procedures \nfound in 14 CFR 39.19. In accordance with \n14 CFR 39.19, send your request to your \nprincipal inspector or local Flight Standards \nDistrict Office, as appropriate. If sending \ninformation directly to the manager of the \ncertification office, send it to the attention of \nthe person identified in paragraph (l) of this \nAD. Information may be emailed to: 9-AWP- \nLAACO-ADS@faa.gov. \n(2) Before using any approved AMOC, \nnotify your appropriate principal inspector, \nor lacking a principal inspector, the manager \nof the local flight standards district office/ \ncertificate holding district office. \n(3) An AMOC that provides an acceptable \nlevel of safety may be used for any repair, \nmodification, or alteration required by this \nAD if it is approved by the Boeing \nCommercial Airplanes Organization \nDesignation Authorization (ODA) that has \nbeen authorized by the Manager, Los Angeles \nACO Branch, to make those findings. To be \napproved, the repair method, modification \ndeviation, or alteration deviation must meet \nthe certification basis of the airplane, and the \napproval must specifically refer to this AD. \n(l) Related Information \nFor more information about this AD, \ncontact Samuel Lee, Aerospace Engineer, \nPropulsion Section, FAA, Los Angeles ACO \nBranch, 3960 Paramount Boulevard, \nLakewood, CA 90712–4137; phone: 562–627– \n5262; fax: 562–627–5210; email: samuel.lee@\nfaa.gov. \n(m) Material Incorporated by Reference \n(1) The Director of the Federal Register \napproved the incorporation by reference \n(IBR) of the service information listed in this \nparagraph under 5 U.S.C. 552(a) and 1 CFR \npart 51. \n(2) You must use this service information \nas applicable to do the actions required by \nthis AD, unless the AD specifies otherwise. \n(i) Boeing 707/720 Airworthiness \nLimitations (AWLs), D6–7552–AWL, dated \nOctober 2016. (Subsection A.2 of this \ndocument includes pages 33 and 34, which \nare not identified in the Table of Contents.) \n(ii) Reserved. \n(3) For service information identified in \nthis AD, contact Boeing Commercial \nAirplanes, Attention: Contractual & Data \nServices (C&DS), 2600 Westminster Blvd., \nMC 110–SK57, Seal Beach, CA 90740–5600; \ntelephone: 562–797–1717; internet: https://\nwww.myboeingfleet.com. \n(4) You may view this service information \nat the FAA, Transport Standards Branch, \n2200 South 216th St., Des Moines, WA. For \ninformation on the availability of this \nmaterial at the FAA, call 206–231–3195. \n(5) You may view this service information \nthat is incorporated by reference at the \nNational Archives and Records \nAdministration (NARA). For information on \nthe availability of this material at NARA, call \n202–741–6030, or go to: http://\nwww.archives.gov/federal-register/cfr/ibr- \nlocations.html. \nIssued in Des Moines, Washington, on \nSeptember 10, 2018. \nMichael Kaszycki, \nActing Director, System Oversight Division, \nAircraft Certification Service. \n[FR Doc. 2018–20631 Filed 9–26–18; 8:45 am] \nBILLING CODE 4910–13–P \nDEPARTMENT OF HEALTH AND \nHUMAN SERVICES \nFood and Drug Administration \n21 CFR Part 884 \n[Docket No. FDA–2017–N–6538] \nObstetrical and Gynecological \nDevices; Reclassification of Single-Use \nFemale Condom, To Be Renamed \nSingle-Use Internal Condom \nAGENCY: Food and Drug Administration, \nHHS. \nACTION: Final order. \nSUMMARY: The Food and Drug \nAdministration (FDA or the Agency) is \nissuing a final order to reclassify single- \nuse female condoms, renaming the \ndevice to ‘‘single-use internal condom,’’ \na postamendments class III device \n(regulated under product code MBU), \ninto class II (special controls) subject to \npremarket notification (510(k)). FDA is \nalso identifying the special controls that \nthe Agency believes are necessary to \nprovide a reasonable assurance of safety \nand effectiveness of the device. FDA is \nfinalizing this reclassification on its \nown initiative based on new \ninformation. FDA is also amending the \nexisting device identification for \n‘‘female condom,’’ a preamendments \nclass III device (product code OBY), by \nrenaming the device ‘‘multiple-use \nfemale condom,’’ to distinguish it from \nthe ‘‘single-use internal condom.’’ This \norder reclassifies single-use internal \ncondoms from class III to class II and \nreduces regulatory burden because these \ntypes of devices will no longer be \nrequired to submit a premarket approval \napplication (PMA), but can instead \nsubmit a less burdensome 510(k) before \nmarketing their device. \nDATES: This order is effective October \n29, 2018. \nFOR FURTHER INFORMATION CONTACT: \nMonica Garcia, Center for Devices and \nRadiological Hea",
    "(FDA)2022-03227.pdf": "4164-01-P\nDEPARTMENT OF HEALTH AND HUMAN SERVICES \nFood and Drug Administration\n21 CFR Parts 4 and 820\n[Docket No. FDA-2021-N-0507]\nRIN 0910-AH99\nMedical Devices; Quality System Regulation Amendments \nAGENCY:  Food and Drug Administration, HHS. \nACTION:  Proposed rule.\nSUMMARY:  The Food and Drug Administration (FDA, the Agency, or we) is proposing to \namend the device current good manufacturing practice (CGMP) requirements of the Quality \nSystem (QS) Regulation to align more closely with the international consensus standard for \ndevices by converging with the quality management system (QMS) requirements used by other \nregulatory authorities from other jurisdictions (i.e., other countries).  We propose to do so \nthrough incorporating by reference an international standard specific for device quality \nmanagement systems set by the International Organization for Standardization (ISO), the 2016 \nedition of ISO 13485 (ISO 13485).  Through this rulemaking we also propose additional \nrequirements to align with existing requirements in the Federal Food, Drug, and Cosmetic Act \n(FD&C Act) and its implementing regulations, and make conforming edits to the Code of \nFederal Regulations (CFR) to clarify the device CGMP requirements for combination products.  \nThis action, if finalized, will continue our efforts to align our regulatory framework with that \nused by other regulatory authorities to promote consistency in the regulation of devices and \nprovide timelier introduction of safe, effective, high-quality devices for patients.\nDATES:  Submit either electronic or written comments on the proposed rule by [INSERT \nDATE 90 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].  \nSubmit written comments (including recommendations) on the collection of information under \nThis document is scheduled to be published in the\nFederal Register on 02/23/2022 and available online at\nfederalregister.gov/d/2022-03227, and on govinfo.gov\n\nthe Paperwork Reduction Act of 1995 (PRA) by [INSERT DATE 30 DAYS AFTER DATE \nOF PUBLICATION IN THE FEDERAL REGISTER]. \nADDRESSES:  You may submit comments as follows.  Please note that late, untimely filed \ncomments will not be considered.  Electronic comments must be submitted on or before \n[INSERT DATE 90 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL \nREGISTER].  The https://www.regulations.gov electronic filing system will accept comments \nuntil 11:59 p.m. Eastern Time at the end of [INSERT DATE 90 DAYS AFTER DATE OF \nPUBLICATION IN THE FEDERAL REGISTER].  Comments received by mail/hand \ndelivery/courier (for written/paper submissions) will be considered timely if they are \npostmarked or the delivery service acceptance receipt is on or before that date.  \nElectronic Submissions\nSubmit electronic comments in the following way:\n•\nFederal eRulemaking Portal:  https://www.regulations.gov.  Follow the instructions for \nsubmitting comments.  Comments submitted electronically, including attachments, to \nhttps://www.regulations.gov will be posted to the docket unchanged.  Because your \ncomment will be made public, you are solely responsible for ensuring that your comment \ndoes not include any confidential information that you or a third party may not wish to \nbe posted, such as medical information, your or anyone else’s Social Security number, or \nconfidential business information, such as a manufacturing process.  Please note that if \nyou include your name, contact information, or other information that identifies you in \nthe body of your comments, that information will be posted on \nhttps://www.regulations.gov. \n•\nIf you want to submit a comment with confidential information that you do not wish to \nbe made available to the public, submit the comment as a written/paper submission and \nin the manner detailed (see “Written/Paper Submissions” and “Instructions”).\nWritten/Paper Submissions\n\nSubmit written/paper submissions as follows:\n•\nMail/Hand delivery/Courier (for written/paper submissions):  Dockets Management Staff \n(HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, \nMD 20852.\n•\nFor written/paper comments submitted to the Dockets Management Staff, FDA will post \nyour comment, as well as any attachments, except for information submitted, marked and \nidentified, as confidential, if submitted as detailed in “Instructions.”\nInstructions:  All submissions received must include the Docket No. FDA-2021-N-0507 \nfor “Medical Devices; Quality System Regulation Amendments.”  Received comments, those \nfiled in a timely manner (see ADDRESSES), will be placed in the docket and, except for those \nsubmitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or \nat the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-\n7500.\n•\nConfidential Submissions--To submit a comment with confidential information that you \ndo not wish to be made publicly available, submit your comments only as a written/paper \nsubmission.  You should ",
    "(FDA)74813-CFR-2023-title21-vol8-part820.pdf": "170 \n21 CFR Ch. I (4–1–23 Edition) \n§ 814.126 \nmay be administered without prior ap-\nproval by an IRB. In such an emer-\ngency situation, the physician shall, \nwithin 5 days after the use of the de-\nvice, provide written notification to \nthe chairman of the IRB of such use. \nSuch written notification shall include \nthe identification of the patient in-\nvolved, the date on which the device \nwas used, and the reason for the use. \n(b) Withdrawal of IRB approval. A \nholder of an approved HDE shall notify \nFDA of any withdrawal of approval for \nthe use of a HUD by a reviewing IRB \nwithin 5 working days after being noti-\nfied of the withdrawal of approval. \n[61 FR 33244, June 26, 1996, as amended at 63 \nFR 59221, Nov. 3, 1998; 82 FR 26349, June 7, \n2017] \n§ 814.126\nPostapproval \nrequirements \nand reports. \n(a) An HDE approved under this sub-\npart H shall be subject to the post-\napproval requirements and reports set \nforth under subpart E of this part, as \napplicable, \nwith \nthe \nexception \nof \n§ 814.82(a)(7). In addition, medical de-\nvice reports submitted to FDA in com-\npliance with the requirements of part \n803 of this chapter shall also be sub-\nmitted to the IRB of record. \n(b) In addition to the reports identi-\nfied in paragraph (a) of this section, \nthe holder of an approved HDE shall \nprepare and submit the following com-\nplete, accurate, and timely reports: \n(1) Periodic reports. An HDE applicant \nis required to submit reports in accord-\nance with the approval order. Unless \nFDA specifies otherwise, any periodic \nreport shall include: \n(i) An update of the information re-\nquired under § 814.102(a) in a separately \nbound volume; \n(ii) An update of the information re-\nquired under § 814.104(b)(2), (b)(3), and \n(b)(5); \n(iii) The number of devices that have \nbeen shipped or sold since initial mar-\nketing approval under this subpart H \nand, if the number shipped or sold ex-\nceeds 8,000, an explanation and esti-\nmate of the number of devices used per \npatient. If a single device is used on \nmultiple patients, the applicant shall \nsubmit an estimate of the number of \npatients treated or diagnosed using the \ndevice together with an explanation of \nthe basis for the estimate; \n(iv) Information describing the appli-\ncant’s clinical experience with the de-\nvice since the HDE was initially ap-\nproved. This information shall include \nsafety information that is known or \nreasonably should be known to the ap-\nplicant, medical device reports made \nunder part 803 of this chapter, any data \ngenerated \nfrom \nthe \npostmarketing \nstudies, and information (whether pub-\nlished or unpublished) that is known or \nreasonably expected to be known by \nthe applicant that may affect an eval-\nuation of the safety of the device or \nthat may affect the statement of con-\ntraindications, warnings, precautions, \nand adverse reactions in the device’s \nlabeling; and \n(v) A summary of any changes made \nto the device in accordance with sup-\nplements submitted under § 814.108. If \ninformation provided in the periodic \nreports, or any other information in \nthe possession of FDA, gives the agen-\ncy reason to believe that a device \nraises public health concerns or that \nthe criteria for exemption are no \nlonger met, the agency may require the \nHDE holder to submit additional infor-\nmation to demonstrate continued com-\npliance with the HDE requirements. \n(2) Other. An HDE holder shall main-\ntain records of the names and addresses \nof the facilities to which the HUD has \nbeen shipped, correspondence with re-\nviewing IRB’s, as well as any other in-\nformation requested by a reviewing \nIRB or FDA. Such records shall be \nmaintained in accordance with the \nHDE approval order. \n[61 FR 33244, June 26, 1996, as amended at 63 \nFR 59221, Nov. 3, 1998; 71 FR 16228, Mar. 31, \n2006; 82 FR 26349, June 7, 2017] \nPART 820—QUALITY SYSTEM \nREGULATION \nSubpart A—General Provisions \nSec. \n820.1\nScope. \n820.3\nDefinitions. \n820.5\nQuality system. \nSubpart B—Quality System Requirements \n820.20\nManagement responsibility. \n820.22\nQuality audit. \nVerDate Sep<11>2014 \n15:46 Jun 06, 2023\nJkt 259078\nPO 00000\nFrm 00180\nFmt 8010\nSfmt 8010\nQ:\\21\\21V8.TXT\nPC31\naworley on LAPBH6H6L3 with DISTILLER\n\n171 \nFood and Drug Administration, HHS \n§ 820.1 \n820.25\nPersonnel. \nSubpart C—Design Controls \n820.30\nDesign controls. \nSubpart D—Document Controls \n820.40\nDocument controls. \nSubpart E—Purchasing Controls \n820.50\nPurchasing controls. \nSubpart F—Identification and Traceability \n820.60\nIdentification. \n820.65\nTraceability. \nSubpart G—Production and Process \nControls \n820.70\nProduction and process controls. \n820.72\nInspection, \nmeasuring, \nand \ntest \nequipment. \n820.75\nProcess validation. \nSubpart H—Acceptance Activities \n820.80\nReceiving, in-process, and finished \ndevice acceptance. \n820.86\nAcceptance status. \nSubpart I—Nonconforming Product \n820.90\nNonconforming product. \nSubpart J—Corrective and Preventive \nAction \n820.100\nCorrective and preventive action. \nSubpart K—Labeling and Packaging \n",
    "(FDA)74907-2024-01709.pdf": "4164-01-P\nDEPARTMENT OF HEALTH AND HUMAN SERVICES\nFood and Drug Administration\n21 CFR Parts 4 and 820\n[Docket No. FDA-2021-N-0507]\nRIN 0910-AH99\nMedical Devices; Quality System Regulation Amendments\nAGENCY:  Food and Drug Administration, HHS.\nACTION:  Final rule.\nSUMMARY:  The Food and Drug Administration (FDA, the Agency, or we) is issuing a final \nrule to amend the device current good manufacturing practice (CGMP) requirements of the \nQuality System (QS) regulation to harmonize and modernize the regulation. We are \nharmonizing to align more closely with the international consensus standard for devices by \nconverging with the quality management system (QMS) requirements used by other regulatory \nauthorities from other jurisdictions (i.e., other countries).  We are doing so by incorporating by \nreference an international standard specific for device quality management systems.  Through \nthis rulemaking we also establish additional requirements and make conforming edits to clarify \nthe device CGMP requirements for such products.  This action will continue our efforts to align \nour regulatory framework with that used by regulatory authorities in other jurisdictions to \npromote consistency in the regulation of devices and provide timelier introduction of safe, \neffective, high-quality devices for patients.\nDATES:  This rule is effective February 2, 2026.  The incorporation by reference of certain \nmaterial listed in this rule is approved by the Director of the Federal Register February 2, 2026.\nADDRESSES:  For access to the docket to read background documents or comments received, \ngo to https://www.regulations.gov and insert the docket number found in brackets in the heading \nThis document is scheduled to be published in the\nFederal Register on 02/02/2024 and available online at\nhttps://federalregister.gov/d/2024-01709, and on https://govinfo.gov\n\nof this final rule into the “Search” box and follow the prompts, and/or go to the Dockets \nManagement Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.  \nFOR FURTHER INFORMATION CONTACT:  With regard to the final rule:  Keisha Thomas \nor Melissa Torres, Center for Devices and Radiological Health, Food and Drug Administration, \n10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-2001, Proposed-Device-\nQMSR-Rule@fda.hhs.gov.\nWith regard to the information collection:  Amber Sanford, Office of Operations, Food \nand Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North \nBethesda, MD 20852, 301-796-8867, PRAStaff@fda.hhs.gov.\nSUPPLEMENTARY INFORMATION: \nTable of Contents\nI.  Executive Summary\nA.  Purpose of the Final Rule\nB.  Summary of the Major Provisions of the Final Rule\nC.  Legal Authority\nD.  Costs and Benefits\nII.  Table of Abbreviations/Commonly Used Acronyms in This Document\nIII.  Background \nA. Introduction \nB. Need for the Regulation\nC. FDA’s Current Regulatory Framework\nD. History of This Rulemaking\nE. Summary of Comments to the Proposed Rule \nF.  General Overview of Final Rule \nG.  Incorporation by Reference \nIV.  Legal Authority \n\nV.  Comments on the Proposed Rule and FDA’s Responses \nA.  General Comments on Proposed Rule\nB.  Scope\nC.  Incorporation by Reference\nD.  Definitions\nE.  Requirement for a Quality Management System\nF.  Clarification of Concepts\nG.  Supplementary Provisions\nH.  Conforming Amendments and FDA Response\nVI.  Effective Date and Implementation Strategy\nA.  Effective Date\nB.  Implementation Strategy\nVII.  Economic Analysis of Impacts\nVIII.  Analysis of Environmental Impact\nIX.  Paperwork Reduction Act of 1995\nX.  Federalism\nXI.  Consultation and Coordination with Indian Tribal Governments\nXII.  References\nI.  Executive Summary\nA.  Purpose of the Final Rule\nFDA has historically recognized the benefits of harmonization with other regulatory \nauthorities and, over time, has taken a number of actions to promote consistency with its \nregulatory counterparts.  As part of such activities, FDA is revising its medical device CGMP \nrequirements as set forth in the QS regulation, codified in part 820 (21 CFR part 820).  FDA is \naccomplishing this primarily by incorporating by reference the 2016 edition of ISO 13485 (ISO \n\n13485).  Through this rulemaking, FDA is harmonizing quality management system \nrequirements for medical devices with requirements used by other regulatory authorities.\nB.  Summary of the Major Provisions of the Final Rule\nWe are amending part 820, primarily through incorporating by reference the quality \nmanagement system requirements of ISO 13485.1  We have determined that the requirements in \nISO 13485 are, when taken in totality, substantially similar to the requirements of the QS \nregulation, providing a similar level of assurance in a firm’s quality management system and \nability to consistently manufacture devices that are safe and effective and otherwise in \ncompliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act).  As such, we are \nretaining the scope of th",
    "(FDA)90530-2024-11564.pdf": "47074 \nFederal Register / Vol. 89, No. 106 / Friday, May 31, 2024 / Rules and Regulations \nexecuting the RNAV (GPS) RWY 27 \napproach. \nIn addition, the existing Class E \nairspace extending upward from 1,200 \nfeet above the surface is removed, as the \narea is already within the Coaldale Class \nE en route domestic airspace area. \nFinally, the FAA is modifying the \nairport’s legal descriptions. The airport \nname within the text headers of both \nairspace legal descriptions, and any \nreference within the bodies, are changed \nto match the new airport name, \nMammoth Yosemite Airport (formerly \nMammoth Lakes Airport). The \ngeographic coordinates located in the \ntext header of both airspace legal \ndescriptions are updated to match the \nFAA’s database. \nRegulatory Notices and Analyses \nThe FAA has determined that this \nregulation only involves an established \nbody of technical regulations for which \nfrequent and routine amendments are \nnecessary to keep them operationally \ncurrent. It, therefore: (1) is not a \n‘‘significant regulatory action’’ under \nExecutive Order 12866; (2) is not a \n‘‘significant rule’’ under DOT \nRegulatory Policies and Procedures (44 \nFR 11034; February 26, 1979); and (3) \ndoes not warrant preparation of a \nregulatory evaluation as the anticipated \nimpact is so minimal. Since this is a \nroutine matter that only affects air traffic \nprocedures and air navigation, it is \ncertified that this rule, when \npromulgated, does not have a significant \neconomic impact on a substantial \nnumber of small entities under the \ncriteria of the Regulatory Flexibility Act. \nEnvironmental Review \nThe FAA has determined that this \naction qualifies for categorical exclusion \nunder the National Environmental \nPolicy Act in accordance with FAA \nOrder 1050.1F, ‘‘Environmental \nImpacts: Policies and Procedures,’’ \nparagraph 5–6.5.a. This airspace action \nis not expected to cause any potentially \nsignificant environmental impacts, and \nno extraordinary circumstances exist \nthat warrant preparation of an \nenvironmental assessment. \nList of Subjects in 14 CFR Part 71 \nAirspace, Incorporation by reference, \nNavigation (air). \nThe Amendment \nIn consideration of the foregoing, the \nFederal Aviation Administration \namends 14 CFR part 71 as follows: \nPART 71—DESIGNATION OF CLASS A, \nB, C, D, AND E AIRSPACE AREAS; AIR \nTRAFFIC SERVICE ROUTES; AND \nREPORTING POINTS \n■1. The authority citation for 14 CFR \npart 71 continues to read as follows: \nAuthority: 49 U.S.C. 106(f), 106(g), 40103, \n40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, \n1959–1963 Comp., p. 389. \n§ 71.1\n[Amended] \n■2. The incorporation by reference in \n14 CFR 71.1 of FAA Order JO 7400.11H, \nAirspace Designations and Reporting \nPoints, dated August 11, 2023, and \neffective September 15, 2023, is \namended as follows: \nParagraph 6002\nClass E Airspace Areas \nDesignated as Surface Areas. \n* \n* \n* \n* \n* \nAWP CA E2\nMammoth Lakes, CA \n[Amended] \nMammoth Yosemite Airport, CA \n(Lat. 37°37′27″ N, long. 118°50′20″ W) \nThat airspace within a 4.1-mile radius of \nMammoth Yosemite Airport and within 1 \nmile either side of the airport’s 096° bearing \nextending from the 4.1-mile radius to 4.6 \nmiles east of the airport. \n* \n* \n* \n* \n* \nParagraph 6005\nClass E Airspace Areas \nExtending Upward From 700 Feet or More \nAbove the Surface of the Earth. \n* \n* \n* \n* \n* \nAWP CA E5\nMammoth Lakes, CA \n[Amended] \nMammoth Yosemite Airport, CA \n(Lat. 37°37′27″ N, long. 118°50′20″ W) \nThat airspace extending upward from 700 \nfeet above the surface within a 6.6-mile \nradius of the Mammoth Yosemite Airport and \nwithin 2.6 miles either side of the airport’s \n091° bearing, extending from the 6.6-mile \nradius to 13.1 miles east. \n* \n* \n* \n* \n* \nIssued in Des Moines, Washington, on May \n24, 2024. \nPaul J Higgins, \nGroup Manager (A), Operations Support \nGroup, Western Service Center. \n[FR Doc. 2024–11894 Filed 5–30–24; 8:45 am] \nBILLING CODE 4910–13–P \nDEPARTMENT OF HEALTH AND \nHUMAN SERVICES \nFood and Drug Administration \n21 CFR Part 1 \n[Docket No. FDA–2021–N–1348] \nRIN 0910–AI59 \nAdministrative Destruction \nAGENCY: Food and Drug Administration, \nHHS. \nACTION: Final rule. \nSUMMARY: The Food and Drug \nAdministration (FDA, Agency, or we) is \nissuing a regulation to implement our \nauthority to destroy a device valued at \n$2,500 or less (or such higher amount as \nthe Secretary of the Treasury may set by \nregulation) that has been refused \nadmission into the United States by \nproviding to the owner or consignee \nnotice and an opportunity to appear and \nintroduce testimony prior to the \ndestruction. We are finalizing the \nchange to our internal procedures for \nadministrative destruction of drugs and \ndevices. The notice of proposed rule \nmaking (NPRM) published in the \nFederal Register (October 7, 2022). \nDATES: This rule is effective July 1, \n2024. \nADDRESSES: For access to the docket to \nread background documents or \ncomments received, go to https://\nwww.regulations.gov and insert the \ndocket number found in brack",
    "(FDA)96972-2024-19882.pdf": "72322 \nFederal Register / Vol. 89, No. 172 / Thursday, September 5, 2024 / Rules and Regulations \n1 FDA notes that the ‘‘ACTION’’ caption for this \nfinal order is styled as ‘‘Final amendment; final \norder,’’ rather than ‘‘Final order.’’ Beginning in \nDecember 2019, this editorial change was made to \nindicate that the document ‘‘amends’’ the Code of \nFederal Regulations. The change was made in \naccordance with the Office of Federal Register’s \n(OFR) interpretations of the Federal Register Act (44 \nU.S.C. chapter 15), its implementing regulations (1 \nCFR 5.9 and parts 21 and 22), and the Document \nDrafting Handbook. \nDEPARTMENT OF HEALTH AND \nHUMAN SERVICES \nFood and Drug Administration \n21 CFR Part 886 \n[Docket No. FDA–2024–N–3970] \nMedical Devices; Ophthalmic Devices; \nClassification of the Hydrophilic Re- \nCoating Solution \nAGENCY: Food and Drug Administration, \nHHS. \nACTION: Final amendment; final order. \nSUMMARY: The Food and Drug \nAdministration (FDA, Agency, or we) is \nclassifying the hydrophilic re-coating \nsolution into class II (special controls). \nThe special controls that apply to the \ndevice type are identified in this order \nand will be part of the codified language \nfor the hydrophilic re-coating solution’s \nclassification. We are taking this action \nbecause we have determined that \nclassifying the device into class II \n(special controls) will provide a \nreasonable assurance of safety and \neffectiveness of the device. We believe \nthis action will also enhance patients’ \naccess to beneficial innovative devices. \nDATES: This order is effective September \n5, 2024. The classification was \napplicable on September 24, 2020. \nFOR FURTHER INFORMATION CONTACT: \nElissa Wong, Center for Devices and \nRadiological Health, Food and Drug \nAdministration, 10903 New Hampshire \nAve., Bldg. 66, Rm. 1246, Silver Spring, \nMD 20993–0002, 240–402–0204, \nElissa.Wong@fda.hhs.gov. \nSUPPLEMENTARY INFORMATION: \nI. Background \nUpon request, FDA has classified the \nhydrophilic re-coating solution as class \nII (special controls), which we have \ndetermined will provide a reasonable \nassurance of safety and effectiveness. \nThe automatic assignment of class III \noccurs by operation of law and without \nany action by FDA, regardless of the \nlevel of risk posed by the new device. \nAny device that was not in commercial \ndistribution before May 28, 1976, is \nautomatically classified as, and remains \nwithin, class III and requires premarket \napproval unless and until FDA takes an \naction to classify or reclassify the device \n(see 21 U.S.C. 360c(f)(1)). We refer to \nthese devices as ‘‘postamendments \ndevices’’ because they were not in \ncommercial distribution prior to the \ndate of enactment of the Medical Device \nAmendments of 1976, which amended \nthe Federal Food, Drug, and Cosmetic \nAct (FD&C Act). \nFDA may take a variety of actions in \nappropriate circumstances to classify or \nreclassify a device into class I or II. We \nmay issue an order finding a new device \nto be substantially equivalent under \nsection 513(i) of the FD&C Act (see 21 \nU.S.C. 360c(i)) to a predicate device that \ndoes not require premarket approval. \nWe determine whether a new device is \nsubstantially equivalent to a predicate \ndevice by means of the procedures for \npremarket notification under section \n510(k) of the FD&C Act (21 U.S.C. \n360(k)) and part 807 (21 CFR part 807). \nFDA may also classify a device \nthrough ‘‘De Novo’’ classification, a \ncommon name for the process \nauthorized under section 513(f)(2) of the \nFD&C Act (see also part 860, subpart D \n(21 CFR part 860, subpart D)). Section \n207 of the Food and Drug \nAdministration Modernization Act of \n1997 (Pub. L. 105–115) established the \nfirst procedure for De Novo \nclassification. Section 607 of the Food \nand Drug Administration Safety and \nInnovation Act (Pub. L. 112–144) \nmodified the De Novo application \nprocess by adding a second procedure. \nA device sponsor may utilize either \nprocedure for De Novo classification. \nUnder the first procedure, the person \nsubmits a 510(k) for a device that has \nnot previously been classified. After \nreceiving an order from FDA classifying \nthe device into class III under section \n513(f)(1) of the FD&C Act, the person \nthen requests a classification under \nsection 513(f)(2). \nUnder the second procedure, rather \nthan first submitting a 510(k) and then \na request for classification, if the person \ndetermines that there is no legally \nmarketed device on which to base a \ndetermination of substantial \nequivalence, that person requests a \nclassification under section 513(f)(2) of \nthe FD&C Act. \nUnder either procedure for De Novo \nclassification, FDA is required to \nclassify the device by written order \nwithin 120 days. The classification will \nbe according to the criteria under \nsection 513(a)(1) of the FD&C Act. \nAlthough the device was automatically \nplaced within class III, the De Novo \nclassification is considered to be the \ninitial classification of the device. \nWhen F",
    "(FDA)96973-2024-19868.pdf": "72320 \nFederal Register / Vol. 89, No. 172 / Thursday, September 5, 2024 / Rules and Regulations \n1 FDA notes that the ‘‘ACTION’’ caption for this \nfinal order is styled as ‘‘Final amendment; final \norder,’’ rather than ‘‘Final order.’’ Beginning in \nDecember 2019, this editorial change was made to \nindicate that the document ‘‘amends’’ the Code of \nFederal Regulations. The change was made in \naccordance with the Office of Federal Register’s \n(OFR) interpretations of the Federal Register Act (44 \nU.S.C. chapter 15), its implementing regulations (1 \nCFR 5.9 and parts 21 and 22), and the Document \nDrafting Handbook. \nDEPARTMENT OF HEALTH AND \nHUMAN SERVICES \nFood and Drug Administration \n21 CFR Part 872 \n[Docket No. FDA–2024–N–3973] \nMedical Devices; Dental Devices; \nClassification of the Radiofrequency \nToothbrush \nAGENCY: Food and Drug Administration, \nHHS. \nACTION: Final amendment; final order. \nSUMMARY: The Food and Drug \nAdministration (FDA or we) is \nclassifying the radiofrequency \ntoothbrush into class II (special \ncontrols). The special controls that \napply to the device type are identified \nin this order and will be part of the \ncodified language for the radiofrequency \ntoothbrush’s classification. We are \ntaking this action because we have \ndetermined that classifying the device \ninto class II (special controls) will \nprovide a reasonable assurance of safety \nand effectiveness of the device. We \nbelieve this action will also enhance \npatients’ access to beneficial innovative \ndevices. \nDATES: This order is effective September \n5, 2024. The classification was \napplicable on September 17, 2020. \nFOR FURTHER INFORMATION CONTACT: \nLauren Giles, Center for Devices and \nRadiological Health, Food and Drug \nAdministration, 10903 New Hampshire \nAve., Bldg. 66, Rm. G309, Silver Spring, \nMD 20993–0002, 301–796–9552, \nLauren.Giles@fda.hhs.gov. \nSUPPLEMENTARY INFORMATION: \nI. Background \nUpon request, FDA has classified the \nradiofrequency toothbrush as class II \n(special controls), which we have \ndetermined will provide a reasonable \nassurance of safety and effectiveness. \nThe automatic assignment of class III \noccurs by operation of law and without \nany action by FDA, regardless of the \nlevel of risk posed by the new device. \nAny device that was not in commercial \ndistribution before May 28, 1976, is \nautomatically classified as, and remains \nwithin, class III and requires premarket \napproval unless and until FDA takes an \naction to classify or reclassify the device \n(see 21 U.S.C. 360c(f)(1)). We refer to \nthese devices as ‘‘postamendments \ndevices’’ because they were not in \ncommercial distribution prior to the \ndate of enactment of the Medical Device \nAmendments of 1976, which amended \nthe Federal Food, Drug, and Cosmetic \nAct (FD&C Act). \nFDA may take a variety of actions in \nappropriate circumstances to classify or \nreclassify a device into class I or II. We \nmay issue an order finding a new device \nto be substantially equivalent under \nsection 513(i) of the FD&C Act (see 21 \nU.S.C. 360c(i)) to a predicate device that \ndoes not require premarket approval. \nWe determine whether a new device is \nsubstantially equivalent to a predicate \ndevice by means of the procedures for \npremarket notification under section \n510(k) of the FD&C Act (21 U.S.C. \n360(k)) and part 807 (21 CFR part 807). \nFDA may also classify a device \nthrough ‘‘De Novo’’ classification, a \ncommon name for the process \nauthorized under section 513(f)(2) of the \nFD&C Act (see also part 860, subpart D \n(21 CFR part 860, subpart D)). Section \n207 of the Food and Drug \nAdministration Modernization Act of \n1997 (Pub. L. 105–115) established the \nfirst procedure for De Novo \nclassification. Section 607 of the Food \nand Drug Administration Safety and \nInnovation Act (Pub. L. 112–144) \nmodified the De Novo application \nprocess by adding a second procedure. \nA device sponsor may utilize either \nprocedure for De Novo classification. \nUnder the first procedure, the person \nsubmits a 510(k) for a device that has \nnot previously been classified. After \nreceiving an order from FDA classifying \nthe device into class III under section \n513(f)(1) of the FD&C Act, the person \nthen requests a classification under \nsection 513(f)(2). \nUnder the second procedure, rather \nthan first submitting a 510(k) and then \na request for classification, if the person \ndetermines that there is no legally \nmarketed device upon which to base a \ndetermination of substantial \nequivalence, that person requests a \nclassification under section 513(f)(2) of \nthe FD&C Act. \nUnder either procedure for De Novo \nclassification, FDA is required to \nclassify the device by written order \nwithin 120 days. The classification will \nbe according to the criteria under \nsection 513(a)(1) of the FD&C Act. \nAlthough the device was automatically \nplaced within class III, the De Novo \nclassification is considered to be the \ninitial classification of the device. \nWhen FDA classifies a device into \nclas",
    "(FDA)97261-2024-20896.pdf": "75491 \nFederal Register / Vol. 89, No. 179 / Monday, September 16, 2024 / Rules and Regulations \nTABLE 1—CLOZAPINE TEST SYSTEM RISKS AND MITIGATION MEASURES—Continued \nIdentified risks to health \nMitigation measures \nIncorrect interpretation of test results ................................\nCertain design verification and validation activities and Certain labeling information. \nFDA has determined that special \ncontrols, in combination with the \ngeneral controls, address these risks to \nhealth and provide reasonable assurance \nof safety and effectiveness. For a device \nto fall within this classification, and \nthus avoid automatic classification in \nclass III, it would have to comply with \nthe special controls named in this final \norder. The necessary special controls \nappear in the regulation codified by this \norder. This device is subject to \npremarket notification requirements \nunder section 510(k) of the FD&C Act. \nIII. Analysis of Environmental Impact \nThe Agency has determined under 21 \nCFR 25.34(b) that this action is of a type \nthat does not individually or \ncumulatively have a significant effect on \nthe human environment. Therefore, \nneither an environmental assessment \nnor an environmental impact statement \nis required. \nIV. Paperwork Reduction Act of 1995 \nThis final order establishes special \ncontrols that refer to previously \napproved collections of information \nfound in other FDA regulations and \nguidance. These collections of \ninformation are subject to review by the \nOffice of Management and Budget \n(OMB) under the Paperwork Reduction \nAct of 1995 (44 U.S.C. 3501–3521). The \ncollections of information in part 860, \nsubpart D, regarding De Novo \nclassification have been approved under \nOMB control number 0910–0844; the \ncollections of information in 21 CFR \npart 814, subparts A through E, \nregarding premarket approval, have \nbeen approved under OMB control \nnumber 0910–0231; the collections of \ninformation in part 807, subpart E, \nregarding premarket notification \nsubmissions, have been approved under \nOMB control number 0910–0120; the \ncollections of information in 21 CFR \npart 820, regarding quality system \nregulation, have been approved under \nOMB control number 0910–0073; and \nthe collections of information in 21 CFR \nparts 801 and 809, regarding labeling, \nhave been approved under OMB control \nnumber 0910–0485. \nList of Subjects in 21 CFR Part 862 \nMedical devices. \nTherefore, under the Federal Food, \nDrug, and Cosmetic Act and under \nauthority delegated to the Commissioner \nof Food and Drugs, 21 CFR part 862 is \namended as follows: \nPART 862—CLINICAL CHEMISTRY \nAND CLINICAL TOXICOLOGY \nDEVICES \n■1. The authority citation for part 862 \ncontinues to read as follows: \nAuthority: 21 U.S.C. 351, 360, 360c, 360e, \n360j, 360l, 371. \n■2. Add § 862.3245 to subpart D to read \nas follows: \n§ 862.3245\nClozapine test system. \n(a) Identification. A clozapine test \nsystem is a device intended to measure \nclozapine in human specimens. \nMeasurements obtained by this device \nare used in monitoring levels of \nclozapine to ensure appropriate therapy \nin patients with treatment-resistant \nschizophrenia. \n(b) Classification. Class II (special \ncontrols). The special controls for this \ndevice are: \n(1) Design verification and validation \nmust include the following: \n(i) Precision study data that \ndemonstrates precision that is clinically \nappropriate, as determined by FDA, for \nthe clozapine test system. Precision \nstudies must include a minimum of \nthree samples containing different \nconcentrations of clozapine including \nnear medical decision points and \nthroughout the expected therapeutic \nrange of clozapine. Samples near the \nmedical decision points must be clinical \nspecimens collected from patients \ntaking clozapine; \n(ii) Method comparison data that \ndemonstrates accuracy that is clinically \nacceptable, as determined by FDA, for \nthe clozapine test system; \n(iii) Data from studies that \ndemonstrate that the device is free from \nclinically significant interference, as \ndetermined by FDA, from commonly co- \nadministered medications that are used \nin patients with treatment-resistant \nschizophrenia; and \n(iv) Data from studies that \ndemonstrate that the device is free from \nclinically significant cross-reactivity, as \ndetermined by FDA, from major \ncirculating metabolites found in the \nintended use population. \n(2) The labeling required under \n§ 809.10 of this chapter must include a \nlimiting statement conveying that the \nassay should only be used in \nconjunction with information available \nfrom clinical evaluations and other \ndiagnostic procedures and that results \nfrom the assay alone should not be used \nin making treatment decisions. \nDated: September 10, 2024. \nLauren K. Roth, \nAssociate Commissioner for Policy. \n[FR Doc. 2024–20895 Filed 9–13–24; 8:45 am] \nBILLING CODE 4164–01–P \nDEPARTMENT OF HEALTH AND \nHUMAN SERVICES \nFood and Drug Administration \n21 CFR Part 866 \n[Docket No. FDA–2024–N–4061] \nMedica",
    "(India)__Public_Notice_BIS_Standards.pdf": "Annexure \nBIS Standards Available \nMedical Equipment and Hospital Planning Department \nCategory 1: Surgical Instruments (MHD-01) \nSI. No. \nIS No. \nTITLE \n1 \nIS 10383 : 1982 \nSpecification for scissors, nail, curved on flat \n2 \nIS 10384 : 1982 \nScissors, Bandage, Smith's Pattern \n3 \nIS 10414 : 1982 \nSpecification for scissors, bowel \n4 \nIS 10445 : 1982 \nSpecification for scissors, bandage and clothing, angled to \nside \n5 \nIS 10599 : 1993 \nSurgical Instruments - Needle Holders, Hegar's Pattern - \nSizes, Shape and Dimensions \n(1 Revision) \n6 \nIS 10637 : 1992 \nSurgical instruments - Forceps, spinter, Arthur's pattern \nShape and dimensions \n(1 Revision) \n7 \nIS 10638 : 1983 \nForceps, Sponge Holding, Foerster's Pattern, Smooth or \nSerrated Jaws \n8 \nIS 10984 : 1984 \nScissors, Dissecting, Curved on Flat, Pott's Pattern \n9 \nIS 11497 : 2014 \nCatheter, Foley’s Rubber, for Prolonged Urinary Drainage \n— Specification \n(1 Revision) \n10 \nIS 11502 : 1992 \nSurgical instruments - Forceps tissue, adson - Browns \npatternshape and dimensions (First Revision) \n(1 Revision) \n11 \nIS 11545 : 1992 \nSurgical instruments - Haemostatic, forceps, Adson's \npattern - Shape and dimensions \n(1 Revision) \n12 \nIS 11558 : 1992 \nSurgical instruments - vessel, forceps,Debakey's pattern - \nSizes, shape and dimensions \n(1 Revision) \n13 \nIS 11595 : 1992 \nSurgical instruments - Peritoneum, forceps, McKulicz's \npattern - Shape and dimensions \n(1 Revision) \n14 \nIS 11640 : Part 1 : 1986 \nRetractor, General Surgery - Part 1 : Schonborn's Pattern \n15 \nIS 11640 : Part 2 : 1987 \nRetractor, General Surgery - Part 2 : Kocher's Pattern \n16 \nIS 11640 : Part 3 : 1987 \nRetractor - Part 3 : Israel's Pattern \n17 \nIS 11640 : Part 4 : 1987 \nRetractor - Part 4 : Abdominal, Fritsch's Pattern \n18 \nIS 11640 : Part 5 : 1987 \nRetractor - Part 5 Korte's Pattern \n19 \nIS 11640 : Part 6 : 1987 \nRetractor, General Surgery - Part 6 : Volkmann's Pattern \n20 \nIS 11640 : Part 7 : 1987 \nRetractor - Part 7 : Abdominal and Liver, Mikulicz's Pattern \n21 \nIS 12103 : 1987 \nSpecification for skin graft expander \n22 \nIS 12815 : 1989 \nSurgical instruments - Knife autopsy - Specification \n23 \nIS 12822 : 1989 \nSurgical Instruments - Forceps Intestinal Mayo-Robson's \nPattern \n\n24 \nIS 12841 : Part 1 : 1989 \nSurgical Instruments - Needle Holders - Part 1 : Mathieu's \nPattern \n25 \nIS 12841 : Part 2 : 1989 \nSurgical Instruments - Needle Holders - Part 2 : With \nCarbide Inserts, Stratte's Pattern \n26 \nIS 12841 : Part 3 : 1989 \nSurgical Instruments - Needle Holders - Part 3 : Heaney's \nPattern \n27 \nIS 12841 : Part 4 : 1989 \nSurgical Instruments - Needle Holders - Part 4 : with \nCarbide Inserts, Debakey's Pattern \n28 \nIS 13127 : 1991 \nSurgical instruments - Suture - Clip applying forceps, \nwachenfeld type shape, dimensions and mass \n29 \nIS 13198 : 1991 \nSurgical instruments - Trocar holding forceps, vogel type - \nShape, dimensions and mass \n30 \nIS 15732 : Part 1 : 2018/ISO \n8600-1 \nEndoscopes - Medical Endoscopes and Endotherapy \nDevices Part 1 General Requirements ( First Revision) \n(1 Revision) \n31 \nIS 15732 : Part 2 : 2019/8600-\n2:2015 \nEndoscopes - Medical endoscopes and endotherapy \ndevices: Part 2 particular requirements for rigid \nbronchoscopes \n32 \nIS 15732 : Part 3 : 2006/ISO \n8600-3: 1997 \nOptics and photonics - Medical endoscopes and \nendotherapy devices: Part 3 determination of field of view \nand direction of view of endoscopes with optics \n33 \nIS 15732 : Part 4 : 2021/ISO \n8600-4:2014 \nEndoscopes - Medical endoscopes and endotherapy \ndevices- Part 4: Determination of maximum width of \ninsertion portion (First Revision) \n(1 Revision) \n34 \nIS 15732 : Part 7 : 2019/ISO \n8600-7: 2012 \nEndoscopes — Medical endoscopes and endotherapy \ndevices — Part 7: Basic requirements for medical \nendoscopes of water-resistant type \n35 \nIS 3318 : 1965 \nGeneral requirements for surgical scalpels and knives \n36 \nIS 3319 : 1995 \nBlades, surgical, detachable (Bard Parker Type) and \nhandles - Specification (Fourth Revision) \n(4 Revision) \n37 \nIS 3320 : 1973 \nSpecification for surgical scalpels (First Revision) \n(1 Revision) \n38 \nIS 3642 : Part 1 : 1990/ISO 7740: \n1985 \nSurgical instruments - Specification: Part 1 non - Cutting, \narticulated instruments (Second Revision) \n(2 Revision) \n39 \nIS 3643 : 1992 \nSurgical instruments - Dissecting forceps (Serrated And \nToothed) - Shapes and dimensions (First Revision) \n(1 Revision) \n40 \nIS 3644 : 1992 \nSurgical instruments - Artery forceps Halsted's Mosquito \npattern - Shape and dimensions \n(1 Revision) \n41 \nIS 3645 : 1992 \nSurgical instruments - Artery forceps Spencer Wells pattern \n\n(1 Revision) \n- Size, shape and dimensions \n42 \nIS 3759 : 1987 \nSpecification for blades, skin grafting (First Revision) \n(1 Revision) \n43 \nIS 3767 : 1966 \nSpecification for hook, skin, gillies pattern \n44 \nIS 3787 : 1966 \nSpecification for gag, mouth, cleft palate \n45 \nIS 4085 : 1967 \nSpecification for knives, amputating \n46 \nIS 4094 : 1967 \nForceps, Sterilizer, Cheatle's Pattern \n47 \nIS 4",
    "(India)_2019jan15insertione_IFU.pdf": "295 GI/2019 \n(1) \n \n \n \njftLVªh laö Mhö ,yö&33004@99 \nREGD. NO. D. L.-33004/99 \n \n \nvlk/kj.k \nEXTRAORDINARY \nHkkx II—[k.M 3—mi&[k.M (i) \nPART II—Section 3—Sub-section (i) \nizkf/dkj ls izdkf'kr \nPUBLISHED BY AUTHORITY \n la- 30] \nubZ fnYyh] eaxyokj] tuojh 15] 2019@ikS\"k 25] 1940 \nNo.  30] \nNEW DELHI, TUESDAY,  JANUARY  15,  2019/PAUSHA  25,  1940 \n\u0001वा\u0001\u0004य और प\nरवार क\fयाण मं\u0010ालय\n\u0001वा\u0001\u0004य और प\nरवार क\fयाण मं\u0010ालय\n\u0001वा\u0001\u0004य और प\nरवार क\fयाण मं\u0010ालय\n\u0001वा\u0001\u0004य और प\nरवार क\fयाण मं\u0010ालय \n((((\u0001वा\u0001\u0004य और प\nरवार क\fयाण िवभाग)\n\u0001वा\u0001\u0004य और प\nरवार क\fयाण िवभाग)\n\u0001वा\u0001\u0004य और प\nरवार क\fयाण िवभाग)\n\u0001वा\u0001\u0004य और प\nरवार क\fयाण िवभाग) \nअिधसूचना\nअिधसूचना\nअिधसूचना\nअिधसूचना \nनई \u0004द\u0006ली, 15 जनवरी, 2019 \nसा\nसा\nसा\nसा....का\nका\nका\nका....िन\nिन\nिन\nिन....    30(\n30(\n30(\n30(अअअअ).).).).—\n—\n—\n—िच\u0004क\f सा युि\u0011 िनयम, 2017 का और संशोधन करने के िलए कितपय िनयम\u001d का \u001eा\u001fप, ओषिध \nऔर \u001eसाधन साम ी अिधिनयम, 1940 (1940 का 23) क\" धारा 12 क\" उप-धारा (1) और धारा 33 क\" उप-धारा (1) क\" \nअपे$ानुसार भारत के राजप', असाधारण, भाग II, खंड 3, उप-खंड (i) तारीख 7 िसत( बर, 2018 म* \u001eकािशत भारत \nसरकार के + वा+ - य और प.रवार क\u0006 याण मं'ालय (+ वा+ - य और प.रवार क\u0006 याण िवभाग) क\" अिधसूचना सं. सा.का.िन. \n848(अ), तारीख 7 िसत( बर, 2018 1ारा \u001eकािशत \u0004कया गया था, िजसम* उन सभी 4 यि\u0011य\u001d से, िजनके उससे \u001eभािवत होने \nक\" संभावना है, उस तारीख से, िजसको उ7 त अिधसूचना को अंत8व9: करने वाले राजप' क\" \u001eितयां जनसाधारण को उपल; ध \nकराई गई थी, तीस \u0004दन क\" अविध के अवसान के पूव9, आ$ेप और सुझाव आंमि'त \u0004कए गए थे; \nऔर उ7 त राजप' क\" \u001eितयां तारीख 14 िसत( बर, 2018 को जनसाधारण को उपल;ध कराई ग> थी;  \nऔर के? @ीय सरकार 1ारा उ7 त िनयम\u001d पर जनसाधारण से \u001eाA त आ$ेप\u001d और सुझाव\u001d पर िवचार कर िलया गया है; \nअत: अब, के? @ीय सरकार, ओषिध और \u001eसाधन साम ी अिधिनयम, 1940  (1940 का 23) क\" धारा 12 और  \nधारा 33 1ारा \u001eद\f त शि\u0011य\u001d का \u001eयोग करते Lए, ओषिध तकनीक\" सलाहकार बोड9 से परामश9 करने के पN चात्, िच\u0004क\f सा \nयुि\u0011 िनयम, 2017 का और संशोधन करने के िलए िन( निलिखत िनयम बनाती है, अथा9त्:―  \n    \n\n2  \n THE GAZETTE OF INDIA : EXTRAORDINARY \n [PART II—SEC. 3(i)] \n1.     (1)  इन िनयम\u001d का संि$Q नाम िच\u0004क\f सा युि\u0011 (संशोधन) िनयम, 2019 है।  \n        (2)  ये राजप' म* \u001eकाशन क\" तारीख को \u001eवृT ह\u001dगे। \n2.     िच\u0004क\f सा युि\u0011 िनयम, 2017 (िजसे इसम* इसके पVात् उ\u0011 िनयम कहा गया है) म*, िनयम 3 के खंड (फ) \nम*, “उपयोग के िलए अनुदेश” श; द\u001d के पVात् “या उपयोग के िलए इले7 Wॉिनक अनुदेश” श; द अंतः+थािपत \u0004कए \nजाएंगे। \n3.     उ7 त िनयम\u001d म*, िनयम 59 के उप-िनयम (3) के खंड (iii) म* “उपयोग के िलए अनुदेश” श; द\u001d के पVात्  \n“या उपयोग के िलए इले7 Wॉिनक अनुदेश” श; द अंतः+थािपत \u0004कए जाएंगे। \n4.     उ7 त िनयम\u001d क\" चौथी अनुसूची म*,― \n(क) भाग 2 म*, “समूह क िच\u0004क\fसा युि\u0011 के िव[य या िवतरण के िलए आयात क\" अनु\\िQ या िविनमा9ण \nक\" अनु\\िQ मंजूर करने के िलए आवेदन के साथ \u001e+तुत क\" जाने वाली जानकारी” शीष9क के अधीन पैरा (क) म*, \nसारणी म*, [म सं] या 4 के सामने दोन\u001d +त(भ (2) और (3) म* आने वाले “आई.एफ.यू.” अ$र\u001d के +थान पर \n“उपयोग के िलए अनुदेश या इले7 Wॉिनक अनुदेश” श; द रखे जाएंगे;  \n(ख) भाग 3 के प.रिशष्  ट II म*,―  \n(i) पैरा 2.1, मद (क) म* “\u001eयोग के िलए अनुदेश” श; द\u001d के +थान पर “उपयोग के िलए अनुदेश या \nउपयोग के िलए इले7 Wॉिनक अनुदेश” श; द रखे जाएंगे;  \n    (ii) पैरा 3.0 म*, मद (ख) के +थान पर िन( निलिखत खंड रखा जाएगा, अथा9त्  :―  \n“(ख) उपयोग के िलए अनुदेश या उपयोग के िलए इले7 Wॉिनक अनुदेश (िनधा9रक का मैनुअल);”;  \n(ग) भाग 4 म*,―  \n(i) पैरा (क) म*, [म सं] या 8 और उससे संबंिधत \u001eिवि:य\u001d के +थान पर िन( निलिखत [म सं] या और \n\u001eिवि:यां रखी जाएंगी, अथा9त्  :― \n“8. उपयोग के िलए \u001e+ तािवत अनुदेश या उपयोग और लेबेल के िलए इले7 Wॉिनक अनुदेश।”; \n(ii) पैरा (ख) म*, [म सं] या 5 और उससे संबंिधत \u001eिवि:य\u001d के +थान पर िन( निलिखत [म सं] या और \n\u001eिवि:यां रखी जाएंगी, अथा9त्  ,― \n“5. उपयोग के िलए \u001e+ तािवत अनुदेश या उपयोग और लेबल के िलए इले7 Wॉिनक अनुदेश।”। \n5.        सातव_ अनुसूची म*,― \n(क) पैरा 1 के उप-पैरा (1) के खंड (v) म*,― \n(i) “\u001eयोग संबंधी अनुदेश” श; द\u001d के +थान पर “उपयोग के िलए अनुदेश या उपयोग के िलए इले7 Wॉिनक \nअनुदेश” श; द रखे जाएंगे; \n(ii) परंतुक म* “\u001eयोग संबंधी अनुदेश” श; द\u001d के +थान पर “उपयोग के िलए अनुदेश या उपयोग के िलए \nइले7 Wॉिनक अनुदेश” श; द रखे जाएंगे; \n\n¹Hkkx IIµ[k.M 3(i)º \nHkkjr dk jkti=k % vlk/kj.k \n3 \n(ख) सारणी 3 म*, [म सं] या 11 और उससे संबंिधत \u001eिवि:य\u001d के +थान पर िन( निलिखत [म सं] या और \n\u001eिवि:यां रखी जाएंगी, अथा9त्  :― \n“11. उपयोग के िलए \u001e+ तािवत अनुदेश या उपयोग और लेबल के िलए इले7 Wॉिनक अनुदेश।”। \n \n [फा. सं. ए7स.11014/20/2018-डीआर] \nडॉ. मनदीप के. भ`डारी, संयु\u0011 सिचव  \n \n\nट\u0013 प\n\nट\u0013 प\n\nट\u0013 प\n\nट\u0013 पणणणण:::: मूल िनयम, भारत के राजप' असाधारण, भाग-II, खंड-3, उप-खंड (i)    म* अिधसूचना सं] या सा.का.िन. \n78(अ), तारीख 31 जनवरी, 2017 1ारा \u001eकािशत \u0004कए गए थे और अंितम बार अिधसूचना सं] या \nसा.का.िन. 729(अ), तारीख 1 अग+त, 2018 1ारा संशोिधत \u0004कए गए थे।  \n \nMINISTRY OF HEALTH AND FAMILY WELFARE \n(Department of Health and Family Welfare) \nNOTIFICATION \nNew Delhi, the 15th January, 2019 \n \nG.S.R. 30(E).—Whereas a draft of certain rules further to amend the Medical Devices Rules, 2017, was \npublished as required by sub-section (1) of section 12 and sub-section (1) of section 33 of the Drugs and Cosmetics Act, \n1940 (23 of 1940) vide notification of the Government of India in the Ministry of Health and Family Welfare \n(Department of Health and Family Welfare) number G.S.R. 848 ",
    "(India)_2021.12.31_Final_GSR_918(E).pdf": "7700 GI/2021 \n(1) \nरजिस्ट्री सं. डी.एल.- 33004/99 \nREGD. No. D. L.-33004/99 \n  \n \n \nxxxGIDHxxx \nxxxGIDExxx \nअसाधारण  \nEXTRAORDINARY \nभाग II—खण् ड 3—उप-खण् ड (i)  \nPART II—Section 3—Sub-section (i) \nप्राजधकार से प्रकाजित \nPUBLISHED BY AUTHORITY \n \nस्ट् वास्ट् ् य रर पिरवार क्‍ याण तंरालय \n(स्ट् वास्ट् ् य रर पिरवार क्‍ याण जवभाग) \nअजधसूचना \nनई दि्‍ ली, 31 दिसम् बर, 2021 \nसा.का.जन. 918(अ).—जचदकत्सा युजि जनयत, 2017 का रर संिोधन करने के जलए कजतपय जनयतों का प्रारूप, रषजध रर \nप्रसाधन सातग्री अजधजनयत, 1940 (1940 का 23) की धारा 12 की उप-धारा (1) रर धारा 33 की उप-धारा (1) अधीन यथा \nअपेजित, भारत सरकार के स्ट् वास्ट् ् य रर पिरवार क्‍ याण तंरालय (स्ट् वास्ट् ् य रर पिरवार क्‍ याण जवभाग) की अजधसूचना सं. \nसा.का.जन. 877(अ), तारीख 23 दिसंबर, 2021 द्वारा भारत के रािपर, असाधारण, भाग II, खंड 3, उपखंड (i) तें प्रकाजित दकया \nगया था, जिसतें उन सभी व् यजियों से, जिनके उससे प्रभाजवत होने की संभावना है उस तारीख से, जिसको उक् त अजधसूचना अन्तर्ववष्ट \nकरने वाली रािपर की प्रजतयां िनता को उपलब् ध करा िी गई थी, पांच दिनों की अवजध के अवसान से पहले आिेप रर सुझाव \nआंतजरत दकए गए थे; \nरर, उि  रािपर की प्रजतयां 23 दिसंबर, 2021 को िनता को उपलब् ध करा िी गई थी; \nरर, उक् त प्रारूप जनयतों पर िनता से प्राप्त आिेप रर सुझावों पर केन् रीय सरकार द्वारा जवचार कर जलया गया है; \n \nअत: अब, केन् रीय सरकार, रषजध रर प्रसाधन सातग्री अजधजनयत, 1940 (1940 का 23) की धारा 12 रर धारा 33 \nद्वारा प्रित् त िजियों का प्रयोग करते हुए, इस जवचार के साथ दक रषजध तकनीकी सलाहकार बोडष से परातिष उपबंधों के अनुसार दकया \nिाएगा, जचदकत्सा युजि जनयत, 2017 का संिोधन करने के जलए जनम् नजलजखत जनयत बनाती है, अथाषत्:— \nसं.   744] \nनई दि्‍ली, िुक्रवार, दिसम् बर 31, 2021/पौष 10, 1943 \n \nNo. 744] \nNEW DELHI, FRIDAY, DECEMBER 31, 2021/PAUSHA 10, 1943 \n \nसी.जी.-डी.एल.-अ.-31122021-232284\nCG-DL-E-31122021-232284\nसी.जी.-डी.एल.-अ.-31122021-232284\nCG-DL-E-31122021-232284\n\n2  \nTHE GAZETTE OF INDIA : EXTRAORDINARY \n   [PART II—SEC. 3(i)] \n1.  (1) इन जनयतों का संजिप्त नात जचदकत्सा युजि (संिोधन) जनयत, 2021 है।   \n(2) ये रािपर तें उनके प्रकािन की तारीख को प्रवृत होंगे।  \n2. जचदकत्सा युजि जनयत, 2017 तें, जनयत 46 के स्ट्थान पर जनम्नजलजखत जनयत को रखा िाएगा, अथाषत:—  \n“46. जचदकत्सा युजि की अजभन्न युजि पहचान.— उस तारीख से प्रभावी जिसे केंरीय सरकार आिेि द्वारा जवजनर्िष्ट करे, \nजवक्रय या जवतरण के जलए जवजनताषण या आयात के जलए अनुतोदित प्रत्येक जचदकत्सा युजि पर एक अजभन्न युजि पहचान \nरहेगी, िो उस रीजत तें होगी जिसे ऐसे आिेि तें जवजनर्िष्ट दकया िाए ।” । \n[फा.सं. एक् स.1111//30/2121–डीआर]  \nडॉ. तनिीप के भण्डारी, संयुक् त सजचव \nििप् पण:- जचदकत्सा युजि जनयत, 2017, रािपर तें अजधसूचना सं. सा.का.जन. 78(अ), तारीख 31 िनवरी, 2017 द्वारा प्रकाजित दकए \nगए थे रर अजधसूचना सं. सा.का.जन. 102(अ), तारीख 11 फ़रवरी, 2020 द्वारा अंजतततः संिोजधत दकए गए थे । \n \nMINISTRY OF HEALTH AND FAMILY WELFARE \n(Department of Health and Family Welfare) \nNOTIFICATION \nNew Delhi, the 31st December, 2021 \n \nG.S.R. 918(E).—Whereas a draft of certain rules further to amend the Medical Devices Rules, 2017, was \npublished as required under sub-section (1) of section 12 and sub-section (1) of section 33 of the Drugs and Cosmetics \nAct, 1940 (23 of 1940) vide notification of the Government of India in the Ministry of Health and Family Welfare \n(Department of Health and Family Welfare) number G.S.R. 877(E), dated the 23rd December, 2021, in the Gazette of \nIndia, Extraordinary, Part II, section 3, sub-section (i), inviting objections and suggestions from persons likely to be \naffected thereby before the expiry of a period of five days from the date on which the copies of the Official Gazette \ncontaining the said notification were made available to the public; \n \nAnd whereas copies of the said Official Gazette were made available to the public on 23rd December, 2021;  \n \nAnd whereas objections and suggestions received from the public on the said draft rules have been \nconsidered by the Central Government; \n \nNow, therefore, in exercise of the powers conferred by sections 12 and 33 of the Drugs and Cosmetics Act, \n1940 (23 of 1940), with consideration that consultation with Drugs Technical Advisory Board shall be held as per the \nprovisions, the Central Government hereby makes the following rules further to amend the Medical Devices Rules, \n2017, namely:―  \n1. \n(1) These rules may be called the Medical Devices (Amendment) Rules, 2021. \n(2) These rules shall come into force on the date of their publication in the Official Gazette. \n2. \nIn the Medical Devices Rules, 2017, for rule 46, the following rule shall be substituted, namely:—  \n“46. Unique device identification of medical device.— With effect from such date as the Central \nGovernment may, by order specify, every medical device approved for manufacture for sale or distribution or \nimport, shall bear a unique device identification in the manner as may be specified in such order.”. \n[F.No. X.11014/30/2021-DR] \nDr. MANDEEP K BHANDARI, Jt. Secy.  \nNote:  The Medical Devices Rules, 2017 was published in the Official Gazette vide notification number G.S.R. 78 \n(E), dated the 31st January, 2017 and last amended v",
    "(India)_IVD_classifiction_updated.pdf": "Page 1 of 11 \n \nAnnexure A (Updated) \n \n \nFile No. IVD/Misc/196/2020 \nDrugs Controller General (India) \nDirectorate General of Health Services \nCentral Drugs Standard Control Organisation  \nFDA Bhawan, Kotla Road, New Delhi \n \n \n \n \nList of In-Vitro Diagnostic Medical Devices (IVD Analyzers)                              \nunder provisions of sub-rule (2) rule 4 of the Medical Devices Rules, 2017 \nSr. \nNo. \nCategory \nName of the  \nIn-Vitro \nDiagnostic \nMedical \nDevices  \n(IVD \nAnalyzers) \nRisk \nClass as \nper  \nPart II, \nFirst \nSchedule \nof MDR \n2017 \nIntended use \n1 Clinical \nchemistry \nAlcohol body-\nfluid analyser \nA \nAn analyzer (other than near-patient testing) \nintended to determine the concentration of \nalcohol in a body-fluid specimen. It is \nintended for in-vitro diagnostic use. \nC \nAn analyzer intended to be used for near-\npatient testing to determine the \nconcentration of alcohol in a body-fluid \nspecimen. It is intended for in-vitro \ndiagnostic use. \n2 \nAmino acid \nanalyser \nA \nAn analyzer intended to be used for the \nqualitative and/or quantitative in vitro \ndetermination of individual amino acids in a \nprotein sample obtained from a clinical \nspecimen. It is intended for in-vitro \ndiagnostic use.  \n3 \nBilirubinometry \nanalyser \nA \nA device (other than near-patient testing) \nthat measures directly or indirectly the \nbilirubin concentration in blood or other \nsamples. It is intended for in-vitro diagnostic \nuse. \nC \nA device intended to be used for near-\npatient testing that measure directly or \nindirectly the bilirubin concentration in blood \nor other samples. It is intended for in-vitro \ndiagnostic use. \n4 \nCatecholamine\ns analyser \nA \nA device that measures catecholamine \nconcentration in biological samples. It is \nintended for in-vitro diagnostic use. \n\n \nPage 2 of 11 \n \nSr. \nNo. \nCategory \nName of the  \nIn-Vitro \nDiagnostic \nMedical \nDevices  \n(IVD \nAnalyzers) \nRisk \nClass as \nper  \nPart II, \nFirst \nSchedule \nof MDR \n2017 \nIntended use \n5 Clinical \nchemistry \nChemilumines\ncent \nimmunoassay \nanalyser \nA \nAn analyzer intended to be used for the \nqualitative and/or quantitative in vitro \ndetermination of chemical and/or biological \nmarkers in a clinical specimen. It is intended \nfor in-vitro diagnostic use. \n6 \nChloride \ncoulometric \ntitration \nanalyser \nA \nAn analyzer intended to be used for the \nquantitative measurement of chloride in a \nclinical specimen using a coulometric \ntitration. It is intended for in-vitro diagnostic \nuse. \n7 \nCholesterol \nanalyser \nA \nA device that measures the cholesterol in \nserum/whole blood. It is intended for in-vitro \ndiagnostic use. \n8 \nClinical \nchemistry \nanalyser \nA \nAn analyzer intended to be used for the \nqualitative and/or quantitative determination \nof one or multiple clinical chemistry analytes \nin a clinical specimen. It is intended for in-\nvitro diagnostic use. \n9 \nCreatinine \nanalyser \nA \nA device that measures creatinine \nconcentration in urine or serum sample. It is \nintended for in-vitro diagnostic use. \n10 \nEnzyme \nanalyser \nA \nA device that measures the enzymatic \nactivity of the sample for diagnosis. It is \nintended for in-vitro diagnostic use. \n11 \nGlycated \nhaemoglobin \n(HbA1C) \nanalyser \nA \nAn analyzer intended to be used for the \nquantitative measurement of glycated \nhaemoglobin (HbA1c) in a clinical \nspecimen. It is intended for in-vitro \ndiagnostic use. \n12 \nHigh \nperformance \nliquid \nchromatograph\ny analyser \nA \nAn analyzer designed to use high \nperformance liquid chromatography (HPLC) \nfor the qualitative and/or quantitative in vitro \ndetermination of chemical and/or biological \nmarkers in a clinical specimen. It is intended \nfor in-vitro diagnostic use. \n13 \nIdentification \nand Antibiotic \nsusceptibility \nanalyser \nA \nA device that identifies infectious/ \npathogenic microorganisms by photometry \nsuch as absorption, fluorescence and \nluminescence, and measures the \nsusceptibility to therapeutic drugs. It is \nintended for in-vitro diagnostic use. \n \n\n \nPage 3 of 11 \n \nSr. \nNo. \nCategory \nName of the  \nIn-Vitro \nDiagnostic \nMedical \nDevices  \n(IVD \nAnalyzers) \nRisk \nClass as \nper  \nPart II, \nFirst \nSchedule \nof MDR \n2017 \nIntended use \n14 Clinical \nchemistry \nIon-selective \nanalyser  \nA \nAn analyzer intended to be used for the \nquantitative measurement of electrolytes \nand/or other ions in a clinical specimen. It is \nintended for in-vitro diagnostic use. \n15 \nLactate \nanalyser \nA \nAn analyzer used to determine the \nconcentration of lactate in various body \nfluids using the lactate oxidase fixation \nelectrode. It is intended for in-vitro \ndiagnostic use. \n16 \nLipid profile \nanalyser  \nA \nAn analyzer intended to be used for the \nqualitative and/or quantitative in vitro \ndetermination of lipid profile analytes in a \nclinical specimen. It is intended for in-vitro \ndiagnostic use. \n17 \nNitrogen body-\nfluid-sample \nanalyser \nA \nAn analyzer used to analyse the nitrogen \n(N2) content in a body fluid. It is intended for \nin-vitro diagnostic use. \n18",
    "(India)_THE_MEDICAL_DEVICES_RULES,_2017.pdf": "Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, Govt. of India                       Page 1 of 248 \n \nTHE MEDICAL DEVICES RULES, 2017 \n[GSR 78(E), dt. 31-1-2017, w.e.f. 1-1-2018] \n(As amended vide GSR 777(E) dt. 14-10-2022(w.e.f. 14-10-2022) \n \nWhereas the draft of the Medical Devices Rules, 2016 was published, as \nrequired under sub-section (1) of Section 12 and sub-section (1) of Section 33 \nof the Drugs and Cosmetics Act, 1940 (23 of 1940), in the Gazette of India, \nExtraordinary, Part II, section 3, sub-section (i), vide notification number \nG.S.R. 983(E), dated the 17th October, 2016, by the Central Government, \nafter consultation with the Drugs Technical Advisory Board, inviting \nobjections and suggestions from all persons likely to be affected thereby, \nbefore the expiry of a period of thirty days from the date on which copies of \nthe said Gazette containing the said notification were made available to the \npublic; \nAnd whereas, copies of the Gazette containing the said notification were \nmade available to the public on the 17th October, 2016; \nAnd whereas, all objections and suggestions received in response to the \nsaid draft notification have been duly considered by the Central Government; \nNow, therefore, in exercise of the powers conferred by Section 12 and \nSection 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central \nGovernment, after consultation with the Drugs Technical Advisory Board, \nhereby makes the following rules, namely: \nCHAPTER I \nPRELIMINARY \n1.    Short title and commencement \n(1)    These rules may be called the Medical Devices Rules, 2017. \n(2)    These rules shall, unless specified otherwise, come into force with \neffect from 1st day of January, 2018. \n2.    Application \nThese rules shall be applicable in respect of,— \n(i)    substances used for in vitro diagnosis and surgical dressings, \nsurgical bandages, surgical staples, surgical sutures, ligatures, blood \n\n \nCentral Drugs Standard Control Organization, Ministry of Health and Family Welfare, Govt. of India                       Page 2 of 248 \n \nand blood component collection bag with or without anticoagulant \ncovered under sub-clause (i); \n(ii)    substances including mechanical contraceptives (condoms, \nintrauterine devices, tubal rings), disinfectants and insecticides notified \nunder sub-clause (ii); and \n(iii)    devices notified from time to time under sub-clause (iv), of \nclause (b) of section 3 of the Drugs and Cosmetics Act, 1940 (23 of \n1940). \n3.    Definitions \nIn these rules, unless the context otherwise requires,— \n(a)    \"academic clinical study\" means a clinical study conducted for academic \npurpose on a medical device for the approved or a new intended use, new \nmaterial of construction, new improved design or new population; \n(b)    \"Act\" means the Drugs and Cosmetics Act, 1940 (23 of 1940); \n(c)    \"active diagnostic medical device\" means any active medical device \nused, whether alone or in combination with other medical devices, to supply \ninformation for detecting, diagnosing or monitoring, or to provide support in \nthe treatment of, any physiological condition, state of health, illness or \ncongenital deformity; \n(d)    \"active medical device\" means a medical device, the operation of which \ndepends on a source of electrical energy or any other source of energy other \nthan the energy generated by human or animal body or gravity; \n(e)    \"active therapeutic medical device\" means any active medical device \nused, whether alone or in combination with any other medical device, to \nsupport, modify, replace or restore biological functions or structures, with a \nview to the treatment or alleviation of any illness, injury or handicap; \n(f)    \"authorised agent\" means a person including any firm or organisation \nwho has been appointed by an overseas manufacturer through a power of \nattorney to undertake import of medical device in India; \n\n \nCentral Drugs Standard Control Organization, Ministry of Health and Family Welfare, Govt. of India                       Page 3 of 248 \n \n(g)    \"body orifice\" means any natural opening in a human body including the \nexternal surface of any eyeball, or any permanent artificial opening, such as a \nstoma or permanent tracheotomy; \n(h)    \"Central Licensing Authority\" means the Drugs Controller General of \nIndia appointed by the Central Government; \n(i)    \"central medical devices testing laboratory\" means a medical devices \nlaboratory established or designated by the Central Government under rule 19 \nand shall be deemed to be a Central Drug Laboratory established for the \npurpose of section 6 of the Act; \n(j) \"change in the constitution of a licensee\" in relation to,— \n(i)    a firm means change from proprietorship to partnership \nincluding Limited Liability Partnership or vice versa; \n(ii)    a company means— \n(A)    its conversion from a private to a public company, or \nfrom a public to a private company; or \n(B)    any change in t",
    "(India)Launch_of_NSWS_portalJAN1.pdf": "National Single Window System (https://www.nsws.gov.in/)\nUser Guide: \nHow to apply for CDSCO Approval\n\nNational Single Window System (https://www.nsws.gov.in/)\n#\nHow to apply for Foreign Investment Approval\nReference slide\n1\nHow to identify the approval\n1.1 How to view, add approval from ‘All Approvals’\n1\n1.2 How to view, add approval through central KYA\n2\n1.3 How to add identified approval to the Dashboard\n4\n2\nHow to Apply for the Selected, identified Approval\n2.1 How to login and apply for approval (New User)\n5\n2.2 How to fill the application form\n6\n2.3 How to view the application form (Legal Form)\n14\n2.4 Checklist Activation\n15\n3\nTechnical Requirements and Contact Us\nTable of Contents\n\nNational Single Window System (https://www.nsws.gov.in/)\nHow to view, add approval from ‘All Approvals’\n11\nHover over ‘Central Approvals’ \nand click on ‘All Approvals’\nSelect “Directorate General of Health \nServices” from the list of Departments\nClick on “Add to \nDashboard”\n\nNational Single Window System (https://www.nsws.gov.in/)\n2\nHow to view, add approval through Central KYA\nClick on ‘Continue with Central’ to \nopen the central KYA\nClick on ‘Know Your Approvals’ \non the NSWS homepage\n\nNational Single Window System (https://www.nsws.gov.in/)\n3\nHow to view, add approval through Central KYA\nTo save a draft of the KYA \nanswers, users must be \nlogged into NSWS\nClick on ‘Reset form’ to remove all \nprevious responses to the questions\n5\nClick on ‘Business Activity Details’\nClick ‘Submit to Know Your Approvals’ \nto view the list of approvals\nClick here to read \nmore information\nSelect “Healthcare” and Answer \nthe questionnaire and find \napplicability of different \napprovals to you\nClick on ‘My Approvals’ \ntab to view the list of \nadded approvals\n\nNational Single Window System (https://www.nsws.gov.in/)\n4\nHow to add identified approval to the Dashboard\nSave the existing list of approvals \nin pdf format using ‘Save PDF’\nExisting users can ‘Sign In’ \nwith their credentials\nTo add the list of approvals on \nthe Dashboard, log into NSWS\nNew users can create an \naccount using ‘Sign Up Now’\nUsers will be redirected to the ‘Sign In’ Page\n\nNational Single Window System (https://www.nsws.gov.in/)\n5\nHow to login and apply for approval (New User)\nSelect the applicable option\nClick on ‘Sign Up Now’\nNew users can create their login credentials.\nAdd their Email ID & Phone Number and verify \nboth of them\nEnter the CIN / LLPIN / Business Name \nand click on ‘Next’\n\nNational Single Window System (https://www.nsws.gov.in/)\n6\nHow to fill the application form\nClick on ‘Apply Now’ to \nproceed with the Application\nClick here to expand \nall section at once\nAdd the details in the Profile \nsection\nClick on the downward arrow \nagainst the section names to \nexpand and fill the form\nNavigate through \ndifferent forms \nfor the approval \nfrom here\n\nNational Single Window System (https://www.nsws.gov.in/)\n7\nHow to fill the application form\nThe ‘*’ indicates a mandatory field to \nbe filled by the user\nThis button will create a duplicate \nsection for the selected section\nSome Data will be pre-populated as \nfilled up in the profile\n\nNational Single Window System (https://www.nsws.gov.in/)\n8\nHow to fill the application form\nThis button will create a duplicate \ngroup for the selected group\nClick on ‘(i)’ icon to read \nAdditional Information\n\nNational Single Window System (https://www.nsws.gov.in/)\n9\nHow to fill the application form\nSelect Document type and Click on \n‘Browse File’ to add attachments \nThis button indicates that the user needs \nto Download a format, fill it up and \nupload the same on that particular field\nUse this button to save the progress \nof the filled up application\nMove to the Checklist form for \nuploading the required documents\n\nNational Single Window System (https://www.nsws.gov.in/)\n10\nHow to fill the application form\nReview the application and \nclick here for final submission\nApplicable \nfee will be \nvisible here\nOnce filled, click on Review and Submit\n\nNational Single Window System (https://www.nsws.gov.in/)\n11\nHow to fill the application form\nPay the amount using the Bharatkosh portal\nClick on the checkbox \nand then “Pay & \nSubmit” button\n\nNational Single Window System (https://www.nsws.gov.in/)\n12\nHow to fill the application form\nThis screen confirms the \nsubmission of application\nAfter payment, user will be redirected to \nNSWS portal where the user has to Digitally \nSign the application\nThis is the document \ncontaining the responses \nof the investor in the \napplication with their DSC. \nAlso knows as Legal Form\n\nNational Single Window System (https://www.nsws.gov.in/)\n13\nHow to fill the application form\nUpload the documents, add the \ninformation\nClick on review and submit, and \nverify the application again using \nDSC as shown earlier\nOnce submitted, user can track the \n‘Application Status’ from here\nIn case the user wants to \nsubmit any additional \ndocument. They can click here \n\nNational Single Window System (https://www.nsws.gov.in/)\n14\nHo",
    "(Royaume-Uni_(RU))189346-Response_to_Assimilated_EU_Law_consultation_proposal.pdf": "1 \n \n \n \nGovernment response to the \nconsultation on Medical Devices \nRegulations: Assimilated EU Law \n \nPublished 26 February 2025 \n \n \n \n \n \n\n \n \n2 \n \nContents \nMinisterial Foreword ................................................................................................. 3 \nExecutive Summary ................................................................................................. 4 \nIntroduction .............................................................................................................. 5 \nRespondents ........................................................................................................ 6 \nAssimilated EU Law ................................................................................................. 8 \nBackground .......................................................................................................... 8 \nProposal ............................................................................................................... 9 \nFeedback .............................................................................................................. 9 \nGovernment response ............................................................................................ 11 \nNext steps .............................................................................................................. 11 \n \n \n \n \n \n\n \n \n3 \n \nMinisterial Foreword \nThe Medical Devices Regulations: Routes to market and in vitro diagnostic devices \nconsultation was an important step in our reform of the medical devices regulations, \nfocusing on some key proposals for legislative change. The consultation also set out in \nhigh-level terms the broader plans that the Medicines and Healthcare products \nRegulatory Agency (MHRA) is driving forwards to ensure that the MedTech ecosystem \ncontinues to support access to innovative medical devices while keeping patient safety \nat the forefront.  \nMaking and implementing new legislation is not quick or simple. I am pleased with the \nprogress being made and am grateful to so many of you for engaging with the \nconsultation and sharing your views. The responses we received from a diverse range \nof partners, including medical device manufacturers, healthcare professionals, patients \nand the public, have been extremely valuable and our legislative plans are informed by \nthe insights provided by that feedback.  \nThis government response relates only to the final proposal in the consultation, relating \nto a small number of important pieces of assimilated EU law. It is clear from the results \nof the consultation that these pieces of law should not be sunsetted on 26 May 2025, \nand should therefore be retained until such time as they are replaced. I can confirm that \nour intention is to replace them – and update the regulatory framework more widely – as \nsoon as is practical, and I know that many people and organisations are keen to be \ninvolved in that process.  \nI am just as interested in ensuring that our partners are involved and commit to keeping \nup regular communication. More information about the outcome of the other proposals \nin the consultation will follow in the coming weeks. \n \nBaroness Merron  \n                                              Parliamentary Under-Secretary of State for Patient Safety, \nWomen’s Health and Mental Health \n \n \n \n \n\n \n \n4 \n \nExecutive Summary \nThis document sets out the responses to the public consultation on the proposed \namendments to the Medical Devices Regulations 2002 regarding four specific pieces of \nassimilated EU law only. The consultation ran from 14 November 2024 to 5 January \n2025 and received 287 responses in total from various stakeholders, such as medical \ndevice suppliers and producers, healthcare professionals, trade associations, and \nindividuals.  \nThe majority of the respondents agreed with the government's proposals to remove the \nrevocation date of the four pieces of assimilated law so that they continue to apply in \nGreat Britain, until such time as they are replaced with updated UK law. Doing so will \navoid disruption to the regulatory framework and ensure continuity for manufacturers \nand all who use medical devices.  \nThe proposed approach applies to the regulatory framework for Great Britain. For \nguidance on the regulation of devices in Northern Ireland, see Regulation of devices in \nNorthern Ireland. \nThe other consultation proposals are not as time-sensitive and require more in-depth \nanalysis. The government response to those parts of the consultation will be published \nseparately in due course. \n \n \n \n \n \n\n \n \n5 \n \nIntroduction \nThe Medicines and Healthcare products Regulatory Agency (MHRA) is the UK \ngovernment agency responsible for the regulation of medical devices.  \nMedical devices are products or equipment that are used for medical purposes, such as \ndiagnosis, prevention, monitoring or treatment of diseases or injuries. They include a \nwide range of products, such as p",
    "(suisse)_Ordonnance_sur_les_dispositifs_medicaux_de_diagnostic_in_vitro_et_modification_de_lordonnance_sur_les_essais_cliniques_de_dispositifs_medicaux_.pdf": "Département fédéral de l'intérieur \nOffice fédéral de la santé publique OFSP \n \n \n \n \n \n \n \nOrdonnance sur les dispositifs médicaux de diagnos-\ntic in vitro et modification de l’ordonnance sur les es-\nsais cliniques de dispositifs médicaux  \n \n \nRapport explicatif  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAvril 2021 \n \n \n\nRapport explicatif ODiv et OClin-Dim \n \n \n2/71 \n \n \nTable des matières \n \n1 \nSituation initiale \n6 \n1.1 \nLes dispositifs médicaux et leur réglementation en Suisse ............................... 6 \n1.2 \nDéveloppements au sein de l’UE .......................................................................... 6 \n1.3 \nAdaptation du droit suisse à la nouvelle réglementation européenne relative \naux dispositifs médicaux ....................................................................................... 8 \n1.4 \nActes délégués et actes d’exécution de la Commission européenne ................ 9 \n2 \nCommentaire des différents articles \n11 \n2.1 \nOrdonnance sur les dispositifs médicaux de diagnostic in vitro (ODiv) .......... 11 \nChapitre 1 Dispositions générales ....................................................................................... 11 \nSection 1 Champ d’application et exceptions .................................................................... 11 \nArt. 1 \nChamp d’application .......................................................................................... 11 \nArt. 2 \nExceptions ......................................................................................................... 12 \nSection 2 Définitions et renvois au droit européen ............................................................. 12 \nArt. 3 \nDispositifs médicaux de diagnostic in vitro et accessoires de dispositifs médicaux \nde diagnostic in vitro .......................................................................................... 12 \nArt. 4 \nAutres définitions ............................................................................................... 12 \nArt. 5 \nRenvois au droit européen ................................................................................. 15 \nChapitre 2 Mise à disposition sur le marché et mise en service .......................................... 16 \nSection 1 Exigences .......................................................................................................... 16 \nArt. 6 \nExigences générales en matière de sécurité et de performances ...................... 16 \nArt. 7 \nVente à distance ................................................................................................ 17 \nArt. 8 \nExigences spécifiques ....................................................................................... 18 \nArt. 9 \nDispositifs fabriqués et utilisés dans des établissements de santé ..................... 18 \nArt. 10 \nDéclaration des dispositifs fabriqués dans un établissement de santé ............... 19 \nArt. 11 \nParties et composants ....................................................................................... 20 \nArt. 12 \nMarquage de conformité et numéro d’identification ............................................ 20 \nArt. 13 \nApposition du marquage de conformité et du numéro d’identification ................ 21 \nSection 2 Classification, étiquetage et identification du dispositif ....................................... 21 \nArt. 14 \nClassification ..................................................................................................... 21 \nArt. 15 \nInformation relative au dispositif......................................................................... 22 \nArt. 16 \nIdentification univoque des dispositifs ................................................................ 22 \nChapitre 3 Évaluation de la conformité, certificat et déclaration .......................................... 23 \nSection 1 Évaluation de la conformité ................................................................................ 23 \nArt. 17 \nPrincipe ............................................................................................................. 23 \nArt. 18 \nExceptions et dérogations.................................................................................. 24 \nArt. 19 \nProcédure .......................................................................................................... 25 \nArt. 20 \nRecours à un organisme désigné ...................................................................... 25 \nSection 2 Certificat de conformité ...................................................................................... 26 \nArt. 21 \nÉtablissement et contenu................................................................................... 26 \nArt. 22 \nDurée de validité ................................................................................................ 27 \nArt. 23 \nSuspension, restriction et révocation ................................................................. 27 \nArt. 24 \nObligation de document",
    "(suisse)189386-MU680_20_009e_WL_Incident_economic_operators.pdf": "Swissmedic | Hallerstrasse 7 | 3012 Berne | www.swissmedic.ch | Tel. +41 58 462 02 11 | anfragen@swissmedic.ch \n \n \nGuidance document \nIncident economic operators \nIdentification number: \nMU680_20_009 \nVersion: \n3.5 \nValid from: \n05.02.2025 \n\n \nMU680_20_009_WL - Wegleitung | 3.5 | 05.02.2025 \n \n2 /12 \nList of contents \n1 \nTerms, definitions, abbreviations ..................................................................................... 2 \n1.1 \nAbbreviations ....................................................................................................................... 2 \n1.2 \nTerms, definitions ................................................................................................................ 3 \n2 \nIntroduction ....................................................................................................................... 4 \n3 \nObjective ............................................................................................................................ 5 \n4 \nLegal basis and guidelines ............................................................................................... 5 \n5 \nObligations of the economic operators involved ............................................................ 5 \n6 \nWhich serious incidents must be reported to Swissmedic? .......................................... 6 \n6.1 \nExemptions from the reporting obligation ............................................................................. 6 \n7 \nHow should serious incidents be reported to Swissmedic? .......................................... 7 \n8 \nWhen should serious incidents be reported? ................................................................. 7 \n9 \nSubmission formats .......................................................................................................... 8 \n9.1 \nReporting procedure MIR .................................................................................................... 8 \n9.1.1 \nInvestigation by the manufacturer/SPPP ............................................................................. 8 \n9.1.2 \nEvaluation by Swissmedic ................................................................................................... 9 \n9.2 \nTrend Reports ..................................................................................................................... 9 \n9.3 \nPeriodic Summary Report (PSR) ......................................................................................... 9 \n9.4 \nSerious adverse events relating to devices in the context of clinical trials ............................ 9 \n10 \nObligations of the manufacturer and SPPP in respect of user reports ....................... 10 \n10.1 \nProcedural obligations ....................................................................................................... 10 \n10.2 \nJustification for “non-reportable incidents” ......................................................................... 11 \n11 \nData protection ................................................................................................................ 11 \n \n1 \nTerms, definitions, abbreviations \n1.1 \nAbbreviations \nClinO-MD \nOrdinance on Clinical Trials with Medical Devices (SR 810.306) \nFSCA  \nField Safety Corrective Action \nIvDO   \nOrdinance of 4 May 2022 on In Vitro Diagnostic Medical Devices (SR 812.219) \nIVDR  \nRegulation (EU) 2017/746 of the European Parliament and of the Council of 5 April \n2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and \nCommission Decision 2010/227/EU  \n \n\n \nMU680_20_009_WL - Wegleitung | 3.5 | 05.02.2025 \n \n3 /12 \nMDR \nRegulation (EU) 2017/745 of the European Parliament and of the Council of 5 April \n2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No. \n178/2002 and Regulation (EC) No. 1223/2009 and repealing Council Directives \n90/385/EEC and 93/42/EEC  \nMedDO  \nMedical Devices Ordinance of 1 July 2020 (SR 812.213) \nPSR \n \nPeriodic Summary Report \nSPPP  \nSystem and Procedure Pack Producer \nTPA   \nTherapeutic Products Act of 15 December 2000 (SR 812.21)  \n1.2 \nTerms, definitions \nDevice: In this guidance document, the term \"device\" refers to medical devices and other products \naccording to Art. 1 MedDO and in vitro diagnostic medical devices and the associated accessories \naccording to Art. 1 para. 1 IvDO. Where provisions apply only to specific devices or groups of devices \nin an ordinance (MedDO or IvDO), this is explicitly stated.  \nIncident1: means  \n§ \nany malfunction or deterioration in the characteristics or performance of a device made available \non the market,  \n§ \nincluding use-error due to ergonomic features,  \n§ \nas well as any inadequacy in the information supplied by the manufacturer.  \n \n§ \nFor devices specifically according to MedDO, the term incident also covers:  \n§ \nany undesirable side-effect \n \n§ \nFor devices specifically according to IvDO, the term incident also covers:  \n§ \nany harm as a consequence ",
    "(suisse)189387-MU680_21_010e_WL_FSCA_economic_operator.pdf": "Swissmedic | Hallerstrasse 7 | 3012 Berne | www.swissmedic.ch | Tel. +41 58 462 02 11 | anfragen@swissmedic.ch \n \n \nGuidance document \nFSCA economic operators \nIdentification number: \nMU680_21_010 \nVersion: \n3.1 \nValid from: \n05.02.2025 \n\n \nMU680_21_010_WL - Wegleitung | 3.1 | 05.02.2025 \n \n2 /9 \nList of contents \n1 \nTerms, definitions, abbreviations ..................................................................................... 2 \n1.1 \nAbbreviations..................................................................................................................... 2 \n1.2 \nTerms, definitions ................................................................................................................ 3 \n2 \nIntroduction ....................................................................................................................... 4 \n3 \nObjective ............................................................................................................................ 4 \n4 \nLegal basis ......................................................................................................................... 4 \n5 \nWhat is an FSCA? .............................................................................................................. 4 \n5.1 \nResponsibilities.................................................................................................................... 5 \n5.2 \nElectronic submission .......................................................................................................... 5 \n5.3 \nTime frame .......................................................................................................................... 6 \n6 \nTasks of Swissmedic ......................................................................................................... 6 \n6.1 \nEvaluation of actions ........................................................................................................... 6 \n6.2 \nFSN publication ................................................................................................................... 6 \n6.3 \nExchange with other authorities ........................................................................................... 7 \n6.3.1 \nNational authorities .............................................................................................................. 7 \n6.3.2 \nForeign authorities ............................................................................................................... 7 \n6.4 \nMonitoring the execution of FSCAs...................................................................................... 7 \n7 \nData protection .................................................................................................................. 7 \n \n1 \nTerms, definitions, abbreviations \n1.1 \nAbbreviations \nFOPH  \nFederal Office of Public Health \nFSCA  \nField Safety Corrective Action \nFSN \n \nField Safety Notice \nIvDO   \nOrdinance of 4 May 2022 on In Vitro Diagnostic Medical Devices (SR 812.219) \nIVDR  \n Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 \non in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission \nDecision 2010/227/EU  \n \nMDR  \n Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 \non medical devices, amending Directive 2001/83/EC, Regulation (EC) No. 178/2002 and \nRegulation (EC) No. 1223/2009 and repealing Council Directives 90/385/EEC and \n93/42/EEC  \nMedDO  \nMedical Devices Ordinance of 1 July 2020 (SR 812.213) \n\n \nMU680_21_010_WL - Wegleitung | 3.1 | 05.02.2025 \n \n3 /9 \nTPA   \nTherapeutic Products Act of 15 December 2000 (SR 812.21)  \n1.2 \nTerms, definitions \nDevice: In this guidance document, the term \"device\" refers to medical devices and other devices \naccording to Art. 1 MedDO and in vitro diagnostic medical devices and the associated accessories \naccording to Art. 1 para. 1 IvDO. Where provisions apply only to specific devices or device groups in \nan ordinance (MedDO or IvDO), this is explicitly stated.  \nField safety corrective action: A field safety corrective action (FSCA) means a corrective action taken \nfor technical or medical reasons1 to prevent or reduce the risk of a serious incident2.  \nManufacturer3: Any natural or legal person who manufactures or fully refurbishes a device or has a \ndevice designed, manufactured or fully refurbished, and markets that device under its name or \ntrademark; this definition is subject to the clarifying explanations and exceptions in Art. 16 para. 1 and \n2 MDR and Art. 16 para. 1 and 2 IVDR.  \nSystem and procedure pack producer: System and procedure pack producer (SPPP) refers to the \nnatural or legal person that assembles a system or procedure pack4. \nAuthorised representative5,*: Any natural or legal person domiciled in Switzerland who has received \nand accepted a written mandate from a manufacturer located in another country to act on the \nmanufacturer's b",
    "(suisse)189388-MU680_20_008e_WL_incident_report_user.pdf": "Swissmedic | Hallerstrasse 7 | 3012 Berne | www.swissmedic.ch | Tel. +41 58 462 02 11 | anfragen@swissmedic.ch \n \n \nGuidance document \nIncident report user \nIdentification number: \nMU680_20_008 \nVersion: \n3.3 \nValid from: \n18.02.2025 \n\n \nMU680_20_008_WL - Wegleitung | 3.3 | 18.02.2025 \n \n2 /9 \nList of contents \n1 \nTerms, definitions, abbreviations ..................................................................................... 2 \n1.1 \nAbbreviations ....................................................................................................................... 2 \n1.2 \nTerms, definitions ................................................................................................................ 3 \n2 \nIntroduction ....................................................................................................................... 3 \n3 \nObjective ............................................................................................................................ 3 \n4 \nWho must report? .............................................................................................................. 3 \n5 \nWhy report? ....................................................................................................................... 4 \n6 \nSerious incident: Definition .............................................................................................. 5 \n7 \nReporting a serious incident to Swissmedic ................................................................... 6 \n8 \nReporting a serious incident to the supplier ................................................................... 7 \n9 \nWhat is a UDI? ................................................................................................................... 7 \n10 \nRequirements for hospitals concerning UDI ................................................................... 7 \n11 \nReporting timelines ........................................................................................................... 7 \n12 \nTasks of Swissmedic in the context of vigilance relating to medical devices .............. 8 \n13 \nIncidents with medicinal products or blood products .................................................... 8 \n \n1 \nTerms, definitions, abbreviations \n1.1 \nAbbreviations \nFSCA  \nField Safety Corrective Action \nIvDO   \nOrdinance of 4 May 2022 on In Vitro Diagnostic Medical Devices (SR 812.219) \nIVDR \n Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 \non in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission \nDecision 2010/227/EU  \nMDR  \nRegulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 \non medical devices, amending Directive 2001/83/EC, Regulation (EC) No. 178/2002 and \nRegulation (EC) No. 1223/2009 and repealing Council Directives 90/385/EEC and \n93/42/EEC  \nMedDO \nMedical Devices Ordinance of 1 July 2020 (SR 812.213) \nSPPP \nSystem and procedure pack producer \nTPA \n \nTherapeutic Products Act of 15 December 2000 (SR 812.21)  \n\n \nMU680_20_008_WL - Wegleitung | 3.3 | 18.02.2025 \n \n3 /9 \n1.2 \nTerms, definitions \nDevice In this guidance document, the term \"device\" refers to medical devices and other groups of \nproducts according to Art. 1 MedDO and in vitro diagnostic medical devices and the associated \naccessories according to Art. 1 para. 1 IvDO. Where provisions apply only to specific devices or \ndevice groups in an ordinance (MedDO or IvDO), this is explicitly stated.  \nManufacturer1: A natural or legal person who manufactures or fully refurbishes a device or has a \ndevice designed, manufactured or fully refurbished, and markets that device under its name or \ntrademark; this definition is subject to the clarifying explanations and exceptions in Art. 16 paras. 1 \nand 2 MDR and Art.16 paras. 1 and 2 IVDR.  \nSystem and procedure pack producer2: System and procedure pack producer refers to the natural \nor legal person that assembles a system or procedure pack. \n2 \nIntroduction \nThe TPA requires professional users in Switzerland and Liechtenstein* to report serious incidents \ninvolving therapeutic products to Swissmedic3. For devices, this reporting obligation is explicitly \nregulated in the MedDO and IvDO4. \n3 \nObjective \nThis guidance document describes the purpose of user reports in the context of vigilance relating to \ndevices and is designed to serve as a guide for users in implementing the legal requirements. \n4 \nWho must report? \nAnyone who uses a device in connection with their work or who uses a device on other people or for \ndiagnosis is subject to the reporting obligation. The reporting requirement therefore affects doctors, \ndentists, therapists, laboratory technicians, paramedics, nurses and other professionals such as \nbeauticians. The professional who becomes aware of a serious incident5 during the use of a device is \nresponsible for reporting that incident6 . This person must report the serious incident either",
    "(suisse)fedlex-data-admin-ch-eli-cc-2013-617-20210526-en-pdf-a.pdf": "1 \n    \nEnglish is not an official language of the Swiss Confederation. This translation is \nprovided for information purposes only and has no legal force. \n   \nFederal Act \non Research involving Human Beings \n(Human Research Act, HRA) \n \nof 30 September 2011 (Status as of 26 May 2021) \n \nThe Federal Assembly of the Swiss Confederation, \non the basis of Article 118b paragraph 1 of the Federal Constitution1, \nand having considered the Dispatch of the Federal Council dated 21 October 20092, \ndecrees: \nChapter 1 \nGeneral Provisions \nSection 1 \nPurpose, Scope and Definitions \nArt. 1 \nPurpose \n1 The purpose of this Act is to protect the dignity, privacy and health of human \nbeings involved in research. \n2 It is also designed to: \na. \ncreate favourable conditions for research involving human beings; \nb. \nhelp to ensure the quality of research involving human beings; \nc. \nensure the transparency of research involving human beings. \nArt. 2 \nScope \n1 This Act applies to research concerning human diseases and concerning the struc-\nture and function of the human body, which involves: \na. \npersons; \nb. \ndeceased persons; \nc. \nembryos and foetuses; \nd. \nbiological material; \ne. \nhealth-related personal data. \n  \n AS 2013 3215 \n1 \nSR 101 \n2 \nBBl 2009 8045 \n810.30 \n\nMedicine and Human Dignity \n2 \n810.30 \n2 It does not apply to research which involves: \na. \nIVF embryos in accordance with the Stem Cell Research Act of \n19 December 20033; \nb. \nanonymised biological material; \nc. \nanonymously collected or anonymised health-related data. \nArt. 3 \nDefinitions \nIn this Act: \na. \nResearch means method-driven search for generalisable knowledge; \nb. \nResearch concerning diseases means research on the causes, prevention, di-\nagnosis, treatment and epidemiology of impairments of physical and mental \nhealth in human beings; \nc. \nResearch concerning the structure and function of the human body means \nbasic research, in particular on human anatomy, physiology and genetics, \nand non-disease-related research concerning interventions and impacts on \nthe human body; \nd. \nResearch project with an expected direct benefit means a research project \nwhose results can be expected to improve the health of the participants; \ne. \nBiological material means bodily substances derived from living persons; \nf. \nHealth-related personal data means information concerning the health or \ndisease of a specific or identifiable person, including genetic data; \ng. \nGenetic data means information on a person's genes, obtained by genetic \ntesting; \nh. \nCoded biological material and coded health-related personal data means \nbiological material and data linked to a specific person via a code; \ni. \nAnonymised biological material and anonymised health-related data means \nbiological material and health-related data which cannot (without dispropor-\ntionate effort) be traced to a specific person; \nj. \nChild means a legal minor under 14 years of age; \nk.  Adolescent means a legal minor aged 14 years or more; \nl.4 \n... \n  \n  \n3 \nSR 810.31 \n4 \nRepealed by Annex of the FA of 22 March 2019, with effect from 26 May 2021 \n(AS 2020 2961; BBl 2019 1). \n\nHuman Research Act \n3 \n810.30 \nSection 2 \nPrinciples \nArt. 4 \nPrimacy of individual interests \nThe interests, health and welfare of the individual human being shall prevail over the \ninterests of science and society. \nArt. 5 \nScientifically relevant topic \nResearch involving human beings may only be carried out if it addresses a topic of \nscientific relevance concerning: \na. \nthe understanding of human diseases; \nb. \nthe structure and function of the human body; or \nc. \npublic health. \nArt. 6 \nNon-discrimination \n1 Nobody is to be subjected to discrimination in connection with research. \n2 With regard to the selection of participants in particular, no group of persons shall \nbe disproportionately included in or excluded from research without good reason. \nArt. 7 \nConsent \n1 Research involving human beings may only be carried out if, in accordance with \nthe provisions of this Act, the persons concerned have given their informed consent \nor, after being duly informed, have not exercised their right to dissent. \n2 The persons concerned may withhold or revoke their consent at any time, without \nstating their reasons. \nArt. 8 \nRight to receive information \n1 The persons concerned are entitled to be informed of results relating to their health. \nThe information is to be communicated in an appropriate manner. The persons \nconcerned may choose to forgo such information. \n2 They are entitled to be informed about all the personal data held in relation to \nthem. \nArt. 95 \nProhibition of commercialisation \n1 It is prohibited to offer, grant, demand or accept payment or any other non-cash \nadvantage in exchange for the human body or parts thereof as such. \n  \n5 \nAmended by Annex No 2 of the FD of 19 June 2020 on the Approval of the Council of \nEurope Convention against Trafficking in Human Organs and on its Implementation, \nin force since 1 Feb",
    "(UE)_97934-OJ_L_202402631_EN_TXT.pdf": "COMMISSION IMPLEMENTING DECISION (EU) 2024/2631 \nof 8 October 2024\namending Implementing Decision (EU) 2021/1182 as regards the harmonised standard for aseptic \nprocessing of health care products \n(Text with EEA relevance) \nTHE EUROPEAN COMMISSION,\nHaving regard to the Treaty on the Functioning of the European Union,\nHaving regard to Regulation (EU) No 1025/2012 of the European Parliament and of the Council of 25 October 2012 on \nEuropean standardisation, amending Council Directives 89/686/EEC and 93/15/EEC and Directives 94/9/EC, 94/25/EC, \n95/16/EC, 97/23/EC, 98/34/EC, 2004/22/EC, 2007/23/EC, 2009/23/EC and 2009/105/EC of the European Parliament \nand of the Council and repealing Council Decision 87/95/EEC and Decision No 1673/2006/EC of the European \nParliament and of the Council (1), and in particular Article 10(6) thereof,\nWhereas:\n(1) \nIn accordance with Article 8(1) of Regulation (EU) 2017/745 of the European Parliament and of the Council (2), \ndevices that are in conformity with the relevant harmonised standards, or the relevant parts of those standards, the \nreferences of which have been published in the Official Journal of the European Union, are to be presumed to be in \nconformity with the requirements of that Regulation covered by those standards or parts thereof.\n(2) \nRegulation (EU) 2017/745 replaced Council Directives 90/385/EEC (3) and 93/42/EEC (4) with effect from 26 May \n2021.\n(3) \nBy Implementing Decision C(2021) 2406 (5), the Commission made a request to the European Committee for \nStandardization (CEN) and the European Committee for Electrotechnical Standardization (CENELEC) for the \nrevision of existing harmonised standards on medical devices developed in support of Directives 90/385/EEC \nand 93/42/EEC and for the drafting of new harmonised standards in support of Regulation (EU) 2017/745 (‘the \nrequest’).\n(4) \nOn the basis of the request, CEN and CENELEC revised the harmonised standard EN ISO 13408-1:2015 for aseptic \nprocessing of health care products, the reference of which is not published in the Official Journal of the European \nUnion, in order to take into account the latest technical and scientific progress and the need to support the \nrequirements of Regulation (EU) 2017/745.\n(5) \nThis resulted in the adoption of the harmonised standard EN ISO 13408-1:2024 (‘the standard’).\nOfficial Journal \nof the European Union \nEN \nL series \n2024/2631 \n9.10.2024\nELI: http://data.europa.eu/eli/dec_impl/2024/2631/oj \n1/3\n(1) OJ L 316, 14.11.2012, p. 12, ELI: http://data.europa.eu/eli/reg/2012/1025/oj.\n(2) Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending \nDirective 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council \nDirectives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p. 1, ELI: http://data.europa.eu/eli/reg/2017/745/oj).\n(3) Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable \nmedical devices (OJ L 189, 20.7.1990, p. 17, ELI: http://data.europa.eu/eli/dir/1990/385/oj).\n(4) Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (OJ L 169, 12.7.1993, p. 1, ELI: http://data.europa.eu/eli/ \ndir/1993/42/oj).\n(5) Commission Implementing Decision C(2021) 2406 of 14 April 2021 on a standardisation request to the European Committee for \nStandardization and the European Committee for Electrotechnical Standardization as regards medical devices in support of Regulation \n(EU) 2017/745 of the European Parliament and of the Council and in vitro diagnostic medical devices in support of Regulation \n(EU) 2017/746 of the European Parliament and of the Council. Available online on: https://ec.europa.eu/growth/tools-databases/ \nenorm/mandate/575_en.\n\n(6) \nThe Commission together with CEN and CENELEC has assessed whether the standard complies with the request.\n(7) \nThe standard satisfies the requirements which it aims to cover, and which are set out in Regulation (EU) 2017/745. It \nis therefore appropriate to publish the reference of the standard in the Official Journal of the European Union.\n(8) \nThe Annex to Commission Implementing Decision (EU) 2021/1182 (6) lists the references of harmonised standards \ndrafted in support of Regulation (EU) 2017/745.\n(9) \nIn order to ensure that the references of harmonised standards drafted in support of Regulation (EU) 2017/745 are \nlisted in one act, the reference of the standard should be included in Implementing Decision (EU) 2021/1182.\n(10) \nImplementing Decision (EU) 2021/1182 should therefore be amended accordingly.\n(11) \nCompliance with a harmonised standard confers a presumption of conformity with the corresponding essential \nrequirements set out in Union harmonisation legislation from the date of publication of the reference of such \nstandard in the Official Journal of the European Union. This Decision should therefore enter into force on the day of its \npublicat",
    "(UE)_COM_2024_43_FIN_EN_TXT.pdf": "EN \n \n EN \n \n \nEUROPEAN \nCOMMISSION \nBrussels, 23.1.2024  \nCOM(2024) 43 final \n2024/0021 (COD) \n \nProposal for a \nREGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL \namending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of \nEudamed, information obligation in case of interruption of supply and the transitional \nprovisions for certain in vitro diagnostic medical devices \n(Text with EEA relevance) \n \n\nEN \n1 \n EN \nEXPLANATORY MEMORANDUM \n1. \nCONTEXT OF THE PROPOSAL \n• \nReasons for and objectives of the proposal \nRegulation (EU) 2017/745 (the ‘Medical Devices Regulation’ (MDR))1 and \nRegulation (EU) 2017/746 (the ‘In Vitro Diagnostic Medical Devices Regulation’ \n(IVDR))2 of the European Parliament and of the Council set a strengthened \nregulatory framework for medical devices and in vitro diagnostic medical devices \n(IVDs). Their objectives are a high level of protection of health for patients and users \nand the smooth functioning of the single market for these products. To achieve these \nobjectives and to address issues identified with the previous regulatory framework, \nthe Regulations set up a more robust system of conformity assessment to ensure the \nquality, safety and performance of devices placed on the EU market.  \nThe MDR has applied since 26 May 20213. The transitional period provided for in \nArticle 120 has been extended by Regulation (EU) 2023/6074 and will end on either \n31 December 2027 or 31 December 2028, depending on the device’s risk class and \nsubject to certain conditions.  \nThe IVDR has applied since 26 May 2022. In January 2022, the European Parliament \nand the Council adopted a staggered extension of its transitional period, ranging from \n26 May 2025 for high-risk IVDs to 26 May 2027 for lower-risk IVDs, and to \n26 May 2028 for certain provisions concerning devices manufactured and used in \nhealth institutions5. This extension was not subject to conditions similar to the ones \nlaid down for medical devices by Regulation (EU) 2023/607.  \nThis proposal for targeted amendments addresses two urgent issues. Firstly, it aims \nto further extend the transitional period for certain IVDs to mitigate the risk of \nshortages of these products, especially of high-risk IVDs, which are used, for \nexample, to test for infections in blood or organ donations or for blood grouping for \ntransfusions.  \nSecondly, the proposal aims to enable a gradual roll-out of the electronic systems \nintegrated into the European database on medical devices (‘Eudamed’) that are \nfinalised, instead of deferring the mandatory use of Eudamed until the last of the six \n \n1 \nRegulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical \ndevices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No \n1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p. 1). \n2 \nRegulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro \ndiagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU \n(OJ L 117, 5.5.2017, p. 176). \n3 \nRegulation (EU) 2020/561 of the European Parliament and of the Council of 23 April 2020 amending \nRegulation (EU) 2017/745 on medical devices, as regards the dates of application of certain of its \nprovisions (OJ L 130, 24.4.2020, p. 18) had postponed the date of application of Regulation (EU) \n2017/745 from 26 May 2020 to 26 May 2021 due to the COVID-19 outbreak and the associated public \nhealth crisis. \n4 \nRegulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending \nRegulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical \ndevices and in vitro diagnostic medical devices (OJ L 80, 20.3.2023, p. 24). \n5 \nRegulation (EU) 2022/112 of the European Parliament and of the Council of 25 January 2022 amending \nRegulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical \ndevices and the deferred application of conditions for in-house devices (OJ L 19, 28.1.2022, p. 3). \n\nEN \n2 \n EN \nmodules is completed. The use of Eudamed – and especially its systems for the \nregistration of economic operators, devices and certificates – will improve \ntransparency and provide information on devices on the EU market, helping to \nmonitor the availability of devices.  \nIn addition, the proposal aims to impose a requirement on manufacturers to give \nprior notice before interrupting the supply of certain critical medical devices and \nIVDs.  \na) \nTransition of devices to the IVDR   \nThere is a wide variety of IVDs, including HIV tests for blood donation screening or \nindividual diagnosis, cancer tests, pregnancy tests or SARS-CoV-2 tests. Around two \nthirds of all clinical decisions are based on information provided by IVDs6. It is \nparamount to ensure both a high level of safety and performance of IVDs and their \navailabili",
    "(UE)_Liste_de_controle_du_SMQ.pdf": "LISTE DE CONTRÔLE \nSMQ \nMDSAP \nISO13485 \nMDR (basé sur MDR + \nexigences ISO13485) \nIVDR (basé sur les \nexigences IVDR+ ISO13485)  \nPartie 820 du CFR \n21 de la FDA \n1. Exigences générales \ndu SMQ \n \n \n \n \n \n1.1 Exigences \ngénérales \n \n☑ \n☑ \n☑ \n \n1.1.1 Stratégie de \nconformité \nréglementaire - \nPlanification, mise en \nœuvre et \nmodifications du SMQ \n \n☑ \n☑ \n☑ \n \n1.1.2 Identification \ndes exigences en \nmatière de sécurité et \nd'efficacité/de GSPR \n☑ \n \n☑ \n☑ \n \n1.2 Exigences en \nmatière de \ndocumentation \n☑ \n☑ \n☑ \n☑ \n \n1.2.1 Politique et \nobjectifs qualité \n \n☑ \n☑ \n☑ \n \n1.2.2 Manuel Qualité \n \n☑ \n☑ \n☑ \n \n1.2.3 Fichier \nd'historique de \nl'appareil \n \n \n \n \n☑ \n1.2.4 Dossier du \ndispositif médical \n(dossier principal du \ndispositif + \ndocumentation \ntechnique) \n \n☑ \n☑ \n☑ \n \n\nLISTE DE CONTRÔLE \nSMQ \nMDSAP \nISO13485 \nMDR (basé sur MDR + \nexigences ISO13485) \nIVDR (basé sur les \nexigences IVDR+ ISO13485)  \nPartie 820 du CFR \n21 de la FDA \n1.2.5 \nEnregistrement/fichier \nmaître du \npériphérique \n☑ \n☑ \n☑ \n☑ \n☑ \n1.2.6 Enregistrement \nde l'historique de \nl'appareil \n \n \n \n \n☑ \n1.2.7 Contrôle des \ndocuments \n☑ \n☑ \n☑ \n☑ \n☑ \n1.2.8 Contrôle des \nenregistrements \n☑ \n☑ \n☑ \n☑ \n \n1.2.8.1 Conservation \ndes documents \n☑ \n☑ \n☑ \n☑ \n \n2. Responsabilité de la \ndirection \n \n \n \n \n \n2.1 Structure \norganisationnelle \n☑ \n☑ \n☑ \n☑ \n☑ \n2.2 Engagement de la \nhaute direction en \nmatière de qualité \n☑ \n☑ \n☑ \n☑ \n☑ \n2.2.1 Orientation \nclient \n \n☑ \n☑ \n☑ \n \n2.3 Responsabilité et \nautorité \n☑ \n☑ \n☑ \n☑ \n☑ \n2.3.1 Représentant de \nla direction \n☑ \n☑ \n☑ \n☑ \n☑ \n\nLISTE DE CONTRÔLE \nSMQ \nMDSAP \nISO13485 \nMDR (basé sur MDR + \nexigences ISO13485) \nIVDR (basé sur les \nexigences IVDR+ ISO13485)  \nPartie 820 du CFR \n21 de la FDA \n2.3.2 Politique de \nqualité \n☑ \n☑ \n☑ \n☑ \n☑ \n2.3.3 Communication \ninterne \n \n☑ \n☑ \n☑ \n \n2.3.4 Revue de \ndirection (entrées et \nsorties de la revue) \n☑ \n☑ \n☑ \n☑ \n☑ \n2.4 Planification \n☑ \n☑ \n☑ \n☑ \n☑ \n2.4.1 Objectifs de \nqualité \n☑ \n☑ \n☑ \n☑ \n \n2.4.2 Planification du \nsystème de gestion de \nla qualité \n☑ \n☑ \n☑ \n☑ \n☑ \n3. Gestion des \nressources \n \n \n \n \n \n3.1 Fourniture de \nmatériel \n☑ \n☑ \n☑ \n☑ \n☑ \n3.1.1 Calendrier \nd'entretien \n \n \n \n \n☑ \n3.1.2 Inspection \n \n \n \n \n☑ \n3.1.3 Réglage \n \n \n \n \n☑ \n3.1.4 Normes et \nenregistrements \nd'étalonnage \n☑ \n \n \n \n☑ \n\nLISTE DE CONTRÔLE \nSMQ \nMDSAP \nISO13485 \nMDR (basé sur MDR + \nexigences ISO13485) \nIVDR (basé sur les \nexigences IVDR+ ISO13485)  \nPartie 820 du CFR \n21 de la FDA \n3.2 Ressources \nhumaines \n☑ \n☑ \n☑ \n☑ \n☑ \n3.2.1 Formation du \npersonnel \n☑ \n☑ \n☑ \n☑ \n☑ \n3.2.2 Registres de \nformation, \nd’éducation, de \ncompétences et \nd’expérience \n☑ \n \n \n \n☑ \n3.2.3 Critères de \nqualité de fabrication \n☑ \n \n \n \n☑ \n3.3 Infrastructure \n☑ \n☑ \n☑ \n☑ \n☑ \n3.3.1 Exigences en \nmatière \nd'infrastructure \n(bâtiments, \néquipements de \ntraitement et services \nde soutien) \n☑ \n☑ \n☑ \n☑ \n☑ \n3.3.2 Enregistrements \ndes activités de \nmaintenance \n☑ \n☑ \n☑ \n☑ \n☑ \n3.4 Environnement de \ntravail et contrôle de \nla contamination \n☑ \n☑ \n☑ \n☑ \n☑ \n3.4.1 Exigences \nrelatives à \nl’environnement de \ntravail \n☑ \n☑ \n☑ \n☑ \n☑ \n\nLISTE DE CONTRÔLE \nSMQ \nMDSAP \nISO13485 \nMDR (basé sur MDR + \nexigences ISO13485) \nIVDR (basé sur les \nexigences IVDR+ ISO13485)  \nPartie 820 du CFR \n21 de la FDA \n3.4.1.1 Santé, \npropreté et \nhabillement du \npersonnel \n☑ \n☑ \n☑ \n☑ \n☑ \n3.4.2 Contrôle de la \ncontamination \n☑ \n☑ \n☑ \n☑ \n☑ \n3.4.2.1 Dispositions \npour le contrôle et la \nprévention de la \ncontamination \n☑ \n☑ \n☑ \n☑ \n \n4. Réalisations de \nproduits \n \n \n \n \n \n4.1 Planification de la \nréalisation du produit \n☑ \n☑ \n☑ \n☑ \n \n4.2 Processus liés aux \nclients \n \n☑ \n☑ \n☑ \n \n4.3 Détermination des \nexigences relatives au \nproduit \n \n☑ \n☑ \n☑ \n \n4.4 Examen des \nexigences liées au \nproduit \n \n☑ \n☑ \n☑ \n \n4.5 Communication \navec le client \n \n☑ \n☑ \n☑ \n \n4.5.1 Informations sur \nle produit \n \n☑ \n☑ \n☑ \n \n4.5.2 Demandes de \nrenseignements, \ncontrats ou traitement \n \n☑ \n☑ \n☑ \n \n\nLISTE DE CONTRÔLE \nSMQ \nMDSAP \nISO13485 \nMDR (basé sur MDR + \nexigences ISO13485) \nIVDR (basé sur les \nexigences IVDR+ ISO13485)  \nPartie 820 du CFR \n21 de la FDA \ndes commandes, y \ncompris les \nmodifications \n4.6 Conception et \ndéveloppement \n☑ \n☑ \n☑ \n☑ \n \n4.6.1 Identification \ndes dispositifs soumis \naux procédures de \nconception et de \ndéveloppement ; \ndocumentation \ntechnique \n☑ \n☑ \n☑ \n☑ \n☑ \n4.6.2 Planification de \nla conception et du \ndéveloppement \n☑ \n☑ \n☑ \n☑ \n☑ \n4.6.3 Entrées de \nconception et de \ndéveloppement \n☑ \n☑ \n☑ \n☑ \n☑ \n4.6.4 Résultats de la \nconception et du \ndéveloppement \n☑ \n☑ \n☑ \n☑ \n☑ \n4.6.5 Examen de la \nconception et du \ndéveloppement \n☑ \n☑ \n☑ \n☑ \n☑ \n4.6.6 Vérification de la \nconception et du \ndéveloppement \n☑ \n☑ \n☑ \n☑ \n☑ \n4.6.7 Validation de la \nconception et du \ndéveloppement \n☑ \n☑ \n☑ \n☑ \n \n\nLISTE DE CONTRÔLE \nSMQ \nMDSAP \nISO13485 \nMDR (basé sur MDR + \nexigences ISO13485) \nIVDR (basé sur les \nexigences IVDR+ ISO13485)  \nPartie 820 du CFR \n21 de la FDA \n4.6.7.1 Exigences \nrelatives aux \ndispositifs médicaux \nstériles \n☑ \n☑ \n☑ \n☑ \n \n4.6.7.2 Exigences \nrelatives à la \nvalidation des \nprocédés de ",
    "(UE)amending_Implementing_Regulation_(EU)_2021,,2226_as_regards_the_medical_devices_for.pdf": "EN \n \n EN \n \n \nEUROPEAN \nCOMMISSION \nBrussels, XXX  \nPLAN/2024/2826 \n(POOL/D3/2024/2826/2826-EN \nfeedback.docx) \n[…](2025) XXX draft \n \nCOMMISSION IMPLEMENTING REGULATION (EU) …/... \nof XXX \namending Implementing Regulation (EU) 2021/2226 as regards the medical devices for \nwhich the instructions for use may be provided in electronic form \n(Text with EEA relevance) \nThis draft has not been adopted or endorsed by the European Commission. Any \nviews expressed are the preliminary views of the Commission services and may not \nin any circumstances be regarded as stating an official position of the Commission. \n \nRef. Ares(2025)1431476 - 21/02/2025\n\n \nEN \n1 \n EN \nCOMMISSION IMPLEMENTING REGULATION (EU) …/... \nof XXX \namending Implementing Regulation (EU) 2021/2226 as regards the medical devices for \nwhich the instructions for use may be provided in electronic form \n(Text with EEA relevance) \nTHE EUROPEAN COMMISSION, \nHaving regard to the Treaty on the Functioning of the European Union, \nHaving regard to Regulation (EU) 2017/745 of the European Parliament and of the Council of \n5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) \nNo 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives \n90/385/EEC and 93/42/EEC1, and in particular Article 5(6) thereof, \nWhereas: \n(1) \nCommission Implementing Regulation (EU) 2021/22262 limits its application to \ncertain medical devices and their accessories. \n(2) \nThe results of a survey on replacing paper-based instructions for use by electronic \ninstructions for use the Commission carried out from 1 August to 10 October 2024 \nshow a clear preference, among healthcare professionals, for receiving instructions for \nuse in electronic form than in paper. Providing instructions for use in electronic form \nhelps the health sector deliver better and faster solutions. \n(3) \nThe scope of application of Implementing Regulation (EU) 2021/2226 should \ntherefore be extended to all medical devices and their accessories covered by \nRegulation (EU) 2017/745 that are intended for professional users. \n(4) \nFrom the moment in which the registration of devices in the European database on \nmedical devices (Eudamed) becomes mandatory, manufacturers should provide to \nEudamed’s Unique Device Identifier (‘UDI’) database the Uniform Resource Locator \n(‘URL’) under which the electronic instructions for use are persistently accessible.  \n(5) \nFor devices that fall under the transitional provisions provided for in Article 120 of \nRegulation (EU) 2017/745, Commission Regulation (EU) No 207/20123, now \nrepealed, should continue to apply until the end of the transitional period provided for \nin paragraph 3a, point (b), of Article 120 of Regulation (EU) 2017/745.  \n(6) \nImplementing Regulation (EU) 2021/2226 should therefore be amended accordingly. \n \n1 \nOJ L 117, 5.5.2017, p. 1, ELI: http://data.europa.eu/eli/reg/2017/745/oj.  \n2 \nCommission Implementing Regulation (EU) 2021/2226 of 14 December 2021 laying down rules for the \napplication of Regulation (EU) 2017/745 of the European Parliament and of the Council as regards \nelectronic instructions for use of medical devices (OJ L 448, 15.12.2021, p. 32, ELI: \nhttp://data.europa.eu/eli/reg_impl/2021/2226/oj). \n3 \nCommission Regulation (EU) No 207/2012 of 9 March 2012 on electronic instructions for use of \nmedical devices (OL L 72, 10.3.2012, p. 28, ELI: http://data.europa.eu/eli/reg/2012/207/oj). \n\n \nEN \n2 \n EN \n(7) \nThe measures provided for in this Regulation are in accordance with the opinion of the \nCommittee on Medical Devices, \nHAS ADOPTED THIS REGULATION: \nArticle 1 \nImplementing Regulation (EU) 2021/2226 is amended as follows:  \n(1) \nin Article 3, paragraph (1) is replaced by the following: \n‘(1) Manufacturers may provide instructions for use in electronic form instead of in \npaper form where those instructions relate to medical devices and their \naccessories covered by Regulation (EU) 2017/745 intended for use by \nprofessional users.’;  \n(2) \nin Article 6, paragraph (4) is replaced by the following: \n‘(4) Where, for implantable medical devices and their accessories covered by \nRegulation (EU) 2017/745, a part of the instructions for use is intended to be \nprovided to the patient, that part shall not be provided in electronic form.’; \n(3) \nin Article 7, the following paragraph is added: \n‘(3) The instructions for use in electronic form shall be available through a \npersistently accessible Uniform Resource Locator (URL), which the \nmanufacturer shall provide to the UDI database in accordance with Part B, \npoint 22, of Annex VI to Regulation (EU) 2017/745, at the latest when the \nregistration of devices in Eudamed applies in accordance with Article 123(3), \npoints (d) and (e), of that Regulation.’; \n(4) \nin Article 10, second subparagraph, the date ‘26 May 2024’ is replaced by ’31 \nDecember 2028, at the latest’. \nArticle 2 \nThis Regulation shall enter into force on the twentieth day following that of its publ",
    "(UE)Application_of_hybrid_audits_to_quality_management_system.pdf": "NBCG-MED 2024-1 \nApplication of hybrid audits to quality management system \nassessments under MDR/IVDR – operational elements \nJune 2024 \n \nThis document has been produced by NBCG-MED – Notified Bodies Coordination Group established in \naccordance with Article 49 of MDR / Article 45 of IVDR,  and reflects the consensus position of notified \nbodies designated under: \n \nMDR (Medical Devices Regulation) – Regulation (EU) 2017/745  \n \nIVDR (In-Vitro Diagnostics Regulation) – Regulation (EU) 2017/746 \n\n \n \n \nNotified Bodies Coordination Group  \nNBCG-MED 2024-1 \n \nPage 1 of 5 \n \nNBCG-MED 2024-1 \nApplication of hybrid audits to quality management system assessments under \nMDR/IVDR – operational elements   \n \nDevelopment and adoption note \nThis document has been initially developed and adopted by notified bodies as Team-NB position paper \n“Notified bodies’ paper on the application of hybrid audits to quality management system assessments \nunder MDR/IVDR” 1. \nIn  this version, the document has been updated taking into consideration the comments of the Notified \nBody Oversight subgroup of MDCG2 and adopted as NBCG-Med position. This is the first version of the \ndocument after its adoption as NBCG-MED position. This document is available in the dedicated \nsection of the European Commission’s website3. \n \n1. Background \nTraditionally, quality management system (QMS) audits are performed on-site. However, during the \ntime of the global pandemic, notified bodies implemented procedures to apply alternative methods \nutilising information and communication technologies (ICT), in alignment with the applicable \nrequirements and guidance such as MDCG 2020-44 and IAF  MD 45. \nThis document has been developed following the advice from the MDCG to further elaborate on \noperational elements of ‘hybrid audits’ including the identification of aspects to be audited on the \nauditee’s premises, as included in MDCG 2022-176. This document represents the notified bodies’ \ncollective position on the aspects to be considered when applying ICT -based auditing methods (‘hybrid \naudits’) specifically to quality management system audits under MDR/IVDR. \n \n1 Team-NB is the European association of notified bodies for medical devices, Team NB (team-nb.org). \n2 MDCG (Medical Device Coordination Group) is an expert group established under Article 103 of MDR and as referenced in Article 98 of \nIVDR. \n3 European Commission / Public Health / Home / Medical Devices - Dialogue between interested parties / Overview (health.ec.europa.eu) \nwebsite, subsection  Notified Body Coordination Group. \n4 MDCG 2020-4 Guidance on temporary extraordinary measures related to medical device notified body audits during COVID-19 quarantine \norders and travel restrictions. \n5 IAF MD 4:2023 Use of Information and Communication Technology (ICT) for Auditing/Assessment Purposes. \n6 MDCG 2022-17 MDCG position paper on “hybrid audits”. \n\n \n \n \nNotified Bodies Coordination Group  \nNBCG-MED 2024-1 \n \nPage 2 of 5 \n \n2. Hybrid audits in the context of legislative requirements \nNotified bodies are required to undertake on-site audits of manufacturer’s QMS both as part of the \ninitial audit and surveillance audits. In  relation to the initial audit, Annex IX  section 2.3 of MDR/IVDR \nstates: \nThe assessment procedure shall include an audit on the manufacturer's premises and, if appropriate, \non the premises of the manufacturer's suppliers and/or subcontractors to verify the manufacturing \nand other relevant processes. \nIn  relation to surveillance audits, Annex IX  section 3.3 of MDR/IVDR states: \nNotified bodies shall periodically, at least once every 12 months, carry out appropriate audits and \nassessments to make sure that the manufacturer in question applies the approved quality \nmanagement system and the post-market surveillance plan. Those audits and assessments shall \ninclude audits on the premises of the manufacturer and, if appropriate, of the manufacturer's suppliers \nand/or subcontractors. \nIn  accordance with these requirements, where quality management system audits to MDR/IVDR are \nperformed using alternative methods based on ICT,  at least a portion of these audits must be performed \non-site to cover the manufacturing and other relevant processes, i.e. the audit must be a hybrid audit \nas defined in MDCG 2022-17: \nA ‘hybrid audit’ should be understood as an audit on the premises of the manufacturer or its supplier(s) \nand/or subcontractor(s) with at least one auditor present on the premises and other members of the \naudit team participating from elsewhere using information and communication technologies (ICT). \nSuch hybrid audits undertaken by appropriately qualified staff would satisfy the on-site audit \nrequirements of MDR/IVDR referenced above. \nFrom experience gained during pandemic, hybrid audits, when appropriately planned, are effective and \nhave the following advantages compared to fully on-site audits: \n \nAccording to notified bodies’ estimation, hybrid au",
    "(UE)OJ_L_202302482_EN_TXT.pdf": "ELI: http://data.europa.eu/eli/reg/2023/2482/oj \n1/4\nCOMMISSION REGULATION (EU) 2023/2482 \nof 13 November 2023\namending Regulation (EC) No 1907/2006 of the European Parliament and of the Council as regards \nthe substance bis(2-ethylhexyl) phthalate (DEHP) in medical devices \n(Text with EEA relevance) \nTHE EUROPEAN COMMISSION,\nHaving regard to the Treaty on the Functioning of the European Union,\nHaving regard to Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006\nconcerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European \nChemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission \nRegulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, \n93/67/EEC, 93/105/EC and 2000/21/EC (1), and in particular Articles 58 and 131 thereof,\nWhereas:\n(1)\nCommission Regulation (EU) 2021/2045 (2) amending Annex XIV to Regulation (EC) No 1907/2006 sets 27 May \n2025 as sunset date and 27 November 2023 as latest application date for uses of the substance bis(2-ethylhexyl) \nphthalate (DEHP) in medical devices. In accordance with Article 56(1) of Regulation (EC) No 1907/2006, such uses \nof DEHP are not allowed after the sunset date unless an authorisation has been granted for a particular use, or \nunless an application for authorisation for a given use was submitted before the latest application date and a \ndecision on the application has not yet been taken.\n(2)\nThe sunset date and the latest application date for DEHP in Regulation (EU) 2021/2045 were aligned with the \ntransitional provisions laid down in Regulations (EU) 2017/745 (3) and (EU) 2017/746 (4) of the European \nParliament and of the Council. Those transitional provisions provided that medical devices with a valid certificate \nissued under Council Directives 90/385/EEC (5) and 93/42/EEC (6) or Directive 98/79/EC of the European \nParliament and the Council (7) could be placed on the market until 26 May 2024 and continue to be made available \non the market or put into service until 26 May 2025.\n(3)\nFor certain in vitro diagnostic medical devices, Regulation (EU) 2022/112 of the European Parliament and the \nCouncil (8) has extended the transitional period laid down in Regulation (EU) 2017/746 until 26 May 2025 for high \nrisk in vitro diagnostics, until 26 May 2026 for medium risk in vitro diagnostics, until 26 May 2027 for lower risk in \nvitro diagnostics, and until 26 May 2028 for certain provisions concerning devices manufactured and used in health \ninstitutions.\n(1) OJ L 396, 30.12.2006, p. 1.\n(2) Commission Regulation (EU) 2021/2045 of 23 November 2021 amending Annex XIV to Regulation (EC) No 1907/2006 of the \nEuropean Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) \n(OJ L 418, 24.11.2021, p. 6).\n(3) Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending \nDirective 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council \nDirectives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p. 1).\n(4) Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and \nrepealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176).\n(5) Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable \nmedical devices (OJ L 189, 20.7.1990, p. 17).\n(6) Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (OJ L 169, 12.7.1993, p. 1).\n(7) Directive 98/79/EC of the European Parliament and the Council of 27 October 1998 on in vitro diagnostic medical devices (OJ L 331, \n7.12.1998, p. 1).\n(8) Regulation (EU) 2022/112 of the European Parliament and of the Council of 25 January 2022 amending Regulation (EU) 2017/746 as \nregards transitional provisions for certain in vitro diagnostic medical devices and the deferred application of conditions for in-house \ndevices (OJ L 9, 28.1.2022, p.3).\nOfficial Journal  \nof the European Union \nEN \nL series    \n2023/2482  \n14.11.2023\n\nELI: http://data.europa.eu/eli/reg/2023/2482/oj \n2/4\n(4)\nIn addition, Regulation (EU) 2023/607 of the European Parliament and of the Council (9) has extended the \ntransitional period laid down in Regulation (EU) 2017/745 applicable to certain medical devices until 31 December \n2027 for devices with a higher risk and until 31 December 2028 for medium and lower risk devices, subject to \ncertain conditions. It has also extended the validity of the certificates issued under Directives 90/385/EEC \nand 93/42/EEC, if the legal conditions are fulfilled. Those measures are intended to ensure that notified bodies can \ncomplete the conformity assessment and issue the certificates in accordance with ",
    "185840-OJ_L_202402853_EN_TXT.pdf": "DIRECTIVE (EU) 2024/2853 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL\nof 23 October 2024\non liability for defective products and repealing Council Directive 85/374/EEC\n(Text with EEA relevance)\nTHE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,\nHaving regard to the Treaty on the Functioning of the European Union, and in particular Article 114 thereof,\nHaving regard to the proposal from the European Commission,\nAfter transmission of the draft legislative act to the national parliaments,\nHaving regard to the opinion of the European Economic and Social Committee (1),\nActing in accordance with the ordinary legislative procedure (2),\nWhereas:\n(1)\nIn order to improve the proper functioning of the internal market, it is necessary to ensure that competition is not \ndistorted and that the movement of goods is not obstructed. Council Directive 85/374/EEC (3) lays down common \nrules on liability for defective products with the aim of removing divergences between the legal systems of Member \nStates that may distort competition and affect the movement of goods within the internal market. Greater \nharmonisation of the common rules on liability for defective products laid down in that Directive would further \ncontribute to the achievement of those objectives, while entailing an increased degree of protection of consumers’ \nand other natural persons’ health or property.\n(2)\nLiability without fault on the part of economic operators remains the sole means of adequately addressing the \nproblem of fair apportionment of risk inherent in modern technological production.\n(3)\nDirective 85/374/EEC has been an effective and important instrument, but it would need to be revised in light of \ndevelopments related to new technologies, including artificial intelligence (AI), new circular economy business \nmodels and new global supply chains, which have led to inconsistencies and legal uncertainty, in particular as \nregards the meaning of the term ‘product’. Experience gained from applying that Directive has also shown that \ninjured persons face difficulties obtaining compensation due to restrictions on making compensation claims and due \nto challenges in gathering evidence to prove liability, especially in light of increasing technical and scientific \ncomplexity. That includes compensation claims in respect of damage related to new technologies. The revision of \nthat Directive would therefore encourage the roll-out and uptake of such new technologies, including AI, while \nensuring that claimants enjoy the same level of protection irrespective of the technology involved and that all \nbusinesses benefit from more legal certainty and a level playing field.\n(4)\nA revision of Directive 85/374/EEC would be needed in order to ensure coherence and consistency with product \nsafety and market surveillance legislation at Union and national level. In addition, there is a need to clarify basic \nnotions and concepts to ensure coherence and legal certainty and a level playing field in the internal market, and to \nreflect the recent case law of the Court of Justice of the European Union.\n(5)\nConsidering the extensive nature of the amendments that would be required in order for Directive 85/374/EEC to \nremain effective and in order to ensure clarity and legal certainty, that Directive should be repealed and replaced with \nthis Directive.\nOfficial Journal \nof the European Union\nEN \nL series\n2024/2853\n18.11.2024\nELI: http://data.europa.eu/eli/dir/2024/2853/oj\n1/22\n(1)\nOJ C 140, 21.4.2023, p. 34.\n(2)\nPosition of the European Parliament of 12 March 2024 (not yet published in the Official Journal) and decision of the Council of \n10 October 2024.\n(3)\nCouncil Directive 85/374/EEC of 25 July 1985 on the approximation of the laws, regulations and administrative provisions of the \nMember States concerning liability for defective products (OJ L 210, 7.8.1985, p. 29).\n\n(6)\nIn order to ensure that the Union’s product liability regime is comprehensive, no-fault liability for defective products \nshould apply to all movables, including software, including when they are integrated into other movables or installed \nin immovables.\n(7)\nLiability for defective products should not apply to damage arising from nuclear accidents, in so far as liability for \nsuch damage is covered by international conventions ratified by Member States.\n(8)\nIn order to create a genuine internal market with a high and uniform level of protection of consumers and other \nnatural persons, and to reflect the case law of the Court of Justice of the European Union, Member States should not, \nin respect of matters within the scope of this Directive, maintain or introduce provisions that are more stringent or \nless stringent than those laid down in this Directive.\n(9)\nUnder the national law of Member States, an injured person could have a claim for damages on the basis of \ncontractual liability or on grounds of non-contractual liability that does not involve the manufacturer’s liability for \n",
    "188134-questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746_en.pdf": "Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands \nAn agency of the European Union      \n \nAddress for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  \nSend us a question Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000 \n© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged. \n30 January 2025 Rev.5 \nEMA/37991/2019 \nHuman Medicines Division \nQuestions & Answers for applicants, marketing \nauthorisation holders of medicinal products and notified \nbodies with respect to the implementation of the \nRegulations on medical devices and in vitro diagnostic \nmedical devices (Regulations (EU) 2017/745 and (EU) \n2017/746) \n \nThis Question and Answer (Q&A) document provides practical considerations concerning the \nimplementation of the medical devices and the in vitro diagnostic medical devices regulations in the \ncontext of combinations of medicinal products with medical devices.  \nThis document has been produced to provide guidance to applicants, marketing authorisation holders \n(MAH) and notified bodies (NB) as regards aspects falling within the scope of the European Medicines \nAgency’s activities and should be read in conjunction with the medical devices Regulation (EU) 2017/745 \n(MDR), the in vitro diagnostic medical devices Regulation (EU) 2017/746  (IVDR) and the Medical Device \nCoordination Group (MDCG)1 guidance documents. The MDR and IVDR replace the three Directives \n(90/385/EEC, 93/42/EEC and 98/79/EC) for medical devices. The MDR came into application on 26 May \n2021 but provides for a transitional period for certain devices. The IVDR came into application on 26 May \n2022 but also provides for a transitional period for certain devices. These regulations include provisions \nconcerning the responsibilities of the EMA, National Competent Authorities (NCA) for medicinal products \nand medical devices and notified bodies as regards combinations of medicinal products with medical \ndevices as follows:  \n• \nFor medical devices that form an integral product with a medicinal product (Regulation (EU) \n2017/745, second subparagraph of Article 1(8) and 1(9)), new requirements to provide an EU \ndeclaration of conformity issued by the medical device manufacturer, or a certificate of conformity \n(so-called hereafter EU certificate) or an opinion from a notified body designated under Regulation \n(EU) 2017/7452 for the type of device in question are applicable in certain circumstances (Art. 117). \n• \nFor medical devices incorporating a medicinal substance with action ancillary to the device, \nRegulation (EU) 2017/745 Article 1 (8), the notified body must seek a scientific opinion from either \nan NCA or EMA3. The notified body must seek the opinion of EMA for medicinal products falling \n \n1 The MDCG is the Member State group responsible for the oversight of implementation of the medical device Regulations. \nIt is set up according to Art. 103 of Regulation (EU) 2017/745 and Art. 98 of Regulation (EU) 2017/746.  \n2 Regulation 2017/745 Article 117 \n3 Regulation 2017/745 Annex IX 5.2 \n\nQuestions & Answers for applicants, marketing authorisation holders of medicinal \nproducts and notified bodies with respect to the implementation of the Regulations on \nmedical devices and in vitro diagnostic medical devices (Regulations (EU) 2017/745 \nand (E  \nEMA/37991/2019 Rev.4 \nPage 2/22 \n \nexclusively within the scope of centralised procedure4, or that incorporate human blood or plasma \nderivatives. \n• \nFor medical devices that are composed of substances, or of combinations of substances, that are \nsystemically absorbed by the body in order to achieve their intended purpose, the notified body must \nseek a scientific opinion from either an NCA or EMA (Regulation (EU) 2017/745 Article 52(11))5. \n• \nFor companion diagnostics, the notified body must seek a scientific opinion from either an NCA or \nEMA (Regulation (EU) 2017/746, Article 48(3) and (4)6). \n \nThis document covers guidance for: \n• \nMedical devices that form an integral product with a medicinal product, \n• \nMedicinal products that include a medical device in the secondary packaging of the medicinal product \n(co-packaged),  \n• \nConsultation procedure for ancillary medicinal substances that are integral part of medical devices, \n• \nConsultation procedure for companion diagnostics. \n \nThis “questions and answers” document provides regulatory and procedural guidance and should be read \nin conjunction with the EMA Guideline on quality documentation for medicinal products when used with \na medical device. This guideline describes the information that should be presented in the Quality part \nof a marketing authorisation dossier for a medicinal product when it is used with a medical device, or \ndevice part, and submitted in accordance with Directive 2001/83/EC and/or Regulation (EC) 726/2004. \nThis guideline focuses on product-specific quality aspects of a medical device, or device part, ",
    "188212-guide-manufacturers-procedure-requesting-advice-expert-panels-clinical-investigations-or-clinical-development-strategies-high-risk-medical-devices_en.pdf": "Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands \nAn agency of the European Union      \n \nAddress for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  \nSend us a question Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000 \n© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged. \n17 January 2025 \nEMA/23357/2025 \nEuropean Medicines Agency \n \nGuide to manufacturers on the procedure for requesting \nadvice from Expert Panels on clinical investigations and/or \nclinical development strategies for high-risk medical \ndevices \nAdvice to manufacturers for high-risk medical devices \n \n1.  Background information \n1.1.  Legal basis \nAccording to Article 61(2) of Regulation (EU) 2017/745 (the Medical Devices Regulation, MDR), the \nmedical device Expert Panels may provide advice on a manufacturer's intended clinical development \nstrategy and proposals for clinical investigation, for class III devices and class IIb active devices \nintended to administer and/or remove a medicinal product from the human body. \n1.2.  Pilot phase \nA pilot programme opened on 27 February 2023 and ran for three phases, with submissions accepted \nuntil 30 June 2024. Following successfully completion of the pilot, EMA is now fully implementing the \nscientific advice programme. \n1.3.  Scope \nThe manufacturers of high-risk devices established in the EU or their authorised representatives can \napply for advice to the expert panels. Applications will be eligible if they meet all of the following \ncriteria: \n• \nThe device is a class III device, or a class IIb active device intended to administer and/or remove a \nmedicinal product from the human body; \n• \nThe questions asked by the manufacturer pertain to clinical aspects only; \n• \nQuestions related to clinical investigations pertain solely to clinical investigations not yet started \n(pre-market or post-market). \n\nGuide to manufacturers on the procedure for requesting advice from Expert Panels on \nclinical investigations and/or clinical development strategies for high-risk medical \ndevices  \n \nPage 2/4\n \nOf note, two of the prioritisation criteria used for the pilot (device for unmet medical needs; novel \ndevice with a possible major clinical or health impact) will only be used for prioritisation should the \nnumber of submissions for a given timeslot exceed the capacity of the expert panels. \nThe advice of the Expert Panels is prospective by nature and is not an assessment of the clinical data \nthat has already been generated.  \nApplicants developing orphan devices are encouraged to consider the separate pilot programme \npublished on EMA website: https://www.ema.europa.eu/en/human-regulatory-overview/medical-\ndevices#expert-panels-support-for-orphan-medical-devices-pilot-programme-67844. Therefore, the \nprioritisation criterion “device intended to benefit a relatively small group of patients in the treatment \nor diagnosis of a disease or condition” used for the pilot will only be used for information purposes. \n1.4.  Fees \nFees are currently not levied for scientific advice submissions in 2025.  \n2.  Procedure and instructions for application \nStep \nInstructions for Applicant \nAdditional comments \n1. Letter of interest \nThe form to be completed to \nexpress interest is at the following \nlink: \nServiceNow \nThe form can be accessed with an \nEMA account. If you have no \naccount, register at the following \nlink: \nEMA Account Management - Self-\nservice Registration \nApplicants will then be able to \ncommunicate with EMA and upload \ndocuments through the ServiceNow \nticket created. \nEMA will confirm receipt of the \napplication by email and offer an \nexplanatory meeting (virtually). \n2. Exploratory meeting \nEMA/ Applicant \nThe Applicant is expected to \ninform EMA about the regulatory \nstatus of the device and is \nwelcome to briefly present their \ndevice and intended questions to \nthe Expert Panel. \nEMA will briefly present the \nprocedure and answer procedural \nquestions. \n3. Draft briefing \ndocument submission* \nThe briefing document template is \npublished on the EMA webpage \nunder the following section: \nMedical devices | European \nMedicines Agency (EMA) \nThe briefing document template \nincludes instructions on how to \ncomplete the application. \nThe draft briefing document \nshould be uploaded using the \noriginal ServiceNow ticket. \nEMA will confirm receipt of the draft \nbriefing document by email and \nschedule the pre-submission \nmeeting (virtually). Feedback can \nalso be provided in writing. \n4. Pre-submission \nmeeting* EMA/Expert \nPanel Chair/Applicant  \nThe Applicant is requested to \nprepare a brief presentation on \ntheir device and proposed \nThe pre-submission meeting will \nfocus on discussing the questions \nfrom the Applicant and feedback on \n\nGuide to manufacturers on the procedure for requesting advice from Expert Panels on \nclinical investigations and/or clinical development strategies for high-risk",
    "188243-Regulations-Regarding-Fees-Payable-In-Terms-Of-The-Provisions-Of-The-Medicines-And-Related-Substances-Act-1965-Act-No-101-Of-1965.pdf": "No. 10177\nRegulation Gazette\nRegulasiekoerant\nN.B. The Government Printing Works will\nnot be held responsible for the quality of\n“Hard Copies” or “Electronic Files”\nsubmitted for publication purposes\nAIDS HELPLINE: 0800-0123-22  Prevention is the cure\nGovernment Gazette\nStaatskoerant\nR E P U B L I C  O F  S O U T H  A F R I CA\nREPUBLIEK VAN SUID AFRIK A\nVol. 716\n12\nFebruary \nFebruarie\nNo. 52106\n2025\n9\n7 7 1 6 8 2 5 8 4 0 0 3\n5 2 1 0 6\nISSN 1682-5845\n\nThis gazette is also available free online at www.gpwonline.co.za\n2    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\nGovernment Notices • Goewermentskennisgewings\nHealth, Department of / Gesondheid, Departement van\n5856\t\nMedicines and Related Substances Act, (101/1965): Regulations regarding fees payable in terms of the Provisions \nof the Act................................................................................................................................................................... \t\n52106\t\n3\nPage\nNo.\nGazette\nNo.\nNo.\nContents\nIMPORTANT NOTICE:\nThe GovernmenT PrinTinG Works Will noT be held resPonsible for any errors \nThaT miGhT occur due To The submission of incomPleTe / incorrecT / illeGible coPy.\nno fuTure queries Will be handled in connecTion WiTh The above.\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    3\nGovernment Notices • Goewermentskennisgewings\nDEPARTMENT OF HEALTH\nNO. 5856\b\n12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n4    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    5\n\nThis gazette is also available free online at www.gpwonline.co.za\n6    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    7\n\nThis gazette is also available free online at www.gpwonline.co.za\n8    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    9\n\nThis gazette is also available free online at www.gpwonline.co.za\n10    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    11\n\nThis gazette is also available free online at www.gpwonline.co.za\n12    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    13\n\nThis gazette is also available free online at www.gpwonline.co.za\n14    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    15\n\nThis gazette is also available free online at www.gpwonline.co.za\n16    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    17\n\nThis gazette is also available free online at www.gpwonline.co.za\n18    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    19\n\nPrinted by and obtainable from the Government Printer, Bosman Street, Private Bag X85, Pretoria, 0001\nContact Centre  Tel: 012-748 6200. eMail: info.egazette@gpw.gov.za\nPublications: Tel: (012) 748 6053, 748 6061, 748 6065\nThis gazette is also available free online at www.gpwonline.co.za\n20    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025",
    "189090-EN_Schwerpunktaktion_PSUR-final.pdf": "Medical Devices\n01/2025\nManufacturers need to monitor their medical devices \non the market because some trends may become visible \nonly after market launch, when a device is used in larg-\ner groups of patients and follow-upperiods are longer. \nManufacturers need to \n•\t\nestablish a system for post-market surveillance1 to \ncapture information on the use of their devices, \n•\t\nplan their activities in post-market surveillance \nplans2, and \n•\t\nbased on their plan, periodically document the re-\nsults of their analyses in safety reports3. \nSwissmedic launched a focus campaign4 to assess \ncompliance with the post-market surveillance require-\nments of the Medical Devices Ordinance (MedDO) for \nhigher-risk legacy devices5.\n1 Art. 56 MedDO in combination with Art. 83 Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medi-\ncal devices (EU-MDR) \n2 Art. 58 MedDO in combination with Annex III Para. 1 EU-MDR \n3 Art. 60-61 MedDO in combination with Annex III Para. 2 EU-MDR \n4 Information on previous focus campaigns: https://www.swissmedic.ch/swissmedic/en/home/medical-devices/market-surveillance-of-medical-\ndevices/announcements-on-market-control-issues.html \n5 Medical devices for which a declaration of conformity and, if applicable, certification according to Directive 93/42/EEC concerning medical \ndevices or Directive 90/385/EEC on active implantable medical devices has been issued and for which the conformity assessment procedure \naccording to MedDO requires the involvement of a designated body (Art. 101 para. 1 let. a and b MedDO) \n6 In 25/28 cases Swiss authorised representatives submitted the documents requested by the due date indicated\nThe sample of 30 legacy devices in risk classes IIa and \nhigher was generated based on vigilance data. 28 out \nof 30 products were from foreign manufacturers. In \nthese cases, the Swiss authorised representative6 was \nthe point of contact for Swissmedic. \n \nFindings\nNon-conformities were raised in 20 out of 30 cas-\nes (Figure 1). A total of 85 non-conformities with the \nrequirements established in Articles 56, 58, 60 and \n61 MedDO (21 clauses) were identified, accounting for \n13.5% of the checks (Figure 2). \nMedical Devices\nSwissmedic assessment of post-market surveillance\ndocumentation\nFigure 1: Cases with and without non-conformities (NCs)\n10 cases without NCs\n20 cases with NCs\n\nFigure 2: Total number of non-conformities (NCs) identified\nhave been observed with regard to the requirements for the PMS plan, safety \nreport and PMS system (21 clauses in MedDO, in combination with EU-MDR)\n85 NCs\nFigure 3: Number of cases with non-conformities (NCs) regarding PMS system, PMS plan and safety report\nPMS System\nPMS Plan\nSafety Report\nNo non-conformities\nNon-conformities\n0%\n40%\n60%\n80%\n100%\n20%\nFigure 4: Preparation of the safety report according to the PMS plan\nthe safety report was not \nprepared according to the PMS plan\nIn 8 cases\nMedical Devices\n01/2025\nFor 11 products there was no post-market surveillance \nplan or the post-market surveillance plan did not fulfil \nthe requirements (Figure 3). For 8 products the safety \nreport was not prepared according to the post-market \nsurveillance plan (Figure 4).\n\nMedical Devices\n01/2025\nConclusions \nThe MedDO requirements on post-market surveillance \nhave been applicable since 26 May 2021. The review \ndemonstrates that while they are responsible for pre-\nparing the post-market surveillance documentation, not \nall manufacturers of higher-risk legacy devices are ad-\nequately implementing these requirements. The focus \ncampaign triggered corrective actions by the manu-\nFor 9 products the information that needs to be includ-\ned in the safety report for the entire device lifetime was \nmissing or incomplete. \nThe number of non-conformities with the different \nclauses of the MedDO regarding the safety report are \nshown in Figure 5. In 8 cases non-conformities related \nto the post-market surveillance system were observed \n(Figure 3).\nfacturers. Swissmedic will follow up on the rectification \nof the non-conformities and impose additional mea-\nsures as needed to ensure that the devices placed on \nthe Swiss market are surveilled according to the require-\nments.\nIn the interest of patient health and safety, Swissmedic \nurges all manufacturers to review their post-market \nsurveillance processes and documentation and ensure \nthe requirements of the MedDO are fulfilled. Adequate \npost-market surveillance processes are fundamental \nto the early detection and resolution of potential \nproblems related to the use of medical devices. Swiss \nauthorised representatives are encouraged to inform the \nmanufacturers with which they have mandates of the \nresults of this focus campaign.\nFigure 5: Number of non-conformities with regard to the safety report \n(CAPA = corrective and preventive action; PMCF = post-market clinical follow-up)\nObligation safety report\nSafety report contains conclusions of \nanalyses per PMS plan\nSafety report set",
    "189128-Diagnostic_Medical_Device_adverse_event_reporting_form.pdf": "Indian Pharmacopoeia Commission  \nMateriovigilance Programme of India (MvPI) \nMinistry of Health and Family Welfare \nGovernment of India \n \nDraft In-vitro Diagnostic medical device (IVD-MD) adverse event reporting form for Comments \n \nPublished on: 17/02/2025 \n \n \n \nLast Date for Submission of Comments: 05/03/2025 \nSubject: Inviting comments from the stakeholders for the draft IVD-MD adverse event reporting form. \nBased on the suggestions provided by the stakeholders, MvPI in collaboration with the CDSCO and the IVD \nmanufacturers associations, has created this draft IVD reporting form. This form will help the stakeholders to capture \nthe adverse events related to In-vitro Diagnostic medical device (IVD-MD). The content of this draft reporting form \nis not final and the text may be subjected to revision before being finalized by the MvPI. \nManufacturers, regulatory authorities, healthcare professionals, and other stakeholders are invited to provide their \nfeedback and comments on this draft proposal. Comments received after the last date will not be considered by the \nMvPI. \nPlease send any comments you may have on this draft document to naveen.v96@gov.in before the last date for \ncomments. \nStakeholder Feedback form \n \nS. No. \nPage No. \nSection \nHeading \nSub-heading \nCurrent Text \nProposed \nText \nExplanation \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nName: _______________________________________________________________________________ \n \nDesignation and Affiliation: _______________________________________________________________ \n \n \n \n\nVersion: 1.0 \n \nPage 1 of 4 \n \nIN-VITRO DIAGNOSTIC MEDICAL DEVICE ADVERSE EVENT REPORTING FORM \nMateriovigilance Programme of India (MvPI) \nThis form is intended to collect information on In-Vitro Diagnostic Medical Devices Adverse Event in India. The form is designed to be used by Domestic \nManufacturer / Importer / Distributor of In-Vitro Diagnostic Medical Devices, Pathology Laboratory, Blood Donation Centre, Government Program In-charge \nand Healthcare Professionals with direct/indirect knowledge of In Vitro Diagnostic Medical Devices Adverse Event. \nDisclaimer \nSubmission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the adverse event. \nSubmission of a Medical Devices Adverse Event (MDAE) Report does not have any legal implication on the reporter. \nConfidentiality \nThe patient/reporter’s identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the \npatient/reporter’s identity in response to a request from the public. \nPrimary Information \n1. \nDate of Report \n: \n2. \nType of Report \n: \nInitial   \n \nFollow up   \n \n     Final   \n  \nTrend   \n \n3. \nReport Reference No. for MDMC1 only \n:   Centre                       Location                               Month – Year                                      Case No. \n4. \nReport Reference No. for MAH2 only \n: \n1MDMC-Medical Device Adverse Event Monitoring Centre, 2MAH-Market Authorisation Holders  \nReporter Details \n1. \nType of Reporter \n:   Manufacturer \n \n \n \n \n \nImporter  \n \n \n \n \n \n \n \n    Distributor \n \n \n \n \n \nHealthcare Professional \n \n \n \n \n \n \n    Pathology Laboratory \n \n \n \n \n \n    Blood Center \n \n \n \n \n \n \n    Government Program In charge \n \n \n \n \n    Others  \n \n \n Specify______________________ \n \n2. \nIn case, Where the Reporter is not the Domestic Manufacturer / Importer of the product, Fill the Following Details: - \na) \nHas the Reporter Informed the Incident to the Domestic Manufacturer / Importer of the product?  \nYes   \n  \nNo  \n \nb) \nIf Yes, Event reported to Manufacturer / Importer via \ni) \nEmail \n \n \n \n \nii) \nWritten communication \n \n  \niii) \nTelephonic communication \n \n \niv) \nOther \n \n \n \n Specify_______________________ \nc) \nIs the Reporter also submitting the report on behalf of the manufacturer?  \n \nYes   \n  \nNo  \n \n \n3. \nReporter Contact Information \n: \na) Name  \n: \n \n \n \n \n \nb) Address \n: \n \n \n \n \n \nc) Tel./ Mobile \n: \n \n \n \n \n \nd) Email  \n: \n \n \n\n \nPage 2 of 4 \n \nA) \nIn-vitro Diagnostic Medical Device Details \nCategory \nSub-category \n1. Kits \n \n \n \n2. Reagents  \n \n \n3. Calibrators \n \n \n4. Controls  \n \n \n5. Analyzers  \n \n \n6. Self-testing Kit  \n \n7. IVD software \n \n \n8. Others  \n \n \n    Specify_____________________ \n \n \n \n1. \nHematology \n \n \n \n2. \nBiochemistry  \n \n \n3. \nMicrobiology  \n \n \n4. \nImmunology  \n \n \n5. \nHistopathology \n \n \n6. \nMolecular Biologics \n \n \n7. \nGastroenterology & Urology \n \n8. \nGynecological  \n \n \n9. \nToxicology \n \n \n \n10. Others \n \n \n \n   Specify_____________________ \n \nGeneric In-Vitro Diagnostic Medical Device Name: \n \nTrade Name/ Brand Name: \n \nDetails \nName \nAddress \nManufacturer \n \n \nImporter \n \n \nDistributor \n \n \nMarketed by \n \n \n \n1. \nIVD-MD Risk Classification as per Indian MDR 2017 \n \n \n: \nA   \n \nB  \n \nC  \n \nD  \n \n2. \nLicense No. (Manufacturer/ Importer) \n \n \n \n: \n3. \nModel No. \n \n \n \n \n \n \n: \n4. \nCatalogue No.  \n \n \n \n \n ",
    "189142-Regulation_(EU)_2017_746_notification.pdf": "From:\nAgencia Española de Medicamentos\ny Productos Sanitarios\nCalle Campezo 1 · Edificio 8\n28022 Madrid\nSpain\nTo:\nEuropean Commission\nGROWTH Directorate-General\n200 Rue de la Loi,\nB-1049 Brussels.\nOther Member States\nReference:\nLegislation: Regulation (EU) 2017/746 on in vitro diagnostic medical devices\nBody name, address, telephone, fax, email, website :\nCENTRO NACIONAL DE CERTIFICACION DE PRODUCTOS SANITARIOS\nCampezo 1. Edificio 7.\n28022 MADRID\nSpain\n+34:91:822 51 30\non0318@certificaps.gob.es\nwww.certificaps.gob.es\nBody info:\nNB 0318\nNotification of a Body in the framework of\na technical harmonization directive\nTasks performed by the Body:\nLast approval date:\n2025-02-19\nPage 1\n\nProduct\nProcedures\nArticles /Annexes Conditions\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-1.   Devices intended to be\nused for blood grouping\n-IVR 0101\nDevices\nintended to determine\nmarkers of the ABO system\n[A (ABO1), B (ABO2), AB\n(ABO3)]\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-1.   Devices intended to be\nused for blood grouping\n-IVR 0102\nDevices\nintended to determine\nmarkers of the Rhesus\nsystem [RH1 (D), RHW1, RH2\n(C), RH3 (E), RH4 (c), RH5 (e)]\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-1.   Devices intended to be\nused for blood grouping\n-IVR 0103\nDevices\nintended to determine\nmarkers of the Kell system\n[Kel1 (K)]\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-1.   Devices intended to be\nused for blood grouping\n-IVR 0104\nDevices\nintended to determine\nmarkers of the Kidd system\n[JK1 (Jka), JK2 (Jkb)]\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-1.   Devices intended to be\nused for blood grouping\n-IVR 0105\nDevices\nintended to determine\nmarkers of the Duffy system\n[FY1 (Fya), FY2 (Fyb)]\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-1.   Devices intended to be\nused for blood grouping\n-IVR 0106\nOther devices\nintended to be used for blood\ngrouping\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\nPage 2\n\nProduct\nProcedures\nArticles /Annexes Conditions\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-2.   Devices intended to be\nused for tissue typing\n-IVR 0201\nDevices\nintended to be used for\ntissue typing (HLA A, B, DR)\nto ensure the immunological\ncompatibility of blood, blood\ncomponents, cells, tissue or\norgans that are intended for\ntransfusion or\ntransplantation or cell\nadministration\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-2.   Devices intended to be\nused for tissue typing\n-IVR 0202\nOther devices\nintended to be used for\ntissue typing\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-3.   Devices intended to be\nused for markers of cancer\nand non-malignant tumours\n-IVR 0301\nDevices\nintended to be used in\nscreening, diagnosis, staging\nor monitoring of cancer\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-4.   Devices intended to be\nused for human genetic\ntesting\n-IVR 0401\nDevices\nintended to be used in\nscreening/confirmation of\ncongenital/inherited\ndisorders\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n -I.   CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-4.   Devices intended to be\nused for human genetic\ntesting\n-IVR 0402\nDevices\nintended to be used to\npredict genetic\ndisease/disorder risk and\nprognosis\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nAnnex IX(I)\nAnnex IX(II)\n",
    "189165-C_17_pubblicazioni_3529_allegato.pdf": "Registro Nazionale degli \nimpianti Protesici Mammari\nRAPPORTO \n2024\n\nRegistro Nazionale degli impianti Protesici Mammari \nRapporto 2024 \n\nIl presente rapporto è stato redatto da: \n \nAntonella Campanale, Marco Ventimiglia, Daniela Minella, Rosa Goffredo, Aurora \nCaddeo, Daniele Mattei, Achille Iachino. \n \nAntonella Campanale, Direttore incaricato dell’Ufficio 5 – Vigilanza sui dispositivi \nmedici, registri dispositivi medici impiantabili e attività ispettiva. \n \nAchille Iachino, Direttore generale della ex Direzione generale dei dispositivi medici \ne del servizio farmaceutico. \n \nFrancesco Saverio Mennini, Capo Dipartimento della programmazione, dei dispositivi \nmedici, del farmaco e delle politiche in favore del Servizio sanitario nazionale. \n \n \n \n \n \nCitare questo report come segue: \nCampanale A, Ventimiglia M, Minella D, Goffredo R, Caddeo A, Mattei D, Mennini F.S., Iachino A. \nRegistro Nazionale degli impianti Protesici Mammari – RNPM – Rapporto 2024. Ministero della salute, 2025. \nISBN: 9791280892164 \n \n \nDomande e commenti possono essere inviati all’indirizzo e-mail: rnpm@sanita.it \n \n\nREGISTRO NAZIONALE DEGLI IMPIANTI PROTESICI MAMMARI \nRAPPORTO 2024 \n \n \n \nSUMMARY \n8 \nINTRODUZIONE \n13 \n1. \nEPIDEMIOLOGIA SULL’UTILIZZO DEGLI IMPIANTI PROTESICI MAMMARI \n15 \n2. \nANALISI DEI DATI \n21 \n2.1 PROCEDURE CHIRURGICHE EFFETTUATE PER FINALITA’ RICOSTRUTTIVA \n28 \n2.2 PROCEDURE CHIRURGICHE EFFETTUATE PER FINALITA’ ESTETICA \n42 \n2.3 CARATTERISTICHE DELLE PROTESI MAMMARIE IMPIANTATE \n59 \n2.4 “GOOD PRACTICES” \n63 \n3.    SORVEGLIANZA DEL MERCATO \n69 \n3.1 TEMPI DI REVISIONE DELL’IMPIANTO \n69 \n3.2 CONDIZIONI CLINICHE POTENZIALMENTE ASSOCIATE ALL’IMPIANTO \n70 \nDI PROTESI MAMMARIE \n \n4. \nI REGISTRI ATTIVI NEL MONDO \n74 \nBIBLIOGRAFIA \n79 \nRINGRAZIAMENTI \n84 \n \n\n4 \n \n \n \n\n5 \n \nPREFAZIONE \n \nI dispositivi medici svolgono un ruolo cruciale nel migliorare la qualità della vita dei \npazienti fornendo soluzioni sanitarie innovative per la prevenzione, la diagnosi e il \ntrattamento delle diverse condizioni cliniche.  \nTutti i dispositivi medici comportano, tuttavia, rischi associati al loro utilizzo, alcuni dei \nquali sono prevedibili e già tenuti in considerazione nell'analisi del rapporto \nrischio/beneficio prima della loro immissione sul mercato. Tra i dispositivi medici a \nmaggior rischio ci sono i dispositivi impiantabili, ai quali il Regolamento 745/2017 ha \ndedicato grande attenzione prevedendo obblighi più stringenti per i fabbricanti. \nInoltre, a riprova della delicatezza della questione, le Istituzioni europee \nraccomandano l’istituzione di registri ai fini di una valutazione indipendente sulla \nsicurezza e prestazione a lungo termine, nonché sulla tracciabilità di questa tipologia \ndi dispositivi. Più nello specifico, le protesi mammarie sono dispositivi medici \nimpiantabili riclassificati nella classe di rischio più alta, la classe III, dal D.lgs. 2 \ndicembre 2004, n. 304. L’importanza di istituire registri per tali dispositivi è riconosciuta \nsia dal mondo scientifico, sia dalle istituzioni deputate al controllo, che hanno visto \nnegli ultimi 13 anni avviare la raccolta dei dati nei vari registri via via istituiti a livello \ninternazionale. Una delle maggiori criticità osservate è, tuttavia, quella di mantenere \ntali registri attivi nel tempo, assicurando una copertura completa sul territorio. È \nimportante sottolineare, infatti, che solo la raccolta sistematica e completa dei dati \npuò garantire un’attenta tracciabilità dei pazienti impiantati, dei dispositivi stessi e \nassicurare validità agli studi epidemiologici condotti sull’utilizzo delle protesi \nmammarie nell’ambito della chirurgia plastica ricostruttiva ed estetica. \nIl Registro Nazionale degli impianti Protesici Mammari (RNPM) in Italia è il primo, nel \npanorama internazionale, ad essere stato istituito a norma di legge presso il Ministero \ndella salute, proprio con l’intento di dotare l’Autorità competente sui dispositivi \nmedici di maggiori strumenti con cui monitorare la sicurezza dei pazienti impiantati e \nle protesi mammarie nella fase di post commercializzazione, nel breve e lungo \ntermine. In particolare, la legge 86/2012 ha istituito il Registro nazionale presso la ex \nDirezione generale dei dispositivi medici e del servizio farmaceutico del Ministero della \nsalute (DGDMF); esso raccoglie tutti i dati provenienti dai registri regionali e provinciali \n\n6 \n \nistituiti rispettivamente presso le Regioni e Province autonome. Si tratta, inoltre, del \nprimo registro per il quale è prevista a norma di legge l’obbligatorietà dell’inserimento \ndei dati e una gestione da parte di autorità pubbliche, presidio di trasparenza e \noggettività nelle attività di monitoraggio clinico ed epidemiologico. \nCon decreto direttoriale è stato istituito inoltre un tavolo tecnico scientifico per \nl'implementazione e la messa in opera del registro nazionale con l’obiettivo di \npromuovere attività formative e sensibilizzare all’utilizzo dei registri, definire le \nprocedure per il",
    "189166-_______.pdf": "음성･수어영상변환용 코드를 활용한 \n의료기기 안전정보 콘텐츠 제작 안내서\n(민원인 안내서)\n2025. 2. 19.\n의료기기안전국\n의료기기관리과\n\n지침서ᆞ안내서 제ᆞ개정 점검표\n명칭\n음성･수어영상변환용 코드를 활용한 의료기기 안전정보 콘텐츠 제작 안내서\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n등록대상\n여부\n□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 \n지침서ㆍ안내서가 있습니까? \n□ 예\n■ 아니오\n☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적\n으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 \n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n(사유 :                                                                 )\n□ 법령(법ㆍ시행령ㆍ시행규칙) 또는 \n행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 \n나열한 것입니까? \n□ 예\n■ 아니오\n□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?\n□ 예\n■ 아니오\n□ 일회성 지시ㆍ명령에 해당하는 내용입니까?\n□ 예\n■ 아니오\n□ 외국 규정을 단순 번역하거나 설명하는 내용입니까?\n□ 예\n■ 아니오\n□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 \n정리한 자료입니까? \n□ 예\n■ 아니오\n☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. \n   지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.\n지침서ㆍ안내서 \n구분\n□ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부\n기준이나 절차를 제시하는 것입니까? (공무원용)\n□ 예(☞지침서) \n■ 아니오\n□ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 \n쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 \n기술하는 것입니까? (민원인용)\n■ 예(☞안내서) \n□ 아니오\n기타 확인\n사항\n□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 \n민원인을 구속하는 내용이 있습니까?\n□ 예 \n■ 아니오\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ\n안내서 제ㆍ개정 절차를 진행하시기 바랍니다.\n상기 사항에 대하여 확인하였음.\n    2025년   2월  19일\n담당자\n확  인(부서장)\n윤상연\n김진휘   \n\n  이 안내서는 「의료기기법」 제23조의2(시각장애인등을 위한 정보제공)에 \n따라 의료기기의 용기나 외장, 외부의 용기나 포장 또는 첨부문서에 표시\n하는 음성·수어영상변환용 코드를 활용한 의료기기 안전정보 콘텐츠 제작 \n시 고려해야 하는 사항에 대해 알기 쉽게 설명하거나 식품의약품안전처\n의 입장을 기술한 것입니다.\n  본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 \n기술방식(‘~하여야 한다’ 등)에도 불구하고 참고로만 활용하시기 바랍니다. \n또한, 본 안내서는 2025년 2월 19일 현재의 과학적ㆍ기술적 사실 및 \n유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규 내용 및 \n구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n ※ “민원인 안내서”란 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 \n알기 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 \n기술하는 것(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 의료기기\n안전국 의료기기관리과에 문의하시기 바랍니다.\n전화번호: 043-719-3810\n팩스번호: 043-719-3800\n\n- 4 -\n제‧개정 이력\n연번\n제·개정번호\n승인일자\n주요내용\n1\n안내서-1417-01\n2025.2.19.\n제정\n음성･수어영상변환용 코드를 활용한 의료기기 안전정보 콘텐츠 제작 안내서\n\n목   차\nⅠ. 일반사항······················································································  1\n  1. 목적\n  2. 관련 법령 및 규정\n  3. 적용 범위\n  4. 용어 정의\nⅡ. 의료기기 안전정보 콘텐츠 제작 ············································  4\n  1. 일반사항\n  2. 의료기기 안전정보 콘텐츠의 제공 항목  \n  3. 의료기기 안전정보 콘텐츠의 제작 절차 \nⅢ. 음성·수어영상변환용 코드 제작 ··········································· 17\n  1. 일반사항\n  2. 음성·수어영상변환용 코드 표시 방법\n  3. 음성·수어영상변환용 코드(QR코드)의 규격\n\n- 1 -\nⅠ\n 일반사항\n1. 목적\n   이 가이드라인은 의료기기 제조·수입업자가 의료기기의 용기나 외장,\n외부의 용기나 포장 또는 첨부문서에 표시하는 음성·수어영상변환용 \n코드를 활용한 의료기기 안전정보 콘텐츠를 제작할 시 고려해야 할 \n사항에 대해 방향을 제시하여 표준화된 의료기기 안전정보 콘텐츠 \n제작을 도모함으로써 시각·청각장애인의 만성질환 관리를 위한 자가 \n사용용 의료기기 정보에 대한 알권리를 보장하고, 정확하고 안전한 \n의료기기 사용을 지원하는 등 국민 보건 향상에 기여함을 목적으로 한다.\n2. 관련 법령 및 규정\n ㅇ「의료기기법」제20조, 제21조, 제22조, 제23조, 제23조의2 등\n ㅇ「의료기기법 시행규칙」제42조, 제43조, 제44조, 제44조의2 등\n ㅇ「한국수화언어법」\n ㅇ「시각장애인의 인쇄물 접근성 향상을 위한 음성변환용 코드 활용지침」\n* 국립전파연구원(http://www.rra.go.kr) > 알림소식> 방송통신표준자료실\n\n- 2 -\n3. 적용 범위\n이 가이드라인은 의료기기 제조·수입업자가 시각‧청각장애인을 위한\n음성·수어영상변환용 코드를 활용한 시각·청각장애인의 만성질환 관리를\n위한 자가 사용용 의료기기의 안전정보 콘텐츠를 제작하고자 할 때 \n적용한다.\n4. 용어 정의\n가. ‘의료기기’란 사람이나 동물에게 단독 또는 조합하여 사용되는 기구\nㆍ기계ㆍ장치ㆍ재료ㆍ소프트웨어 또는 이와 유사한 제품으로서 \n다음 중의 어느 하나에 해당하는 제품을 말한다.\n- 질병을 진단ㆍ치료ㆍ경감ㆍ처치 또는 예방할 목적으로 사용되는 제품\n- 상해(傷害) 또는 장애를 진단ㆍ치료ㆍ경감 또는 보정할 목적으로 \n사용되는 제품\n- 구조 또는 기능을 검사ㆍ대체 또는 변형할 목적으로 사용되는 제품\n- 임신을 조절할 목적으로 사용되는 제품\n나. ‘한국수어’는 대한민국 농문화 속에서 시각ㆍ동작 체계를 바탕으로\n생겨난 고유한 형식의 언어로 대한민국 농인의 공용어이다.\n다. ‘감수(監修)’는 수어통역사의 수어 표현을 지도하고 감독하는 행위를\n말한다.\n라. ‘검수(檢修)’는 영상의 품질을 검사하는 행위를 말한다.\n마. ‘지문자’는 수어에서 한글 자모음이나 알파벳을 손가락으로 표시하는 \n방법을 말한다.\n\n- 3 -\n바. ‘음성·수어영상변환용 코드’는 인쇄물의 정보를 음성 및 수어 영상으로\n변환시켜주는 전자적 표시를 말한다.\n사. 이 가이드라인에서 ‘QR 코드’는 텍스트, URL, 전화번호, 이메일 \n주소 등 다양한 정보를 저장할 수 있는 2차원 바코드의 일종으로 \n사각형 모양의 격자무늬로 구성된 코드를 말하며, 음성·수어영상\n변환용 코드의 한 종류이다.\n\n- 4 -\nⅡ\n 의료기기 안전정보 콘텐츠 제작\n1. 일반사항\n가. 음성·수어영상변환용 코드를 통해 제공되는 의료기기 안전정보\n콘텐츠는 시각‧청각장애의 특성에 맞춰 접근성을 높이기 위한  \n음성정보나 수어영상을 제공하는 것을 기본 원칙으로 한다.\n나. 의료기기 용기나 외장 또는 포장에 품목명 등을 점자로 표시하는 \n것만으로는 시각장애인에게 충분한 의료기기 정보가 전달되지 않을\n수 있으므로 의료기기 안전정보 콘텐츠를 제작하여 품목명을 포함한\n허가(인증·신고)사항을 음성이나 영상으로 확인할 수 있도록 한다.\n다. 음성·수어영상 제작 시 수어* 사용을 원칙으로하나 고유명사(업체명,\n모델명 등)이거나 수어 단어가 존재하지 않는 경우에는 지문자로 \n표현할 수 있다. 지문자로 표현할 때에는 청각 장애인의 이해를 \n돕기 위해 텍스트 및 이미지 정보를 함께 제공한다.\n* 수어는「한국수화언어법」및국립국어원에서제공하고있는인터넷‘한국\n수어사전’ (http://sldict.korean.go.kr)을따른다.\n라. 음성·수어영상 제작 지침과 관련해서는 국립장애인도서관의 ‘한국\n수어영상도서 제작지침’과 방송통신위원회의 ‘장애인방송 프로그램\n제공 가이드라인’을 참고할 수 있다.\n마. 음성·수어영상변환용 코드를 통해 제공되는 콘텐츠는 음성정보와 \n수어영상을 포함하고, 콘텐츠가 제공되는 온라인 플랫폼이 정보통신\n접근성* 인증 심사기준에 부합하는지 검토가 필요하다.\n\n- 5 -\n*「지능정보화기본법」제46조(장애인·고령자등의지능정보서비스접근및이용보장)에따라\n국가기관등(국가기관ㆍ지방자치단체및공공기관)은정보통신망을통하여정보나서비스를제공\n할때장애인ㆍ고령자등이웹사이트와이동통신단말장치(「전파법」에따라할당받은주파수를\n사용하는기간통신역무를이용하기위하여필요한단말장치를말한다. 이하같다)에설치되는\n응용소프트웨어등대통령령으로정하는유ㆍ무선정보통신을쉽게이용할수있도록접근성을\n보장하여야한다.\n2. 의료기기 안전정보 콘텐츠 제공 항목\n가. 의료기기의 용기나 외장, 외부의 용기나 포장 또는 첨부문서에\n표시된 음성·수어영상변환용 코드를 통해서 의료기기 안전정보\n콘텐츠를제공하며, 가능하면 비장애인에게 제공되는 내용과 동일한\n정보를 제공하도록 한다.\n나. 의료기기 허가 또는 인증받거나 신고한 사항을 그대로 제공하는 \n것이 기본 원칙이나 시각‧청각장애인이 이해하는 데 어려움이\n없도록 추가적인 설명을 제공할 수 있으며, 시각적이거나 모호한 \n표현은 지양하고 전문용어는 쉬운 용어로 변경하여 제공할 수 있다.\n다. 의료기기 허가(인증·신고)사항의 내용이 방대할 경우 일부를 발췌 및\n요약하여 의료기기 안전정보 콘텐츠를 제작할 수 있으며, 정확한 \n허가사항은 자사 홈페이지 등을 통해 확인이 가능함을 추가적으로\n고지할 수 있다.\n라. 기본적으로 제공되어야 하는 요약정보 및 상세정보의 항목은 다음과 \n같으며, 추가적으로 정보를 제공할 수 있다.\n\n- 6 -\n1) 요약 정보\n○기본사항(품목명/모델명/업체명, 허가(인증·신고)번호)\n ",
    "189327-Regulation_(EU)_2017_745_notification.pdf": "From:\nFinnish Medicins Agency\nP.O. Box 55\nFI-00034 FIMEA\nFinland\nTo:\nEuropean Commission\nGROWTH Directorate-General\n200 Rue de la Loi,\nB-1049 Brussels.\nOther Member States\nReference:\nLegislation: Regulation (EU) 2017/745 on medical devices\nBody name, address, telephone, fax, email, website :\nSGS FIMKO OY\nTakomotie 8\n00380 HELSINKI\nFinland\n+358 9 696 361\nnb.fimko@sgs.com\nwww.sgs.fi\nBody info:\nNB 0598\nNotification of a Body in the framework of a\ntechnical harmonization directive\nTasks performed by the Body:\nLast approval date:\n2025-02-22\nPage 1\n\nnull\nProcedures\nArticles /Annexes null\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-2.   Active non-implantable\ndevices for imaging,\nmonitoring and/or diagnosis\n-MDA 0201\nActive non-\nimplantable imaging devices\nutilising ionizing radiation\nConformity assessment based on\ntype-examination\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nConformity assessment based on\nproduct conformity verification\nAnnex X\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nAnnex XI(B)\nUp to class IIb\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-2.   Active non-implantable\ndevices for imaging,\nmonitoring and/or diagnosis\n-MDA 0202\nActive non-\nimplantable imaging devices\nutilising non-ionizing\nradiation\nConformity assessment based on\ntype-examination\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nConformity assessment based on\nproduct conformity verification\nAnnex X\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nAnnex XI(B)\nUp to class IIb\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-2.   Active non-implantable\ndevices for imaging,\nmonitoring and/or diagnosis\n-MDA 0203\nActive non-\nimplantable devices for\nmonitoring of vital\nphysiological parameters\nConformity assessment based on\ntype-examination\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nConformity assessment based on\nproduct conformity verification\nAnnex X\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nAnnex XI(B)\nUp to class IIb\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-2.   Active non-implantable\ndevices for imaging,\nmonitoring and/or diagnosis\n-MDA 0204\nOther active\nnon-implantable devices for\nmonitoring and/or diagnosis\nConformity assessment based on\ntype-examination\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nConformity assessment based on\nproduct conformity verification\nAnnex X\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nAnnex XI(B)\nUp to class IIb,\nexcluding\naudiometers\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-3.   Active non-implantable\ntherapeutic devices and\ngeneral active non-\nimplantable devices\n-MDA 0301\nActive non-\nimplantable devices utilising\nionizing radiation\nConformity assessment based on\ntype-examination\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nConformity assessment based on\nproduct conformity verification\nAnnex X\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nAnnex XI(B)\nUp to class IIb\nPage 2\n\nnull\nProcedures\nArticles /Annexes null\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-3.   Active non-implantable\ntherapeutic devices and\ngeneral active non-\nimplantable devices\n-MDA 0302\nActive non-\nimplantable devices utilising\nnon-ionizing radiation\nConformity assessment based on\ntype-examination\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nConformity assessment based on\nproduct conformity verification\nAnnex X\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nAnnex XI(B)\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-3.   Active non-implantable\ntherapeutic devices and\ngeneral active non-\nimplantable devices\n-MDA 0303\nActive non-\nimplantable devices utilising\nhyperthermia/hypothermia\nConformity assessment based on\ntype-examination\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nConformity assessment based on\nproduct conformity verification\nAnnex X\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nAnnex XI(B)\nUp to class IIb,\nexcluding b",
    "2017_745_Medical_Devices_Summary_list_of_harmonised_standards_Generated_on_9.10.2024_(1).pdf": "1 \n \n \nEUROPEAN COMMISSION \nDirectorate-General for Internal Market, Industry, Entrepreneurship and SMEs  \nEcosystems III: Construction, Machinery and Standardisation \nStandards Policy \nBrussels, 9.10.2024 \n \n \nSummary of references of harmonised standards published in the Official Journal – Regulation (EU) 2017/7451  of the European Parliament and of the Council of 5 April 2017 on medical devices, \namending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC \n \nThe summary below consolidates the references of harmonised standards published by the Commission in the Official Journal of the European Union (OJ). It reproduces information already published in the L or C \nseries of the OJ as indicated in columns (2), (5) and/or (7). It contains all references which, when the summary was generated, still provided a presumption of conformity together with references already withdrawn \nfrom the OJ. \nThe Commission services provide this summary for information purposes only. Although they take every possible precaution to ensure that the summary is updated regularly and is correct, errors may occur and the \nsummary may not be complete at a certain point in time. The summary does not as such generate legal effects. \nThis summary was generated on 9 October 2024. \nLegislation \nreference \n(A) \nESO (B) Reference number of the standard  \n(C) \nTitle of the standard  \n(D) \nDate of start \nof \npresumption \nof conformity \n(1) \nOJ \nreference \nfor \npublication \nin OJ  \n(2) \nRestriction \n(3) \nDate of start \nof \npresumption \nof conformity \nwith \nrestriction (4) \nOJ reference \nfor \npublication \nof a \nrestriction in \nOJ  \n(5) \nDate of \nwithdrawal \nfrom OJ (end \nof presumption \nof conformity) \n(6) \nOJ \nreference \nfor \nwithdrawal \nfrom OJ  \n(7) \n2017/745 \nCEN \nEN 285:2015+A1:2021 \nSterilization - Steam sterilizers - Large \nsterilizers \n17/05/2022 \nOJ L 138 - \n17/05/2022 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN 455-3:2023 \nMedical gloves for single use - Part 3: \nRequirements and testing for biological \nevaluation \n08/03/2024 \nOJ L, \n2024/815 - \n08/03/2024 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN ISO 10993-9:2021 \nBiological evaluation of medical devices - Part \n9: Framework for identification and \nquantification of potential degradation products \n(ISO 10993-9:2019) \n05/01/2022 \nOJ L 1 - \n05/01/2022 \n- \n \n- \n \n- \n \n1 OJ L 117 5.5.2017, p. 1-175 \nCommission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË  \nContact: grow-has-administrator@ec.europa.eu \n  \n \n\n2 \n \nLegislation \nreference \n(A) \nESO (B) Reference number of the standard  \n(C) \nTitle of the standard  \n(D) \nDate of start \nof \npresumption \nof conformity \n(1) \nOJ \nreference \nfor \npublication \nin OJ  \n(2) \nRestriction \n(3) \nDate of start \nof \npresumption \nof conformity \nwith \nrestriction (4) \nOJ reference \nfor \npublication \nof a \nrestriction in \nOJ  \n(5) \nDate of \nwithdrawal \nfrom OJ (end \nof presumption \nof conformity) \n(6) \nOJ \nreference \nfor \nwithdrawal \nfrom OJ  \n(7) \n2017/745 \nCEN \nEN ISO 10993-10:2023 \nBiological evaluation of medical devices - Part \n10: Tests for skin sensitization (ISO 10993-\n10:2021) \n05/07/2023 \nOJ L 170 - \n05/07/2023 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN ISO 10993-12:2021 \nBiological evaluation of medical devices - Part \n12: Sample preparation and reference materials \n(ISO 10993-12:2021) \n05/01/2022 \nOJ L 1 - \n05/01/2022 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN ISO 10993-15:2023 \nBiological evaluation of medical devices - Part \n15: Identification and quantification of \ndegradation products from metals and alloys \n(ISO 10993-15:2019) \n08/03/2024 \nOJ L, \n2024/815 - \n08/03/2024 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN ISO 10993-17:2023 \nBiological evaluation of medical devices - Part \n17: Toxicological risk assessment of medical \ndevice constituents (ISO 10993-17:2023) \n08/03/2024 \nOJ L, \n2024/815 - \n08/03/2024 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN ISO 10993-18:2020,  \nEN ISO 10993-18:2020/A1:2023 \nBiological evaluation of medical devices - Part \n18: Chemical characterization of medical device \nmaterials within a risk management process \n(ISO 10993-18:2020) \n08/03/2024 \nOJ L, \n2024/815 - \n08/03/2024 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN ISO 10993-23:2021 \nBiological evaluation of medical devices - Part \n23: Tests for irritation (ISO 10993-23:2021) \n19/07/2021 \nOJ L 256 - \n19/07/2021 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN ISO 11135:2014,  \nEN ISO 11135:2014/A1:2019 \nSterilization of health-care products - Ethylene \noxide - Requirements for the development, \nvalidation and routine control of a sterilization \nprocess for medical devices (ISO 11135:2014) \n19/07/2021 \nOJ L 256 - \n19/07/2021 \n- \n \n- \n \n- \n2017/745 \nCEN \nEN ISO 11137-1:2015,  \nEN ISO 11137-1:2015/A2:2019 \nSterilization of health care products - Radiation \n- Part 1: Requirements for development, \nvalidation and routine control of a sterilization \nprocess for medical devices (ISO 11137-\n1:2006, including Amd 1:2013) \n19/07/2021 \nOJ L 256 - \n19/07/2",
    "2017_746_In_Vitro_Diagnostic_Medical_Devices_Summary_list_of_harmonised_standards_Generated_on_9.10.2024.pdf": "1 \n \n \nEUROPEAN COMMISSION \nDirectorate-General for Internal Market, Industry, Entrepreneurship and SMEs  \nEcosystems III: Construction, Machinery and Standardisation \nStandards Policy \nBrussels, 9.10.2024 \n \n \nSummary of references of harmonised standards published in the Official Journal – Regulation (EU) 2017/7461 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic \nmedical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU \n \nThe summary below consolidates the references of harmonised standards published by the Commission in the Official Journal of the European Union (OJ). It reproduces information already published in the L or C \nseries of the OJ as indicated in columns (2), (5) and/or (7). It contains all references which, when the summary was generated, still provided a presumption of conformity together with references already withdrawn \nfrom the OJ. \nThe Commission services provide this summary for information purposes only. Although they take every possible precaution to ensure that the summary is updated regularly and is correct, errors may occur and the \nsummary may not be complete at a certain point in time. The summary does not as such generate legal effects. \nThis summary was generated on 9 October 2024. \nLegislation \nreference \n(A) \nESO (B) \nReference number of the \nstandard  \n(C) \nTitle of the standard  \n(D) \nDate of start \nof \npresumption \nof conformity \n(1) \nOJ \nreference \nfor \npublication \nin OJ  \n(2) \nRestriction \n(3) \nDate of start \nof \npresumption \nof conformity \nwith \nrestriction (4) \nOJ reference \nfor \npublication \nof a \nrestriction in \nOJ  \n(5) \nDate of \nwithdrawal \nfrom OJ (end \nof presumption \nof conformity) \n(6) \nOJ \nreference \nfor \nwithdrawal \nfrom OJ  \n(7) \n2017/746 \nCEN \nEN ISO 11135:2014,  \nEN ISO \n11135:2014/A1:2019 \nSterilization of health-care products - Ethylene oxide - \nRequirements for the development, validation and \nroutine control of a sterilization process for medical \ndevices (ISO 11135:2014) \n20/07/2021 \nOJ L 258 - \n20/07/2021 \n- \n \n- \n \n- \n2017/746 \nCEN \nEN ISO 11137-1:2015,  \nEN ISO 11137-\n1:2015/A2:2019 \nSterilization of health care products - Radiation - Part \n1: Requirements for development, validation and \nroutine control of a sterilization process for medical \ndevices (ISO 11137-1:2006, including Amd 1:2013) \n20/07/2021 \nOJ L 258 - \n20/07/2021 \n- \n \n- \n \n- \n \n1 OJ L 117 5.5.2017, p. 176-332 \nCommission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË  \nContact: grow-has-administrator@ec.europa.eu \n  \n \n\n2 \n \nLegislation \nreference \n(A) \nESO (B) \nReference number of the \nstandard  \n(C) \nTitle of the standard  \n(D) \nDate of start \nof \npresumption \nof conformity \n(1) \nOJ \nreference \nfor \npublication \nin OJ  \n(2) \nRestriction \n(3) \nDate of start \nof \npresumption \nof conformity \nwith \nrestriction (4) \nOJ reference \nfor \npublication \nof a \nrestriction in \nOJ  \n(5) \nDate of \nwithdrawal \nfrom OJ (end \nof presumption \nof conformity) \n(6) \nOJ \nreference \nfor \nwithdrawal \nfrom OJ  \n(7) \n2017/746 \nCEN \nEN ISO 11137-2:2015,  \nEN ISO 11137-\n2:2015/A1:2023 \nSterilization of health care products - Radiation - Part \n2: Establishing the sterilization dose (ISO 11137-\n2:2013) \n08/03/2024 \nOJ L, \n2024/817 - \n08/03/2024 \n- \n \n- \n \n- \n2017/746 \nCEN \nEN ISO 11607-1:2020,  \nEN ISO 11607-\n1:2020/A1:2023 \nPackaging for terminally sterilized medical devices - \nPart 1: Requirements for materials, sterile barrier \nsystems and packaging systems (ISO 11607-1:2019) \n08/03/2024 \nOJ L, \n2024/817 - \n08/03/2024 \n- \n \n- \n \n- \n2017/746 \nCEN \nEN ISO 11607-2:2020,  \nEN ISO 11607-\n2:2020/A1:2023 \nPackaging for terminally sterilized medical devices - \nPart 2: Validation requirements for forming, sealing \nand assembly processes (ISO 11607-2:2019) \n08/03/2024 \nOJ L, \n2024/817 - \n08/03/2024 \n- \n \n- \n \n- \n2017/746 \nCEN \nEN ISO 11737-1:2018,  \nEN ISO 11737-\n1:2018/A1:2021 \nSterilization of health care products - Microbiological \nmethods - Part 1: Determination of a population of \nmicroorganisms on products (ISO 11737-1:2018) \n07/01/2022 \nOJ L 4 - \n07/01/2022 \n- \n \n- \n \n- \n2017/746 \nCEN \nEN ISO 11737-2:2020 \nSterilization of health care products - Microbiological \nmethods - Part 2: Tests of sterility performed in the \ndefinition, validation and maintenance of a sterilization \nprocess (ISO 11737-2:2019) \n20/07/2021 \nOJ L 258 - \n20/07/2021 \n- \n \n- \n \n- \n2017/746 \nCEN \nEN ISO 13408-1:2024 \nAseptic processing of health care products - Part 1: \nGeneral requirements (ISO 13408-1:2023) \n09/10/2024 \nOJ L, \n2024/2625 - \n09/10/2024 \n- \n \n- \n \n- \n2017/746 \nCEN \nEN ISO 13408-6:2021 \nAseptic processing of health care products - Part 6: \nIsolator systems (ISO 13408-6:2021) \n07/01/2022 \nOJ L 4 - \n07/01/2022 \n- \n \n- \n \n- \n2017/746 \nCEN \nEN ISO 13485:2016,  \nEN ISO \n13485:2016/AC:2018,  \nEN ISO \n13485:2016/A11:2021 \nMedical devices - Quality management systems - \nRequirements for regulatory purposes (ISO \n13485:2016) \n07/01/2022 \nOJ L 4 - \n",
    "2025.02.10_MHRA_guidance_on_DMHT_-_Device_characterisation_regulatory_qualification_and_classification__1_.pdf": "Digital Mental Health Technology - \nRegulation and Evaluation for Safe & \nEffective Products \nDevice characterisation, regulatory qualification and classification \n \nVersion 1.1 \n \n \n \n \n\n \nPage 2 of 52 \n \nContents  \nGlossary .............................................................................................................................. 3 \nDevelopment of this guidance ............................................................................................. 5 \nApplication of this guidance ................................................................................................. 5 \nDMHTs ................................................................................................................................ 6 \nDevice characterisation ....................................................................................................... 8 \nDetermining qualification as SaMD ...................................................................................... 9 \n1. \nDoes the DMHT have a medical purpose? ............................................................. 10 \n2. Does the DMHT have sufficient functionality? ............................................................ 18 \nAccessories, multi-modular and inter-connected DMHTs............................................... 44 \nDetermining regulatory classification ................................................................................. 44 \nUK MDR & EU MDD classification rules for DMHTs ...................................................... 45 \nEU MDR classification rules for DMHTs ......................................................................... 47 \nAppendix 1 - MHRA DMHT characterisation form ............................................................. 49 \nRevision history ................................................................................................................. 52 \n \n \n\n \nPage 3 of 52 \n \nGlossary \nAB \nApproved body - A conformity assessment body appointed by a UK \nCompetent Authority to undertake conformity assessment activities \nfor the purposes of UKCA certification of products to be placed on \nthe GB market \nAI \nArtificial intelligence \nAR \nAugmented reality \nCBT \nCognitive behavioural therapy \nCE certification  \nCertification that indicates a product’s compliance with relevant EU \nregulations  \nDMHT \nDigital mental health technology  \nDSM-5 \nDiagnostic and Statistical Manual of Mental Disorders, Fifth Edition \nDTAC \nDigital Technology Assessment Criteria \nDTC \nDirect-to-consumer  \nEU \nEuropean Union \nEU AIMDD \nEU Directive 90/385/EEC on active implantable medical devices  \nEU MDD \nEU Directive 93/42/EEC on medical devices \nEU IVDD \nEU Directive 98/79/EC on in vitro diagnostic medical devices  \nEU IVDR \nEU In Vitro Diagnostic Regulation 2017-746 \nEU MDR \nEU Medical Device Regulation 2017-745  \nGAD-7 \nGeneralised Anxiety Disorder Assessment  \nGB \nGreat Britain  \nICD-11 \nInternational Classification of Diseases – 11th revision  \nIFU \nInstructions for use \n\n \nPage 4 of 52 \n \nIMDRF \nInternational Medical Device Regulators Forum  \nJITAI \nJust-in-time-adaptive intervention \nMHRA \nMedicines and Healthcare products Regulatory Agency \nMR \nMixed reality \nNB \nNotified Body - A conformity assessment body appointed by an EU \nCompetent Authority to undertake conformity assessment activities \nfor the purposes of CE certification of products to be placed on the \nEU market \nNHS \nNational Health Service \nNI \nNorthern Ireland \nNICE \nNational Institute for Health and Care Excellence \nPHQ-9 \nNine-item patient health questionnaire \nPROMs \nPatient reported outcome measures \nSaMD \nSoftware as a medical device \nSNOWMED CT \nSystematized Nomenclature of Medicine Clinical Terms \ntDCS \nTranscranial direct current stimulation  \nUK \nUnited Kingdom  \nUKCA certification \nCertification that indicates United Kingdom Conformity Assessed \nUK MDR \nUK Medical Device Regulations 2002 (SI 2002 No 618, as \namended) \nVR \nVirtual reality \nWSAS \nWork and social adjustment scale \nWHO \nWorld Health Organisation  \n \n\n \nPage 5 of 52 \n \n \nDevelopment of this guidance \nThis guidance is part of a series related to the regulation and evaluation of digital mental \nhealth technology (DMHT). These documents were developed as part of a Wellcome funded \nproject, led by the MHRA in partnership with NICE. The project commenced in May 2023 \nand more information can be accessed here. \nApplication of this guidance \nThis guidance is applicable to DMHTs placed on the United Kingdom (UK) market. This \nincludes Great Britain (GB: England, Wales and Scotland) and Northern Ireland (NI).  \nIt explains the regulation and evaluation of DMHT to ensure only safe and effective products \nare made available in the UK. Some DMHTs qualify as software as a medical device (SaMD) \nso must comply with relevant medical device regulations. This guidance explains how to \ndetermine this and how UKCA / CE certification shows compliance with these regulations.  \nIn Gr",
    "Allemagne_(Evaluation_de_la_conformite_des_systemes_et_des_unites_de_traitement_-_applicabilite_du__10_MPG_aux_ensembles.pdf": "Antworten und Beschlüsse des EK-Med \nSysteme und Behandlungseinheiten \n3.10  A 1 \n \n \nZentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten  Sebastianstraße 189  53115 Bonn  Germany\nTelefon +49 228 97794-0  Fax +49 228 97794-44  E-Mail zlg@zlg.nrw.de  Website www.zlg.de \n310-0508.A01 \n© ZLG \n1/11\n \n \nKonformitätsbewertung von Systemen und Behandlungs-\neinheiten – Anwendbarkeit des § 10 MPG auf Sets \nDie Auffassungen von Herstellern, Benannten Stellen und auch Behörden differieren bei identi-\nscher Rechts- und Sachlage zum Teil erheblich. Zur Vereinheitlichung der Vorgehensweise bei \nder Konformitätsbewertung von Sets und Behandlungseinheiten sollen deshalb folgende Frage-\nstellungen  \n1. Wann ist § 10 MPG Absatz 1 anwendbar? \n2. Wann ist § 10 MPG Absatz 2 anwendbar? \n3. Welches Konformitätsbewertungsverfahren wird angewendet, wenn bei der Zusammenset-\nzung eines Systems/Behandlungseinheit die vom Hersteller der einzelnen Medizinprodukte \nfestgelegte Zweckbestimmung nicht verändert wird, aber Prozesse stattfinden, die die Pro-\nduktqualität beeinflussen können? \n4. Dürfen im oben genannten Fall (3.) die Kennzeichnung und Gebrauchsinformation der Her-\nsteller der einzelnen Medizinprodukte weiter verwendet werden, d.h. im System verbleiben? \n5. Wie hat bei Sets, in denen die enthaltenen Medizinprodukte nur teilweise CE-gekennzeich-\nnet sind, die Kennzeichnung zu erfolgen? \n6. Was ist zusätzlich zu berücksichtigen, wenn das Set sterile Produkte enthält oder vor dem \nerstmaligen Inverkehrbringen sterilisiert wird? \n7. Welche Anforderungen an die Kennzeichnung ergeben sich aus den einzelnen \nFallkonstellationen? \nunter Beachtung folgender Konstellationen  \n– \nEinzelprodukte CE-gekennzeichnet und vorgesehener Anwendungszweck nicht geän-\ndert \n– \nEinzelprodukt nicht CE-gekennzeichnet  \n– \nEinzelprodukte CE-gekennzeichnet, jedoch vorgesehener Anwendungszweck geändert \n– \nEinzelprodukt CE-gekennzeichnet, jedoch wird ein anderes Sterilisationsverfahren als \nvom Hersteller des Einzelproduktes vorgegeben verwendet \n– \nEinzelprodukt wird als Bulk unsteril zugekauft (nicht einzeln verpackt, i.d.R. nicht CE-\ngekennzeichnet) \n– \nWie werden Nicht-Medizinprodukte behandelt (z.B. Abwurfschale aus Altpapier)? \n– \nDürfen Primärverpackungen von Einzelprodukten entfernt werden?  \n– \nKennzeichnung der Behandlungseinheit auf allen Verpackungsstufen  \n\nAntworten und Beschlüsse des EK-Med \n3.10  A 1 \n \n \n310-0508.A01 \n© ZLG \n2/11\n \n \n– \nHandhabung der Gebrauchsanweisungen \nbehandelt werden. \n \nWeder die Richtlinie 93/42/EWG noch das Medizinproduktegesetz enthalten eine Definition des \nBegriffes System oder Behandlungseinheit. Auch der häufig verwendete Begriff „Set“ ist nicht \ndefiniert. Einzelne Autoren [1] verwenden darüber hinaus noch den Begriff Sammelpackung und \nunterscheiden all diese von sogenannten „Sachgesamtheiten“ wie z.b. Kfz-Verbandskästen. \nNicht zuletzt die fehlenden Definitionen führen zu den oben genannten Unsicherheiten im Hin-\nblick auf Anwendbarkeit und Auslegung.  \nIm Folgenden soll die Anwendbarkeit des § 10 Medizinproduktegesetz auf die Zusammenstel-\nlung von Medizinprodukten in Form von Operations- oder Behandlungssets näher beleuchtet \nwerden. Solche Sets sind definiert zusammengestellte Behandlungseinheiten beispielsweise \nzur Appendektomie oder Tonsillektomie, d. h. die Zusammenstellung von Geräten/Instrumen-\nten, Besteck, Tupfern, Nahtmaterial, Zubehör einschließlich der Kombination mit anderen Pro-\ndukten, die nicht dem MPG unterliegen (sog. „sonstige Produkte“). \nZur Arbeitserleichterung und zum besseren Verständnis sind im Anhang Artikel 12 der Richtlinie \n93/42/EWG sowie der davon auch inhaltlich abweichende § 10 Medizinproduktegesetz zusam-\nmen mit einem Auszug anderer benötigter Vorschriften aus dem MPG und der Medizinprodukte-\nVerordnung (MPV) abgedruckt. \nFür die weiteren Betrachtungen wird unter Zusammensetzung verstanden, dass mehrere Medi-\nzinprodukte – auch Zubehör zu Medizinprodukten – und andere Produkte so zusammengepackt \nwerden, dass sie als funktionell zusammengestellte Einheit von Produkten mit eindeutig defi-\nnierter Zweckbestimmung (nachfolgend Set genannt) erstmalig in den Verkehr gebracht werden \nkönnen. Voraussetzung für eine Anwendung des § 10 MPG ist, dass das Set eine medizinische \nZweckbestimmung besitzt und in seiner Gesamtheit unter die Definition des § 3 Nr. 1 ff MPG \nfällt. \nFür die natürliche oder juristische Person, die solche Sets in eigenem Namen erstmalig in den \nVerkehr bringt, gelten die dem Hersteller nach § 3 Nr. 15 MPG obliegenden Verpflichtungen.  \n1.  \nWann ist § 10 MPG Absatz 1 anwendbar? \n§ 10 (1) MPG setzt voraus, dass das Set ausschließlich CE-gekennzeichnete Medizinpro-\ndukte enthält. Diese müssen entsprechend ihrer Zweckbestimmung und nach den Vorgaben \ndes jeweiligen Herstellers innerhalb der von diesem vorgesehenen Anwendungsbeschränkun-\ngen „zusammengesetzt“ werden.  \nDies bedeutet, dass Absatz 1 nur anwendbar ist, so",
    "Allemagne(_Ordonnance_reglementant_la_distribution_des_dispositifs_medicaux.pdf": "Ein Service des Bundesministeriums der Justiz sowie des Bundesamts für\nJustiz ‒ www.gesetze-im-internet.de\n- Seite 1 von 4 -\nVerordnung zur Regelung der Abgabe von Medizinprodukten\n(Medizinprodukte-Abgabeverordnung - MPAV)\nMPAV\nAusfertigungsdatum: 25.07.2014\nVollzitat:\n\"Medizinprodukte-Abgabeverordnung vom 25. Juli 2014 (BGBl. I S. 1227), die zuletzt durch Artikel 2a des Gesetzes\nvom 17. Juli 2023 (BGBl. 2023 I Nr. 190) geändert worden ist\"\nStand:\nZuletzt geändert durch Art. 2a G v. 17.7.2023 I Nr. 190\nFußnote\n(+++ Textnachweis ab: 29.7.2014 +++)\n \n \nDie V wurde als Artikel 1 der V v. 25.7.2014 I 1227 vom Bundesministerium für Gesundheit im Einvernehmen mit\ndem Bundesministerium für Wirtschaft und Energie und dem Bundesministerium des Innern mit Zustimmung des\nBundesrates erlassen. Sie tritt gem. Art. 6 Abs. 1 Satz 1 dieser V am 29.7.2014 in Kraft.\n§ 1 Verschreibungspflicht\n(1) Medizinprodukte, die nach der Zweckbestimmung zur Anwendung durch Laien vorgesehen sind und\n1.  \nStoffe oder Zubereitungen aus Stoffen enthalten, die der Verschreibungspflicht nach der\nArzneimittelverschreibungsverordnung unterliegen oder auf die solche Stoffe aufgetragen sind, oder\n \n2.  \nin Anlage 1 zu dieser Verordnung aufgeführt sind,\n \ndürfen nur bei Vorliegen einer ärztlichen oder zahnärztlichen Verschreibung an andere Personen als Ärzte\nund Zahnärzte abgegeben werden (verschreibungspflichtige Medizinprodukte). Satz 1 gilt nicht, soweit ein\nverschreibungspflichtiges Medizinprodukt an andere Hersteller von Medizinprodukten oder deren Bevollmächtigte\noder Händler von Medizinprodukten abgegeben wird.\n(2) Die Verschreibung muss enthalten:\n1.  \nName, Vorname, Berufsbezeichnung und Anschrift der Praxis oder der Klinik der verschreibenden\närztlichen oder zahnärztlichen Person (verschreibende Person) einschließlich einer Telefonnummer zur\nKontaktaufnahme,\n \n2.  \nDatum der Ausfertigung,\n \n3.  \nNamen, Vornamen sowie Geburtsdatum der Person, für die das Medizinprodukt bestimmt ist,\n \n4.  \nBezeichnung des Medizinprodukts sowie bei Sonderanfertigungen die spezifischen Auslegungsmerkmale,\nnach denen dieses Produkt eigens angefertigt werden soll,\n \n5.  \nabzugebende Menge oder gegebenenfalls Maße des verschriebenen Medizinproduktes,\n \n6.  \nbei Medizinprodukten, die in der Apotheke hergestellt werden sollen, eine Gebrauchsanweisung, soweit\ndiese nach Anhang I Kapitel III der Verordnung (EU) 2017/745 des Europäischen Parlaments und des Rates\nvom 5. April 2017 über Medizinprodukte, zur Änderung der Richtlinie 2001/83/EG, der Verordnung (EG)\nNr. 178/2002 und der Verordnung (EG) Nr. 1223/2009 und zur Aufhebung der Richtlinien 90/385/EWG und\n93/42/EWG des Rates (ABl. L 117 vom 5.5.2017, S. 1; L 117 vom 3.5.2019, S. 9; L 334 vom 27.12.2019, S.\n165), die durch die Verordnung (EU) 2020/561 (ABl. L 130 vom 24.4.2020, S. 18) geändert worden ist, in\nder jeweils geltenden Fassung nicht entbehrlich ist,\n \n7.  \ndie eigenhändige Unterschrift der verschreibenden Person oder, bei Verschreibungen in elektronischer\nForm, deren qualifizierte elektronische Signatur.\n \n(3) Den aus Deutschland stammenden ärztlichen und zahnärztlichen Verschreibungen für Medizinprodukte, die\nrechtmäßig in den Verkehr gebracht wurden, sind entsprechende Verschreibungen aus den Mitgliedstaaten der\n\nEin Service des Bundesministeriums der Justiz sowie des Bundesamts für\nJustiz ‒ www.gesetze-im-internet.de\n- Seite 2 von 4 -\nEuropäischen Union, aus den Vertragsstaaten des Abkommens über den Europäischen Wirtschaftsraum und aus\nder Schweiz gleichgestellt, sofern die Verschreibungen die Angaben nach Absatz 2 aufweisen und dadurch ihre\nAuthentizität und ihre Ausstellung durch eine dazu berechtigte ärztliche oder zahnärztliche Person nachweisen.\n(4) Eine ärztliche oder zahnärztliche Verschreibung, die zu dem Zweck ausgestellt wird, in einem anderen\nMitgliedstaat der Europäischen Union, in einem Vertragsstaat des Abkommens über den Europäischen\nWirtschaftsraum oder in der Schweiz eingelöst zu werden, muss enthalten:\n1.  \nNamen, Vornamen sowie Geburtsdatum der Person, für die das Medizinprodukt bestimmt ist,\n \n2.  \nDatum der Ausfertigung,\n \n3.  \nNamen, Vornamen sowie eine die berufliche Qualifikation erkennen lassende Berufsbezeichnung der\nverschreibenden ärztlichen oder zahnärztlichen Person (verschreibende Person),\n \n4.  \nAnschrift der verschreibenden Person einschließlich der Bezeichnung des Mitgliedstaates, ihrer Telefon-\noder Telefaxnummer unter Angabe der Ländervorwahl und ihrer E-Mail-Adresse,\n \n5.  \nhandschriftliche oder digitale Unterschrift der verschreibenden Person je nach Medium der Verschreibung,\n \n6.  \ngebräuchliche Bezeichnung des Medizinproduktes.\n \n§ 2 Apothekenpflicht\nMedizinprodukte\n1.  \nnach § 1 Absatz 1 Satz 1 Nummer 1,\n \n2.  \ndie zur Anwendung durch Laien bestimmt sind, soweit sie Stoffe oder Zubereitungen aus Stoffen\nenthalten, die nach der Verordnung über apothekenpflichtige und freiverkäufliche Arzneimittel\napothekenpflichtig sind, oder\n \n3.  \ndie in Anlage 2 zu dieser V",
    "Allemagne(Examen_CE_de_type_-_satisfaction_des_exigences_essentielles).pdf": "Antworten und Beschlüsse des EK-Med \nKonformitätsbewertung \n3.9.3  A 1 \n \n309.3-1002.A01.doc \n© ZLG \n1/2\n \nEG-Baumusterprüfung \nErfüllung der grundlegenden Anforderungen \nWie verhält es sich bei einer EG-Baumusterprüfung nach Anhang III der Richtlinie \n93/42/EWG, bei der besondere Festlegungen für elektrisch betriebene Medizinprodukte \nzu Grunde gelegt werden (Teile 2 der EN 60601), und deren Norminhalte nicht \nvollständig erfüllt werden können?  \nGibt es hier Möglichkeiten zum Beispiel über eine Risikoanalyse nach DIN EN ISO \n14971, die Nichterfüllung einzelner Punkte der Norm zu entkräften, und zu einer \nerfolgreichen Zertifizierung zu gelangen? Gibt es hierzu Vorgaben an die Notified \nBodies?  \nIst das Verfahren, mit Hilfe einer Risikoanalyse bestimmte Norminhalte, die für den \nAnwendungszweck des Medizinproduktes nicht zutreffen, zu entkräften, zugelassen? \nMedizinprodukte dürfen in der EU nur in den Verkehr gebracht und/oder in Betrieb genommen \nwerden, wenn sie die Anforderungen der Richtlinie 93/42/EWG erfüllen (93/42/EWG Artikel 2). \nDazu gehört auch, dass sie die grundlegenden Anforderungen gemäß Anhang I der Richtlinie \nerfüllen (Artikel 3). Dabei gehen die Mitgliedstaaten von der Einhaltung der grundlegenden \nAnforderungen aus, wenn die Produkte den einschlägigen harmonisierten Normen genügen \n(Artikel 5). \nDas heißt, dass die Einhaltung harmonisierter Normen eine Vermutungswirkung hinsichtlich der \nErfüllung der grundlegenden Anforderungen auslöst [1]. \nArtikel 3 der Richtlinie 93/42/EWG bestimmt zudem, dass Medizinprodukte nur solche \ngrundlegenden Anforderungen gemäß Anhang I zu erfüllen haben, die „unter Berücksichtigung \nihrer Zweckbestimmung anwendbar sind“. Das bedeutet, dass unter Umständen auch nur \nsolche Teile von harmonisierten Normen relevant sind, die sich explizit auf die für die Zweck-\nbestimmung des betreffenden Medizinproduktes zutreffenden Anforderungen beziehen. \nTeil der Dokumentation, die zum Antrag auf EG-Baumusterprüfung gehört, ist u.a. „eine Liste \nder ganz oder teilweise angewandten Normen gemäß Artikel 5 sowie eine Beschreibung der \nLösungen zur Einhaltung der grundlegenden Anforderungen dieser Richtlinie, sofern die in \nArtikel 5 genannten Normen nicht vollständig angewandt worden sind“. Ein Teil dieser \nBeschreibung kann natürlich auch ein Verweis auf die obligatorische Risikoanalyse sein.  \nBei der EG-Baumusterprüfung hat die Benannte Stelle festzustellen, ob die vom Hersteller \ngewählten Lösungen tatsächlich zu einer Erfüllung der grundlegenden Anforderungen führen. \nEntscheidend ist somit, dass die zutreffenden grundlegenden Anforderungen des Anhangs I \nder Richtlinie 93/42/EWG erfüllt sind. Die Einhaltung harmonisierter Normen ist der von der \nRichtlinie bevorzugte Weg. Allerdings kann der Hersteller auch andere Wege zur Einhaltung \nder grundlegenden Anforderungen wählen. Er muss dann belegen, dass diese Lösungen \ntatsächlich wirksam sind, und die Benannte Stelle hat dies im Rahmen der EG-Baumuster-\nprüfung zu bewerten. \n\nAntworten und Beschlüsse des EK-Med \n3.9.3  A 1 \n \n \n309.3-1002.A01.doc \n© ZLG \n2/2\n \n \nBezug \n93/42/EWG Artikel 2, 3, 5 sowie Anhänge I und III,  \nMPG §§ 7, 8 und 11 \nQuellen \n[1] Leitfaden für die Umsetzung der nach dem Neuen Konzept und dem \nGesamtkonzept verfassten Richtlinien, Europäischen Kommission (1999), \nAbschnitt 4.3 \nSchlüsselwörter \nEG-Baumusterprüfung, grundlegende Anforderungen, harmonisierte \nNormen, Konformitätsbewertung, Vermutungswirkung",
    "Allemagne(l'evaluation_et_a_la_defense_des_risques_lies_aux_dispositifs_medicaux_Ordonnance_relative_au_plan_de_securite_des_dispositifs_medicaux_(OSDM).pdf": "- Seite 1 von 16 - \n  \nAmtliche Abkürzung: \nMPSV \nDokumenttyp: \nRechtsverordnung \n \nQuelle: \n \nFNA: \nFNA 7102-47-8 \n  \n  \nVerordnung über die Erfassung, Bewertung und Abwehr von Risiken bei Medizinprodukten \nMedizinprodukte-Sicherheitsplanverordnung \nGesamtausgabe in der Gültigkeit vom 26.05.2020 bis 25.05.2021 \n \nV aufgeh. durch Art. 9 Abs. 1 Satz 2 Nr. 2 V v. 21.4.2021 I 833 (MPEUAnpV) mWv 26.5.2021 \nFußnoten \n  \n  \n  \n  \n  \n  \n(+++ Textnachweis ab: 28.6.2002 +++) \n \n(+++ Zur Anwendung bis 25.5.2022 vgl. § 1 Satz 2 MPAMIV +++) \n \n(+++ Amtlicher Hinweis des Normgebers auf EG-Recht: \n \n Umsetzung der \n \n EGRL 47/2007 (CELEX Nr: 32007L0047) vgl. G v. 29.7.2009 I 2326 \n \n Durchführung der \n \n EGV 765/2008 (CELEX Nr: 32008R0765) vgl. G v. 29.7.2009 I 2326 +++) \n \n  \n  Die V wurde als Artikel 1 d. V v. 24.6.2002 I 2131 vom Bundesministerium für Gesundheit im Einvernehmen mit den \nBundesministerien für Wirtschaft und Technologie, des Innern, für Arbeit und Sozialordnung und für Umwelt, \nNaturschutz und Reaktorsicherheit mit Zustimmung des Bundesrates erlassen. Sie ist gem. Art. 5 dieser V am 28.6.2002 \nin Kraft getreten.  \n  \n  \n  \n  \nNichtamtliches Inhaltsverzeichnis \nTitel \nFassung vom \nVerordnung über die Erfassung, Bewertung und Abwehr von Risiken bei Medizinprodukten \n24.06.2002 \n\n \n- Seite 2 von 16 - \nAbschnitt 1 Anwendungsbereich, Begriffsbestimmungen \n24.06.2002 \n§ 1 Anwendungsbereich \n29.07.2009 \n§ 2 Begriffsbestimmungen \n27.09.2016 \nAbschnitt 2 Meldung von Vorkommnissen und Rückrufen \n24.06.2002 \n§ 3 Meldepflichten \n07.07.2017 \n§ 4 Ausnahmen von der Meldepflicht und besondere Verfahren \n14.06.2007 \n§ 5 Fristen \n27.09.2016 \n§ 6 Meldung durch Vertreiber \n24.06.2002 \n§ 7 Modalitäten der Meldung \n27.09.2016 \nAbschnitt 3 Risikobewertung durch die zuständige Bundesoberbehörde \n24.06.2002 \n§ 8 Aufgaben der Behörde \n29.07.2009 \n§ 9 Ziel und Inhalt der Risikobewertung \n27.09.2016 \n§ 10 Verfahren der Risikobewertung \n29.07.2009 \n§ 11 Befugnisse der Behörde \n02.07.2018 \n§ 12 Mitwirkungspflichten \n27.09.2016 \n§ 13 Abschluss der Risikobewertung \n29.07.2009 \nAbschnitt 4 Korrektive Maßnahmen \n24.06.2002 \n§ 14 Eigenverantwortliche korrektive Maßnahmen des Verantwortlichen nach § 5 des \nMedizinproduktegesetzes \n27.09.2016 \n§ 14a Eigenverantwortliche korrektive Maßnahmen des Sponsors von klinischen Prüfungen \noder Leistungsbewertungsprüfungen \n10.05.2010 \n§ 15 Maßnahmen der zuständigen Behörden \n29.07.2009 \n§ 16 Verpflichtung zur Mitwirkung an den korrektiven Maßnahmen \n25.07.2014 \n§ 17 Maßnahmen der zuständigen Behörden gegen Betreiber und Anwender \n24.06.2002 \n§ 18 Notfallplanung der zuständigen Behörden \n31.10.2006 \nAbschnitt 5 Unterrichtungspflichten und Informationsaustausch \n24.06.2002 \n§ 19 Unterrichtung des Bundesministeriums für Gesundheit durch die zuständige Bundes-\nbehörde \n31.10.2006 \n§ 20 Informationsaustausch zwischen der zuständigen Bundesoberbehörde und den \nzuständigen Landesbehörden \n19.05.2020 \n§ 21 Europäischer und internationaler Informationsaustausch \n29.07.2009 \n§ 22 Unterrichtung sonstiger Behörden, Organisationen und Stellen \n19.05.2020 \n§ 23 Wissenschaftliche Aufarbeitung der durchgeführten Risikobewertungen \n24.06.2002 \n§ 24 Veröffentlichung von Informationen über das Internet \n29.07.2009 \nAnlage (weggefallen) \n25.07.2014 \n \nAbschnitt 1 Anwendungsbereich, Begriffsbestimmungen \n\n \n- Seite 3 von 16 - \n \n§ 1 Anwendungsbereich \nDiese Verordnung regelt die Verfahren zur Erfassung, Bewertung und Abwehr von Risiken im Verkehr oder in Betrieb \nbefindlicher Medizinprodukte. \nFußnoten \n  \n  \n  \n  \n § 1: Früherer Satz 2 aufgeh. durch Art. 3 Nr. 1 G v. 29.7.2009 I 2326 mWv 21.3.2010  \n  \n  \n  \n  \n \n§ 2 Begriffsbestimmungen \nIm Sinne dieser Verordnung ist  \n1. Vorkommnis eine Funktionsstörung, ein Ausfall, eine Änderung der Merkmale oder der Leistung oder eine \nunsachgemäße Kennzeichnung oder Gebrauchsanweisung eines Medizinproduktes, die oder der unmittelbar oder \nmittelbar zum Tod oder zu einer schwerwiegenden Verschlechterung des Gesundheitszustands eines Patienten, \neines Anwenders oder einer anderen Person geführt hat, geführt haben könnte oder führen könnte; als \nFunktionsstörung gilt auch ein Mangel der Gebrauchstauglichkeit, der eine Fehlanwendung verursacht, \n2. korrektive Maßnahme eine Maßnahme zur Beseitigung, Verringerung oder Verhinderung des erneuten Auftretens \neines von einem Medizinprodukt ausgehenden Risikos, \n3. Rückruf eine korrektive Maßnahme, mit der die Rücksendung, der Austausch, die Um- oder Nachrüstung, die \nAussonderung oder Vernichtung eines Medizinprodukts veranlasst wird oder Anwendern, Betreibern oder Patienten \nHinweise für die weitere sichere Anwendung oder den Betrieb von Medizinprodukten gegeben werden, \n4. Maßnahmenempfehlung eine Mitteilung des Verantwortlichen nach § 5 des Medizinproduktegesetzes, mit der ein \nRückruf veranlasst wird, \n5. schwerwiegendes unerwünschtes Ereignis jedes in einer genehmigungspflichtigen klinischen Prüfung oder einer \ngenehmigungspflichtige",
    "Allemagne(Marquage_CE).pdf": "Antworten und Beschlüsse des EK-Med \nCE-Kennzeichnung \n3.14  B 1 \n \n314-0197.B01.doc \n© ZLG \n1/2\n \nCE-Kennzeichnung nach Artikel 17 und Anhang XII der Richtlinie \n93/42/EWG des Rates vom 14. Juni 1993 über Medizinprodukte \n1 \nDie CE-Kennzeichnung muß, sofern dies durchführbar und zweckmäßig ist, in deutlich \nsichtbarer, leicht lesbarer und unauslöschbarer Form auf dem Produkt oder auf dem steri-\nlen Verpackungsmaterial sowie auf der Gebrauchsanweisung angebracht sein. \nWenn möglich, muß die CE-Kennzeichnung auch auf der Handelsverpackung angebracht \nsein [1]. \n2 \nDie sich aus dem im Anhang XII der Richtlinie abgebildeten Raster ergebenden Proportio-\nnen müssen bei Verkleinerung oder Vergrößerung der Kennzeichnung eingehalten werden \n[2]. \n3 \nDie verschiedenen Bestandteile der CE-Kennzeichnung müssen etwa gleich hoch sein: Die \nMindesthöhe beträgt 5 mm.  \nVon der Mindesthöhe kann bei kleinen Produkten abgewichen werden [2]. \n4 \nDie Kennummer der Benannten Stelle steht hinter der CE-Kennzeichnung [3].  \nIst für ein Medizinprodukt ein Konformitätsbewertungsverfahren vorgeschrieben, das nicht \nvon einer Benannten Stelle durchgeführt werden muß, darf der CE-Kennzeichnung keine \nKennummer einer Benannten Stelle hinzugefügt werden [4]. \n5 \nDie CE-Kennzeichnung darf mit einer Umrandung versehen werden [5]. \n6 \nDie Kennummer der Benannten Stelle darf kleiner als die CE-Kennzeichnung sein [5]. \n7 \nDie Darstellung des Logos einer Benannten Stelle innerhalb der Umrandung ist nicht statt-\nhaft [5]. \n8 \nKennzeichnungen, die geeignet sind, Dritte im Hinblick auf die Bedeutung und das \nSchriftbild der CE-Kennzeichnung in die Irre zu führen, dürfen nicht angebracht werden [1]. \nDas gleichzeitige Anbringen von beispielsweise GS- oder PTB-Zeichen neben der CE-\nKennzeichnung auf der Grundlage des Medizinproduktegesetzes beziehungsweise der \nRichtlinie 93/42/EWG des Rates vom 14. Juni 1993 über Medizinprodukte  ist nicht statthaft \n[6]. \n9 \nDer Hersteller – ob mit Sitz innerhalb oder außerhalb der Europäischen Union – bringt die \nCE-Kennzeichnung selbst an.  \n10 In Verbindung mit der Kennummer der Benannten Stelle darf die CE-Kennzeichnung nur \nangebracht werden, wenn die Benannte Stelle das Qualitätssicherungssystem für dieses \nProdukt genehmigt hat und überwacht. \n \nBezug \n[1] 93/42/EWG Artikel 17 \n[2] 93/42/EWG Anhang XII \n\nAntworten und Beschlüsse des EK-Med \n3.14  B 1 \n \n \n314-0197.B01.doc \n© ZLG \n2/2\n \n[3] Beschluß des Rates vom 22. Juli 1993 über die in technischen Har-\nmonisierungsrichtlinien zu verwendenden Module für die verschiede-\nnen Phasen der Konformitätsbewertungsverfahren und die Regeln für \ndie Anbringung und Verwendung der CE-Konformitätskennzeichnung \n(93/465/EWG), Anhang I B 2 g \n[4] Medizinproduktegesetz § 9 (3) Satz 5 \n[5] Schreiben 237-456015/13 des BMG vom 17.02.95 \n[6] Ergebnisniederschrift der Bund-Länder-Besprechung zum Medizin-\nproduktegesetz am 27.04.1995, Schreiben 237-456000/06 des BMG \nvom 04.09.95 \nQuellen \nBS-36, BS-53, BS-54 \nSchlüsselwörter \nCE-Kennzeichnung (→ 5), Hersteller (→ 5), Kennummer (→ 5)",
    "Allemagne(Traitement_des_dispositifs_medicaux_-_differences_entre_la_premiere_mise_sur_le_marche_et_la_sterilisation_avant_mise_sur_le_marche_-_focus_sur_les_blanchisseries).pdf": "Antworten und Beschlüsse des EK-Med \nAufbereitung von Medizinprodukten \n3.16  A 2 \n \n \nZentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten  Sebastianstraße 189  53115 Bonn  Germany\nTelefon +49 228 97794-0  Fax +49 228 97794-44  E-Mail zlg@zlg.nrw.de  Website www.zlg.de \n316-0508.A02 \n© ZLG \n1/10\n \n \nAufbereitung1 von Medizinprodukten – Unterschiede zum \nerstmaligem Inverkehrbringen und der Sterilisation vor dem \nInverkehrbringen – Schwerpunkt Wäschereien \nDie beobachteten unterschiedlichen Vorgehensweisen von Benannten Stellen/Zertifizierungs-\nstellen bei der Zertifizierung von Wäschereien machen es erforderlich, die Besonderheiten bei \nder Aufbereitung von Medizinprodukten und insbesondere die Unterschiede zum erstmaligen \nInverkehrbringen von Medizinprodukten und der Sterilisation vor dem Inverkehrbringen aufzu-\nzeigen. Die nachfolgende Darlegung soll dazu dienen, ein gemeinsames Verständnis der ge-\nsetzlichen Bestimmungen zwischen Aufbereitern, Benannten Stellen, Betreibern, Herstellern, \nSterilisationsunternehmen und den zuständigen Behörden zu erreichen.  \nBetrachtet man die gesetzlichen Bestimmungen im Medizinproduktegesetz (MPG), der Medi-\nzinprodukte-Verordnung (MPV) sowie der Medizinprodukte-Betreiberverordnung (MPBetreibV) \nzusammen mit den Vorgaben der darin in Bezug genommenen Richtlinie 93/42/EWG über Me-\ndizinprodukte genauer, so sind im Hinblick auf die Praxis (mindestens) die folgenden Fälle zu \nunterscheiden:  \nFall 1: Erstmaliges Inverkehrbringen \nFall 1a: Erstmaliges Inverkehrbringen von neuen Medizinprodukten \nFall 1b: Erstmaliges Inverkehrbringen von neu aufbereiteten Medizinprodukten \nFall 1c: Kombiniertes erstmaliges Inverkehrbringen von neuen und neu aufbereiteten \nMedizinprodukten \nFall 2: Sterilisation vor (erstmaligem) Inverkehrbringen \nFall 3: Aufbereitung ohne anschließendes erstmaliges Inverkehrbringen \nFall 3a: Selbsttätige Aufbereitung eigener Medizinprodukte \nFall 3b: Aufbereitung eigener Medizinprodukten durch externe Dienstleister \n \nRelevante Auszüge der gesetzlichen Bestimmungen sind zur Arbeitserleichterung im Anhang \nabgedruckt.  \n \n                                                 \n1 Definition des Begriffes Aufbereitung nach MPG § 3 Punkt 14: Die Aufbereitung von bestimmungsge-\nmäß keimarm oder steril zur Anwendung kommenden Medizinprodukten ist die nach deren Inbetrieb-\nnahme zum Zwecke der erneuten Anwendung durchgeführte Reinigung, Desinfektion und Sterilisation \neinschließlich der damit zusammenhängenden Arbeitsschritte sowie die Prüfung und Wiederherstellung \nder technisch-funktionellen Sicherheit \n\nAntworten und Beschlüsse des EK-Med \n3.16  A 2 \n \n \n316-0508.A02 \n© ZLG \n2/10\n \n \nFall 1: Erstmaliges Inverkehrbringen \nErstmaliges Inverkehrbringen liegt nach § 3 MPG Nr. 11 immer dann vor, wenn neue oder als \nneu aufbereitete Medizinprodukten an andere im Europäischen Wirtschaftsraum abgegeben \nwerden.  \nEine Abgabe an andere liegt nicht vor, wenn Medizinprodukte für einen anderen aufbereitet und \nan diesen zurückgegeben werden.  \nFall 1a: Erstmaliges Inverkehrbringen von neuen Medizinprodukten \nWerden Produkte erstmalig in den Verkehr gebracht, hat der Hersteller – hier die Wäscherei –\ngemäß § 7 Medizinprodukteverordnung (MPV) ein von der jeweiligen Klasse des Produktes \nabhängiges Konformitätsbewertungsverfahren durchzuführen, das im Falle von Sterilprodukten \nimmer die Einschaltung einer Benannten Stelle voraussetzt.  \nBei Produkten der Klasse Is ist nach § 7 (4) MPV ein Verfahren nach 93/42/EWG Anhang VII in \nVerbindung mit Anhang IV, V oder VI anzuwenden, wobei effektiv nur Anhang V einschlägig ist \n(vgl. z. B. [2]). Die Anwendung des Anhangs V und das Tätigwerden der Benannten Stelle be-\nschränken sich dabei ausschließlich auf die Herstellungsschritte im Zusammenhang mit der \nSterilisation und der Aufrechterhaltung der Sterilität. Die Benannte Stelle stellt eine Bescheini-\ngung entsprechend dem gewählten Anhang der Richtlinie aus, aus der die von der Bescheini-\ngung erfassten Produkte/Produktkategorien eindeutig hervorgehen. Ein Zertifikat z. B. nach DIN \nEN ISO 13485 [3] genügt hierfür nicht. \nAm Ende dieses Verfahrens stellt der Hersteller eine Konformitätserklärung aus und bringt die \nCE-Kennzeichnung – zusammen mit der Kennnummer der beteiligten Benannten Stelle – am \nProdukt an.  \nDieser Fall gilt auch, wenn Wäschereien nicht CE-gekennzeichnete Wäsche zukaufen, diese \nverpacken und sterilisieren oder auch bereits CE-gekennzeichnete Neuware (steril oder unste-\nril) unter eigenem Namen CE-gekennzeichnet in den Verkehr bringen (auch vermieten). \nWerden Produkte, deren Produktion nicht beim Hersteller im Sinne der Richtlinie stattfindet \n(Subunternehmer), erstmalig in den Verkehr gebracht, sind die einschlägigen EK-Med Doku-\nmente [4] zu beachten. \nFall 1b: Erstmaliges Inverkehrbringen von neu aufbereiteten Medizinprodukten \nBei diesem Fall ist wesentlich, dass die Produkte weder für einen anderen aufbereitet und an \ndi",
    "Allemange(CE_relative_aux_diagnostics_in_vitro_-_Verification_des_produits_fabriques_conformement_a_l'annexe_II,_liste_A_).pdf": "Antworten und Beschlüsse des EK-Med \nKonformitätsbewertung \n3.9.8  E 14 \n \n3098-0606.E14 \n© ZLG \n1/5\n \nRichtlinie 98/79/EG über In-vitro-Diagnostika – \nÜberprüfung der hergestellten Produkte nach Anhang II Liste A \nFür die Überprüfung der hergestellten Produkte nach Anhang II Liste A werden die In-vitro-\nDiagnostika in die folgenden 3 Kategorien1 eingeteilt. Über die Kategorien werden die Häufig-\nkeit und Modalitäten der Chargenprüfung durch die Benannten Stellen festgelegt, die in Ergän-\nzung zur verpflichtenden Prüfung der vom Hersteller vorzulegenden Prüfprotokolle (QC release \ndata) vorzunehmen sind.  \nKategorie 1  Screening assays: serological & NAT \ni.e. reagents and reagent products, including related calibrators and control materials, for the \ndetection and quantification in human specimens of markers of HIV infection (HIV 1 and 2), HTLV I \nand II, and hepatitis B, C and D \nKategorie 2  Confirmation assays for screening assays  \ni.e. reagents and reagent products, including related calibrators and control materials, for the \nconfirmation in human specimens of markers of HIV infection (HIV 1 and 2), HTLV I and II, and \nhepatitis B, C and D \nDiagnostic markers and respective confirmation assays of diagnosis assays \ni.e. reagents and reagent products, including related calibrators and control materials, for the \ndetection, confirmation and quantification in human specimens of markers of HIV infection (HIV 1 \nand 2), HTLV I and II, and hepatitis B, C and D \nReagents and reagent products for determining the following blood groups: AB0 \nsystem and Rhesus D \nKategorie 3   Reagents and reagent products for determining the following blood groups: \nRhesus (C, c, E, e) and Kell system \nRelated calibrators and control materials for reagents and reagent products \nincluding tests cells for determining the following blood groups: AB0 system, \nRhesus (C, c, D, E, e) and Kell system \nFür die experimentelle Prüfung sind ausschließlich die folgenden Modalitäten zugelassen: \nVariante I  \nPrüfung in einem Labor der Benannten Stelle oder in einem von der Benannten \nStelle beauftragten unabhängigen Laboratorium (Unterauftragnehmer) \nVariante II \nHersteller prüft nach vereinbarten Bedingungen mit von der Benannten Stelle zur \nVerfügung gestellten anonymisierten Proben  \nVariante III \nPrüfung beim Hersteller durch Experten der Benannten Stelle mit von der \nBenannten Stelle festgelegten (nicht herstellereigenen) Kontrollproben \nDas in NB-Med/2.5.4/Rec2 [1] beschriebene „Witness testing“ steht der Benannten Stelle als \nzusätzliche Überwachungsmöglichkeit frei.  \n                                                \n1 Kategorien entsprechend den Diskussionen in der Medical Devices „IVD Technical Group“ der \nEuropäischen Kommission \n\nAntworten und Beschlüsse des EK-Med \n3.9.8  E 14 \n \n \n3098-0606.E14 \n© ZLG \n2/4\n \nFür Kategorie 1 ist eine experimentelle Prüfung jeder Charge durch die Benannte Stelle \noder ein von ihr beauftragtes unabhängiges Laboratorium verpflichtend. \nFür Kategorie 2 ist eine experimentelle Prüfung durch die Benannte Stelle oder ein von ihr \nbeauftragtes unabhängiges Laboratorium der ersten 20 Chargen (bei Reagenzien/Reagenz-\nprodukten zur Blutgruppenbestimmung der ersten sechs Chargen) verpflichtend. \nWenn die Ergebnisse dieser Prüfungen belegen, dass die Produkte unter beherrschten Bedin-\ngungen und innerhalb der vorgegebenen Spezifikationen hergestellt werden und keine Funk-\ntionsstörungen, Ausfälle oder Fehlfunktionen aufgetreten sind, kann die Benannte Stelle die \nHäufigkeit der Prüfungen auf minimal jede fünfte Charge reduzieren. Werden im Jahr weniger \nals fünf Chargen hergestellt, muss mindestens eine Charge pro Jahr geprüft werden.  \nAlternativ zur experimentellen Prüfung in einem externen Laboratorium (Variante I) kann die \nBenannte Stelle auch Fachexperten zum Hersteller entsenden, um dort mit externen Proben-\nmaterial die Überprüfung vorzunehmen (sog. on-site testing, Variante III), oder dem Hersteller \nanonymisierte Referenzmaterialien zusenden. In diesem Fall muss der Hersteller Proben der zu \nüberprüfenden Charge mit diesem Referenzmaterial und nach vereinbarten Verfahren prüfen \n(Variante II).  \nEine Reduktion der externen experimentellen Prüfungen ist grundsätzlich nur zulässig, wenn \ndie Gesamtzahlen der nach Vereinbarung mit der Benannten Stelle vom Hersteller zu testen-\nden Proben bei Reagenzien zur Blutgruppenbestimmung höher als die in Tabelle 10 der \nGemeinsamen Technischen Spezifikationen2 angegebenen sind.  \nBei Auffälligkeiten sind die Häufigkeit und/oder die Art der experimentellen Prüfung anzupas-\nsen. \nFür Kategorie 3 ist die experimentelle Prüfung durch die Benannte Stelle oder ein von ihr be-\nauftragtes unabhängiges Laboratorium mindestens der ersten Charge verpflichtend.  \nAnmerkung: Die Benannte Stelle kann zu der Entscheidung gelangen, dass die experimentelle \nPrüfung nur einer Charge für eine zukünftige Freigabe alleine auf Basis der Prüfung der \nHerstellerdokumentation nicht au",
    "Australie.pdf": "Prepared by the Office of Parliamentary Counsel, Canberra\nTherapeutic Goods (Medical Devices) \nRegulations 2002\nStatutory Rules No. 236, 2002\nmade under the\nTherapeutic Goods Act 1989\nCompilation No. 66\nCompilation date:\n14 December 2024\nIncludes amendments:\nF2024L01673\nAuthorised Version F2025C00021 registered 07/01/2025\n\nAbout this compilation\nThis compilation\nThis is a compilation of the Therapeutic Goods (Medical Devices) Regulations 2002 that \nshows the text of the law as amended and in force on 14 December 2024 (the compilation \ndate).\nThe notes at the end of this compilation (the endnotes) include information about amending \nlaws and the amendment history of provisions of the compiled law.\nUncommenced amendments\nThe effect of uncommenced amendments is not shown in the text of the compiled law. Any \nuncommenced amendments affecting the law are accessible on the Register \n(www.legislation.gov.au). The details of amendments made up to, but not commenced at, the \ncompilation date are underlined in the endnotes. For more information on any uncommenced \namendments, see the Register for the compiled law.\nApplication, saving and transitional provisions for provisions and amendments\nIf the operation of a provision or amendment of the compiled law is affected by an \napplication, saving or transitional provision that is not included in this compilation, details are \nincluded in the endnotes.\nEditorial changes\nFor more information about any editorial changes made in this compilation, see the endnotes.\nModifications\nIf the compiled law is modified by another law, the compiled law operates as modified but the \nmodification does not amend the text of the law. Accordingly, this compilation does not show \nthe text of the compiled law as modified. For more information on any modifications, see the \nRegister for the compiled law.\nSelf-repealing provisions\nIf a provision of the compiled law has been repealed in accordance with a provision of the \nlaw, details are included in the endnotes.\n  \n  \n  \nAuthorised Version F2025C00021 registered 07/01/2025\n\nTherapeutic Goods (Medical Devices) Regulations 2002\ni\nCompilation No. 66\nCompilation date: 14/12/2024\nContents\nPart 1—Preliminary\n1\n1.1\nName of Regulations ....................................................................................1\n1.3\nDefinitions—the dictionary etc.....................................................................1\n1.4\nMedical devices with a measuring function .................................................1\n1.5\nRefurbishment (Act s 3(1))...........................................................................1\n1.6\nKinds of medical devices—other common characteristics (Act \ns 41BE(1)(e)) ................................................................................................2\n1.7\nDevice nomenclature system codes (Act s 41BE(3)) ...................................2\n1.8\nClasses of persons that are not manufacturers of a medical device..............3\nPart 2—Essential principles\n4\n2.1\nEssential principles (Act s 41CA).................................................................4\nPart 3—Conformity assessment procedures\n5\nDivision 3.1—Medical device classifications\n5\n3.1\nMedical device classifications (Act s 41DB)................................................5\n3.2\nClassification of medical devices .................................................................5\n3.3\nPrinciples for applying the classification rules.............................................5\nDivision 3.2—Conformity assessment procedures\n7\n3.4\nConformity assessment procedures (Act s 41DA)........................................7\n3.5\nPowers and functions of Secretary in relation to conformity \nassessment.....................................................................................................7\n3.6\nClass III medical devices (other than medical devices used for a \nspecial purpose) ............................................................................................7\n3.6A\nClass 4 IVD medical devices (other than medical devices to be used \nfor a special purpose)....................................................................................8\n3.6B\nClass 4 in-house IVD medical devices (other than medical devices \nto be used for a special purpose)...................................................................8\n3.7\nClass IIb medical devices (other than medical devices used for a \nspecial purpose) ............................................................................................8\n3.7A\nClass 3 IVD medical devices (other than devices to be used for a \nspecial purpose) ............................................................................................9\n3.7B\nClass 3 in-house IVD medical devices .........................................................9\n3.8\nClass IIa medical devices (other than medical devices used for a \nspecial purpose) ............................................................................................9\n3.8",
    "Bresil_(__Prevoit_la_regularisation_des_logiciels_en_tant_que_dispositifs_medicaux_(Software_as_a_Medical_Device_-_SaMD).pdf": "Ministério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nRESOLUÇÃO DE DIRETORIA COLEGIADA - RDC Nº 657, DE 24 DE MARÇO DE 2022 \n(Publicada no DOU nº 61, de 30 de março de 2022) \nDispõe \nsobre \na \nregularização \nde \nsoftware \ncomo \ndispositivo \nmédico \n(Software as a Medical Device - SaMD). \nA Diretoria Colegiada Da Agência Nacional De Vigilância Sanitária, no uso \ndas competências que lhe conferem os arts. 7º, inciso III, e 15, incisos III e IV, da Lei n º \n9.782, de 26 de janeiro de 1999, e considerando o disposto no art. 187, inciso VI e §§ \n1º e 3º, do Regimento Interno, aprovado pela Resolução de Diretoria Colegiada - RDC \nn° 585, de 10 de dezembro de 2021, resolve adotar a seguinte Resolução de Diretoria \nColegiada, conforme deliberado em reunião realizada em 23 de março de 2022, e eu, \nDiretor-Presidente, determino a sua publicação: \nCAPÍTULO I \nDISPOSIÇÕES INICIAIS \nArt. 1º Esta Resolução dispõe sobre a regularização de software como \ndispositivo médico (Software as a Medical Device - SaMD). \n§ 1º Para os fins desta Resolução são considerados dispositivos médicos os \nprodutos médicos e os produtos para diagnóstico in vitro regulamentados pela \nResolução de Diretoria Colegiada - RDC nº 185, de 22 de outubro de 2001, Resolução \nde Diretoria Colegiada - RDC nº 36, de 26 de agosto de 2015, e Resolução de Diretoria \nColegiada - RDC nº 40, de 26 de agosto de 2015, ou regulamentos posteriores. \n§ 2º Esta Resolução não se aplica aos seguintes softwares: \nI - para bem-estar; \nII - relacionado em lista disponibilizada pela Agência Nacional de Vigilância \nSanitária (Anvisa) de produtos não regulados; \nIII - utilizado exclusivamente para gerenciamento administrativo e \nfinanceiro em serviço de saúde; \nIV - que processa dados médicos demográficos e epidemiológicos, sem \nqualquer finalidade clínica diagnóstica ou terapêutica; e \nV - embarcado em dispositivo médico sob regime de vigilância sanitária. \n \n \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nArt. 2º Para fins desta Resolução, aplicam-se as seguintes definições: \nI - associação clínica válida ou validade científica: Extensão a qual a saída \ndo SaMD (conceito, conclusão, medições) é clinicamente aceita ou bem \nfundamentada, com base em um quadro científico estabelecido ou evidência, e \ncorresponde com precisão no mundo real à situação e condições de saúde \nidentificadas na declaração de escopo do SaMD; \nII - avaliação clínica: Conjunto de atividades conduzidas na avaliação e na \nanálise da segurança clínica, eficácia e desempenho de um SaMD, conforme finalidade \npretendida pelo fabricante; \nIII - cibersegurança: Um estado em que informações e sistemas são \nprotegidos contra atividades não autorizadas, como acesso, uso, divulgação, \ninterrupção, modificação ou destruição, a um nível em que os riscos relacionados à \nconfidencialidade, integridade e disponibilidade sejam mantidos em um nível aceitável \npor todo o ciclo de vida; \nIV - compatibilidade: Capacidade de um dispositivo, incluindo software, \npara, quando utilizado juntamente com um ou mais dispositivos de acordo com a sua \nfinalidade prevista: funcionar sem perder ou comprometer a capacidade para ter o \ndesempenho pretendido, integrar ou funcionar sem necessidade de alteração ou \nadaptação de qualquer das partes dos dispositivos combinados, ou ser utilizado em \nconjunto sem conflito/interferência ou reação adversa; \nV - descaracterização da identidade visual: Qualquer alteração que tenha \nimpacto significativo sobre a usabilidade do software ou alteração visual que impeça o \nreconhecimento do software conforme havia sido regularizado; \nVI - interoperabilidade: Capacidade de dois ou mais dispositivos, incluindo \nsoftware, do mesmo fabricante ou de fabricantes diferentes, para trocar informações e \nutilizar as informações trocadas para a correta execução de uma função especificada \nsem alterar o conteúdo dos dados e comunicar entre si, ou funcionar em conjunto \nconforme pretendido; \nVII - software como um dispositivo médico (Software as a Medical Device - \nSaMD): Software que atende à definição de dispositivo médico, podendo ser de \ndiagnóstico in vitro (IVD) ou não, sendo destinado a uma ou mais indicações médicas, e \nque realizam essas finalidades sem fazer parte de hardware de dispositivo médico. \nInclui os aplicativos móveis e softwares com finalidades in vitro, se suas indicações \nestiverem incluídas na definição geral de dispositivos médicos. Incluem-se nesta \ndefinição, entre outros, o software licenciado por assinatura e hospedado \ncentralmente (Software as a Service), que se enquadre na definição de dispositivos \nmédicos; \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nVIII - softwa",
    "bresil_(_Fournit_de_bonnes_pratiques_en_Fabrication_de_produits_medicaux_et_Produits_de_diagnostic_d'utilisation_In_vitro..pdf": "Ministério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nRESOLUÇÃO DA DIRETORIA COLEGIADA - RDC Nº 665, DE 30 DE MARÇO DE 2022 \n(Publicada no DOU nº 62, de 31 de março de 2022) \nDispõe sobre as Boas Práticas de \nFabricação de Produtos Médicos e \nProdutos para Diagnóstico de Uso \nIn Vitro. \nA Diretoria Colegiada da Agência Nacional de Vigilância Sanitária, no uso \ndas atribuições que lhe confere o art. 15, III e IV, aliado ao art. 7º, III e IV, da Lei nº \n9.782, de 26 de janeiro de 1999, e ao art. 187, VI, § 1º do Regimento Interno aprovado \npela Resolução de Diretoria Colegiada - RDC nº 585, de 10 de dezembro de 2021, \nresolve adotar a seguinte Resolução, conforme deliberado em Reunião Extraordinária - \nRExtra nº 6, realizada em 30 de março de 2022, e eu, Diretor-Presidente, determino a \nsua publicação. \nCAPÍTULO I \nDISPOSIÇÕES INICIAIS \nSeção I \nObjetivo \nArt. 1º Esta Resolução dispõe sobre as Boas Práticas de Fabricação (BPF) \nde Produtos Médicos e Produtos para Diagnóstico de Uso In Vitro, estabelecendo os \nrequisitos que descrevem as BPF para métodos e controles usados no projeto, \ncompras, fabricação, embalagem, rotulagem, armazenamento, distribuição, instalação \ne assistência técnica aplicáveis à fabricação de produtos médicos e produtos para \ndiagnóstico de uso in vitro. \n§ 1º Os requisitos de que trata o caput deste artigo se destinam a \nassegurar que os produtos médicos e produtos para diagnóstico de uso in vitro sejam \nseguros e eficazes. \n§ 2º Esta Resolução incorpora ao ordenamento jurídico nacional a \nResolução do Grupo Mercado Comum (GMC) MERCOSUL nº 20, de 17 de novembro de \n2011, MERCOSUL/GMC/RES. nº 20/11, \"Regulamento Técnico MERCOSUL de Boas \nPráticas de Fabricação de Produtos Médicos e Produtos para Diagnóstico de Uso In \nVitro (revogação das Res. GMC nº 04/95, 38/96, 65/96 e 131/96)\". \n \n \n \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nSeção II \nAbrangência \nArt. 2º Esta Resolução se aplica a fabricantes, distribuidores, \narmazenadores e importadores de produtos médicos e produtos para diagnóstico de \nuso in vitro que sejam comercializados no Brasil. \n§ 1º Quando os fabricantes de que trata o caput deste artigo concluírem \nque determinados requisitos estabelecidos nesta Resolução não são aplicáveis a seus \nprocessos, estes devem documentar justificativa para tal entendimento. \n§ 2º Os distribuidores de produtos médicos e produtos para diagnóstico \nde uso in vitro devem cumprir, minimamente, os seguintes requisitos desta Resolução: \nI - Capítulos I, VII e VIII, integralmente; \nII - Capítulo II, integralmente, exceto Seção IV; \nIII - Capítulo III, Seção I; \nIV - Capítulo V, artigos 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 e 77, além da \nSeção IV; e \nV - Capítulo VI, integralmente, exceto art. 119. \n§ 3º Os armazenadores de produtos médicos e produtos para diagnóstico \nde uso in vitro devem cumprir, minimamente, os seguintes requisitos desta Resolução: \nI - Capítulos I e VII, integralmente; \nII - Capítulo II, integralmente, exceto Seção IV; \nIII - Capítulo III, Seção I; \nIV - Capítulo V, artigos 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 e 77; e \nV - Capítulo VI, integralmente, exceto art. 119. \n§ 4º Os importadores de produtos médicos e produtos para diagnóstico de \nuso in vitro devem cumprir, minimamente, os seguintes requisitos desta Resolução: \nI - Capítulos I, II, VII, VIII e IX integralmente; \nII - Capítulo III, Seção I e Seção III; \nIII - Capítulo IV, art. 63, incisos III, IV e V; \nIV - Capítulo V, artigos 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 85, 86 e 87, \nalém das Seções III e IV; e \nV - Capítulo VI, integralmente, exceto art. 119. \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \n§ 5º As empresas que exerçam mais de uma atividade deverão cumprir os \nrequisitos específicos definidos para cada atividade. \n§ 6º Os requisitos mínimos a serem cumpridos, definidos nos §§ 2º, 3º e \n4º deste artigo, são aplicáveis aos distribuidores, armazenadores e importadores, \nmesmo que o dispositivo mencione apenas a palavra fabricante. \nSeção III \nDefinições \nArt. 3º Para efeito desta Resolução, são adotadas as seguintes definições: \nI - assistência técnica: manutenção ou reparo de um produto acabado, a \nfim de devolvê-lo às suas especificações; \nII - auditoria de qualidade: um exame estabelecido, sistemático e \nindependente de todo o sistema de qualidade de um fabricante, executado em \nintervalos regulares e com frequência suficiente para assegurar que, tanto as \natividades do sistema de qualidade, quanto seus resultados satisfaçam os \nprocedimentos especificados em seu sistema de qualidade; \nIII \n- \ncomponente: \nmatéria \nprima, \nsubstância, \npeça, \nparte, software, hardware, embalagem, ",
    "Bresil_(_Prevoit_les_criteres_d'octroi_ou_de_renouvellement_de_la_certification_des_bonnes_pratiques_de_fabrication_des_dispositifs_medicaux.).pdf": "Ministério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nRESOLUÇÃO DA DIRETORIA COLEGIADA - RDC Nº 687, DE 13 DE MAIO DE 2022 \n(Publicada no DOU nº 93, de 18 de maio de 2022) \nDispõe sobre os critérios para a \nconcessão \nou \nrenovação \nda \nCertificação de Boas Práticas de \nFabricação de Dispositivos Médicos. \nA Diretoria Colegiada da Agência Nacional de Vigilância Sanitária, no uso \ndas competências que lhe conferem os arts. 7º, inciso III, e 15, incisos III e IV da Lei nº \n9.782, de 26 de janeiro de 1999, e ao art. 187, VI, § 1º do Regimento Interno aprovado \npela Resolução de Diretoria Colegiada - RDC nº 585, de 10 de dezembro de 2021, \nresolve adotar a seguinte Resolução, conforme deliberado em reunião realizada em 12 \nde maio de 2022, e eu, Diretor-Presidente, determino a sua publicação. \nCAPÍTULO I \nDISPOSIÇÕES INICIAIS \nSeção I \nObjeto \nArt. 1º Esta Resolução dispõe sobre os programas de inspeção e \nestabelece critérios para a concessão e renovação da Certificação de Boas Práticas de \nFabricação de Dispositivos Médicos, em complemento às disposições gerais de \nprocedimentos administrativos para concessão de Certificação de Boas Práticas de \nFabricação. \nSeção II \nAbrangência \nArt. 2º Esta Resolução se aplica à concessão e renovação da Certificação \nde Boas Práticas de Fabricação de Dispositivos Médicos para estabelecimentos \nfabricantes que atendam aos critérios definidos por esta Resolução e demais \nnormativas aplicáveis. \nArt. 3º As unidades fabris de dispositivos médicos das classes de risco III e \nIV enquadradas em uma das condições abaixo serão objeto de Certificação de Boas \nPráticas de Fabricação de Dispositivos Médicos pela Anvisa: \nI - unidade fabril que produz um produto final em seu nome ou para outra \nempresa; \nII - unidade fabril que realiza a liberação final do produto final, associada a \npelo menos uma etapa de produção, excluídas as etapas de projeto, distribuição, \nesterilização, embalagem e rotulagem; \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nIII - unidade fabril de software médico (Software as a Medical Device - \nSaMD). \n§ 1º A atividade de acondicionamento em embalagem considerada como \nsistema de barreira estéril de produtos declarados como estéreis é considerada como \netapa de produção passível de certificação de boas práticas de fabricação para fins do \ndisposto no inciso II. \n§ 2º As unidades fabris de dispositivos médicos para diagnóstico in vitro \nque executem as etapas de impregnação, laminação ou corte de tiras de \nimunocromatografia são passíveis de certificação de boas práticas de fabricação nos \ntermos do inciso II. \nSeção III \nDefinições \nArt. 4º Para efeitos desta Resolução, são adotadas as seguintes definições: \nI - fabricante legal: pessoa jurídica, pública ou privada, com \nresponsabilidade pelo projeto, manufatura, embalagem e rotulagem de um produto, \ncom a intenção de disponibilizá-lo para uso sob seu nome, sendo estas operações \nrealizadas pela própria empresa ou por terceiros em seu nome; \nII - liberação final: aprovação final do lote ou série do produto acabado por \npessoa formalmente designada para assegurar que os critérios de aceitação tenham \nsido atendidos; \nIII - produto final: é o produto objeto de regularização que está apto para \no uso ou funcionalmente completo, estando ou não embalado, rotulado ou \nesterilizado; \nIV - produto acabado: produto terminado que tenha passado por todas as \netapas de produção, incluindo rotulagem, embalagem final e esterilização (quando \naplicável); \nV - relatório de inspeção: relatório que descreva a situação da empresa \nquanto ao cumprimento das boas práticas de fabricação, de acordo com as normas \nreferenciadas no escopo do relatório; \nVI - unidade fabril: local onde ocorre uma ou mais etapas de fabricação, \npodendo ser o próprio fabricante legal, fabricante contratado ou fabricante original de \nproduto. \n \n \n \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nCAPÍTULO II \nDOCUMENTOS DE PETICIONAMENTO \nArt. 5º Os processos de concessão de Certificação de Boas Práticas de \nFabricação de que trata esta Resolução devem ser instruídos com os seguintes \ndocumentos: \nI - formulário de petição específico para Certificação de Boas Práticas de \nFabricação de Dispositivos Médicos, devidamente preenchido; \nII - fluxograma geral de produção relativo aos produtos fabricados, \nidentificando quais etapas são executadas no estabelecimento objeto da certificação; \nIII - leiaute do estabelecimento objeto da certificação, incluindo a planta \nbaixa da unidade fabril; \nIV - lista de todos os produtos passíveis de regularização sanitária no Brasil \nfabricados na unidade fabril objeto da certificação, contendo nome técnico, linha ",
    "Bresil_(_usage_compassionnel_des_dispositifs_medicaux)_.pdf": "Ministério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nRESOLUÇÃO DA DIRETORIA COLEGIADA - RDC Nº 608, DE 25 DE FEVEREIRO DE 2022 \n(Publicada no DOU nº 41, de 2 de março de 2022) \nDispõe sobre o uso compassivo de \ndispositivos médicos. \n \nA Diretoria Colegiada da Agência Nacional de Vigilância Sanitária, no uso das \natribuições que lhe confere o art. 15, III e IV, aliado ao art. 7º, III e IV da Lei nº 9.782, \nde 26 de janeiro de 1999, e ao art. 187, VI, § 1º do Regimento Interno aprovado pela \nResolução de Diretoria Colegiada - RDC nº 585, de 10 de dezembro de 2021, resolve \nadotar a seguinte Resolução de Diretoria Colegiada, conforme deliberado em reunião \nrealizada em 23 de fevereiro de 2022, e eu, Diretor-Presidente, determino a sua \npublicação. \n \nCAPÍTULO I \nDISPOSIÇÕES INICIAIS \n  \nSeção I \nObjeto \n \nArt. 1º Esta Resolução dispõe sobre os requisitos para submissão e anuência de \nprogramas de uso compassivo de dispositivos médicos. \n \nSeção II \nAbrangência  \n  \nArt. 2º Os critérios estabelecidos nesta Resolução se aplicam à submissão e \nanuência de programas de uso compassivo de dispositivos médicos. \n \nParágrafo único. Esta Resolução não se aplica a dispositivos médicos sob \nmedida, paciente-específico ou adaptável, que continuam regidos pela Resolução de \nDiretoria Colegiada - RDC nº 305, de 24 de setembro de 2019 ou Resolução que vier a \nsubstituí-la. \n  \nArt. 3º As solicitações de anuência dos programas de uso compassivo de \ndispositivos médicos são aplicáveis às seguintes situações, quando ocorrerem de forma \nsimultânea: \n  \nI - paciente que apresente doença debilitante grave; e \n  \nII - ausência de alternativa terapêutica satisfatória no país para a condição \nclínica apresentada; e \n  \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nIII - relação benefício-risco favorável ao uso do dispositivo médico solicitado.  \n  \nArt. 4º O dispositivo médico proposto deve possuir um relatório conclusivo \nbaseado na literatura científica, em dados clínicos e estudos da respectiva doença, sua \nevolução ou estado mórbido a ser tratado e estar na fase de validação do projeto e \ndesenvolvimento. \n  \nParágrafo único. O relatório conclusivo de que trata o caput deve conter análise \nfavorável de benefício-risco, considerada a gravidade da doença e a indisponibilidade \nde outras terapias e recursos.  \n  \nSeção III \nDefinições \n  \nArt. 5º Para efeitos desta Resolução, são adotadas as seguintes definições: \n  \nI - comunicado especial específico para uso compassivo de dispositivo médico \n(CEE-UCDM): documento de caráter autorizador, emitido pela Anvisa, necessário para \na execução de um programa de uso compassivo no Brasil de um dispositivo médico \nainda sem registro na Anvisa e, quando aplicável, para a importação do dispositivo \nmédico a ser utilizado no programa de uso compassivo; \n  \nII - doença debilitante grave: aquela que prejudica substancialmente os seus \nportadores no desempenho das tarefas da vida diária e doença crônica que, se não \ntratada, progredirá na maioria dos casos, levando a perdas cumulativas de autonomia, \nsequelas ou óbito; \n  \nIII - médico assistente: médico que estabelece a justificativa para o uso do \ndispositivo médico através de relatório técnico, prescreve, assiste o paciente e é \nresponsável por prestar atendimento nas ocorrências relacionadas à intervenção \nespecífica e respectivo acompanhamento clínico cirúrgico; \n  \nIV - organização representativa do patrocinador (ORP): empresa regularmente \ninstalada em território nacional, incluindo organizações representativas de pesquisa \nclínica (ORPC), instituições de ensino e hospitalares, contratada pelo patrocinador, que \nassume parcial ou totalmente, junto à Anvisa, as atribuições do patrocinador; \n  \nV - patrocinador: pessoa física ou jurídica, pública ou privada, que apoia \nfinanceiramente os programas de uso compassivo de dispositivo médico; \n  \n \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nVI - programa de uso compassivo de dispositivo médico: disponibilização de \ndispositivo médico inovador ainda sem registro na Anvisa, para uso exclusivo de \npacientes, que esteja em processo de validação, destinado a pacientes portadores de \ndoenças debilitantes graves e/ou que ameacem a vida e sem alternativa terapêutica \nsatisfatória com produtos registrados no país; e \n  \nVII - instruções de uso: documento contendo informações prestadas pelo \nfabricante para esclarecer ao usuário sobre a finalidade pretendida de um dispositivo, \nsua correta utilização e eventuais precauções. \n  \nCAPÍTULO II \nDOS PROCEDIMENTOS \n  \nSeção I \nSolicitação e Anuência \n  \nArt. 6º A solicitação de adesão ao programa de uso compassivo de dispositivo \nmédico deverá ",
    "bresil(_Prevoit_les_bonnes_pratiques_de_fabrication_des_produits_medicaux_et_des_produits_de_diagnostic_in_vitro).pdf": "Ministério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nRESOLUÇÃO DA DIRETORIA COLEGIADA - RDC Nº 665, DE 30 DE MARÇO DE 2022 \n(Publicada no DOU nº 62, de 31 de março de 2022) \nDispõe sobre as Boas Práticas de \nFabricação de Produtos Médicos e \nProdutos para Diagnóstico de Uso \nIn Vitro. \nA Diretoria Colegiada da Agência Nacional de Vigilância Sanitária, no uso \ndas atribuições que lhe confere o art. 15, III e IV, aliado ao art. 7º, III e IV, da Lei nº \n9.782, de 26 de janeiro de 1999, e ao art. 187, VI, § 1º do Regimento Interno aprovado \npela Resolução de Diretoria Colegiada - RDC nº 585, de 10 de dezembro de 2021, \nresolve adotar a seguinte Resolução, conforme deliberado em Reunião Extraordinária - \nRExtra nº 6, realizada em 30 de março de 2022, e eu, Diretor-Presidente, determino a \nsua publicação. \nCAPÍTULO I \nDISPOSIÇÕES INICIAIS \nSeção I \nObjetivo \nArt. 1º Esta Resolução dispõe sobre as Boas Práticas de Fabricação (BPF) \nde Produtos Médicos e Produtos para Diagnóstico de Uso In Vitro, estabelecendo os \nrequisitos que descrevem as BPF para métodos e controles usados no projeto, \ncompras, fabricação, embalagem, rotulagem, armazenamento, distribuição, instalação \ne assistência técnica aplicáveis à fabricação de produtos médicos e produtos para \ndiagnóstico de uso in vitro. \n§ 1º Os requisitos de que trata o caput deste artigo se destinam a \nassegurar que os produtos médicos e produtos para diagnóstico de uso in vitro sejam \nseguros e eficazes. \n§ 2º Esta Resolução incorpora ao ordenamento jurídico nacional a \nResolução do Grupo Mercado Comum (GMC) MERCOSUL nº 20, de 17 de novembro de \n2011, MERCOSUL/GMC/RES. nº 20/11, \"Regulamento Técnico MERCOSUL de Boas \nPráticas de Fabricação de Produtos Médicos e Produtos para Diagnóstico de Uso In \nVitro (revogação das Res. GMC nº 04/95, 38/96, 65/96 e 131/96)\". \n \n \n \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nSeção II \nAbrangência \nArt. 2º Esta Resolução se aplica a fabricantes, distribuidores, \narmazenadores e importadores de produtos médicos e produtos para diagnóstico de \nuso in vitro que sejam comercializados no Brasil. \n§ 1º Quando os fabricantes de que trata o caput deste artigo concluírem \nque determinados requisitos estabelecidos nesta Resolução não são aplicáveis a seus \nprocessos, estes devem documentar justificativa para tal entendimento. \n§ 2º Os distribuidores de produtos médicos e produtos para diagnóstico \nde uso in vitro devem cumprir, minimamente, os seguintes requisitos desta Resolução: \nI - Capítulos I, VII e VIII, integralmente; \nII - Capítulo II, integralmente, exceto Seção IV; \nIII - Capítulo III, Seção I; \nIV - Capítulo V, artigos 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 e 77, além da \nSeção IV; e \nV - Capítulo VI, integralmente, exceto art. 119. \n§ 3º Os armazenadores de produtos médicos e produtos para diagnóstico \nde uso in vitro devem cumprir, minimamente, os seguintes requisitos desta Resolução: \nI - Capítulos I e VII, integralmente; \nII - Capítulo II, integralmente, exceto Seção IV; \nIII - Capítulo III, Seção I; \nIV - Capítulo V, artigos 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 e 77; e \nV - Capítulo VI, integralmente, exceto art. 119. \n§ 4º Os importadores de produtos médicos e produtos para diagnóstico de \nuso in vitro devem cumprir, minimamente, os seguintes requisitos desta Resolução: \nI - Capítulos I, II, VII, VIII e IX integralmente; \nII - Capítulo III, Seção I e Seção III; \nIII - Capítulo IV, art. 63, incisos III, IV e V; \nIV - Capítulo V, artigos 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 85, 86 e 87, \nalém das Seções III e IV; e \nV - Capítulo VI, integralmente, exceto art. 119. \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \n§ 5º As empresas que exerçam mais de uma atividade deverão cumprir os \nrequisitos específicos definidos para cada atividade. \n§ 6º Os requisitos mínimos a serem cumpridos, definidos nos §§ 2º, 3º e \n4º deste artigo, são aplicáveis aos distribuidores, armazenadores e importadores, \nmesmo que o dispositivo mencione apenas a palavra fabricante. \nSeção III \nDefinições \nArt. 3º Para efeito desta Resolução, são adotadas as seguintes definições: \nI - assistência técnica: manutenção ou reparo de um produto acabado, a \nfim de devolvê-lo às suas especificações; \nII - auditoria de qualidade: um exame estabelecido, sistemático e \nindependente de todo o sistema de qualidade de um fabricante, executado em \nintervalos regulares e com frequência suficiente para assegurar que, tanto as \natividades do sistema de qualidade, quanto seus resultados satisfaçam os \nprocedimentos especificados em seu sistema de qualidade; \nIII \n- \ncomponente: \nmatéria \nprima, \nsubstância, \npeça, \nparte, software, hardware, embalagem, ",
    "bresil(Prevoit_la_classification_des_dispositifs_medicaux_).pdf": "Ministério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nRESOLUÇÃO DA DIRETORIA COLEGIADA - RDC Nº 751, DE 15 DE SETEMBRO DE 2022 \n(Publicada no DOU nº 180, de 21 de setembro de 2022) \nDispõe sobre a classificação de \nrisco, os regimes de notificação e \nde registro, e os requisitos de \nrotulagem e instruções de uso de \ndispositivos médicos. \nA Diretoria Colegiada da Agência Nacional de Vigilância Sanitária, no uso \ndas atribuições que lhe confere o art. 15, III e IV, aliado ao art. 7º, III e IV da Lei nº 9.782, \nde 26 de janeiro de 1999, e ao art. 187, VI, § 1º do Regimento Interno aprovado pela \nResolução de Diretoria Colegiada - RDC nº 585, de 10 de dezembro de 2021, resolve \nadotar a seguinte Resolução, conforme deliberado em reunião realizada em 14 de \nsetembro de 2022, e eu, Diretor-Presidente, determino a sua publicação. \nCAPÍTULO I \nDAS DISPOSIÇÕES INICIAIS \nSeção I \nObjetivo \nArt. 1º Esta Resolução define as regras de classificação de risco de \ndispositivos médicos, os requisitos de rotulagem e de instruções de uso, e os \nprocedimentos para notificação, registro, alteração, revalidação e cancelamento de \nnotificação ou registro de dispositivos médicos. \nSeção II \nAbrangência \nArt. 2º Esta Resolução se aplica aos dispositivos médicos nela definidos, \nsendo obrigatório a notificação ou o registro destes, conforme classificação de risco. \n§ 1º A classificação de risco, os procedimentos e as especificações descritas \nneste documento, para fins de notificação e registro, se aplicam aos dispositivos \nmédicos e seus acessórios. \n§ 2º Esta Resolução não se aplica aos dispositivos médicos usados ou \nrecondicionados, os quais estão submetidos às regras específicas estabelecidas na \nResolução de Diretoria Colegiada - RDC nº 579, de 25 de novembro de 2021, publicada \nno DOU nº 225, de 1° de dezembro de 2021. \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \n§ 3º Esta Resolução não se aplica aos dispositivos médicos personalizados, \nos quais estão submetidos às regras específicas estabelecidas na Resolução de Diretoria \nColegiada - RDC nº 305, de 24 de setembro de 2019, publicada no DOU nº 186, de 25 de \nsetembro de 2019, Seção 1, pag. 69. \n§ 4º Esta Resolução não se aplica aos dispositivos médicos para diagnóstico \nin vitro, incluindo os instrumentos para diagnóstico in vitro, os quais estão submetidos \nàs regras específicas estabelecidas na Resolução de Diretoria Colegiada - RDC nº 36, de \n26 de agosto de 2015, publicada no DOU nº 164, de 27 de agosto de 2015, Seção 1, pág. \n43. \n§ 5º Esta Resolução não se aplica aos medicamentos, células, tecidos, \nórgãos ou sangue de origem humana ou derivados, cosméticos, saneantes ou gêneros \nalimentícios tratados por outros regulamentos. \n§ 6º Os dispositivos ativos (equipamentos) indicados para correção estética \ne embelezamento são considerados dispositivos médicos. \n§ 7º Os dispositivos ativos (equipamentos) especificamente destinados à \nlimpeza, desinfecção ou esterilização de dispositivos médicos são considerados \ndispositivos médicos. \n§ 8º Estão isentos de notificação ou registro os dispositivos médicos \ndestinados a investigações clínicas, cumpridas as disposições legais da autoridade \nsanitária competente para realização desta atividade, estando proibidos a \ncomercialização e o uso para outros fins. \n§ 9º Estão isentas de notificação ou registro as apresentações constituídas \npor dois ou mais dispositivos médicos notificados ou registrados e em suas embalagens \nindividuais de apresentação íntegras, devendo conter no rótulo as informações dos \ndispositivos médicos correspondentes, incluindo os números de notificação ou registro. \n§ 10. Estão isentos de notificação ou registro os acessórios produzidos por \num fabricante exclusivamente para integrar os dispositivos médicos de sua fabricação já \nnotificados ou registrados e cujos dossiês técnicos contenham informações sobre estes \nacessórios. \n§ 11. Os novos acessórios poderão ser incluídos nas notificações ou nos \nregistros originais, detalhando os fundamentos de funcionamento, ação e conteúdo. \nArt. 3º A Anvisa também concederá a notificação ou o registro para famílias, \nsistemas e conjuntos (ou kits) de dispositivos médicos. \nParágrafo único. O agrupamento de produtos, com finalidade de notificação \nou registro, dar-se-á segundo as regras previstas em regulamento específico. \n \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nSeção III \nDefinições \nArt. 4º Para fins da presente Resolução serão aplicadas as seguintes \ndefinições, as quais podem ter significado distinto em outro contexto. \nI - acessório (de um dispositivo médico): produto destinado pelo seu \nfabricante a ser utilizado em conjunto com um ou v",
    "bresil(Prevoit_les_criteres_d'octroi_ou_de_renouvellement_de_la_certification_des_bonnes_pratiques_de_fabrication_des_dispositifs_medicaux..pdf": "Ministério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nRESOLUÇÃO DA DIRETORIA COLEGIADA - RDC Nº 687, DE 13 DE MAIO DE 2022 \n(Publicada no DOU nº 93, de 18 de maio de 2022) \nDispõe sobre os critérios para a \nconcessão \nou \nrenovação \nda \nCertificação de Boas Práticas de \nFabricação de Dispositivos Médicos. \nA Diretoria Colegiada da Agência Nacional de Vigilância Sanitária, no uso \ndas competências que lhe conferem os arts. 7º, inciso III, e 15, incisos III e IV da Lei nº \n9.782, de 26 de janeiro de 1999, e ao art. 187, VI, § 1º do Regimento Interno aprovado \npela Resolução de Diretoria Colegiada - RDC nº 585, de 10 de dezembro de 2021, \nresolve adotar a seguinte Resolução, conforme deliberado em reunião realizada em 12 \nde maio de 2022, e eu, Diretor-Presidente, determino a sua publicação. \nCAPÍTULO I \nDISPOSIÇÕES INICIAIS \nSeção I \nObjeto \nArt. 1º Esta Resolução dispõe sobre os programas de inspeção e \nestabelece critérios para a concessão e renovação da Certificação de Boas Práticas de \nFabricação de Dispositivos Médicos, em complemento às disposições gerais de \nprocedimentos administrativos para concessão de Certificação de Boas Práticas de \nFabricação. \nSeção II \nAbrangência \nArt. 2º Esta Resolução se aplica à concessão e renovação da Certificação \nde Boas Práticas de Fabricação de Dispositivos Médicos para estabelecimentos \nfabricantes que atendam aos critérios definidos por esta Resolução e demais \nnormativas aplicáveis. \nArt. 3º As unidades fabris de dispositivos médicos das classes de risco III e \nIV enquadradas em uma das condições abaixo serão objeto de Certificação de Boas \nPráticas de Fabricação de Dispositivos Médicos pela Anvisa: \nI - unidade fabril que produz um produto final em seu nome ou para outra \nempresa; \nII - unidade fabril que realiza a liberação final do produto final, associada a \npelo menos uma etapa de produção, excluídas as etapas de projeto, distribuição, \nesterilização, embalagem e rotulagem; \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nIII - unidade fabril de software médico (Software as a Medical Device - \nSaMD). \n§ 1º A atividade de acondicionamento em embalagem considerada como \nsistema de barreira estéril de produtos declarados como estéreis é considerada como \netapa de produção passível de certificação de boas práticas de fabricação para fins do \ndisposto no inciso II. \n§ 2º As unidades fabris de dispositivos médicos para diagnóstico in vitro \nque executem as etapas de impregnação, laminação ou corte de tiras de \nimunocromatografia são passíveis de certificação de boas práticas de fabricação nos \ntermos do inciso II. \nSeção III \nDefinições \nArt. 4º Para efeitos desta Resolução, são adotadas as seguintes definições: \nI - fabricante legal: pessoa jurídica, pública ou privada, com \nresponsabilidade pelo projeto, manufatura, embalagem e rotulagem de um produto, \ncom a intenção de disponibilizá-lo para uso sob seu nome, sendo estas operações \nrealizadas pela própria empresa ou por terceiros em seu nome; \nII - liberação final: aprovação final do lote ou série do produto acabado por \npessoa formalmente designada para assegurar que os critérios de aceitação tenham \nsido atendidos; \nIII - produto final: é o produto objeto de regularização que está apto para \no uso ou funcionalmente completo, estando ou não embalado, rotulado ou \nesterilizado; \nIV - produto acabado: produto terminado que tenha passado por todas as \netapas de produção, incluindo rotulagem, embalagem final e esterilização (quando \naplicável); \nV - relatório de inspeção: relatório que descreva a situação da empresa \nquanto ao cumprimento das boas práticas de fabricação, de acordo com as normas \nreferenciadas no escopo do relatório; \nVI - unidade fabril: local onde ocorre uma ou mais etapas de fabricação, \npodendo ser o próprio fabricante legal, fabricante contratado ou fabricante original de \nproduto. \n \n \n \n \n\n \nMinistério da Saúde - MS \nAgência Nacional de Vigilância Sanitária – ANVISA \n \nEste texto não substitui o(s) publicado(s) em Diário Oficial da União. \n \nCAPÍTULO II \nDOCUMENTOS DE PETICIONAMENTO \nArt. 5º Os processos de concessão de Certificação de Boas Práticas de \nFabricação de que trata esta Resolução devem ser instruídos com os seguintes \ndocumentos: \nI - formulário de petição específico para Certificação de Boas Práticas de \nFabricação de Dispositivos Médicos, devidamente preenchido; \nII - fluxograma geral de produção relativo aos produtos fabricados, \nidentificando quais etapas são executadas no estabelecimento objeto da certificação; \nIII - leiaute do estabelecimento objeto da certificação, incluindo a planta \nbaixa da unidade fabril; \nIV - lista de todos os produtos passíveis de regularização sanitária no Brasil \nfabricados na unidade fabril objeto da certificação, contendo nome técnico, linha ",
    "budi_mdr_en.pdf": "Basic UDI-DI  \n•Applicable legislation (MDR) (*) \n•2. Basic UDI-DI value (*)  \n•2b Basic UDI-DI Issuing entity (*); \n•6. Manufacturer SRN (*) \n•5. Name and address of manufacturer \n•7. Name and address and SRN of AR  \n•9. Risk class (*)  \n•Implantable (Y/N) (*)  \n•For IIb implantable: Suture, staple, \ndental filling, dental brace, tooth \ncrown, screw, wedge, plate, wire, pin, \nclip, connector (Y/N) \n•Measuring function (Y/N) (*) \n•Reusable surgical instrument (Y/N) \n(*) \n•Active device (Y/N) (*) \n•Intended to administer/remove a \nmedicinal substance (Y/N) (*) \n•11. A. Name and/or, if applicable, \ndevice model that identifies the \ndevice(s) with this BASIC UDI-DI in the \ntechnical documentation and/or \ncertificate or declaration of conformity                                     \n(Name and/or model shall be provided) \nUDI-DIs  \n•0. UDI-DI value (*)  \n•0b. UDI-DI Issuing Entity (*) \n•Secondary DI (value and issuing entity) \n•11.B. Reference, Article or Catalogue number (*) \n•Device with Direct marking (Y/N) (*)  \n•Direct marking UDI-DI value (*) \n•Direct marking UDI-DI issuing entity (*) \n•1. Quantity of device(s) (*) \n•3. Type of UDI-PI (*) \n•4. Unit of use UDI-DI (*) \n•12. Clinical size (*) \n•14. Storage/handling conditions  \n•10-15. Name(s)/Trade name(s) (including \nlanguages) \n•13. Additional product description \n•22. URL for additional information \n•16. Labelled as single use (Y/N) (*) \n•17. Maximum number of reuse (*) \n•18. Device labelled as sterile (Y/N) (*) \n•19. Need for sterilisation (Y/N) (*) \n•20. Containing latex (Y/N) (*) \n•21. CMR/Endocrine disruptor  \n•23. Critical warnings or contra-indications \n•8. Medical device nomenclature (CND) code (1) \n•24. Status \n•25. (A.2.6) Reprocessed single-use (Y/N) (*) \n•26. (A.2.12) Annex XVI (*) \n•27. (A.2.13) In the case of devices designed and \nmanufactured by another legal or natural person as \nreferred in Article 10(15), the name, address and \ncontact details of that Natural/legal person \nUDI-DIs \n(container \npackage DI) \n \n•0. UDI-DI value \n(*) \n• 0b. Issuing entity \n(*) \n•1. Quantity per \npackage (*) \n•24. Status \nMandatory \nMandatory if applicable \nOptional \nPrinciple: Each UDI-DI inherits the attributes of its linked Basic UDI-DI and devices DI \n \n(*) may not be changed \n1 Basic UDI-DI & UDI-DI attributes\nBasic UDI-DI & UDI-DI attributes \nBasic UDI-DI set of data in UDI database \nVersion April 2019 \nMDR \nDevice \n \n(1) Nomenclature \ndecision:  \nhttps://ec.europa.eu/doc\nsroom/documents/34264 \n \n\nBasic UDI-DI  \n \n•A.2.2 Certificate IDs (NB, type .. Link); \n•A.2.14 SSCP;  \n•A.2.11 Clinical Investigations IDs (..link); \n•A.2.9 Presence of Human tissues/Cells \n(Y/N) (*); \n•A.2.10 Presence of Animal tissues/Cells \n(Y/N) (*);  \n•A.2.7 Presence of medicinal product \nsubstance (Y/N) (*); \n•A.2.8 Presence of medicinal product \nsubstance derived from human blood or \nhuman plasma (Y/N) (*);  \n•Special device types: Software (Y/N), \ncontact lenses (Y/N) … (max one choice) \n(*); \n•System which is a device in itself (Y/N) \n(*); \n•Procedure pack which is a device in itself \n(Y/N) (*);  \n \nUDI-DIs  \n• A.2.7 Medicinal product Substance(s); \n• A.2.8 Medicinal product Substance(s) derived from \nhuman blood or human plasma;  \n• A.2.3 Member State of the Placing on the EU Market \nof the Device (*); \n• A.2.4 Member State(s) were the Device is made \navailable in the Country;  \nMandatory \nMandatory if applicable \nOptional \n(*) may not be changed \n2 Other Device Data attributes\nOther Device Data attributes \nVersion April 2019 \nMDR \nOther Device Data  \n \nProvided by NB or for certificate ID under Art \n29(3) provided by manufacturer and \nconfirmed by NB  \n\nBasic UDI-DI  \nApplicable legislation (MDR) (*) \n•2.Basic UDI-DI value (*)  \n•2b Basic UDI-DI issuing entity (*);  \n•6. SPPP SRN (*) \n•5. Name and address of SPPP \n•9. Risk class (highest risk class of \nthe device components ) (*)  \n•11. A. Name and/or, if applicable, \nsystem or procedure pack model \nthat identifies the product with this \nBASIC UDI-DI in the statement \ndrawn in accordance with Art 22.1 \n•2.a. Indication of specific medical \npurpose of the System or Procedure \npack;  \n•System or Procedure pack \n(S/P)(*); \nUDI-DIs   \n•0. UDI-DI value (*) \n•UDI-DI issuing entity (*) \n•Secondary DI (value and issuing entity) \n•11.B. Reference, Article or Catalogue number \n(*) \n•3. Type of UDI-PI (*) \n•14. Storage/handling conditions  \n•10-15. Name(s)/Trade name(s) (including \nlanguages) \n•13. Additional product description \n•22. URL for additional information \n•18. Labelled as sterile (Y/N) (*) \n•19. Need for sterilisation (Y/N) (*) \n•23. Critical warnings or contra-indications \n•8. Medical device nomenclature (CND) code (1) \n•24. Status  \nUDI-DIs \n(container \npackage DI) \n•Issuing entity (*) \n•0. UDI-DI value (*)  \n•1. Quantity per \npackage (*) \n•24. Status \nMandatory \nMandatory if applicable \nOptional \nPrinciple: Each UDI-DI inherits the attributes of its linked Basic UDI-DI and devices DI \n \n(*) may not be changed \n3 Basic UDI-D",
    "Cnada.pdf": "Current to January 22, 2025\nLast amended on December 14, 2024\nÀ jour au 22 janvier 2025\nDernière modification le 14 décembre 2024\nPublished by the Minister of Justice at the following address:\nhttp://laws-lois.justice.gc.ca\nPublié par le ministre de la Justice à l’adresse suivante :\nhttp://lois-laws.justice.gc.ca\nCANADA\nCONSOLIDATION\nMedical Devices Regulations\nCODIFICATION\nRèglement sur les instruments\nmédicaux\nSOR/98-282\nDORS/98-282\n\nCurrent to January 22, 2025\nLast amended on December 14, 2024\nÀ jour au 22 janvier 2025\nDernière modification le 14 décembre 2024\nOFFICIAL STATUS\nOF CONSOLIDATIONS\nCARACTÈRE OFFICIEL\nDES CODIFICATIONS\nSubsections 31(1) and (3) of the Legislation Revision and\nConsolidation Act, in force on June 1, 2009, provide as\nfollows:\nLes paragraphes 31(1) et (3) de la Loi sur la révision et la\ncodification des textes législatifs, en vigueur le 1er juin\n2009, prévoient ce qui suit :\nPublished consolidation is evidence\nCodifications comme élément de preuve\n31 (1) Every copy of a consolidated statute or consolidated\nregulation published by the Minister under this Act in either\nprint or electronic form is evidence of that statute or regula-\ntion and of its contents and every copy purporting to be pub-\nlished by the Minister is deemed to be so published, unless\nthe contrary is shown.\n31 (1) Tout exemplaire d'une loi codifiée ou d'un règlement\ncodifié, publié par le ministre en vertu de la présente loi sur\nsupport papier ou sur support électronique, fait foi de cette\nloi ou de ce règlement et de son contenu. Tout exemplaire\ndonné comme publié par le ministre est réputé avoir été ainsi\npublié, sauf preuve contraire.\n...\n[...]\nInconsistencies in regulations\nIncompatibilité — règlements\n(3) In the event of an inconsistency between a consolidated\nregulation published by the Minister under this Act and the\noriginal regulation or a subsequent amendment as registered\nby the Clerk of the Privy Council under the Statutory Instru-\nments Act, the original regulation or amendment prevails to\nthe extent of the inconsistency.\n(3) Les dispositions du règlement d'origine avec ses modifica-\ntions subséquentes enregistrées par le greffier du Conseil pri-\nvé en vertu de la Loi sur les textes réglementaires l'emportent\nsur les dispositions incompatibles du règlement codifié publié\npar le ministre en vertu de la présente loi.\nLAYOUT\nThe notes that appeared in the left or right margins are\nnow in boldface text directly above the provisions to\nwhich they relate. They form no part of the enactment,\nbut are inserted for convenience of reference only.\nMISE EN PAGE\nLes notes apparaissant auparavant dans les marges de\ndroite ou de gauche se retrouvent maintenant en carac-\ntères gras juste au-dessus de la disposition à laquelle\nelles se rattachent. Elles ne font pas partie du texte, n’y\nfigurant qu’à titre de repère ou d’information.\nNOTE\nNOTE\nThis consolidation is current to January 22, 2025. The last\namendments came into force on December 14, 2024. Any\namendments that were not in force as of January 22,\n2025 are set out at the end of this document under the\nheading “Amendments Not in Force”.\nCette codification est à jour au 22 janvier 2025. Les\ndernières \nmodifications \nsont \nentrées \nen \nvigueur\nle 14 décembre 2024. Toutes modifications qui n'étaient\npas en vigueur au 22 janvier 2025 sont énoncées à la fin\nde ce document sous le titre « Modifications non en\nvigueur ».\n\nCurrent to January 22, 2025\nLast amended on December 14, 2024\niii\nÀ jour au 22 janvier 2025\nDernière modification le 14 décembre 2024\nTABLE OF PROVISIONS\nTABLE ANALYTIQUE\nMedical Devices Regulations\nRèglement sur les instruments médicaux\n1\nInterpretation\n1\nDéfinitions\n2\nApplication\n2\nChamp d’application\n6\nClassification of Medical Devices\n6\nClassification\n8\nPART 1\nGeneral\n8\nPARTIE 1\nDispositions générales\n8\nApplication\n8\nChamp d’application\n9\nManufacturer’s Obligations\n9\nObligation du fabricant\n10\nSafety and Effectiveness Requirements\n10\nExigences en matière de sûreté et\nd’efficacité\n21\nLabelling Requirements\n21\nÉtiquetage\n24\nContraceptive Devices — Advertising\n24\nMoyens contraceptifs — publicité\n25\nClass I Medical Devices\n25\nInstruments médicaux de classe I\n26\nClass II, III and IV Medical Devices\n26\nInstruments médicaux de classe II, III et IV\n26\nProhibition\n26\nInterdictions\n28\nMedical Devices Deemed Licensed\n28\nPrésomptions d’homologation\n32\nApplication for a Medical Device Licence\n32\nDemande d’homologation\n32.1\nQuality Management System Certificate\n32.1\nCertificat de système de gestion de la qualité\n33\nForeign Manufacturers\n33\nFabricants étrangers\n34\nApplication for a Medical Device Licence\nAmendment\n34\nDemande de modification de l’homologation\n35\nAdditional Information and Samples\n35\nRenseignements complémentaires et\néchantillons\n36\nIssuance\n36\nDélivrance\n37\nLot of In Vitro Diagnostic Devices\n37\nLot d’instruments diagnostiques in vitro\n38\nRefusal to Issue\n38\nRefus\n\nMedical Devices Regulations\nRèglement sur les instruments médicaux\nTABLE OF PROVISIONS",
    "Commission_Implementing_Regulation_(EU)_2025,117_of_24_January_2025.pdf": "COMMISSION IMPLEMENTING REGULATION (EU) 2025/117 \nof 24 January 2025\nlaying down rules for the application of Regulation (EU) 2021/2282 with regard to the procedures \nfor joint scientific consultations on medical devices and in vitro diagnostic medical devices \n(Text with EEA relevance) \nTHE EUROPEAN COMMISSION,\nHaving regard to the Treaty on the Functioning of the European Union,\nHaving regard to Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on \nhealth technology assessment and amending Directive 2011/24/EU (1), and in particular Article 20(1), points (a), (b) and \n(d), thereof,\nWhereas:\n(1) \nRegulation (EU) 2021/2282 lays down a support framework and procedures for cooperation between Member \nStates on health technologies at Union level and establishes the Member State Coordination Group on Health \nTechnology Assessment (‘the Coordination Group’).\n(2) \nPursuant to Article 16(1) of Regulation (EU) 2021/2282, the Coordination Group is to carry out joint scientific \nconsultations in order to exchange information with health technology developers on their development plans for a \nmedical device or in vitro diagnostic medical device. The aim of such consultations is to facilitate the process of \npreparing joint clinical assessments for medical devices and in vitro diagnostic medical devices, as they will allow \nhealth technology developers to obtain guidance from the Coordination Group on the information, data, analyses \nand other evidence that are likely to be required from clinical studies for the joint clinical assessment of those \ndevices. Joint scientific consultations can also facilitate the process of preparing relevant updates of joint clinical \nassessments for medical devices and in vitro diagnostic medical devices when the requests meet the eligibility and \nselection criteria.\n(3) \nIn order to ensure sufficient predictability for health technology developers as to their opportunity to engage in joint \nscientific consultations on medical devices and in vitro diagnostic medical devices with the Coordination Group, it is \nnecessary to specify the deadline for the Coordination Group to set the dates of request periods for joint scientific \nconsultation on medical devices and in vitro diagnostic medical devices for the subsequent year, as well as the \nminimum number of such request periods per year. Under Article 6(2), point (b), of Regulation (EU) 2021/2282, \nthe Coordination Group is to set out in its annual work programme the planned number of joint scientific \nconsultations. To allow the health technology developers sufficient time to plan and prepare for joint scientific \nconsultations on medical devices and in vitro diagnostic medical devices, the Coordination Group should set the \nrequest periods for those consultations at the latest by the day on which it adopts its annual work programme, that \nis, by 30 November each year.\n(4) \nUnder Article 30(1) of Regulation (EU) 2021/2282, the Commission is to set up and maintain an IT platform \nconsisting of, inter alia, a secure system for the exchange of information between the Coordination Group and its \nsubgroups with health technology developers and experts participating in the joint work (‘the HTA IT platform’). \nThe health technology developers should therefore submit the requests for joint scientific consultations, the dossier \nof information, data, analyses and other evidence for joint scientific consultation on medical devices and in vitro \ndiagnostic medical devices including the list of questions (‘the briefing package’) and any further data through the \nHTA IT platform. Those requests and dossiers should be presented using the templates set out by the Coordination \nGroup pursuant to Article 21, points (a) and (b), of Regulation (EU) 2021/2282.\nOfficial Journal \nof the European Union \nEN \nL series \n2025/117 \n27.1.2025\nELI: http://data.europa.eu/eli/reg_impl/2025/117/oj \n1/12\n(1) OJ L 458, 22.12.2021, p. 1, ELI: http://data.europa.eu/eli/reg/2021/2282/oj.\n\n(5) \nUpon request from a health technology developer, joint scientific consultations on medical devices may take place in \nparallel with the consultation with an expert panel designated in accordance with Article 106(1) of Regulation \n(EU) 2017/745 of the European Parliament and of the Council (2) (‘expert panel’), pursuant to Article 61(2), of that \nRegulation (‘the expert panel consultation’). In order for the subgroup on joint scientific consultations of the \nCoordination Group (‘JSC Subgroup’) to be able to identify the requests for joint scientific consultation to be carried \nout in parallel with the expert panel consultation, the health technology developer should indicate in the request for \njoint scientific consultation whether, in parallel, it is requesting the expert panel consultation.\n(6) \nPursuant to Article 28, point (i), of Regulation (EU) 2021/2282, the Commission acting as secretariat of the \nCoordination Group (‘HTA secretariat’) is",
    "CUBA.pdf": "Calle 5ta A, Número 6020, entre 60 y 62, Reparto Miramar, Playa, La Habana. CUBA. CP. 11300 \nTeléf.: 53 7 216 4100, 53 7 216 4147, 53 7 216 4148. E-mail: cecmed@cecmed.cu Web: www.cecmed.cu \nANEXO ÚNICO \n \n \n \n \n \nREPÚBLICA DE CUBA \nMINISTERIO DE SALUD PÚBLICA \nCENTRO PARA EL CONTROL ESTATAL \nDE MEDICAMENTOS, EQUIPOS Y DISPOSITIVOS MÉDICOS \nCECMED \n \n \n \n \n \nREGULACIÓN E 127-25 \nPROTOCOLO PARA EL CONTROL DE CALIDAD A  \nSISTEMAS DE IMÁGENES POR RESONANCIA MAGNÉTICA \n \n \n \n \n \n \n \n \n \n \n \n\n \nTabla de contenido \n1. \nGeneralidades ...................................................................................................................................... 5 \n2. \nTérminos y definiciones ...................................................................................................................... 5 \n3. \nPruebas de control de calidad para sistemas de imágenes de resonancia magnética .......................... 8 \n3.1 \nInspección visual de las salas que forman parte del Sistema ........................................................ 8 \n3.2 \nDistorsión geométrica .................................................................................................................... 8 \n3.3 \nRelación Señal-Ruido .................................................................................................................... 9 \n3.4 \nNo uniformidad ........................................................................................................................... 11 \n3.5 \nEspesor de corte........................................................................................................................... 12 \n3.6 \nNivel de fantasmas en la señal..................................................................................................... 13 \n3.7 \nResolución espacial ..................................................................................................................... 15 \n4. \nBibliografía ....................................................................................................................................... 16 \nAnexo I. Lista de chequeo para la inspección visual del servicio de resonancia magnética ....................... 18 \nAnexo II. Tabla de recogida de datos de la distorsión geométrica .............................................................. 19 \nAnexo III. Otro maniquí utilizado ............................................................................................................... 20 \n\n \nPágina 5 de 18 \n1. \nGeneralidades \nLa obtención de Imágenes por Resonancia Magnética (IRM) se ha convertido en una técnica \nindispensable en el ambiente clínico-hospitalario debido a sus grandes prestaciones y el bajo riesgo \nque implica su utilización.  \nA pesar de los elevados costos, la introducción de nuevos sistemas de IRM en el Sistema Nacional \nde Salud, ha permitido aumentar la capacidad de diagnóstico en muchas especialidades y patologías \nasociadas. \nEn el marco regulador nacional, ya existen disposiciones reguladoras (DR) para otras técnicas de \nimagen, pero ninguna abarca esta tecnología, aunque algunas instituciones cuenten con sus propios \nmanuales para realizar el control de la calidad. Establecer por parte del CECMED un protocolo \nnacional de control de calidad (CC) para este tipo de equipamiento, será una nueva herramienta \nque unifique y estandarice los estándares de calidad de los servicios de imagenología del país, lo \nque se traduce en una capacidad diagnóstica de mejor calidad y mayor seguridad para los usuarios \nde esta tecnología en beneficio de la salud. \nEsta DR establece los requisitos regulatorios y metodológicos para el control de calidad a los \nsistemas de IRM teniendo en cuenta los principios de las Buenas Prácticas Reguladoras vigentes \ndel CECMED. Su contenido está alineado con guías y normas internacionales como el Manual de \nControl de la Calidad de las IRM del Colegio Americano de Radiología (ACR por sus siglas en \ninglés), la norma IEC 62464-1 Equipo de resonancia magnética para imágenes médicas - \nDeterminación de los parámetros esenciales de calidad de imagen, de la Comisión Electrotécnica \nInternacional (IEC por sus siglas en inglés) y Métodos para el aseguramiento de la calidad y \nmaniquíes para las IRM, de la Asociación Americana de Física Médica (AAPM por sus siglas en \ninglés). Su alcance comprende a todas las instituciones que emplean esta tecnología en el territorio \nnacional, pertenecientes o no al Sistema Nacional de Salud y constituyen la referencia para las \nevaluaciones que el CECMED lleva a cabo mediante auditorías y visitas técnicas. \n2. \nTérminos y definiciones \n2.1 \nAncho de ventana: Escala de grises seleccionada y que se muestra en la imagen en un monitor \ndel dispositivo o en otro formato gráfico. Para mayores anchos de ventana se obtendrán \nescalas de grises más largas. Una anchura de ventana reducida produce alto contraste. \n2.2 \nArtefactos: Cualquier estructura o patrón visible en la imagen reconstru",
    "draft-guidance-on-managing-applications-for-medical-device-licences-eng.pdf": "Unclassified / Non classifié \nDraft guidance on \n1 \nmanaging \n2 \napplications for \n3 \nmedical device \n4 \nlicences \n \n5 \n\n \n \n \n2 \nHealth Canada is the federal department responsible for helping the people of Canada maintain and improve \n6 \ntheir health. Health Canada is committed to improving the lives of all of Canada's people and to making this country's \n7 \npopulation among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health \n8 \ncare system. \n9 \n \n10 \n \n11 \n \n12 \n \n13 \n \n14 \n \n15 \nÉgalement disponible en français sous le titre : \n16 \nÉbauche de ligne directrice sur la gestion des demandes d’homologation d’instruments médicaux \n17 \n \n18 \nTo obtain additional information, please contact: \n19 \n \n20 \nHealth Canada \n21 \nAddress Locator 0900C2 \n22 \nOttawa, ON  K1A 0K9 \n23 \nTel.: 613-957-2991 \n24 \nToll free: 1-866-225-0709 \n25 \nFax: 613-941-5366 \n26 \nTTY: 1-800-465-7735 \n27 \nE-mail: publications-publications@hc-sc.gc.ca \n28 \n \n29 \n© His Majesty the King in Right of Canada, as represented by the Minister of Health, 2025 \n30 \n \n31 \nPublication date: February 2025 \n32 \n \n33 \nInformation contained in this publication or product may be reproduced, in whole or in part, and by any means, for \n34 \npersonal or public non-commercial purposes without charge or further permission, unless otherwise specified. \n35 \nCommercial reproduction and distribution are prohibited except with written permission from Health Canada. To obtain \n36 \npermission to reproduce any content owned by the Government of Canada available for commercial purposes, please \n37 \ncontact pubsadmin@hc-sc.gc.ca.  \n38 \n \n39 \n \n40 \n \n41 \n \n42 \n \n43 \n \n44 \n \n45 \n \n46 \n \n47 \n \n48 \n \n49 \n \n50 \n \n51 \n \n52 \n \n53 \n \n54 \n \n55 \n \n56 \n \n57 \n \n58 \n \n59 \n \n60 \n \n61 \n \n62 \n \n63 \n \n64 \n\n \n \n \n3 \nForeword \n65 \nGuidance documents provide assistance to industry on how to comply with governing \n66 \nstatutes and regulations. They also provide guidance to Health Canada staff on how \n67 \nmandates and objectives should be met fairly, consistently and effectively. \n68 \nGuidance documents are administrative, not legal, instruments. This means that flexibility \n69 \ncan be applied. However, to be acceptable, alternate approaches to the principles and \n70 \npractices described in this document must be supported by adequate justification. They \n71 \nshould be discussed in advance with the relevant program area to avoid the possible \n72 \nfinding that applicable statutory or regulatory requirements have not been met. \n73 \nAs always, Health Canada reserves the right to request information or material, or define \n74 \nconditions not specifically described in this document, to help us adequately assess the \n75 \nsafety, effectiveness or quality of a medical device. We are committed to ensuring that \n76 \nsuch requests are justifiable and that decisions are clearly documented. \n77 \nThis document should be read along with the relevant sections of the regulations and other \n78 \napplicable guidance documents. \n79 \n \n80 \n \n81 \n \n82 \n \n83 \n \n84 \n \n85 \n \n86 \n \n87 \n \n88 \n \n89 \n \n90 \n\n \n \n \n4 \nDocument change log \n91 \nDate \nLocation (section, \nparagraph) \nNature of and reason for change \nFebruary 20, 2025 \nReconsideration   \nprocess \nUpdated to reflect the revamped \nreconsideration process and include a \nreconsideration process map and request for \nreconsideration form. \nDeficient \napplications – \nadditional \ninformation letter \nIncluded information on the different types of \nadditional information letters. \nWithdrawal letter \n(under Screening \nprocess) \nIncluded information on withdrawing an \napplication during the screening process. \nDeficient \napplications – \nscreening deficiency \nletter \nAdjusted response times to screening \ndeficiency letters to ensure consistency across \napplications. \nClarification request \n(under Regulatory \nscreening) \nIncluded information on clarification requests \nduring regulatory screening. \nFull document \nEdited to make clearer and enhance flow and \nreadability. \nApril 1, 2020 \nFull document \nMade significant changes as new fees and a \nrevised fee policy came into force on April 1, \n2020. \n\n \n \n \n5 \n \n92 \n \n93 \n \n94 \n \n95 \n \n96 \n \n97 \nDate \nLocation (section, \nparagraph) \nNature of and reason for change \nNovember 4, 2019 \nFull document \nRevised the format of the guidance document. \nJanuary 11, 2019 \nFull document \nRewrote content to make clearer and conform \nto good guidance practices. \nFull document \nRemoved information on investigational testing \nauthorizations as this information is now \npublished in a separate guidance titled \nApplications for Medical Device Investigational \nTesting Authorizations Guidance Document – \nSummary. \nFull document \nAdded information on new and amendment \nprivate label licence applications. \nFull document \nUpdated text in fee status sections throughout \ndocument for clarity and consistency. \nPause the clock \nIncluded information resulting from “pause the \nclock” consultation. \n\n \n \n \n6 \nTable ",
    "Essai_de_mise_en_uvre_de_l'examen_prioritaire_des_dispositifs_medicaux_(japon).pdf": "薬生機審発0630 第２号 \n令和５年６月3 0 日 \n \n \n各都道府県衛生主管部（局）長 殿 \n \n \n厚生労働省医薬・生活衛生局医療機器審査管理課長 \n（ \n \n公 \n \n印 \n \n省 \n \n略 \n \n） \n \n \nプログラム医療機器に係る優先的な審査等の試行的実施（第二回）について \n \n \n令和４年度に「プログラム医療機器に係る優先的な審査等の試行的実施につい\nて」（令和４年９月２日薬生機審発0902 第２号厚生労働省医薬・生活衛生局医療\n機器審査管理課長通知）を実施したところですが、本年度においても、下記のとお\nり、プログラム医療機器の特性を踏まえた要件設定を行った上で、プログラム医療\n機器に係る優先的な審査等の対象品目を指定し、優先的な相談・審査、コンシェル\nジュ対応等を試行的に実施することとしたので、貴管下関係団体、関係事業者等に\n周知方お願いします。 \n \n記 \n \n１．指定の要件 \n  優先的な審査等の指定を受けるプログラム医療機器は、以下の３つのすべての\n要件を満たすこと。 \nなお、３つのすべての要件を満たす場合であっても、当該プログラム医療機器\nと同等の原理に基づく使用目的又は効果を有する他の医療機器が既に承認されて\nいる場合には原則として指定しない。 \n \n（１）指定要件１：治療法、診断法又は予防法の画期性 \n原則として、プログラム医療機器としての原理が、既存の医療機器（プログラ\nム医療機器を含む。以下同じ。）、又は標準的な治療法、診断法若しくは予防法\nと比べて明らかに異なるものであり、その治療法、診断法又は予防法が画期的で\nあること。 \n \n（２）指定要件２：対象疾患に係る医療上の有用性 \n以下のいずれかに該当するものであること。 \nア 根治療法となり得る既存の治療法がない、又は既存の予防法若しくは診断法\nがない疾患において、臨床上の必要性が高く、臨床試験等（公的な競争的資金\nにより実施された臨床研究を含む。以下同じ。）において有効性及び安全性が\n見込まれること。 \n \n写\n\n \nイ 臨床試験等において、既存の治療法、予防法若しくは診断法に比べて高い有\n効性及び安全性が見込まれること。 \n \nウ 臨床試験等において、既存の治療法、予防法若しくは診断法に比べて同等以\n上の有効性及び安全性が見込まれていることに加え、患者の肉体的・精神的な\n負担等の観点から、既存の治療法、予防法又は診断法と比べて医療上特に有用\nであると見込まれること。 \n \n例えば、以下のような例が挙げられる。 \n・根治率の向上や合併症の軽減等を可能とする疾病治療用プログラム \n・重篤な疾病の早期発見を可能とする疾病診断用プログラム \n・発作の兆候を検知して転倒等を回避するための行動を促す疾病診断用プロ\nグラム \n・既存の診断法と比較して明らかに高い診断性能により従来の診療フローの\n改善が可能な疾病診断用プログラム \n・難治性疾患における治療薬の減量・休薬等が可能な疾病治療用プログラム \n・既存の侵襲性が高い検査・診断法と同等の検査・診断を侵襲なく実施でき\nる疾病診断用プログラム \n  \n（３）指定要件３：世界に先駆けて日本で早期開発及び承認申請する意思並びに体\n制 \n日本における早期開発を重視し、世界に先駆けて又は同時に日本で承認申請\nされる（最初の国の承認申請を起算日とし、同日から30 日以内の申請は同時申\n請とみなす。ただし、申請日と申請受理日が存在する国においては、申請受理\n日を起算日とする。）予定のものであること。それに加え、独立行政法人医薬\n品医療機器総合機構(以下「総合機構」という。）で実施されている先駆け総\n合評価相談を活用し承認申請できる体制及び迅速な承認審査に対応できる体制\nを有していること。なお、指定を希望する品目と同様の原理による類似製品が\n世界において既に流通している場合は、指定の対象とならない。 \n \n２．指定の手続き \n（１）品目の公募（指定希望品目の登録申込み） \nプログラム医療機器に係る優先的な審査等の対象品目への指定を希望する場合\nは、当該候補品目について、令和５年６月30 日から同年９月15 日までの公募期\n間を設定するので、所定期間内に様式１（プログラム医療機器に係る優先的な審\n査等の指定希望品目登録申込書）（別紙含む）により、厚生労働省医薬・生活衛\n生局医療機器審査管理課（以下「医療機器審査管理課」という。）に登録の申し\n込みをすること。様式１（別紙含む）は、電子メール（令和５年９月15 日17:00\nまで）又は郵送（３部）（令和５年９月15 日必着）にて提出すること。 \n （電子メールの場合） \n   kikisaisei@mhlw.go.jp \n（郵送の場合） \n〒100-8916 東京都千代田区霞が関１－２－２ \n厚生労働省医薬・生活衛生局医療機器審査管理課宛て \n\n \n（２）ヒアリングと応募資料の様式確認 \n （１）により申込みが行われた登録申込品目について、登録申込日の１週間後か\nら令和５年10 月6 日までの期間に医療機器審査管理課においてヒアリングを実\n施する。ヒアリングは様式１（プログラム医療機器に係る優先的な審査等の指定\n希望品目登録申込書）（別紙含む）及びその根拠資料に基づき実施するので、根\n拠資料をヒアリング実施予定日の１週間前までに電子メール又は郵送（３部）に\nて提出すること。提出先については、２（１）を参照すること。 \n \n（３）予備的審査 \n医療機器審査管理課において明らかに指定要件に該当しないと判断される品目\nをふるいにかける「予備的審査」を行う。令和５年10 月31 日までに、医療機器\n審査管理課より、予備的審査を行った場合にはその結果を登録申込者に連絡し、\n予備的審査を行わない場合には当該登録申込者にその旨を連絡する。 \n \n（４）指定の申請、評価及び指定 \n予備的審査を通過した候補品目の登録申込者又は予備的審査を実施しなかった\n旨の連絡を受けた登録申込者は、令和５年11 月10 日までに、様式２（プログラ\nム医療機器に係る優先的な審査等の指定申請書）（別紙を含む）及びその根拠資\n料の紙媒体（正本１部、副本２部）及び電子媒体（１部）を郵送又は持参により\n提出すること。提出先については、２（１）を参照すること。 \n医療機器審査管理課で指定申請書を受理した後、総合機構における評価を踏ま\nえ、指定の可否について最終的な審査を行う。分野ごとに指定基準への該当性を\n確認した上で、特に優れていると判断されたものを選定し、その結果について薬\n事・食品衛生審議会薬事分科会に報告した上で公表する。 \n \n３．指定されたプログラム医療機器の優先的な取扱い及び留意事項 \n（１）優先相談 \n総合機構で実施されている対面助言等で、他の医療機器等に優先した取扱いを\n受けることができるので、実施時期等について総合機構に相談すること。 \n \n（２）事前評価の充実 \n承認申請から承認までの期間を短縮させるため（すべて申請区分において６か\n月以内）、後述するコンシェルジュに相談し、指定を受けた後から承認申請まで\nに、原則、総合機構で実施されている先駆け総合評価相談を利用すること。 \nなお、上記の事前評価が十分でない場合（評価に必要なデータが揃わない場合\nや総合機構の助言内容等に充分な対応が行われていない場合を含む。）、承認申\n請から承認までの期間を評価の状況を踏まえて個別に設定することがある。 \n \n（３）優先審査 \n指定品目はその内容に鑑み、医薬品、医療機器等の品質、有効性及び安全性の\n確保等に関する法律（昭和35 年法律第145 号）第23 条の２の５第10 項に規定\nする「医療上特にその必要性が高いと認められるもの」に該当すると考えられる\nため、対象品目への指定をもって優先審査の取扱いを行うこととする。 \n \n\n \n（４）コンシェルジュ \n厚生労働省及び総合機構の連絡調整を行うことができる適当な者として、総合\n機構において指名される者（以下「コンシェルジュ」という。）が、当該対象品\n目の開発の進捗管理の相談、承認申請者及び承認審査関係部署との調整を行う。\n指定後早期に当該対象品目に係るコンシェルジュについては、当該対象品目につ\nいて指定を受けた者（以下「指定者」という。）に連絡する。 \n \n４．指定の取消し \n  指定の取消しは１．の指定の要件のいずれかに該当しないこと、指定後に実施\nされた試験等の結果により指定要件２で想定した程度の極めて高い有用性が見込\nまれないこと又は指定後に有効性又は安全性に係る大幅なプログラムの変更を行\nったこと又はプログラムの変更が必要であることが明確になった時点で、厚生労\n働省は指定の取消しを行うことができるものとする。指定者は、指定の要件を充\n足しないこと等が判明した時点でコンシェルジュを通じて医療機器審査管理課に\n報告することとし、医療機器審査管理課はその後速やかに薬事・食品衛生審議会\n薬事分科会に報告する。 \nなお、医療機器審査管理課に指定要件を充足しない旨の報告がされた日又は医\n療機器審査管理課が指定要件を充足しないと判断した日をもって、３．に掲げる\n優先的な取扱いは停止することとし、薬事・食品衛生審議会薬事分科会への報告\n日をもって指定を取消すものとする。 \n \n５．その他 \n（１）プログラムが医療機器の総体として主たる役割を有しているが、使用に際\nし必須の構成品が存在する等の理由からプログラム医療機器及び併用機器（有\n体物の医療機器）で構成される製品については、併用機器が承認されていない\n場合には、当該プログラム医療機器優先審査指定をもって指定品目に準じた取\nり扱いとする可能性がある。 \n \n（２）令和６年度以降の運用等については、本プログラム医療機器に係る優先的\nな審査等の試行的実施の状況を踏まえ、別途示すこととする。 \n \n \n\n \n様式１ \n \nプログラム医療機器に係る優先的な審査等の指定希望品目登録申込書 \n \n厚生労働省医薬・生活衛生局医療機器審査管理課御中 \n \n下記の品目について、プログラム医療機器に係る優先的な審査等の指定希望品目の登録\nを申し込みます。 \n \n令和○年○月○日 \n記 \n \n申請者名 \n \n承認番号※１ \n \n名称 \n一般的名称※２ \n \n販売名※３ \n \n予定される使用目的又は効果※４ \n \n形状、構造及び原理 \n \n予定される使用方法※５ \n \n指定要件への該当性※６ \n指定要件１ \n治療法、診断法又は\n予防法の画期性 \n \n指定要件２ \n対象疾患に係る医療\n上の有用性 \n \n指定要件３ \n世界に先駆けて日本\nで早期開発・申請す\nる意思・体制 \n \nヒアリング希\n望日※７ \n第１希望 \n \n第２希望 \n \n第３希望 \n \n第４希望 \n \n第５希望 \n \n担当者連絡先\n氏名 \n \n部署名 \n \n電話番号 \n \nFAX 番号 \n \nE-mail \n \n特記事項※８ \n \n \n注：A4 １枚に収まるように記載する。本様式に収まらない場合は別紙に添付する旨を記載した上で、指定した別紙にて記載\nすることで可。 \n※１：既に承認を取得している場合に記載、未承認の場合には「―」と記載。 \n※２：一般的名称が決まっていない場合には「新設」と記載。 \n※３：既に決まっている場合に記載。販売名の名称が決まっていない場合には「開発記号等」又は仮称を記載すること。 \n※４：申請時点で予定している使用目的又は効果を記載。 \n※５：申請時点で予定している使用方法を記載。 \n※６：指定基準への該当性について、端的に根拠に基づいて記載。根拠となる臨床又は非臨床試験成績の概要は別紙に添付\nすることで可。 \n※７：ヒアリング希望日時については、１時間を１コマとして「○月○日○時～○時」と記載する。 \n※８：併用医療機器がある場合、その詳細を特記事項欄へ記載すること。 \n \n \n \n \n\n \n（別紙） \n \nプログラム医療機器に係る優",
    "IVDR.pdf": "REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL \nof 5 April 2017 \non in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision \n2010/227/EU \n(Text with EEA relevance) \nTHE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, \nHaving regard to the Treaty on the Functioning of the European Union, and in particular Article 114 and \nArticle 168(4)(c) thereof, \nHaving regard to the proposal from the European Commission, \nAfter transmission of the draft legislative act to the national parliaments, \nHaving regard to the opinion of the European Economic and Social Committee (1), \nAfter consulting the Committee of the Regions, \nActing in accordance with the ordinary legislative procedure (2), \nWhereas: \n(1)  \nDirective 98/79/EC of the European Parliament and of the Council (3) constitutes the Union regulatory \nframework for in vitro diagnostic medical devices. However, a fundamental revision of that Directive is needed to \nestablish a robust, transparent, predictable and sustainable regulatory framework for in vitro diagnostic medical \ndevices which ensures a high level of safety and health whilst supporting innovation. \n(2)  \nThis Regulation aims to ensure the smooth functioning of the internal market as regards in vitro diagnostic \nmedical devices, taking as a base a high level of protection of health for patients and users, and taking into \naccount the small and medium-sized enterprises that are active in this sector. At the same time, this Regulation \nsets high standards of quality and safety for in vitro diagnostic medical devices in order to meet common safety \nconcerns as regards such products. Both objectives are being pursued simultaneously and are inseparably linked \nwhilst one not being secondary to the other. As regards Article 114 of the Treaty on the Functioning of the \nEuropean Union (TFEU), this Regulation harmonises the rules for the placing on the market and putting into \nservice of in vitro diagnostic medical devices and their accessories on the Union market thus allowing them to \nbenefit from the principle of free movement of goods. As regards Article 168(4)(c) TFEU, this Regulation sets \nhigh standards of quality and safety for in vitro diagnostic medical devices by ensuring, among other things, that \ndata generated in performance studies are reliable and robust and that the safety of subjects participating in \nperformance studies is protected. \n(3)  \nThis Regulation does not seek to harmonise rules relating to the further making available on the market of in \nvitro diagnostic medical devices after they have already been put into service, such as in the context of second- \nhand sales. \n(4)  \nKey elements of the existing regulatory approach, such as the supervision of notified bodies, risk classification, \nconformity assessment procedures, performance evaluation and performance studies, vigilance and market \nsurveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding \nin vitro diagnostic medical devices should be introduced, to improve health and safety. \n(5)  \nTo the extent possible, guidance developed for in vitro diagnostic medical devices at international level, in \nparticular in the context of the Global Harmonization Task Force and its follow-up initiative, the International \nMedical Devices Regulators Forum, should be taken into account to promote the global convergence of \n5.5.2017 \nL 117/176 \nOfficial Journal of the European Union \nEN     \n(1) Opinion of 14 February 2013 (OJ C 133, 9.5.2013, p. 52). \n(2) Position of the European Parliament of 2 April 2014 (not yet published in the Official Journal) and position of the Council at first reading \nof 7 March 2017 (not yet published in the Official Journal). \n(3) Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices (OJ L 331, \n7.12.1998, p. 1). \n\nregulations which contributes to a high level of safety protection worldwide, and to facilitate trade, in particular \nin the provisions on Unique Device Identification, general safety and performance requirements, technical \ndocumentation, classification rules, conformity assessment procedures and clinical evidence. \n(6)  \nThere are specific features of in vitro diagnostic medical devices, in particular in terms of risk classification, \nconformity assessment procedures and clinical evidence, and of the in vitro diagnostic medical device sector \nwhich require the adoption of specific legislation, distinct from the legislation on other medical devices, whereas \nthe horizontal aspects common to both sectors should be aligned. \n(7)  \nThe scope of application of this Regulation should be clearly delimited from other legislation concerning \nproducts, such as medical devices, general laboratory products and products for research use only. \n(8)  \nIt should be the responsibility of the Member States to decide on a case-by-",
    "Jabon_.pdf": "平成十六年厚生労働省令第百三十五号\n医薬品、医薬部外品、化粧品、医療機器及び再生\n医療等製品の製造販売後安全管理の基準に関する\n省令\n薬事法（昭和三十五年法律第百四十五号）第十二条の二第二号の規定に基づき、\n医薬品、医薬部外品、化粧品及び医療機器の製造販売後安全管理の基準に関する省\n令を次のように定める。\n目次\n第一章　総則（第一条―第二条）\n第二章　第一種製造販売業者の製造販売後安全管理の基準（第三条―第十二条）\n第三章　第二種製造販売業者の製造販売後安全管理の基準（第十三条―第十四\n条）\n第四章　第三種製造販売業者の製造販売後安全管理の基準（第十五条）\n第五章　雑則（第十六条）\n附則\n第一章　総則\n（趣旨）\n第一条　この省令は、医薬品、医療機器等の品質、有効性及び安全性の確保等に関\nする法律（昭和三十五年法律第百四十五号。以下「法」という。）第十二条の二\n第一項第二号、第二十三条の二の二第一項第二号及び第二十三条の二十一第一項\n第二号に規定する製造販売後安全管理（以下「製造販売後安全管理」という。）\nに係る厚生労働省令で定める基準を定めるものとする。\n（定義）\n第二条　この省令で「安全管理情報」とは、医薬品、医薬部外品、化粧品、医療機\n器又は再生医療等製品（以下「医薬品等」という。）の品質、有効性及び安全性\nに関する事項その他医薬品等の適正な使用のために必要な情報をいう。\n２　この省令で「安全確保業務」とは、製造販売後安全管理に関する業務のうち、\n安全管理情報の収集、検討及びその結果に基づく必要な措置（以下「安全確保措\n置」という。）に関する業務をいう。\n３　この省令で「医薬品リスク管理」とは、安全確保業務のうち、医薬品（体外診\n断用医薬品を除く。以下同じ。）の製造販売業者が、安全性及び有効性に関し特\nに検討すべき事項を有する医薬品について、その安全性及び有効性に係る情報収\n集、調査、試験その他医薬品を使用することに伴うリスクの最小化を図るための\n活動を実施するとともに、その結果に基づく評価及びこれに基づく必要な措置を\n講ずることにより、当該医薬品の安全性及び有効性に係る適切なリスク管理を行\nうものであって、法第七十九条第一項の規定により法第十四条第一項又は第十九\n条の二第一項の規定による承認に条件として付されるものをいう。\n４　この省令で「医療機器等リスク管理」とは、安全確保業務のうち、医療機器又\nは体外診断用医薬品の製造販売業者が、安全性及び有効性に関し特に検討すべき\n\n事項を有する医療機器又は体外診断用医薬品について、その安全性及び有効性に\n係る情報収集、調査、試験その他医療機器又は体外診断用医薬品を使用すること\nに伴うリスクの最小化を図るための活動を実施するとともに、その結果に基づく\n評価及びこれに基づく必要な措置を講ずることにより、当該医療機器又は体外診\n断用医薬品の安全性及び有効性に係る適切なリスク管理を行うものであって、法\n第二十三条の二の五第十二項（法第二十三条の二の十七第五項において準用する\n場合を含む。）又は法第七十九条第一項の規定により法第二十三条の二の五第一\n項又は第二十三条の二の十七第一項の規定による承認に条件として付されるもの\nをいう。\n５　この省令で「医薬情報担当者」とは、医薬品の適正な使用に資するために、医\n療関係者を訪問すること等により安全管理情報を収集し、提供することを主な業\n務として行う者をいう。\n６　この省令で「医療機器等情報担当者」とは、医療機器又は体外診断用医薬品の\n適正な使用に資するために、医療関係者を訪問すること等により安全管理情報を\n収集し、提供することを主な業務として行う者をいう。\n７　この省令で「再生医療等製品情報担当者」とは、再生医療等製品の適正な使用\nに資するために、医療関係者を訪問すること等により安全管理情報を収集し、提\n供することを主な業務として行う者をいう。\n８　この省令で「第一種製造販売業者」とは、法第四十九条第一項に規定する厚生\n労働大臣の指定する医薬品（以下「処方箋医薬品」という。）、高度管理医療機\n器又は再生医療等製品の製造販売業者をいう。\n９　この省令で「第二種製造販売業者」とは、処方箋医薬品以外の医薬品、管理医\n療機器又は体外診断用医薬品の製造販売業者をいう。\n１０　この省令で「第三種製造販売業者」とは、医薬部外品、化粧品又は一般医療\n機器の製造販売業者をいう。\n第二章　第一種製造販売業者の製造販売後安全管理の基準\n（総括製造販売責任者の業務）\n第三条　第一種製造販売業者は、次の各号に掲げる業務を法第十七条第二項に規定\nする医薬品等総括製造販売責任者、法第二十三条の二の十四第二項に規定する医\n療機器等総括製造販売責任者又は法第二十三条の三十四第二項に規定する再生医\n療等製品総括製造販売責任者（以下「総括製造販売責任者」と総称する。）に行\nわせなければならない。\n一　次条第二項に規定する安全管理責任者を監督すること。\n二　前号の安全管理責任者の意見を尊重すること。\n三　第一号の安全管理責任者と品質保証責任者等（医薬品、医薬部外品、化粧品\n及び再生医療等製品の品質管理の基準に関する省令（平成十六年厚生労働省令\n第百三十六号）第四条第三項（同令第二十一条において準用する場合を含\nむ。）及び第十七条に規定する品質保証責任者並びに医療機器及び体外診断用\n医薬品の製造管理及び品質管理の基準に関する省令（平成十六年厚生労働省令\n第百六十九号）第七十二条第一項（同令第七十二条の三第三項において準用す\nる場合を含む。）に規定する国内品質業務運営責任者をいう。以下同じ。）そ\n\nの他の処方箋医薬品、高度管理医療機器又は再生医療等製品の製造販売に係る\n業務の責任者との密接な連携を図らせること。\n四　第一種製造販売業者が医薬品リスク管理又は医療機器等リスク管理（以下\n「医薬品等リスク管理」という。）を行う場合にあっては、当該医薬品等リス\nク管理が適切に行われるよう、製造販売後調査等管理責任者（医薬品の製造販\n売後の調査及び試験の実施の基準に関する省令（平成十六年厚生労働省令第百\n七十一号）第四条第一項又は医療機器の製造販売後の調査及び試験の実施の基\n準に関する省令（平成十七年厚生労働省令第三十八号）第四条第一項に規定す\nる製造販売後調査等管理責任者をいう。以下同じ。）との相互の密接な連携を\n図ること。\n（安全確保業務に係る組織及び職員）\n第四条　第一種製造販売業者は、次に掲げる要件を満たす安全確保業務の統括に係\nる部門（以下この章において「安全管理統括部門」という。）を置かなければな\nらない。\n一　総括製造販売責任者の監督下にあること。\n二　安全確保業務（第四項の規定により安全管理責任者以外の者に行わせる業務\nを除く。）を適正かつ円滑に遂行しうる能力を有する人員を十分に有するこ\nと。\n三　医薬品等の販売に係る部門その他安全確保業務の適正かつ円滑な遂行に支障\nを及ぼすおそれのある部門から独立していること。\n２　第一種製造販売業者は、次に掲げる要件を満たす安全確保業務の責任者（以下\nこの章において「安全管理責任者」という。）を置かなければならない。\n一　安全管理統括部門の責任者であること。\n二　安全確保業務その他これに類する業務に三年以上従事した者であること。\n三　安全確保業務を適正かつ円滑に遂行しうる能力を有する者であること。\n四　医薬品等の販売に係る部門に属する者でないことその他安全確保業務の適正\nかつ円滑な遂行に支障を及ぼすおそれがない者であること。\n３　第一種製造販売業者は、次項に規定する場合を除き、安全管理責任者に安全確\n保業務を行わせなければならない。\n４　第一種製造販売業者は、安全確保業務であって医薬品、医療機器等の品質、有\n効性及び安全性の確保等に関する法律施行規則（昭和三十六年厚生省令第一号。\n以下「規則」という。）第九十七条各号、第百十四条の五十九各号又は第百三十\n七条の五十九各号に掲げるものの全部又は一部を安全管理責任者以外の者に行わ\nせる場合にあっては、当該業務を適正かつ円滑に遂行しうる能力を有する当該業\n務の実施に係る責任者（以下「安全管理実施責任者」という。）を置かなければ\nならない。\n（製造販売後安全管理業務手順書等）\n第五条　第一種製造販売業者は、製造販売後安全管理を適正かつ円滑に行うため、\n次に掲げる手順を記載した製造販売後安全管理業務手順書を作成しなければなら\nない。\n一　安全管理情報の収集に関する手順\n二　安全管理情報の検討及びその結果に基づく安全確保措置の立案に関する手順\n\n三　安全確保措置の実施に関する手順\n四　安全管理責任者から総括製造販売責任者への報告に関する手順\n五　安全管理実施責任者から安全管理責任者への報告に関する手順\n六　第一種製造販売業者が医薬品等リスク管理を行う場合にあっては、医薬品等\nリスク管理に関する手順（第九条の二第一項第一号に規定する医薬品リスク管\n理計画書に基づき第十条第一項に規定する市販直後調査を行う場合は、当該市\n販直後調査に関する手順を含む。）\n七　第一種製造販売業者が第十条の二において準用する第十条第一項に規定する\n市販直後調査を行う場合にあっては、市販直後調査に関する手順\n八　自己点検に関する手順\n九　製造販売後安全管理に関する業務に従事する者に対する教育訓練に関する手\n順\n十　製造販売後安全管理に関する業務に係る記録の保存に関する手順\n十一　品質保証責任者等その他の処方箋医薬品、高度管理医療機器又は再生医療\n等製品の製造販売に係る業務の責任者との相互の連携に関する手順\n十二　第一種製造販売業者が医薬品等リスク管理を行う場合にあっては、製造販\n売後調査等管理責任者との相互の連携に関する手順\n十三　その他製造販売後安全管理に関する業務を適正かつ円滑に行うために必要\nな手順\n２　第一種製造販売業者は、製造販売後安全管理に関する業務に従事する者の責務\n及び管理体制を文書により適切に定めなければならない。\n３　第一種製造販売業者は、総括製造販売責任者又は安全管理責任者に、安全確保\n業務の適正かつ円滑な実施のために必要な事項を文書により定めさせなければな\nらない。\n４　第一種製造販売業者は、第一項の手順書又は第二項の文書を作成し、又は改訂\nしたときは、当該手順書又は文書にその日付を記録し、これを保存しなければな\nらない。\n５　第一種製造販売業者は、総括製造販売責任者又は安全管理責任者が第三項の文\n書を作成し、又は改訂したときは、当該文書にその日付を記録させ、これを保存\nさせなければならない。\n６　第一種製造販売業者は、総括製造販売責任者がその業務を行う事務所に第一項\nの手順書、第二項及び第三項の文書並びにその取り扱う処方箋医薬品、高度管理\n医療機器又は再生医療等製品の安全性に関する文書その他安全確保業務に必要な\n文書（以下この章において「製造販売後安全管理業務手順書等」という。）を備\nえ付けるとともに、安全確保業務を行うその他の事務所に製造販売後安全管理業\n務手順書等のうち、その事務所が担当する物に係るものの写しを備え付けなけれ\nばならない。\n（安全管理責任者の業務）\n第六条　第一種製造販売業者は、製造販売後安全管理業務手順書等に基づき、次に\n掲げる業務を安全管理責任者に行わせなければならない。\n一　安全確保業務を統括すること。\n二　安全確保業務が適正かつ円滑に行われているか確認し、その記録を作成し、\n保存すること。\n\n三　安全確保業務について必要があると認めるときは、総括製造販売責任者に対\nし文書により意見を述べ、その写しを保存すること。\n四　第一種製造販売業者が医薬品等リスク管理を行う場合にあっては、当該医薬\n品等リスク管理が適切に行われるよう、製造販売後調査等管理責任者との相互\nの密接な連携を図ること。\n（安全管理情報の収集）\n第七条　第一種製造販売業者は、製造販売後安全管理業務手順書等",
    "Japon_QMS.pdf": "医薬監麻発0131第１号 \n令和７年１月3 1 日 \n \n \n 各都道府県衛生主管部（局）長 殿 \n \n \n厚生労働省医薬局監視指導・麻薬対策課長\n \n（ \n \n公 \n \n印 \n \n省 \n \n略 \n \n） \n \n \n \n「医療機器及び体外診断用医薬品の製造管理及び品質管理の基準 \nに関する省令の一部改正について」の一部改正について \n \n \n医療機器及び体外診断用医薬品の製造管理及び品質管理の基準に関する省令\n（平成16年厚生労働省令第169号。以下「ＱＭＳ省令」という。）の具体的運用に\nついては、「医療機器及び体外診断用医薬品の製造管理及び品質管理の基準に関\nする省令の一部改正について」（令和３年３月26日付け薬生監麻発0326第４号厚\n生労働省医薬・生活衛生局監視指導・麻薬対策課長通知。以下「課長通知」とい\nう。）により示しているところです。 \n今般、規制改革実施計画（令和６年６月21日閣議決定）において、ＱＭＳ省令\n第72条第１項第２号に規定する国内品質業務運営責任者の要件の一つである\n「品質管理業務その他これに類する業務に３年以上従事した者であること。」に\nついて、「スタートアップ等によるＳａＭＤの開発及び生産を円滑化する観点か\nら、国内品質業務運営責任者の資格要件の一つである３年以上の品質管理業務\n等の職務経験について、講習の受講等により代替することを可能とする方向で\n検討する」こととされました。 \nこのことを踏まえ、管理医療機器であるプログラム医療機器（医薬品、医療\n機器等の品質、有効性及び安全性の確保等に関する法律（昭和35年法律第145号）\n第２条第13項に規定する医療機器プログラム又はこれを記録した記録媒体たる\n医療機器をいう。）の製造販売のみを行う第二種医療機器製造販売業者のうち、\n中小企業基本法（昭和38年法律第154号）第２条第５項に規定する小規模企業者\nにあっては、国内品質業務運営責任者に所定の研修を修了させ、当該国内品質\n業務運営責任者への助言を外部アドバイザーに委託することを条件に、ソフト\nウェア開発業務等に３年以上従事した者をＱＭＳ省令第72条第１項第２号に規\n\n \n \n定する「品質管理業務その他これに類する業務に３年以上従事した者」に含む\nこととします。つきましては、下記のとおり課長通知を改正し、令和７年４月\n１日から適用しますので、御了知の上、貴管下関係事業者等に周知いただきま\nすようご配慮願います。 \nなお、本運用は、医療機器業界において、ソフトウェア開発及び品質管理の\n両領域の知見を有する人材が充実するまでの間の暫定的な運用であり、医療機\n器業界において今後定期的に実施される本運用の利用実態調査の結果等を踏ま\nえ、取扱いを変更・廃止する際には、厚生労働省からその旨を連絡するので、御\n留意いただくようお願いいたします。 \nなお、改正後の課長通知を参考として添付します。 \nまた、本通知の写しについて、別記の団体等宛てに連絡するので、念のため\n申し添えます。 \n \n記 \n \n改正後 \n改正前 \n第２ 逐条解説 \n１～83 （略） \n84．第72条（国内品質業務運営責任者）\n関係 \n（１）～（２） （略） \n（３）第１項第２号の規定は、医療機\n器等に係る国内品質業務運営責任者\nは、製品リスクを勘案し、品質管理業\n務に関する経験を十分有する等、関係\n業務を熟知した者であるべきことか\nら設けられた規定であること。「品質\n管理業務その他これに類する業務に\n３年以上従事した者」としては、第一\n種医療機器製造販売業者にあっては\n以下の1）から5）までに掲げるいず\nれかの者として３年以上従事した者、\n第二種若しくは第三種医療機器製造\n販売業者又は体外診断用医薬品製造\n販売業者にあっては以下の1）から6）\nまでに掲げるいずれかの者として３\n第２ 逐条解説 \n１～83 （略） \n84．第72条（国内品質業務運営責任者）\n関係 \n（１）～（２） （略） \n（３）第１項第２号の規定は、医療機\n器等に係る国内品質業務運営責任者\nは、製品リスクを勘案し、品質管理業\n務に関する経験を十分有する等、関係\n業務を熟知した者であるべきことか\nら設けられた規定であること。「品質\n管理業務その他これに類する業務に\n３年以上従事した者」としては、第一\n種医療機器製造販売業者にあっては\n以下の1）から5）までに掲げる者、第\n二種若しくは第三種医療機器製造販\n売業者又は体外診断用医薬品製造販\n売業者にあっては以下の1）から6）ま\nでに掲げる者がそれぞれ該当する。な\nお、「３年以上」とは、自社、他社を\n\n \n \n年以上従事した者、管理医療機器であ\nるプログラム医療機器（法第２条第\n13 項に規定する医療機器プログラム\n又はこれを記録した記録媒体たる医\n療機器をいう。以下同じ。）の製造販\n売のみを行う第二種医療機器製造販\n売業者のうち中小企業基本法（昭和\n38 年法律第154 号）第２条第５項に\n規定される小規模企業者（以下「小規\n模ＳａＭＤ製造販売業者」という。）\nにあっては、以下の1)から6)までに\n掲げるいずれかの者として３年以上\n従事した者のほか、1）から6）までに\n掲げる者を国内品質業務運営責任者\nとして置くことが困難な場合は、7)か\nら9）までに掲げるいずれかの者であ\nって、厚生労働省が指定する表１の研\n修を修了した者がそれぞれ該当する。\nなお、「３年以上」とは、自社、他社\nを問わず該当する業務の合計年数で\nもよいこと。 \n1)～6) （略） \n7） プログラム医療機器の製造販売\n業者又は製造業者において、プログ\nラム医療機器のプログラムの設計\n開発に係る業務に３年以上従事し\nた者 \n8) プログラム医療機器の製造販売\n業者又は製造業者において、プログ\nラム医療機器のプログラムの設計\n開発に係る業務及び品質管理に係\nる業務に合わせて３年以上従事し\nた者 \n9) ソフトウェア開発に係る業務に\n主たる開発の責任者として３年以\n上従事した者 \n問わず該当する業務の合計年数でも\nよいこと。 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n1)～6) （略） \n7） （新設） \n \n \n \n \n8） （新設） \n \n \n \n \n \n9） （新設） \n \n \n\n \n \n \n表１ 研修内容 \n \nまた、小規模ＳａＭＤ製造販売業者\nが、7)から9)までに掲げる者であっ\n科目 \n時間 \n一 医薬品、医療機器等\nの品質、有効性及び安\n全性の確保等に関する\n法律（昭和35 年法律第\n145 号）その他関連法規\n二 国内品質業務運営責\n任者の役割 \n三 医療機器及び体外診\n断用医薬品の製造管理\n及び品質管理の基準 \n四 医療機器又は体外診\n断用医薬品の製造管理\n又は品質管理に係る業\n務を行う体制の基準に\n関する省令（平成26 年\n厚生労働省令第94 号）・\n医薬品、医療機器等の\n品質、有効性及び安全\n性の確保等に関する法\n律第二十三条の二の五\n第八項第一号に規定す\nる医療機器又は体外診\n断用医薬品の区分を定\nめる省令（平成26 年厚\n生労働省令第95 号）・\nＱＭＳ調査 \n五 医療機器の不具合報\n告制度・回収報告制度 \n六 医療機器の製造販売\n後安全管理の基準 \n８時間 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \nて、表１の研修を修了した者を国内品\n質業務運営責任者とする場合は、表２\nの要件を全て満たす外部アドバイザ\nーとの間で契約を締結し、当該外部ア\nドバイザーに対して、表３の業務を委\n託すること。 \n \n表２ 外部アドバイザーの要件 \n一 1）から6）までに掲げるいずれ\nかの者として３年以上従事した\n者  \n二 国内の品質管理業務を適正か\nつ円滑に遂行しうる能力を有す\nる者 \n三 他の製造販売業者の国内品質\n業務運営責任者を兼務していな\nいこと。なお、複数の小規模Ｓａ\nＭＤ製造販売業者の外部アドバ\nイザーを兼務する場合は、各小規\n模ＳａＭＤ製造販売業者におけ\nる業務に支障を来さないように\nすること。 \n \n表３ 外部アドバイザーの業務内容 \n一 定期的に国内品質業務運営責\n任者と会議を実施するとともに、\n国内品質業務運営責任者が第72\n条第２項に係る業務を適切かつ\n遅滞なく遂行できるように、必要\nな指導、助言を行う \n二 医療機器の使用による保健衛\n生上の危害の発生及び拡大の防\n止のために、国内に流通する製品\nの品質等に関する情報を得たと\nきや製品の回収を行うとき等、速\nやかな対応を要する場合におい\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \nては、国内品質業務運営責任者に\nよる対応が適切かつ迅速に行わ\nれるよう、必要な指導、助言を行\nう \n \n（４）～（27） （略） \n85～104 （略） \n \n \n \n \n \n（４）～（27） （略） \n85～104 （略） \n \n \n \n\n \n \n別記 \n \n各地方厚生局 \n \n独立行政法人医薬品医療機器総合機構 \n \n医薬品医療機器等法登録認証機関協議会 \n \n一般社団法人 日本医療機器産業連合会 \n \n日本製薬団体連合会 \n \n一般社団法人 日本臨床検査薬協会 \n \n一般社団法人 米国医療機器・IVD 工業会 \n \n欧州ビジネス協会医療機器・IVD 委員会 \n \n一般社団法人日本医療ベンチャー協会 \n \n日本デジタルヘルス・アライアンス \n \nＡＩ医療機器協議会 \n \n公益財団法人医療機器センター \n \n \n\n \n \n薬生監麻発0326第４号 \n令和３年３月2 6 日 \n[一部改正]令和７年１月31日 \n \n \n 各都道府県衛生主管部（局）長 殿 \n \n \n厚生労働省医薬・生活衛生局監視指導・麻薬対策課長 \n（ \n \n公 \n \n印 \n \n省 \n \n略 \n \n） \n \n \n \n医療機器及び体外診断用医薬品の製造管理及び品質管理の基準 \nに関する省令の一部改正について \n \n \n今般、医療機器の品質マネジメントシステムの国際規格であるISO13485:2016\nと整合を図ることを目的として、医療機器及び体外診断用医薬品の製造管理及\nび品質管理の基準に関する省令の一部を改正する省令（令和３年厚生労働省令\n第60号。以下「改正省令」という。）により医療機器及び体外診断用医薬品の製\n造管理及び品質管理の基準に関する省令（平成16年厚生労働省令第169号。以下\n「ＱＭＳ省令」という。）の一部改正を行いました。 \n改正省令による改正後のＱＭＳ省令（以下「改正ＱＭＳ省令」という。）の具\n体的運用については、下記のとおり取り扱うこととしましたので、御了知の上、\n貴管下関係事業者等に周知いただきますよう御配慮願います。 \nなお、本通知の写しを各地方厚生局長、独立行政法人医薬品医療機器総合機\n構理事長、一般社団法人日本医療機器産業連合会会長、日本製薬団体連合会会\n長、一般社団法人日本臨床検査薬協会会長、一般社団法人米国医療機器・ＩＶ\nＤ工業会会長、欧州ビジネス協会医療機器・ＩＶＤ委員会委員長及び医薬品医\n療機器等法登録認証機関協議会代表幹事宛て送付することとしています。 \n \n記 \n \n目次 \n第１ 改正の要旨 \n第２ 逐条解説 \n\n \n \n第３ 経過措置 \n第１ 改正の要旨 \n１．「植込医療機器」、「類似製品グループ」、「市販後監視」、「購買物品等」、「無\n菌バリアシステム」及び「使用性」について定義を規定したこと。（第２条） \n２．製造販売業者等は、改正ＱＭＳ省令で文書化することを求められている全\nての要求事項、手順、活動及び実施要領を、確立し、実施し、及び維持しなけ\nればならないこととしたこと。（第５条第２項） \n３．製造販売業者等は、製品に係る医療機器",
    "la_suisse(Ordonnance_sur_les_dispositifs_medicaux_de_diagnostic_in_vitro_et_modification_de_lordonnance_sur_les_essais_cliniques_de_dispositifs_medicaux_.pdf": "Département fédéral de l'intérieur \nOffice fédéral de la santé publique OFSP \n \n \n \n \n \n \n \nOrdonnance sur les dispositifs médicaux de diagnos-\ntic in vitro et modification de l’ordonnance sur les es-\nsais cliniques de dispositifs médicaux  \n \n \nRapport explicatif  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAvril 2021 \n \n \n\nRapport explicatif ODiv et OClin-Dim \n \n \n2/71 \n \n \nTable des matières \n \n1 \nSituation initiale \n6 \n1.1 \nLes dispositifs médicaux et leur réglementation en Suisse ............................... 6 \n1.2 \nDéveloppements au sein de l’UE .......................................................................... 6 \n1.3 \nAdaptation du droit suisse à la nouvelle réglementation européenne relative \naux dispositifs médicaux ....................................................................................... 8 \n1.4 \nActes délégués et actes d’exécution de la Commission européenne ................ 9 \n2 \nCommentaire des différents articles \n11 \n2.1 \nOrdonnance sur les dispositifs médicaux de diagnostic in vitro (ODiv) .......... 11 \nChapitre 1 Dispositions générales ....................................................................................... 11 \nSection 1 Champ d’application et exceptions .................................................................... 11 \nArt. 1 \nChamp d’application .......................................................................................... 11 \nArt. 2 \nExceptions ......................................................................................................... 12 \nSection 2 Définitions et renvois au droit européen ............................................................. 12 \nArt. 3 \nDispositifs médicaux de diagnostic in vitro et accessoires de dispositifs médicaux \nde diagnostic in vitro .......................................................................................... 12 \nArt. 4 \nAutres définitions ............................................................................................... 12 \nArt. 5 \nRenvois au droit européen ................................................................................. 15 \nChapitre 2 Mise à disposition sur le marché et mise en service .......................................... 16 \nSection 1 Exigences .......................................................................................................... 16 \nArt. 6 \nExigences générales en matière de sécurité et de performances ...................... 16 \nArt. 7 \nVente à distance ................................................................................................ 17 \nArt. 8 \nExigences spécifiques ....................................................................................... 18 \nArt. 9 \nDispositifs fabriqués et utilisés dans des établissements de santé ..................... 18 \nArt. 10 \nDéclaration des dispositifs fabriqués dans un établissement de santé ............... 19 \nArt. 11 \nParties et composants ....................................................................................... 20 \nArt. 12 \nMarquage de conformité et numéro d’identification ............................................ 20 \nArt. 13 \nApposition du marquage de conformité et du numéro d’identification ................ 21 \nSection 2 Classification, étiquetage et identification du dispositif ....................................... 21 \nArt. 14 \nClassification ..................................................................................................... 21 \nArt. 15 \nInformation relative au dispositif......................................................................... 22 \nArt. 16 \nIdentification univoque des dispositifs ................................................................ 22 \nChapitre 3 Évaluation de la conformité, certificat et déclaration .......................................... 23 \nSection 1 Évaluation de la conformité ................................................................................ 23 \nArt. 17 \nPrincipe ............................................................................................................. 23 \nArt. 18 \nExceptions et dérogations.................................................................................. 24 \nArt. 19 \nProcédure .......................................................................................................... 25 \nArt. 20 \nRecours à un organisme désigné ...................................................................... 25 \nSection 2 Certificat de conformité ...................................................................................... 26 \nArt. 21 \nÉtablissement et contenu................................................................................... 26 \nArt. 22 \nDurée de validité ................................................................................................ 27 \nArt. 23 \nSuspension, restriction et révocation ................................................................. 27 \nArt. 24 \nObligation de document",
    "MDR.pdf": "I \n(Legislative acts) \nREGULATIONS \nREGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL \nof 5 April 2017 \non medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and \nRegulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC \n(Text with EEA relevance) \nTHE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, \nHaving regard to the Treaty on the Functioning of the European Union, and in particular Article 114 and \nArticle 168(4)(c) thereof, \nHaving regard to the proposal from the European Commission, \nAfter transmission of the draft legislative act to the national parliaments, \nHaving regard to the opinion of the European Economic and Social Committee (1), \nAfter consulting the Committee of the Regions, \nActing in accordance with the ordinary legislative procedure (2), \nWhereas: \n(1)  \nCouncil Directive 90/385/EEC (3) and Council Directive 93/42/EEC (4) constitute the Union regulatory framework \nfor medical devices, other than in vitro diagnostic medical devices. However, a fundamental revision of those \nDirectives is needed to establish a robust, transparent, predictable and sustainable regulatory framework for \nmedical devices which ensures a high level of safety and health whilst supporting innovation. \n(2)  \nThis Regulation aims to ensure the smooth functioning of the internal market as regards medical devices, taking \nas a base a high level of protection of health for patients and users, and taking into account the small- and \nmedium-sized enterprises that are active in this sector. At the same time, this Regulation sets high standards of \nquality and safety for medical devices in order to meet common safety concerns as regards such products. Both \nobjectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the \nother. As regards Article 114 of the Treaty on the Functioning of the European Union (TFEU), this Regulation \nharmonises the rules for the placing on the market and putting into service of medical devices and their \naccessories on the Union market thus allowing them to benefit from the principle of free movement of goods. \n5.5.2017 \nL 117/1 \nOfficial Journal of the European Union \nEN     \n(1) Opinion of 14 February 2013 (OJ C 133, 9.5.2013, p. 52). \n(2) Position of the European Parliament of 2 April 2014 (not yet published in the Official Journal) and position of the Council at first reading \nof 7 March 2017 (not yet published in the Official Journal). \n(3) Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable \nmedical devices (OJ L 189, 20.7.1990, p. 17). \n(4) Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (OJ L 169, 12.7.1993, p. 1). \n\nAs regards Article 168(4)(c) TFEU, this Regulation sets high standards of quality and safety for medical devices by \nensuring, among other things, that data generated in clinical investigations are reliable and robust and that the \nsafety of the subjects participating in a clinical investigation is protected. \n(3)  \nThis Regulation does not seek to harmonise rules relating to the further making available on the market of \nmedical devices after they have already been put into service such as in the context of second-hand sales. \n(4)  \nKey elements of the existing regulatory approach, such as the supervision of notified bodies, conformity \nassessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be \nsignificantly reinforced, whilst provisions ensuring transparency and traceability regarding medical devices should \nbe introduced, to improve health and safety. \n(5)  \nTo the extent possible, guidance developed for medical devices at international level, in particular in the context \nof the Global Harmonization Task Force (GHTF) and its follow-up initiative, the International Medical Devices \nRegulators Forum (IMDRF), should be taken into account to promote the global convergence of regulations \nwhich contributes to a high level of safety protection worldwide, and to facilitate trade, in particular in the \nprovisions on Unique Device Identification, general safety and performance requirements, technical documen­\ntation, classification rules, conformity assessment procedures and clinical investigations. \n(6)  \nFor historical reasons, active implantable medical devices, covered by Directive 90/385/EEC, and other medical \ndevices, covered by Directive 93/42/EEC, were regulated in two separate legal instruments. In the interest of \nsimplification, both directives, which have been amended several times, should be replaced by a single legislative \nact applicable to all medical devices other than in vitro diagnostic medical devices. \n(7)  \nThe scope of application of this Regulation should be clearly delimited from other Union harmonisation \nlegislation concerning products, such as in vitro diagnostic m",
    "Questions_et_reponses_(Exigences_relatives_aux_organismes_notifies_.pdf": "Medical Devices \n     \nMedical Device Coordination Group Document  \nMDCG  2019-6-Rev.3 \n \nPage 1 of 21 \n \n \n \n \n \nMDCG  2019-6 Rev5  \n \n         \n \n \n \nQuestions and answers:  \n \n \nRequirements relating to notified bodies \n \n \nRevision 5 - February 2025 \n \n \n \n \n \n \nThis document has been endorsed by the Medical Device Coordination Group \n(MDCG) established by Article 103 of Regulation (EU) 2017/745. The MDCG is \ncomposed of representatives of all Member States and it is chaired by a \nrepresentative of the European Commission. \nThe document is not a European Commission document and it cannot be regarded \nas reflecting the official position of the European Commission. Any views expressed \nin this document are not legally binding and only the Court of Justice of the European \nUnion can give binding interpretations of Union law. \n \n \n \n\nMedical Devices \n     \nMedical Device Coordination Group Document  \nMDCG  2019-6-Rev.3 \n \nPage 2 of 21 \n \nRevision table \nMDCG 2019-6 revision 5 changes \nQuestions I.5.1 and \nI.5.2 \nAdded to replace I.5  \nQuestions I.6.1, I.6.2 \nand I.6.3  \nAdded to replace I.6  \nQuestion I.9.  \nUpdated \nQuestion IV.1. \nUpdated  \nQuestion IV.7. \nUpdated \nQuestion IV.10. \nUpdated \nQuestion IV.12. \nUpdate \nQuestion IV.13.  \nNew Q&A added  \n \nIntroduction \nThis document presents questions and answers on requirements relating to notified \nbodies under Regulation (EU) 2017/745 on medical devices (MDR) and Regulation \n(EU) 2017/746 on in vitro diagnostic medical devices (IVDR). The issues covered by \nthis document have been identified in the context of joint assessments, and the \ndocument may be updated from time to time as new issues are identified. \nI. \nORGANISATIONAL AND GENERAL REQUIREMENTS \nI.1. \nAre CABs obliged to follow guidance endorsed by the Medical \nDevices Coordination Group (MDCG)? \nGuidance documents are by definition not compulsory. However, all guidance \ndocuments endorsed by the MDCG reflect the interpretation of the EU law jointly \nagreed by the authorities which are in charge of interpreting and applying the EU law. \nHence notified bodies should be encouraged to apply these guidance documents \n(also taking into consideration Section 1.6.2 of Annex VII to the MDR/IVDR1). \nFurthermore, it is to be noticed that the European Court of Justice often refers to \nguidance documents when developing its rulings. Hence Notified Bodies have an \ninterest, also in terms of liability risk, to follow that guidance.  \n \n1 1.6.2. The notified body shall take into consideration guidance and best practice documents. \n\nMedical Devices \n     \nMedical Device Coordination Group Document  \nMDCG  2019-6-Rev.3 \n \nPage 3 of 21 \n \nI.2. \nWhat is the meaning of “legal personality” under Section 1.1.1 \nof Annex VII2? \nThe CAB needs to have legal personality, meaning that it has to exist as a legal \nentity. To that end, it must be registered as legal entity, also called \"legal person\". \nThe wording of the MDR/IVDR does not exclude that only a part of a legal entity \nundertakes conformity assessment activities in the field of medical devices. In this \ncase, where the CAB is part of a wider legal entity, the documentation provided \nshould be clear as to where the CAB sits within that legal entity. In case the entire \nlegal entity is the CAB, the documentation to be provided refers to the legal entity as \nsuch. It is always this legal entity as such which is designated (and not its \norganisational part). \nI.3. \nWhat is the meaning of “organisation” as described in 1.1.2 of \nAnnex VII? \nThe term of \"organisation\" as described in 1.1.2 refers to the whole organisation (e.g. \ncorporate group) to which the CAB belongs including the CAB's legal entity. The \nconcept of \"organisation\" should be based not only on ownership rights (e.g. shares), \nbut also functional/hierarchical links, such as voting/management/other control rights. \nOne typical example of organisation is a holding company owning different \ncompanies (i.e. separate legal entities), one of them being or containing the CAB.  \nI.4. \nDoes the term “organisational structure” as per 1.1.5 refer only \nto hierarchical relationships? \nIf a notified body is part of a larger organisation, both hierarchical (i.e. mother and \ndaughter companies of the CAB) and horizontal relationships (e.g. sister companies \nwhere there is a common mother company) between the notified body and other \nentities belonging to that organisation are covered by the term \"organisational \nstructure\".  \nThe organisational structure of the CAB will vary depending on the complexity of the \nlegal entity and the organisation to which it belongs. For instance, in the case of \nholding companies, the CAB could provide a matricial organisational chart with dual \nreporting relationships (i.e. functional and managerial). In this case, hierarchical and \nreporting lines should be clear and should match the information provided in job \ndescriptions for the activities related to the MDR/ IVDR certification. \nI.5",
    "Regulation_(EU)_2017_745_notification.pdf": "From:\nNational Center for Public Health\nand Pharmacy (NNGYK)\nSzabolcs Str. 33\n1135 Budapest\nHungary\nTo:\nEuropean Commission\nGROWTH Directorate-General\n200 Rue de la Loi,\nB-1049 Brussels.\nOther Member States\nReference:\nLegislation: Regulation (EU) 2017/745 on medical devices\nBody name, address, telephone, fax, email, website :\nNEOEMKI Nemzeti Orvostechnikai Eszköz Megfelelőségértékelő és Tanúsító Korlátolt Felelősségű Társaság\n(NEOEMKI LLC)\nAlbert Flórián út 3. A. ép\nH-1097 Budapest\nHungary\n+36-20-268-7595\ncert@emki.hu\nwww.emki.hu\nBody info:\nNB 1011\nNotification of a Body in the framework of\na technical harmonization directive\nTasks performed by the Body:\nLast approval date:\n2024-10-09\nPage 1\n\nProduct\nProcedures\nArticles /Annexes Conditions\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-2.   Active non-implantable\ndevices for imaging,\nmonitoring and/or diagnosis\n-MDA 0201\nActive non-\nimplantable imaging devices\nutilising ionizing radiation\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-2.   Active non-implantable\ndevices for imaging,\nmonitoring and/or diagnosis\n-MDA 0202\nActive non-\nimplantable imaging devices\nutilising non-ionizing\nradiation\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-2.   Active non-implantable\ndevices for imaging,\nmonitoring and/or diagnosis\n-MDA 0203\nActive non-\nimplantable devices for\nmonitoring of vital\nphysiological parameters\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-2.   Active non-implantable\ndevices for imaging,\nmonitoring and/or diagnosis\n-MDA 0204\nOther active\nnon-implantable devices for\nmonitoring and/or diagnosis\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nRestriction:\nReview of\naudiological\ndevices only.\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-3.   Active non-implantable\ntherapeutic devices and\ngeneral active non-\nimplantable devices\n-MDA 0302\nActive non-\nimplantable devices utilising\nnon-ionizing radiation\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nPage 2\n\nProduct\nProcedures\nArticles /Annexes Conditions\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-3.   Active non-implantable\ntherapeutic devices and\ngeneral active non-\nimplantable devices\n-MDA 0305\nActive non-\nimplantable devices for\nstimulation or inhibition\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-3.   Active non-implantable\ntherapeutic devices and\ngeneral active non-\nimplantable devices\n-MDA 0306\nActive non-\nimplantable devices for\nextra-corporal circulation,\nadministration or removal of\nsubstances and\nhaemapheresis\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-3.   Active non-implantable\ntherapeutic devices and\ngeneral active non-\nimplantable devices\n-MDA 0310\nActive non-\nimplantable devices for ear,\nnose and throat\nConformity assessment based on a\nquality management system\nConformity assessment based on\nassessment of technical\ndocumentation\nConformity assessment based on\nproduct quality assurance\nAnnex IX(I)\nAnnex IX(II)\nAnnex XI(A)\nRestriction:\nReview of\nhearing aids only.\n-I. CODES REFLECTING THE\nDESIGN AND INTENDED\nPURPOSE OF THE DEVICE\n-A.   Active devices\n-3.   Active non-implantable\ntherapeutic devices and\ngeneral active non-\nimplantable devices\n-MDA 0312\nOther active\nnon-implantable surgical\ndevices\nConformity assessment b",
    "Regulations_Afrique_du_sud.pdf": "No. 10177\nRegulation Gazette\nRegulasiekoerant\nN.B. The Government Printing Works will\nnot be held responsible for the quality of\n“Hard Copies” or “Electronic Files”\nsubmitted for publication purposes\nAIDS HELPLINE: 0800-0123-22  Prevention is the cure\nGovernment Gazette\nStaatskoerant\nR E P U B L I C  O F  S O U T H  A F R I CA\nREPUBLIEK VAN SUID AFRIK A\nVol. 716\n12\nFebruary \nFebruarie\nNo. 52106\n2025\n9\n7 7 1 6 8 2 5 8 4 0 0 3\n5 2 1 0 6\nISSN 1682-5845\n\nThis gazette is also available free online at www.gpwonline.co.za\n2    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\nGovernment Notices • Goewermentskennisgewings\nHealth, Department of / Gesondheid, Departement van\n5856\t\nMedicines and Related Substances Act, (101/1965): Regulations regarding fees payable in terms of the Provisions \nof the Act................................................................................................................................................................... \t\n52106\t\n3\nPage\nNo.\nGazette\nNo.\nNo.\nContents\nIMPORTANT NOTICE:\nThe GovernmenT PrinTinG Works Will noT be held resPonsible for any errors \nThaT miGhT occur due To The submission of incomPleTe / incorrecT / illeGible coPy.\nno fuTure queries Will be handled in connecTion WiTh The above.\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    3\nGovernment Notices • Goewermentskennisgewings\nDEPARTMENT OF HEALTH\nNO. 5856\b\n12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n4    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    5\n\nThis gazette is also available free online at www.gpwonline.co.za\n6    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    7\n\nThis gazette is also available free online at www.gpwonline.co.za\n8    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    9\n\nThis gazette is also available free online at www.gpwonline.co.za\n10    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    11\n\nThis gazette is also available free online at www.gpwonline.co.za\n12    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    13\n\nThis gazette is also available free online at www.gpwonline.co.za\n14    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    15\n\nThis gazette is also available free online at www.gpwonline.co.za\n16    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    17\n\nThis gazette is also available free online at www.gpwonline.co.za\n18    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025\n\nThis gazette is also available free online at www.gpwonline.co.za\n\t\nSTAATSKOERANT, 12 Februarie 2025\b\nNo. 52106    19\n\nPrinted by and obtainable from the Government Printer, Bosman Street, Private Bag X85, Pretoria, 0001\nContact Centre  Tel: 012-748 6200. eMail: info.egazette@gpw.gov.za\nPublications: Tel: (012) 748 6053, 748 6061, 748 6065\nThis gazette is also available free online at www.gpwonline.co.za\n20    No. 52106\t\nGOVERNMENT GAZETTE, 12 February 2025",
    "Royaume-Uni__.pdf": "Status:  This is the original version (as it was originally made). This\nitem of legislation is currently only available in its original format.\nSTATUTORY INSTRUMENTS\n2024 No. 1368\nMEDICAL DEVICES\nThe Medical Devices (Post-market Surveillance\nRequirements) (Amendment) (Great Britain) Regulations 2024\nMade       -      -      -      -\n16th December 2024\nComing into force in accordance with regulation 1(2)\nThe Secretary of State makes these Regulations in exercise of the powers conferred by sections\n15(1), 16(1)(a), (b), (g), (i) and (j), 17(1)(b) and (c) and 43(2) of the Medicines and Medical Devices\nAct 2021(1).\nThe Secretary of State has carried out a public consultation in accordance with section 45(1) of that\nAct.\nIn accordance with section 15(2) to (4) of that Act, the Secretary of State’s overarching objective\nin making these Regulations is safeguarding public health, the Secretary of State has had regard to\nthe matters specified in section 15(3) of that Act, and the Secretary of State considers that, where\nthese Regulations may have an impact on the safety of medical devices, the benefits of making these\nRegulations outweigh the risks.\nIn accordance with section 47(3) and (6)(a) of that Act, a draft of this instrument has been laid before\nand approved by a resolution of each House of Parliament.\nCitation, commencement, extent and application\n1.—(1)  These Regulations may be cited as the Medical Devices (Post-market Surveillance\nRequirements) (Amendment) (Great Britain) Regulations 2024.\n(2)  These Regulations come into force 6 months after the day on which they are made.\n(3)  Subject to paragraph (4), these Regulations extend to England and Wales, Scotland and\nNorthern Ireland.\n(4)  Regulation 4 extends to England and Wales and Scotland only.\nAmendments to the Medical Devices Regulations 2002\n2. The Medical Devices Regulations 2002(2) are amended in accordance with regulations 3 to 6.\n(1)\n2021 c. 3. Section 17 was amended by S.I. 2021/905. There are other amendments to the Act not relevant to these Regulations.\n(2)\nS.I. 2002/618.\n\nDocument Generated: 2024-12-20\nStatus:  This is the original version (as it was originally made). This\nitem of legislation is currently only available in its original format.\nAmendment to regulation 2 (interpretation)\n3. In regulation 2(1)(3)—\n(a) for the definition of “relevant essential requirements” substitute—\n““relevant essential requirements”—\n(a)\nin Part 4A, has the meaning given in regulation 44ZC;\n(b)\nin all other Parts, in relation to a medical device, means the essential\nrequirements set out in Annex 1 of Directive 90/385, Annex I of Directive\n93/42 or Annex I of Directive 98/79 which apply to it, but not including, in the\ncase of a device intended for clinical investigation, such of those requirements,\nor aspects of them, as are the subject of the investigation;”;\n(b) for the definition of “Regulation (EU) No 722/2012” substitute—\n““Regulation (EU) No 722/2012”—\n(a)\nin Part 4A, has the meaning given in regulation 44ZC;\n(b)\nin all other Parts means Commission Regulation (EU) No 722/2012 of 8\nAugust 2012 concerning particular requirements as regards the requirements\nlaid down in Council Directives 90/385/EEC and 93/42/EEC with respect to\nactive implantable medical devices and medical devices manufactured utilising\ntissues of animal origin (as retained under section 3 of the European Union\n(Withdrawal) Act 2018 and modified under section 8 of that Act);”;\n(c) after the definition of “UK responsible person” insert—\n““working day” means any day which is not Saturday, Sunday, Christmas Day, Good\nFriday or a day which is a bank holiday in any part of Great Britain under the Banking\nand Financial Dealings Act 1971.”.\nNew Part 4A (post-market surveillance requirements)\n4. After regulation 44ZB(4) (obligations in Part IV of these Regulations which are met by\ncomplying with obligations in Regulation (EU) 2017/746) insert—\n“PART 4A\nPost-market surveillance requirements\nInterpretation of Part 4A\n44ZC. In this Part—\n“corrective action” means action taken in order to—\n(a)\neliminate the cause of a potential or actual non-conformity of a device, or\n(b)\nreduce any other risk posed by a device,\nthat has already been manufactured and may include recalling the device, withdrawing\nit from the market, and taking it out of service;\n“field safety corrective action” means a corrective action taken by the manufacturer\nto prevent or reduce the risk of a serious incident in relation to a device which has\nalready been placed on the market or put into service;\n(3)\nRelevant amending instruments are S.I. 2003/1697, 2013/2327, 2021/873.\n(4)\nRegulation 44ZB was inserted by S.I. 2019/791.\n2\n\nDocument Generated: 2024-12-20\nStatus:  This is the original version (as it was originally made). This\nitem of legislation is currently only available in its original format.\n“incident” means in relation to a device that has been placed on the market or put\ninto service—\n(a)\na malfunction or deterioration in the",
    "Royaume-Uni_1.pdf": "Changes to legislation: The Medical Devices Regulations 2002 is up to date with all changes known to be in force on or\nbefore 16 May 2024. There are changes that may be brought into force at a future date. Changes that have been made\nappear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes\nSTATUTORY INSTRUMENTS\n2002 No. 618\nCONSUMER PROTECTION\nThe Medical Devices Regulations 2002\nMade       -      -      -      -\n20th May 2002\nLaid before Parliament \n21st May 2002\nComing into force       -      -\n13th June 2002\nThe Secretary of State, being a Minister designated for the purposes of section 2(2) of the European\nCommunities Act 1972M1 in relation to measures relating to medical devicesM2, in exercise of the\npowers conferred by the said section 2(2), in exercise, with the consent of the Treasury, of the\npowers conferred by section 56(1) and (2) of the Finance Act 1973M3, in exercise of the powers\nconferred by sections 11 and 27(2) of the Consumer Protection Act 1987M4, and in exercise of all\nother powers enabling him in that behalf, after consultation in accordance with section 11(5) of the\nConsumer Protection Act 1987 with organisations appearing to him to be representative of interests\nsubstantially affected by these Regulations, with such other persons considered by him appropriate\nand with the Health and Safety Commission, hereby makes the following Regulations:—\nModifications etc. (not altering text)\nC1\nRegulations: power to amend conferred (11.2.2021) by Medicines and Medical Devices Act 2021\n(c. 3), ss. 15(1), 50(1)(f)\nMarginal Citations\nM1\n1972 c. 68.\nM2\nThe Secretary of State was designated in relation to measures relating to active implantable medical\ndevices in S.I. 1991/2289, and in relation to measures relating to medical devices other than active\nimplantable medical devices in S.I. 1993/2661.\nM3\n1973 c. 51.\nM4\n1987 c. 43.\n\nDocument Generated: 2024-05-16\nChanges to legislation: The Medical Devices Regulations 2002 is up to date with all changes known to be in force on or\nbefore 16 May 2024. There are changes that may be brought into force at a future date. Changes that have been made\nappear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes\nPART I\nIntroductory Provisions Relating to all Medical Devices\nCitation and commencement\n1. These Regulations may be cited as the Medical Devices Regulations 2002 and shall come into\nforce 13th June 2002.\nExpiry of certain provisions in these Regulations\n[F11ZA.—(1)  Subject to paragraph (3), regulations 19B and 30A cease to have effect at 23:59\non 30 June 2028.\n(2)  Subject to paragraph (3), regulations 19C, 44ZA and 44ZB cease to have effect at 23:59 on\n30 June 2030.\n(3)  The following cease to have effect at 23:59 on 30 June 2023—\n(a) regulation 19B(4), (5), (8) and (9);\n(b) regulation 19C(8) and (9);\n(c) regulation 30A(4) to (7);\n(d) regulation 44ZA(4) and (5);\n(e) regulation 44ZB(4) and (5).]\nTextual Amendments\nF1\nReg. 1ZA substituted (30.6.2023) by The Medical Devices (Amendment) (Great Britain) Regulations\n2023 (S.I. 2023/627), regs. 2(1), 4\n[F2Schedules\n1A. Schedules 2 and 2A have effect.]\nTextual Amendments\nF2\nRegs. 1ZA, 1A inserted (E.W.S.) (31.12.2020) by The Medical Devices (Amendment etc.) (EU Exit)\nRegulations 2019 (S.I. 2019/791), regs. 1(1), 3(2) (as amended by S.I. 2020/1478, reg. 1(3), Sch. 2\nparas. 2, 3); 2020 c. 1, Sch. 5 para. 1(1)\nInterpretation E+W+S\n2.—(1)  F3... In these Regulations F4...—\nF5...\n“active implantable medical device” means a medical device which—\n(a)\nrelies for its functioning on a source of electrical energy or a source of power other than\nthat generated directly by the human body or by gravity; and\n(b)\nis intended to be totally or partially introduced into the human body (whether surgically\nor medically, including being introduced into a natural orifice) and which is intended to\n2\n\nDocument Generated: 2024-05-16\nChanges to legislation: The Medical Devices Regulations 2002 is up to date with all changes known to be in force on or\nbefore 16 May 2024. There are changes that may be brought into force at a future date. Changes that have been made\nappear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes\nremain in the human body after completion of the surgical or medical procedure during\nwhich it is introduced,\neven if it is intended to administer a medicinal product or incorporates as an integral part a\nsubstance which, if used separately, would be a medicinal product;\nF6...\n[F7“approved body” is to be construed in accordance with regulation A45;]\nF8...\nF9...\n“CE marking” means a conformity marking consisting of the initials “CE”;\nF10...\n[F11“clinical data” means the safety or performance information that is generated from the use\nof a device, derived from—\n(a)\nclinical investigations of the device concerned; or\n(b)\nclinical investigations or othe",
    "Royaume-Uni_2.pdf": "Draft Legislation: This is a draft item of legislation. This draft has since been made as a UK Statutory Instrument: The\nMedical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 No. 1368\nDraft Regulations laid before Parliament under section 47(3) and (6)(a) of the Medicines and\nMedical Devices Act 2021, for approval by resolution of each House of Parliament.\nDRAFT STATUTORY INSTRUMENTS\n2024 No.\nMEDICAL DEVICES\nThe Medical Devices (Post-market Surveillance\nRequirements) (Amendment) (Great Britain) Regulations 2024\nMade       -      -      -      -\n***\nComing into force       -      -\n***\nThe Secretary of State makes these Regulations in exercise of the powers conferred by sections\n15(1), 16(1)(a), (b), (g), (i) and (j), 17(1)(b) and (c) and 43(2) of the Medicines and Medical Devices\nAct 2021(1).\nThe Secretary of State has carried out a public consultation in accordance with section 45(1) of that\nAct.\nIn accordance with section 15(2) to (4) of that Act, the Secretary of State’s overarching objective\nin making these Regulations is safeguarding public health, the Secretary of State has had regard to\nthe matters specified in section 15(3) of that Act, and the Secretary of State considers that, where\nthese Regulations may have an impact on the safety of medical devices, the benefits of making these\nRegulations outweigh the risks.\nIn accordance with section 47(3) and (6)(a) of that Act, a draft of this instrument has been laid before\nand approved by a resolution of each House of Parliament.\nCitation, commencement, extent and application\n1.—(1)  These Regulations may be cited as the Medical Devices (Post-market Surveillance\nRequirements) (Amendment) (Great Britain) Regulations 2024.\n(2)  These Regulations come into force 6 months after the day on which they are made.\n(3)  Subject to paragraph (4), these Regulations extend to England and Wales, Scotland and\nNorthern Ireland.\n(4)  Regulation 4 extends to England and Wales and Scotland only.\n(1)\n2021 c. 3. Section 17 was amended by S.I. 2021/905. There are other amendments to the Act not relevant to these Regulations.\n\nDocument Generated: 2024-12-20\nDraft Legislation: This is a draft item of legislation. This draft has since been made as a UK Statutory Instrument: The\nMedical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 No. 1368\nAmendments to the Medical Devices Regulations 2002\n2. The Medical Devices Regulations 2002(2) are amended in accordance with regulations 3 to 6.\nAmendment to regulation 2 (interpretation)\n3. In regulation 2(1)(3)—\n(a) for the definition of “relevant essential requirements” substitute—\n““relevant essential requirements”—\n(a)\nin Part 4A, has the meaning given in regulation 44ZC;\n(b)\nin all other Parts, in relation to a medical device, means the essential\nrequirements set out in Annex 1 of Directive 90/385, Annex I of Directive\n93/42 or Annex I of Directive 98/79 which apply to it, but not including, in the\ncase of a device intended for clinical investigation, such of those requirements,\nor aspects of them, as are the subject of the investigation;”;\n(b) for the definition of “Regulation (EU) No 722/2012” substitute—\n““Regulation (EU) No 722/2012”—\n(a)\nin Part 4A, has the meaning given in regulation 44ZC;\n(b)\nin all other Parts means Commission Regulation (EU) No 722/2012 of 8\nAugust 2012 concerning particular requirements as regards the requirements\nlaid down in Council Directives 90/385/EEC and 93/42/EEC with respect to\nactive implantable medical devices and medical devices manufactured utilising\ntissues of animal origin (as retained under section 3 of the European Union\n(Withdrawal) Act 2018 and modified under section 8 of that Act);”;\n(c) after the definition of “UK responsible person” insert—\n““working day” means any day which is not Saturday, Sunday, Christmas Day, Good\nFriday or a day which is a bank holiday in any part of Great Britain under the Banking\nand Financial Dealings Act 1971.”.\nNew Part 4A (post-market surveillance requirements)\n4. After regulation 44ZB(4) (obligations in Part IV of these Regulations which are met by\ncomplying with obligations in Regulation (EU) 2017/746) insert—\n“PART 4A\nPost-market surveillance requirements\nInterpretation of Part 4A\n44ZC. In this Part—\n“corrective action” means action taken in order to—\n(a)\neliminate the cause of a potential or actual non-conformity of a device, or\n(b)\nreduce any other risk posed by a device,\n(2)\nS.I. 2002/618.\n(3)\nRelevant amending instruments are S.I. 2003/1697, 2013/2327, 2021/873.\n(4)\nRegulation 44ZB was inserted by S.I. 2019/791.\n2\n\nDocument Generated: 2024-12-20\nDraft Legislation: This is a draft item of legislation. This draft has since been made as a UK Statutory Instrument: The\nMedical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 No. 1368\nthat has already been manufactured and may include recalling the device, withdrawing\nit from ",
    "suisse_(_Ordonnance_relative_aux_essais_cliniques_avec_des_dispositifs_medicaux_(ClinO-MD).pdf": "1 \n   \nEnglish is not an official language of the Swiss Confederation. This translation is \nprovided for information purposes only and has no legal force. \n \nOrdinance  \non Clinical Trials with Medical Devices \n(ClinO-MD)  \nof 1 July 2020 (Status as of 26 May 2021) \n \nThe Swiss Federal Council, \nbased on the Human Research Act of 30 September 20111 (HRA) \nand on Articles 54 paragraphs 3, 6 and 8, 54b paragraphs 2 and 3 and 82  \nof the Therapeutic Products Act of 15 December 20002 (TPA), \nordains: \nChapter 1 \nGeneral Provisions \nSection 1 \nSubject matter, Definitions and Applicable Provisions \nArt. 1 \nSubject matter \n1 This Ordinance shall regulate: \na. \nthe requirements pertaining to clinical trials with medical devices and other \ndevices in accordance with Article 1 of the Medical Devices Ordinance of 1 \nJuly 2020 (MedDO)3; \nb. \nthe approval and reporting procedures for clinical trials involving the devic-\nes in accordance with letter a; \nc. \nthe duties and responsibilities of research ethics committees (Ethics Com-\nmittees), the Swiss Agency for Therapeutic Products (Swissmedic) and the \nFederal Office of Public Health (FOPH) in connection with the approval and \nreporting procedures; \nd. \nthe registration of clinical trials involving devices in accordance with let-\nter a; \ne. \npublic access to information concerning clinical trials. \n2 In this Ordinance, the term devices is used to designate all products defined in \nparagraph 1 letter a. \n  \n AS 2020 3033 \n1  \nSR 810.30 \n2  \nSR 812.21 \n3  \nSR 812.213 \n810.306\n\nTherapeutic Products \n2 \n810.306 \nArt. 2 \nDefinitions \nThe following definitions shall apply in this Ordinance: \na. \nclinical trial means the systematic investigation of a device involving one or \nmore persons for the purpose of assessing the safety or performance of the \ndevice; \nb. \nconformity-related clinical trial means a clinical trial conducted to demon-\nstrate the conformity of the device being investigated; \nc. \ncontracting state means any state that is bound to mutually recognise con-\nformity assessments and conformity procedures for devices by an agreement \nwith Switzerland under international law based on equivalent legislation; \nd. \nsponsor means any individual or institution or organisation that takes re-\nsponsibility for the initiation of a clinical trial – specifically its instigation, \nmanagement and financing – in Switzerland; \ne. \ninvestigator means any individual responsible for the conduct of a clinical \ntrial and for the protection of the participants at a clinical trial site; any par-\nticipant who assumes responsibility for initiating a clinical trial in Switzer-\nland is simultaneously the trial’s sponsor. \nArt. 3 \nApplicable provisions \n1 The following provisions of the Ordinance of 20 September 20134 on Clinical \nTrials in Human Research (ClinO) apply to clinical trials with devices: \na. \nfor scientific integrity and scientific quality: Articles 3 and 4 ClinO; \nb. \nfor participant information, consent and withdrawal of consent: Articles 7–9 \nClinO; \nc. \nfor liability and indemnification: Article 10 paragraphs 1 letter c and 2 and \nArticle 11–14 ClinO; \nd. \nfor the conduct of clinical trials in emergency situations: Articles 15–17 Cli-\nnO; \ne. \nfor the storage of personal health data and biological material: Article 18 \nClinO; \nf. \nfor inspections and administrative measures: Article 46 paragraphs 1, 2, 4 \nand 5 and Article 47 and 48 ClinO. \n2 The powers exercised by Swissmedic and the duty to cooperate and provide infor-\nmation incumbent on the sponsor and investigator in the event of inspections and \nadministrative measures are governed mutatis mutandis by Articles 77 and 78 Med-\nDO5. \n  \n4  \nSR 810.305 \n5  \nSR 812.213 \n\nClinical trials with medical devices. O \n3 \n810.306 \n3 Clinical trials with in vitro diagnostic devices, devices as specified in Art. 2a \nparagraph 2 TPA or combinations as specified in Article 2 paragraph 1 letters f and \ng MedDO are subject to ClinO.6 \n \nSection 2  \nGeneral Obligations of the Sponsor and Investigator and Professional \nQualifications \nArt. 4 \nGeneral obligations of the sponsor and investigator \n1 The sponsor and investigator must conduct clinical trials in accordance with Arti-\ncle 72 and Chapters I and III of Annex XV to Regulation (EU) 2017/7457 on medi-\ncal devices (EU-MDR). \n2 Compliance with the requirements of paragraph 1, specified in greater detail by \ndesignated technical standards8 or common specifications in accordance with Arti-\ncle 9 paragraph 1 EU-MDR, is presumed if the clinical trial is conducted in accord-\nance with those standards or specifications. Article 6 paragraph 5 MedDO9 applies \nmutatis mutandis. \n3 If the sponsor is not domiciled in Switzerland and does not have a place of busi-\nness there, it must designate an agent that is domiciled or has a place of business in \nSwitzerland as an address for correspondence. This agent must ensure compliance \nwith the sponsor’s obligations. \nArt. 5 \nProfessional qualifications \n",
    "Suisse_(_Ordonnance_sur_les_essais_cliniques_avec_des_dispositifs_medicaux_(ClinO-MD)).pdf": "1 / 26 \n   \nEnglish is not an official language of the Swiss Confederation. This translation is \nprovided for information purposes only and has no legal force. \n \nOrdinance  \non Clinical Trials with Medical Devices \n(ClinO-MD)  \nof 1 July 2020 (Status as of 1 November 2023) \n \nThe Swiss Federal Council, \nbased on the Human Research Act of 30 September 20111 (HRA) \nand on Articles 54 paragraphs 3, 6 and 8, 54b paragraphs 2 and 3 and 82  \nof the Therapeutic Products Act of 15 December 20002 (TPA), \nordains: \nChapter 1 \nGeneral Provisions \nSection 1 \nSubject matter, Definitions and Applicable Provisions \nArt. 1 \nSubject matter \n1 This Ordinance shall regulate: \na.3 the requirements pertaining to clinical trials: \n1. \nwith medical devices and other devices in accordance with Article 1 of \nthe Medical Devices Ordinance of 1 July 20204 (MedDO), \n2. \nwith in vitro diagnostic medical devices and their accessories in accord-\nance with Article 1 paragraph 1 of the Ordinance of 4 May 20225 on in \nVitro Diagnostic Medical Devices (IvDO); \nb. \nthe approval and reporting procedures for clinical trials involving the devices \nin accordance with letter a; \nc. \nthe duties and responsibilities of research ethics committees (Ethics Commit-\ntees), the Swiss Agency for Therapeutic Products (Swissmedic) and the Fed-\neral Office of Public Health (FOPH) in connection with the approval and re-\nporting procedures; \nd. \nthe registration of clinical trials involving devices in accordance with letter a; \n  \n AS 2020 3033 \n1  \nSR 810.30 \n2  \nSR 812.21 \n3 \nAmended by No I of the O of 4 May 2022, in force since 26 May 2022 (AS 2022 294). \n4  \nSR 812.213 \n5  \nSR 812.219 \n810.306 \n\nTherapeutic Products \n2 / 26 \n810.306 \ne. \npublic access to information concerning clinical trials. \n2 In this Ordinance, the term devices is used to designate all products defined in para-\ngraph 1 letter a. \nArt. 2 \nDefinitions \nIn this Ordinance: \na 6 clinical trial means a clinical investigation and a performance study; \nabis7. clinical investigation means any systematic investigation involving one or \nmore persons undertaken to assess the safety or performance of the device in \naccordance with the MedDO\n8; \nater.9 performance study means a study undertaken to establish or confirm the ana-\nlytical or clinical performance of a device in accordance with the IvDO10 and \nin which the test results:  \n1. \nmay influence patient management decisions or treatment (interventional per-\nformance study);  \n2.  cannot influence patient management decisions or treatment (non-interven-\ntional performance study). \nb. \nconformity-related clinical trial means a clinical trial conducted to demon-\nstrate the conformity of the device being investigated; \nc. \ncontracting state means any state that is bound to mutually recognise con-\nformity assessments and conformity procedures for devices by an agreement \nwith Switzerland under international law based on equivalent legislation; \nd. \nsponsor means any person or institution that takes responsibility for organis-\ning a clinical trial – specifically its initiation, management and financing – in \nSwitzerland; \ne. \ninvestigator means any individual responsible in Switzerland for the conduct \nof a clinical trial and for the protection of the participants at a clinical trial \nsite; any investigator who assumes responsibility for initiating a clinical trial \nin Switzerland is simultaneously the trial’s sponsor. \nArt. 2a11 \nExceptions from the scope \n1 The conduct of non-interventional performance studies is governed by Chapter 2 of \nthe Human Research Ordinance of 20 September 201312 (HRO) when:  \na. \nbiological material is collected from the participants without a surgically in-\nvasive procedure; or \n  6 \nAmended by No I of the O of 4 May 2022, in force since 26 May 2022 (AS 2022 294). \n7 \nInserted by No I of the O of 4 May 2022, in force since 26 May 2022 (AS 2022 294). \n8  \nSR 812.213 \n9 \nInserted by No I of the O of 4 May 2022, in force since 26 May 2022 (AS 2022 294). \n10  \nSR 812.219 \n11 \nInserted by No I of the O of 4 May 2022, in force since 26 May 2022 (AS 2022 294). \n12  \nSR 810.301 \n\nClinical trials with medical devices. O \n3 / 26 \n810.306\nb. \nthe participants do not undergo additional invasive or burdensome procedures \ncompared to the procedures performed under the normal conditions of use of \nthe device to be investigated. \n2 The conduct of non-interventional performance studies in which only already sam-\npled biological material or already collected health-related personal data are further \nused is governed by Chapter 3 of the HRO. \n3 The conduct of non-interventional performance studies in which only already sam-\npled anonymised biological material or already collected anonymised health-related \ndata are further used is governed by Articles 3 and 4 of the Ordinance of 20 September \n201313 on Clinical Trials (ClinO), Article 25 HRO and Article 57 of Regulation (EU) \n2017/74614 (EU-IVDR).15 \n4 The conduct of clinical trials with",
    "Suisse_(fedlex-data-admin-ch-eli-cc-2001-422-20220101-en-pdf-a.pdf": "1 \n    \nEnglish is not an official language of the Swiss Confederation. This translation is \nprovided for information purposes only and has no legal force. \n   \nFederal Act  \non Medicinal Products and Medical Devices \n(Therapeutic Products Act, TPA) \n \nof 15 December 2000 (Status as of 1 January 2022) \n \nThe Federal Assembly of the Swiss Confederation, \nbased on Articles 95 paragraph 1 and 118 paragraph 2 of the Federal Constitution1, \nand having considered the Federal Council Dispatch dated 1 March 19992, \ndecrees: \nChapter 1 \nGeneral Provisions \nArt. 1 \nPurpose \n1 The purpose of this Act is to protect human and animal health and to guarantee that \nonly high quality, safe and effective therapeutic products are placed on the market. \n2 It shall furthermore: \na. \nprotect the consumers of therapeutic products against fraud; \nb. \nhelp to ensure that the therapeutic products placed on the market are used in \naccordance with their purpose and in moderation; \nc. \nhelp to ensure that a reliable and well-organised supply of therapeutic prod-\nucts, together with the necessary technical information and advice, is availa-\nble throughout the country. \n3 In the implementation of this Act, in particular in the enactment of the regulations \nand in the application to an individual case, it must be ensured that: \na. \nthe efficiency and independence of the control of therapeutic products is \nguaranteed in Switzerland; \nb. \nfavourable conditions exist for research and development in the therapeutic \nproduct sector; \nc. \nall players competing in the market fulfil the same legal requirements of \nsafety and quality. \n  \n AS 2001 2790 \n1  \nSR 101 \n2  \nBBl 1999 3453 \n812.21\n\nTherapeutic Products \n2 \n812.21 \nArt. 2 \nScope \n1 This Act applies to: \na.3 the handling of medicinal products and medical devices (therapeutic prod-\nucts); \nb. \nnarcotics as defined in the Narcotics Act of 3 October 19514, insofar as they \nare used as therapeutic products; \nc. \ntherapeutic treatments, such as gene therapy, insofar as they directly relate to \ntherapeutic products; the Federal Council may enact provisions specific to \nthis subject. \n2 The Federal Council may completely or partially exempt medical devices intended \nfor use on animals or in veterinary diagnostics from the scope of this Act. \n3 It may make subject to this Act certain products without an intended medical \npurpose which are comparable to medical devices in terms of functioning and risks \nprofile.5 \nArt. 2a6 \nDevitalised human tissue or cells \n1 For therapeutic products which contain or consist of devitalised human tissues or \ncells, or derivatives thereof, the Federal Council shall specify requirements for the \ndonation, removal, testing and devitalisation of these tissues or cells. \n2 It may make subject to specific requirements of this Act and of the Transplantation \nAct of 8 October 20047 products which contain or consist of devitalised human \ntissues or cells, or derivatives thereof, and are not therapeutic products, but function \nas therapeutic products. In addition, it may also specify requirements for the dona-\ntion, removal, testing and devitalisation of such tissues or cells, or derivatives there-\nof. \n3 Human tissue or human cells may only be removed or used for the manufacture of \nproducts as specified in paragraphs 1 and 2 if consent has been obtained for removal. \nFor this tissue and these cells, neither financial gain nor any other advantage may be \noffered, granted, demanded or accepted. \nArt. 3 \nDue diligence \n1 Any person handling therapeutic products must take all measures necessary accord-\ning to the state of the art to ensure that human or animal health is not endangered. \n  \n3 \nAmended by No I of the FA of 22 March 2019, in force since 26 May 2021  \n(AS 2020 2961; BBl 2019 1). \n4  \nSR 812.121 \n5 \nInserted by No I of the FA of 22 March 2019, in force since 26 May 2021  \n(AS 2020 2961; BBl 2019 1). \n6 \nInserted by No I of the FA of 22 March 2019, in force since 26 May 2021  \n(AS 2020 2961; BBl 2019 1). \n7 \nSR 810.21 \n\nTherapeutic Products Act \n3 \n812.21 \n2 The state of the art in science and technology must be considered for complemen-\ntary medicines without indications, including the principles of the corresponding \ntherapy approach.8 \nArt. 4 \nDefinitions \n1 In this Act: \na. \nMedicinal products means products of chemical or biological origin which \nare intended or claimed to have a medicinal effect on the human or animal \norganism, in particular in the diagnosis, prevention or treatment of diseases, \ninjuries and handicaps; blood and blood products are also considered to be \nmedicinal products; \nabis.9 Medicinal products with indications means medicinal products with an offi-\ncially authorised indication in a specific field of application which are in-\ntended for use in accordance with the rules of the medical and pharmaceuti-\ncal sciences;  \nater.10 Complementary medicines with indications means medicinal products with \nan officially authorised indication in a s",
    "Suisse_(Ordonnance_sur_les_dispositifs_medicaux.pdf": "1 \nMedizinprodukteverordnung \n(MepV)  \nvom 1. Juli 2020 (Stand am 26. Mai 2021) \n \nDer Schweizerische Bundesrat \ngestützt auf das Heilmittelgesetz vom 15. Dezember 20001 (HMG),  \nArtikel 21 Ziffer 2 des Elektrizitätsgesetzes vom 24. Juni 19022,  \nArtikel 5 des Bundesgesetzes vom 17. Juni 2011 über das Messwesen3,  \nArtikel 4 Absatz 1 des Bundesgesetzes vom 12. Juni 20094 über die \nProduktesicherheit,  \nArtikel 37 des Strahlenschutzgesetzes vom 22. März 19915 sowie  \nin Ausführung des Bundesgesetzes vom 6. Oktober 19956 über die technischen \nHandelshemmnisse, \nverordnet: \n1. Kapitel: Allgemeine Bestimmungen \n1. Abschnitt: Geltungsbereich und Ausnahmen \nArt. 1 \nGeltungsbereich \n1 Diese Verordnung gilt für: \na. \nMedizinprodukte und deren Zubehör im Sinne von Artikel 3; \nb. \nProduktgruppen ohne medizinische Zweckbestimmung nach Anhang 1. \n2 In dieser Verordnung wird der Begriff Produkte für die Produkte nach Absatz 1 \nverwendet. \n3 Diese Verordnung gilt auch für: \na. \nProdukte, die beim Inverkehrbringen oder bei der Inbetriebnahme als integ-\nralen Bestandteil ein Arzneimittel enthalten, dem eine unterstützende Funk-\ntion im Produkt zukommt; \nb. \nProdukte, die dazu bestimmt sind, ein Arzneimittel abzugeben; \nc. \nProdukte, die hergestellt sind: \n1.  aus Geweben oder Zellen tierischen Ursprungs, oder ihren Derivaten, \ndie nicht lebensfähig sind oder abgetötet wurden, \n  \n AS 2020 2977 \n1  \nSR 812.21 \n2  \nSR 734.0 \n3  \nSR 941.20 \n4  \nSR 930.11 \n5  \nSR 814.50 \n6 \nSR 946.51 \n812.213 \n\nHeilmittel \n2 \n812.213\n2.  aus Derivaten von Geweben oder Zellen menschlichen Ursprungs, die \nnicht lebensfähig sind oder abgetötet wurden; \nd. \nProdukte, die beim Inverkehrbringen oder bei der Inbetriebnahme als integ-\nralen Bestandteil nicht lebensfähiges Gewebe oder nicht lebensfähige Zellen \nmenschlichen Ursprungs oder deren Derivate enthalten, denen im Rahmen \ndes Produkts eine unterstützende Funktion zukommt; \ne. \nProdukte, die beim Inverkehrbringen oder bei der Inbetriebnahme als integ-\nralen Bestandteil ein In-vitro-Diagnostikum enthalten; für diesen Bestandteil \nsind die Bestimmungen über In-vitro-Diagnostika anwendbar. \nArt. 2 \nAusnahmen \n1 Diese Verordnung gilt nicht für: \na. \nmenschliches Blut, Blutprodukte, Blutplasma oder Blutzellen menschlichen \nUrsprungs oder Produkte, die beim Inverkehrbringen oder bei der Inbetrieb-\nnahme solche Blutprodukte, solches Blutplasma oder solche Blutzellen ent-\nhalten, mit Ausnahme der Produkte nach Artikel 1 Absatz 3 Buchstabe a; \nb. \nvitale Organe, Gewebe oder Zellen sowie Transplantatprodukte menschli-\nchen Ursprungs; \nc. \nvitale Organe, Gewebe oder Zellen sowie Transplantatprodukte tierischen \nUrsprungs; \nd. \nandere als die unter den Buchstaben a–c genannten Erzeugnisse, die aus le-\nbensfähigen biologischen Substanzen oder lebensfähigen Organismen, ein-\nschliesslich lebender Mikroorganismen, Bakterien, Pilzen oder Viren, beste-\nhen oder solche enthalten, um die Zweckbestimmung des Produkts zu \nerreichen oder zu unterstützen; \ne.  In-vitro-Diagnostika; vorbehalten bleiben die Artikel 105 und 107; \nf. \nuntrennbare Kombinationen aus einem Produkt, das zur Abgabe eines Arz-\nneimittels bestimmt ist, und einem Arzneimittel, die ausschliesslich zur \nVerwendung in dieser Kombination bestimmt und nicht wiederverwendbar \nsind; \ng. \nKombinationen, die beim Inverkehrbringen oder bei der Inbetriebnahme ne-\nben dem Produkt als integralen Bestandteil ein Arzneimittel enthalten, dem \neine hauptsächliche Funktion zukommt; \nh. \nKombinationen, die beim Inverkehrbringen oder bei der Inbetriebnahme ne-\nben dem Produkt als integralen Bestandteil nicht lebensfähiges Gewebe oder \nnicht lebensfähige Zellen menschlichen Ursprungs oder deren Derivate ent-\nhalten, denen eine hauptsächliche Funktion zukommt; \ni. \nMedizinprodukte, die ausschliesslich zur Anwendung an Tieren oder zur ve-\nterinärmedizinischen Diagnostik bestimmt sind. \n2 In den Fällen nach Absatz 1 Buchstaben f–h sind die grundlegenden Sicherheits- \nund Leistungsanforderungen nach Artikel 6 für den Teil der Kombination, der als \nProdukt gilt, zu erfüllen. \n\nMedizinprodukteverordnung \n3 \n812.213 \n \n2. Abschnitt: Begriffe und Verweise auf Europäisches Recht \nArt. 3  \nMedizinprodukt und deren Zubehör \n1 Als Medizinprodukte gelten Instrumente, Apparate, Geräte, Software, Implantate, \nReagenzien, Materialien oder andere Gegenstände: \na. \ndie dem Hersteller zufolge für Menschen bestimmt sind; \nb. \nderen bestimmungsgemässe Hauptwirkung im oder am menschlichen Körper \nweder durch pharmakologische oder immunologische Mittel noch metabo-\nlisch erreicht wird, deren Wirkungsweise aber durch solche Mittel unter-\nstützt werden kann; und \nc. \ndie allein oder in Kombination einen oder mehrere der folgenden spezifi-\nschen medizinischen Zwecke erfüllen: \n1.  Diagnose, Verhütung, Überwachung, Vorhersage, Prognose, Behand-\nlung oder Linderung von Krankheiten, \n2.  Diagnose, Überwachung, Behandlung, Linderung von oder Kompensie-\nrung von Verletzungen oder Behinderungen, \n3",
    "suisse_(Reglement_sur_les_dispositifs_medicaux_de_diagnostic_in_vitro)_.pdf": "1 \nVerordnung  \nüber In-vitro-Diagnostika \n(IvDV)  \nvom 4. Mai 2022 (Stand am 26. Mai 2022) \n \nDer Schweizerische Bundesrat, \ngestützt auf das Heilmittelgesetz vom 15. Dezember 20001 (HMG),  \nArtikel 21 Ziffer 2 des Elektrizitätsgesetzes vom 24. Juni 19022,  \nArtikel 5 des Messgesetzes vom 17. Juni 20113,  \nArtikel 4 Absatz 1 des Bundesgesetzes vom 12. Juni 20094 über die \nProduktesicherheit,  \nArtikel 37 Absatz 1 des Strahlenschutzgesetzes vom 22. März 19915  \nsowie in Ausführung des Bundesgesetzes vom 6. Oktober 19956  \nüber die technischen Handelshemmnisse, \nverordnet: \n1. Kapitel: Allgemeine Bestimmungen \n1. Abschnitt: Geltungsbereich und Ausnahmen \nArt. 1 \nGeltungsbereich \n1 Diese Verordnung gilt für In-vitro-Diagnostika und deren Zubehör im Sinne von \nArtikel 3 (Produkte). \n2 Für Produkte, die beim Inverkehrbringen oder bei der Inbetriebnahme als integra-\nlen Bestandteil ein Medizinprodukt nach Artikel 3 Absätze 1 und 2 der Medizinpro-\ndukteverordnung vom 1. Juli 20207 (MepV) enthalten, gilt diese Verordnung ledig-\nlich für den In-vitro-Diagnostikum-Teil. \nArt. 2 \nAusnahmen \nDiese Verordnung gilt nicht für: \na. \nErzeugnisse für den allgemeinen Laborbedarf oder Erzeugnisse, die allein \nfür Forschungszwecke bestimmt sind, es sei denn, sie sind aufgrund ihrer \nMerkmale vom Hersteller speziell für In-vitro-Untersuchungen bestimmt; \n  \n AS 2022 291 \n1  \nSR 812.21 \n2  \nSR 734.0 \n3  \nSR 941.20 \n4  \nSR 930.11 \n5  \nSR 814.50 \n6 \nSR 946.51 \n7 \nSR 812.213 \n812.219\n\nHeilmittel \n2 \n812.219 \nb. \ninvasive Erzeugnisse, die zur Entnahme von Proben bestimmt sind, oder Er-\nzeugnisse, die zum Zweck der Probenahme direkt am menschlichen Körper \nangewendet werden; \nc. \nauf internationaler Ebene zertifizierte Referenzmaterialien; \nd. \nMaterialien, die für externe Qualitätsbewertungsprogramme verwendet wer-\nden; \ne. \nProdukte, die ausschliesslich zur veterinärmedizinischen Diagnostik be-\nstimmt sind.  \n2. Abschnitt: Begriffe und Verweise auf europäisches Recht \nArt. 3 \nIn-vitro-Diagnostikum und dessen Zubehör \n1 Als In-vitro-Diagnostikum gilt ein Medizinprodukt nach Artikel 3 Absätze 1 und 2 \nMepV8, dass: \na. \nals Reagenz, Reagenzprodukt, Kalibrator, Kontrollmaterial, Kit, Instrument, \nApparat, Gerät, Software oder System einzeln oder in Verbindung miteinan-\nder vom Hersteller zur In-vitro-Untersuchung von aus dem menschlichen \nKörper stammenden Proben, einschliesslich Blut- und Gewebespenden, be-\nstimmt ist; und \nb. \nausschliesslich oder hauptsächlich dazu dient, Informationen zu einem oder \nmehreren der folgenden Punkte zu liefern: \n1. \nüber physiologische oder pathologische Prozesse oder Zustände, \n2. \nüber kongenitale körperliche oder geistige Beeinträchtigungen, \n3. \nüber die Prädisposition für einen bestimmten gesundheitlichen Zustand \noder eine bestimmte Krankheit, \n4. \nzur Feststellung der Unbedenklichkeit und Verträglichkeit bei den po-\ntenziellen Empfängerinnen und Empfängern, \n5. \nüber die voraussichtliche Wirkung einer Behandlung oder die voraus-\nsichtlichen Reaktionen darauf, \n6. \nzur Festlegung oder Überwachung therapeutischer Massnahmen. \n2 Probenbehältnisse gelten ebenfalls als In-vitro-Diagnostika. \n3 Zubehör eines In-vitro-Diagnostikums ist ein Gegenstand, der an sich kein In-vitro-\nDiagnostikum ist, aber vom Hersteller dazu bestimmt ist, zusammen mit einem oder \nmehreren bestimmten In-vitro-Diagnostika verwendet zu werden, und: \na. \nder speziell dessen oder deren Verwendung gemäss seiner oder ihrer \nZweckbestimmung ermöglicht; oder \nb. \nmit dem die medizinische Funktion des In-vitro-Diagnostikums oder der In-\nvitro-Diagnostika im Hinblick auf dessen oder deren Zweckbestimmung \ngezielt und unmittelbar unterstützt werden soll. \n  \n8 \nSR 812.213 \n\nIn-vitro-Diagnostika. V \n3 \n812.219 \nArt. 4 \nWeitere Begriffe \n1 In dieser Verordnung bedeuten: \na. \nBereitstellung auf dem Markt: jede entgeltliche oder unentgeltliche Übertra-\ngung oder Überlassung eines Produkts, mit Ausnahme von Produkten für \nLeistungsstudien, zum Vertrieb, zum Verbrauch oder zur Verwendung auf \ndem Schweizer Markt im Rahmen einer gewerblichen Tätigkeit; \nb. \nInverkehrbringen: erstmalige Bereitstellung eines Produkts auf dem Schwei-\nzer Markt, mit Ausnahme von Produkten für Leistungsstudien; \nc. \nInbetriebnahme: Zeitpunkt, zu dem erstmals ein gebrauchsfertiges Produkt, \nmit Ausnahme von Produkten für Leistungsstudien, den Endanwenderinnen \nund Endanwendern zur Verwendung auf dem Schweizer Markt entsprechend \nseiner Zweckbestimmung zur Verfügung gestellt wird; \nd. \nInstandhaltung: Massnahmen wie Wartung, Softwareupdates, Inspektion, \nReparatur, Vorbereitung zur Erstverwendung sowie Aufbereitung zur Wie-\nderverwendung, zur Erhaltung oder Wiederherstellung des funktionsfähigen \nZustandes eines Produkts; \ne. \nHersteller: jede natürliche oder juristische Person, die ein Produkt herstellt \noder neu aufbereitet oder entwickeln, herstellen oder neu aufbereiten lässt \nund dieses Produkt unter ihrem eigenen Namen oder ihrer eigenen Marke \nvermarktet; die",
    "Suisse(__Loi_federale_sur_les_medicaments_et_les_dispositifs_medicaux).pdf": "1 \n    \nEnglish is not an official language of the Swiss Confederation. This translation is \nprovided for information purposes only and has no legal force. \n   \nFederal Act  \non Medicinal Products and Medical Devices \n(Therapeutic Products Act, TPA) \n \nof 15 December 2000 (Status as of 1 January 2022) \n \nThe Federal Assembly of the Swiss Confederation, \nbased on Articles 95 paragraph 1 and 118 paragraph 2 of the Federal Constitution1, \nand having considered the Federal Council Dispatch dated 1 March 19992, \ndecrees: \nChapter 1 \nGeneral Provisions \nArt. 1 \nPurpose \n1 The purpose of this Act is to protect human and animal health and to guarantee that \nonly high quality, safe and effective therapeutic products are placed on the market. \n2 It shall furthermore: \na. \nprotect the consumers of therapeutic products against fraud; \nb. \nhelp to ensure that the therapeutic products placed on the market are used in \naccordance with their purpose and in moderation; \nc. \nhelp to ensure that a reliable and well-organised supply of therapeutic prod-\nucts, together with the necessary technical information and advice, is availa-\nble throughout the country. \n3 In the implementation of this Act, in particular in the enactment of the regulations \nand in the application to an individual case, it must be ensured that: \na. \nthe efficiency and independence of the control of therapeutic products is \nguaranteed in Switzerland; \nb. \nfavourable conditions exist for research and development in the therapeutic \nproduct sector; \nc. \nall players competing in the market fulfil the same legal requirements of \nsafety and quality. \n  \n AS 2001 2790 \n1  \nSR 101 \n2  \nBBl 1999 3453 \n812.21\n\nTherapeutic Products \n2 \n812.21 \nArt. 2 \nScope \n1 This Act applies to: \na.3 the handling of medicinal products and medical devices (therapeutic prod-\nucts); \nb. \nnarcotics as defined in the Narcotics Act of 3 October 19514, insofar as they \nare used as therapeutic products; \nc. \ntherapeutic treatments, such as gene therapy, insofar as they directly relate to \ntherapeutic products; the Federal Council may enact provisions specific to \nthis subject. \n2 The Federal Council may completely or partially exempt medical devices intended \nfor use on animals or in veterinary diagnostics from the scope of this Act. \n3 It may make subject to this Act certain products without an intended medical \npurpose which are comparable to medical devices in terms of functioning and risks \nprofile.5 \nArt. 2a6 \nDevitalised human tissue or cells \n1 For therapeutic products which contain or consist of devitalised human tissues or \ncells, or derivatives thereof, the Federal Council shall specify requirements for the \ndonation, removal, testing and devitalisation of these tissues or cells. \n2 It may make subject to specific requirements of this Act and of the Transplantation \nAct of 8 October 20047 products which contain or consist of devitalised human \ntissues or cells, or derivatives thereof, and are not therapeutic products, but function \nas therapeutic products. In addition, it may also specify requirements for the dona-\ntion, removal, testing and devitalisation of such tissues or cells, or derivatives there-\nof. \n3 Human tissue or human cells may only be removed or used for the manufacture of \nproducts as specified in paragraphs 1 and 2 if consent has been obtained for removal. \nFor this tissue and these cells, neither financial gain nor any other advantage may be \noffered, granted, demanded or accepted. \nArt. 3 \nDue diligence \n1 Any person handling therapeutic products must take all measures necessary accord-\ning to the state of the art to ensure that human or animal health is not endangered. \n  \n3 \nAmended by No I of the FA of 22 March 2019, in force since 26 May 2021  \n(AS 2020 2961; BBl 2019 1). \n4  \nSR 812.121 \n5 \nInserted by No I of the FA of 22 March 2019, in force since 26 May 2021  \n(AS 2020 2961; BBl 2019 1). \n6 \nInserted by No I of the FA of 22 March 2019, in force since 26 May 2021  \n(AS 2020 2961; BBl 2019 1). \n7 \nSR 810.21 \n\nTherapeutic Products Act \n3 \n812.21 \n2 The state of the art in science and technology must be considered for complemen-\ntary medicines without indications, including the principles of the corresponding \ntherapy approach.8 \nArt. 4 \nDefinitions \n1 In this Act: \na. \nMedicinal products means products of chemical or biological origin which \nare intended or claimed to have a medicinal effect on the human or animal \norganism, in particular in the diagnosis, prevention or treatment of diseases, \ninjuries and handicaps; blood and blood products are also considered to be \nmedicinal products; \nabis.9 Medicinal products with indications means medicinal products with an offi-\ncially authorised indication in a specific field of application which are in-\ntended for use in accordance with the rules of the medical and pharmaceuti-\ncal sciences;  \nater.10 Complementary medicines with indications means medicinal products with \nan officially authorised indication in a s",
    "Suisse(Ordonnance_sur_les_dispositifs_medicaux_SR_).pdf": "1 / 62 \n   \nEnglish is not an official language of the Swiss Confederation. This translation is \nprovided for information purposes only and has no legal force. \n \nMedical Devices Ordinance \n(MedDO)  \nof 1 July 2020 (Status as of 1 November 2023) \n \nThe Swiss Federal Council, \nbased on the Therapeutic Products Act of 15 December 20001 (TPA),  \nArticle 21 number 2 of the Electricity Act of 24 June 19022,  \nArticle 5 of the Metrology Act of 17 June 20113,  \nArticle 4 paragraph 1 of the Federal Act of 12 June 20094 on Product Safety,  \nArticle 37 paragraph 1 of the Radiological Protection Act of 22 March 19915 and \nin implementation of the Federal Act of 6 October 19956 on Technical Barriers to \nTrade,7 \nordains: \nChapter 1 \nGeneral Provisions \nSection 1 \nScope and Exceptions \nArt. 1 \nScope \n1 This Ordinance applies to: \na. \nmedical devices and the associated accessories, as defined in Article 3; \nb. \ngroups of products without an intended medical purpose in accordance with \nAnnex 1. \n2 In this Ordinance, the term devices is used to designate the products defined in par-\nagraph 1. \n3 This Ordinance also applies to: \n  \n AS 2020 2977 \n1  \nSR 812.21 \n2  \nSR 734.0 \n3  \nSR 941.20 \n4  \nSR 930.11 \n5 \nSR 814.50 \n6 \nSR 946.51 \n7 \nAmended by Annex 5 No 1 of the O of 4 May 2022 on In Vitro Diagnostic Medical De-\nvices, in force since 26 May 2022 (AS 2022 291). \n812.213 \n\nTherapeutic Products \n2 / 62 \n812.213 \na. \ndevices which, when placed on the market or put into service, incorporate as \nan integral part a medicinal product that has an action ancillary to that of the \ndevice; \nb. \ndevices intended to administer a medicinal product; \nc. \ndevices manufactured: \n1.  from tissues or cells of animal origin, or their derivatives, which are non-\nviable or are rendered non-viable, \n2.  from derivatives of tissues or cells of human origin that are non-viable or \nare rendered non-viable; \nd. \ndevices which, when placed on the market or put into service, incorporate as \nan integral part non-viable tissues or non-viable cells of human origin or their \nderivatives that have an action ancillary to that of the device; \ne. \ndevices that incorporate as an integral part an in vitro diagnostic medical de-\nvice; such constituent parts shall be subject to the provisions for in vitro med-\nical devices. \nArt. 2 \nExceptions \n1 This Ordinance does not apply to: \na. \nhuman blood, blood products, plasma or blood cells of human origin, or de-\nvices which incorporate, when placed on the market or put into service, such \nblood products, plasma or cells except for devices referred to in Article 1 par-\nagraph 3 letter a; \nb. \nvital organs, tissues or cells and transplant products of human origin; \nc. \nvital organs, tissues or cells and transplant products of animal origin; \nd. \nproducts other than those referred to in letters a–c that contain or consist of \nviable biological material or viable organisms, including living micro-organ-\nisms, bacteria, fungi or viruses, in order to achieve or support the intended \npurpose of the product; \ne.  in vitro diagnostic medical devices; these are subject to Articles 105 and 107; \nf. \nnon-separable combinations of a medicinal product and device intended to \nadminister a medicinal product that are intended solely for use in this combi-\nnation and are not reusable; \ng. \ncombinations which, when placed on the market or put into service, incorpo-\nrate as an integral part a medicinal product in addition to the device, where \nthe medicinal product assumes a primary function in such combinations; \nh. \ncombinations which, when placed on the market or put into service, incorpo-\nrate as an integral part non-viable tissues or non-viable cells of human origin \nor their derivatives in addition to the device, where such tissues, cells or de-\nrivatives assume a primary function in the device; \ni. \nmedical devices intended solely for use in animals or veterinary diagnostics; \n\nMedical Devices. O \n3 / 62 \n812.213\nj.8 \ncombinations which, when placed on the market or put into service, incorpo-\nrate as an integral part transplant products in addition to the device. \n2 In the cases specified in paragraph 1 letters f–h and j, the part of the combination \nthat is deemed to be a device must satisfy the general safety and performance require-\nments set out in Article 6.9  \nSection 2 \nDefinitions and References to European Legislation \nArt. 3  \nMedical device and accessories \n1 Medical devices are instruments, apparatus, appliances, softwares, implants, rea-\ngents, materials or other articles: \na. \nthat are intended by their manufacturer to be used for human beings; \nb. \nthat do not achieve their principal intended action in or on the human body by \npharmacological, immunological or metabolic means, but which may be as-\nsisted in their function by such means; and \nc. \nthat serve to fulfil one or more of the following specific medical purposes \neither alone or in combination: \n1.  diagnosis, prevention, monitoring, prediction, prognosis,",
    "UE-Guidance_on_classification_of_medical_devices.pdf": "Medical Devices \nMedical Device Coordination Group Document  \n  \n \n \nMDCG 2021- 24  \n \n1 \n \n \n \n \nMDCG 2021-24 \nGuidance on classification of medical devices \n \n \n \n \n \n \n \n \n         \n \n \nOctober 2021 \n \n \nThis document has been endorsed by the Medical Device Coordination Group (MDCG) established by Article 103 of Regulation (EU) \n2017/745. The MDCG is composed of representatives of all Member States and it is chaired by a representative of the European \nCommission. \nThe document is not a European Commission document and it cannot be regarded as reflecting the official position of the European \nCommission. Any views expressed in this document are not legally binding and only the Court of Justice of the European Union can give \nbinding interpretations of Union law. \n \n \n\nMedical Devices \nMedical Device Coordination Group Document  \n  \n \n \nMDCG 2021- 24  \n \n2 \n \nTable of contents \n1 \nPurpose of medical device classification ........................................................................................................................................................................... 4 \n2 \nPractical relevance of classification .................................................................................................................................................................................... 4 \n2.1 \nGeneral requirements ...................................................................................................................................................................................................... 4 \n2.2 \nConformity assessment ................................................................................................................................................................................................... 5 \n2.3 \nClinical evaluation and investigation ......................................................................................................................................................................... 5 \n2.4 \nPost-market surveillance ................................................................................................................................................................................................ 6 \n2.5 \nTraceability .......................................................................................................................................................................................................................... 6 \n2.6 \nInstructions for use .......................................................................................................................................................................................................... 7 \n3 \nHow to carry out classification ............................................................................................................................................................................................. 7 \n3.1 \nBasic terms and definitions ........................................................................................................................................................................................... 7 \n \nSpecific medical purpose ........................................................................................................................................................................................ 7 \n \nDuration of use ........................................................................................................................................................................................................... 7 \n \nContinuous use ........................................................................................................................................................................................................... 8 \n \nInvasiveness ................................................................................................................................................................................................................ 8 \n \nActive medical devices .......................................................................................................................................................................................... 10 \n \nDevices with a measuring function................................................................................................................................................................... 12 \n \nSystems and procedure packs ........................................................................................................................................................................... 12 \n \nOther terms ............................................................................................................................................................................................................... 13 \n3.2 \nApplication of the classification rules.........................................................",
    "UE-Guidance_on_standardisation_for_medical_devices.pdf": "Medical Devices \nMedical Device Coordination Group Document \n \n \n         MDCG 2021-5 Rev. 1 \n \nPage 1 of 27 \n \n \n \n \n \nMDCG 2021-5 Rev. 1 \n \nGuidance on standardisation for medical devices  \n \nRevision 1 – July 2024 \n \n \n \nThis document has been endorsed by the Medical Device Coordination Group \n(MDCG) established by Article 103 of Regulation (EU) 2017/745. The MDCG is \ncomposed of representatives of all Member States and it is chaired by a representative \nof the European Commission. \nThe document is not a European Commission document and it cannot be regarded as \nreflecting the official position of the European Commission. Any views expressed in \nthis document are not legally binding and only the Court of Justice of the European \nUnion can give binding interpretations of Union law. \n \n \n\nMedical Devices \nMedical Device Coordination Group Document \n \n \n         MDCG 2021-5 Rev. 1 \n \nPage 2 of 27 \n \nMDCG 2021-5 revision 1 main changes \nPages 4, 8 and 10 \nRemoval of references to the Directives and integration \ninto those to the Regulations \nPages 4-8, 10-24 \nUpdate of footnotes and links \nPages 6-7 \nAddition of references: Communications, Guidelines, \n“Task Force” \nPages 8-9 \nAddition of considerations on the references to EN ISO \n15189 and ISO 14155:2011 \nPage 12 \nAddition of references to the MDR/IVDR standardisation \nrequest and its amendments \nPage 13 \nUpdates on the HAS consultants \nPage 14 \nAddition of considerations on information and clarification \nby CEN and CENELEC and their Technical Committees \nPage 15 \nUpdates on the IMDRF \nPages 16-18 \nUpdates on the “state of the art” \nPages 18-21 \nAddition of point 3.6 on rulings of the European Court of \nJustice \nPage 21-22 \nAddition of point 3.7 on European Pharmacopoeia \nPages 22-23 \nAddition of point 3.8 on common specifications \nPage 24 \nUpdates on SFHS (former ABHS) \nPages 25-27 \nAdditions and updates of references and links \n \n \n\nMedical Devices \nMedical Device Coordination Group Document \n \n \n         MDCG 2021-5 Rev. 1 \n \nPage 3 of 27 \n \nGuidance on standardisation for medical devices \nIntroduction: scope and contents \nThis document aims to provide guidance on different aspects related to standards in the medical \ndevices sector in support of the requirements laid down in the applicable EU legislation, taking \ninto account its specificities. \nThe contents of this document: \n1. EU legislation on medical devices within the “New Approach” and the “New \nLegislative Framework” \n2. The general framework for harmonised European standards \n2.1. Main references \n2.2. Voluntary use of standards \n2.3. The relationship between harmonised European standards and EU legislation: the \n“Annex Z” \n3. Harmonised European standards in support of the EU legislation on medical devices \n3.1. Legal references, European standardisation organisations and standardisation \nmandates or requests \n3.2. Development of harmonised European standards for medical devices and \nassessment by the HAS consultants \n3.3. Publication in the OJEU of references of harmonised European standards to confer \npresumption of conformity \n3.4. International aspects of standardisation \n3.5. The concept of “state of the art”, European standardisation and conformity \nassessment for medical devices \n3.6. The rulings of the Court of Justice of the European Union on standardisation \n3.7. European Pharmacopoeia \n3.8. Common specifications \n4. Governance structure for standards in the medical devices sector \n4.1. The MDCG Subgroup on Standards (Working Group 2) \n4.2. The CEN-CENELEC Sector Forum on Healthcare Standards (SFHS) \nare not intended to be exhaustive, and must be read and used within the legal and guidance \nframework on EU harmonisation legislation for health, safety and performance of products in \nthe internal market, in particular for European standardisation. \nWider information on such legal and guidance framework is available from the references and \nsources of information indicated in the footnotes and at the end of this document. \n\nMedical Devices \nMedical Device Coordination Group Document \n \n \n         MDCG 2021-5 Rev. 1 \n \nPage 4 of 27 \n \n1. EU legislation on medical devices within the “New Approach” and the \n“New Legislative Framework” \nThe EU legislative framework on medical devices currently consists of two Regulations1, \nadopted and entered into force in 2017: \n• Regulation (EU) 2017/745 on medical devices2 (MDR), applicable from 26 May 2021, \nreplacing the previous Directives 90/385/EEC on active implantable medical devices3 \n(AIMDD) and 93/42/EEC on medical devices4 (MDD), through specific transition \nprovisions, as amended; \n• Regulation (EU) 2017/746 on in vitro diagnostic medical devices5 (IVDR), applicable \nfrom 26 May 2022, replacing the previous Directive 98/79/EC on in vitro diagnostic \nmedical devices6 (IVDD), through specific transition provisions, as amended. \nThese legislative acts are part of the EU harmonisation legislation on health, safety and \nperformance of products i",
    "Union_europeenne_(Resume_des_exigences_reglementaires)_.pdf": "Union européenne (Résumé des exigences réglementaires) \nEXIGENCE  \nINFORMATION \nNiveau de régulation \nHaut \nDernière mise à jour : 25/03/2024 \nPré-inscription \n \nAutorité \nCommission européenne (CE) et autorités nationales de l'UE \n \nRéférences: \n- https://health.ec.europa.eu/medical-devices-sector/new-regulations/contacts_en \n \nDernière mise à jour : 17/01/2025 \nRèglement principal \nRèglement (UE) 2017/745 du Parlement européen et du Conseil du 5 avril 2017 relatif aux \ndispositifs médicaux, modifiant la directive 2001/83/CE, le règlement (CE) n° 178/2002 et le \nrèglement (CE) n° 1223/2009 et abrogeant les directives 90/385/CEE et 93/42/CEE du Conseil. \nRèglement (UE) 2017/746 du Parlement européen et du Conseil du 5 avril 2017 relatif aux \ndispositifs médicaux de diagnostic in vitro et abrogeant la directive 98/79/CE et la décision \n2010/227/UE de la Commission. \n \nRéférences: \n- https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02017R0745-20240709 \n- https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02017R0746-20240709 \n \nDernière mise à jour : 17/01/2025 \nRèglements Délais \nimportants \nCalendrier du MDR 2017/745 (MD) de l’UE :  \n \nÀ partir du 26 mai 2017, les dispositifs conformes au MDR de l'UE peuvent être \ncertifiés conformément au MDR et être mis sur le marché. \n \nÀ partir du 25 mai 2021, les certificats délivrés dans le cadre de la MDD avant l'entrée \nen vigueur complète du MDR de l'UE (26 mai 2021) seront valables jusqu'à la période \ntransitoire qui s'applique à la classe spécifique. \nDélais de la période transitoire : \n \nDispositifs implantables sur mesure de classe III : 26 mai 2026 \n \nDispositifs implantables de classe III et de classe IIb : 31 décembre 2027 \n \nClasse IIb non implantable : 31 décembre 2028 \n \nSutures, agrafes, obturations dentaires, appareils dentaires, couronnes dentaires, vis, \ncales, plaques, fils, broches, clips et connecteurs de classe IIb : 31 décembre 2028 \n \nClasse IIa et Classe I (Is/Im) : 31 décembre 2028 \n \nDispositifs reclassés selon le nouveau règlement MDR 2017/745 de l'UE vers une \nclasse supérieure à I : 31 décembre 2028 \nLe règlement (UE) 2023/607 prolonge la validité des certificats délivrés jusqu'au 26 mai 2021, \njusqu'à la date limite applicable à chaque classe (voir ci-dessus) \nLe règlement (UE) 2023/607 supprime la date de « vente » du MDR \n \n\nEXIGENCE \nINFORMATION \nLa Commission européenne a publié le règlement (UE) 2024/1860   afin de prolonger les délais \nde transition pour certains dispositifs de diagnostic in vitro (DIV) dans le cadre du règlement \nIVDR. Les fabricants de certains dispositifs de diagnostic in vitro (DIV) existants peuvent \nbénéficier d'un délai de grâce plus long pour se conformer aux nouvelles réglementations, mais \nuniquement si des conditions spécifiques sont remplies. \nCes conditions s'appliquent à toutes les classes : \n \nL'appareil continue de répondre aux exigences de l'IVDD. \n \nIl n’y a pas de changements significatifs dans la conception ou dans l’usage prévu de \nl’appareil. \n \nL’appareil ne présente pas de risque inacceptable pour la santé et la sécurité du patient. \n \nAu plus tard le 26 mai 2025, le fabricant a mis en place un système de gestion de la \nqualité \nPour les dispositifs de classe B et les dispositifs de classe A mis sur le marché à l'état stérile, la \npériode de transition est prolongée jusqu'au 31 décembre 2029 et ils doivent satisfaire aux \nexigences supplémentaires suivantes : \n \nLe fabricant a déposé une demande formelle auprès d'un organisme notifié avant le 26 \nmai 2027  \n \nL'organisme notifié et le fabricant ont signé un accord écrit avant le 26 septembre 2027 \nPour les appareils de classe C, la période de transition est prolongée jusqu'au 31 décembre 2028 \net ils doivent satisfaire aux exigences supplémentaires suivantes : \n \nLe fabricant a déposé une demande formelle auprès d'un organisme notifié avant le 26 \nmai 2026  \n \nL'organisme notifié et le fabricant ont signé un accord écrit avant le 26 septembre 2026 \nPour les appareils de classe D, la période de transition est prolongée jusqu'au 31 décembre 2027 \net ils doivent satisfaire aux exigences supplémentaires suivantes : \n \nLe fabricant a déposé une demande formelle auprès d'un organisme notifié avant le 26 \nmai 2025  \n \nL'organisme notifié et le fabricant ont signé un accord écrit avant le 26 septembre 2025 \nUne série de questions-réponses sur l’extension de l’IVDR a été publiée par la CE. \n \nEUDAMED: \n \nLe règlement (UE) 2024/1860 permettra la mise en œuvre progressive des modules \nEUDAMED dès qu’ils auront été audités et déclarés fonctionnels. \n \nCela permettra l’utilisation obligatoire de plusieurs modules à partir de fin 2025. \n \nL'utilisation de chaque module devient obligatoire six mois après la publication par la \nCommission européenne d'un avis confirmant sa fonctionnalité au Journal officiel de \nl'Union européenne (JOUE). Jusqu'à cette date, les dispositions nationales s'appliquent. \n \nLes fabricants, "
}